# EDGAR Filing Document

**Accession Number:** 0002078607
**File Stem:** 0001477932-26-004058
**Filing Date:** 2026-6
**Character Count:** 1010110
**Document Hash:** 63c3b3a619f7f7e7614828631909a910
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-26-004058.hdr.sgml**: 20260629

**ACCESSION NUMBER**: 0001477932-26-004058

**CONFORMED SUBMISSION TYPE**: 1-A

**PUBLIC DOCUMENT COUNT**: 89

**FILED AS OF DATE**: 20260629

**DATE AS OF CHANGE**: 20260626

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** WUND Healing Biopharmaceuticals, Inc.
- **CENTRAL INDEX KEY:** 0002078607
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 813752318
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 1-A
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 024-12778
- **FILM NUMBER:** 261130885

**BUSINESS ADDRESS:**
- **STREET 1:** 8683 W SAHARA AVE STE 280
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89117
- **BUSINESS PHONE:** (702) 800-0030

**MAIL ADDRESS:**
- **STREET 1:** 8683 W SAHARA AVE STE 280
- **CITY:** LAS VEGAS
- **STATE:** NV
- **ZIP:** 89117

## Part

An offering statement pursuant to Regulation A relating to these securities has been filed with the Securities and Exchange Commission. Information contained in this Preliminary Offering Circular is subject to completion or amendment. These securities may not be sold nor may offers to buy be accepted before the offering statement filed with the Commission is qualified. This Preliminary Offering Circular shall not constitute an offer to sell or the solicitation of an offer to buy nor may there be any sales of these securities in any state in which such offer, solicitation or sale would be unlawful before registration or qualification under the laws of any such state. We may elect to satisfy our obligation to deliver a Final Offering Circular by sending you a notice within two business days after the completion of our sale to you that contains the URL where the Final Offering Circular or the offering statement in which such Final Offering Circular was filed may be obtained.

Preliminary Offering Circular Subject to Completion Dated: June 26, 2026

![](wund_1aimg1.jpg)

**WUND Healing BioPharmaceuticals, Inc.**

**8683 W. Sahara Avenue, Suite 280**

**Las Vegas, NV 89117**

**(702) 800-0030**

<u>www.wundbio.com</u>

$10,000,000

$10.00 per Share

1,000,000 Shares,

Minimum Investment 500 Shares ($5,000)

This is the public offering of securities of WUND Healing BioPharmaceuticals, Inc., a Nevada Corporation. We are offering up to 1,000,000 shares of our common stock, par value $0.001 ("Common Stock"), at an offering price of $10.00 per share (the "Offered Shares" or "Shares") by the Company, pursuant to Tier 2 of Regulation A of the United States Securities and Exchange Commission (the "SEC").

This offering is being conducted on a "best-efforts" basis, which means that there is no minimum number of Shares that must be sold by us for this offering to close; thus, we may receive no or minimal proceeds from this offering. None of the proceeds received will be placed in an escrow or trust account. All proceeds from this offering will become immediately available to us and may be used as they are accepted. Purchasers of the Shares will not be entitled to a refund and could lose their entire investments.

We estimate that this offering will commence within two days of SEC qualification; this offering will terminate at the earliest of (a) the date on which the maximum offering has been sold, (b) one year from the date of SEC qualification, or (c) the date on which this offering is earlier terminated by us, in our sole discretion. See "Plan of Distribution".

There is no minimum target for this offering and the Company may accept investor subscriptions on a rolling basis. After each acceptance of subscriptions, funds tendered by investors will be available to the Company for its use.

There is no public market for the Shares, provided that following the closing of this offering, the Company currently plans to apply for quotation on the OTCQB Market maintained by OTC Markets; however, there can be no assurance that we will obtain such quotation, or as to the level of trading that might occur if we do.

**These securities are speculative securities. Investment in the Company's stock involves significant risk. You should purchase these securities only if you can afford a complete loss of your investment. See the "Risk Factors" section on page 16 of this Offering Circular.**

Subscriptions are irrevocable and the purchase price is non-refundable as expressly stated in this offering circular. The Company, by determination of the Board of Directors, in its sole discretion, may issue the Shares under this offering for cash, promissory notes, services, and/or other consideration without notice to subscribers. Any of the foregoing non-cash consideration received by the Company shall be valued according to the Note to Rule 251(a)(1) of Regulation A.

---

| | | | |
|:---|:---|:---|:---|
|  | Price to public | Commissions<sup>(1)</sup> | Proceeds to issuer |
| Per share | $10.00 | $0.70 | $9.30 |
| Total  | $10000000.00 | $700000.00 | $9300000.00 |

---

(1) We have engaged Benjamin Securities, Inc. (" <u>Benjamin Securities</u> ") and D. Boral (collectively, the " <u>Placement Agents</u> ") to act as placement agent for this offering, in exchange for a fee of 7% of the aggregate offering price of the Shares sold in this offering. We have also agreed to issue warrants to Benjamin Securities, and have also agreed to reimburse Benjamin Securities for certain accountable expenses. We refer you to "*Pl an of Distribution* ", below for additional information regarding Placement Agent compensation.

In the event that we become a reporting company under the Securities Exchange Act of 1934, we intend to take advantage of the provisions that relate to "Emerging Growth Companies" under the JOBS Act of 2012. See "Offering Circular Summary–Implications of Being an Emerging Growth Company."

**You should carefully consider the risk factors set forth under "Risk Factors", beginning on page 16 of this offering circular before you make your decision to invest in our common stock.** 

**The United States Securities and Exchange Commission does not pass upon the merits of or give its approval to any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering circular or other solicitation materials. These securities are offered pursuant to an exemption from registration with the Commission; however, the Commission has not made an independent determination that the securities offered are exempt from registration.** 

**Generally, no sale may be made to you in this offering if the aggregate purchase price you pay is more than 10% of the greater of your annual income or net worth. Different rules apply to accredited investors and non-natural persons. Before making any representation that your investment does not exceed applicable thresholds, we encourage you to review Rule 251(d)(2)(i)(C) of Regulation A. For general information on investing, we encourage you to refer to *<u>www.investor.gov</u>*.**

We are offering to sell, and seeking offers to buy, our shares only in jurisdictions where such offers and sales are permitted. You should rely only on the information contained in this offering circular. We have not authorized anyone to provide you with any information other than the information contained in this offering circular. The information contained in this offering circular is accurate only as of its date, regardless of the time of its delivery or of any sale or delivery of our Shares. Neither the delivery of this offering circular nor any sale or delivery of our Shares shall, under any circumstances, imply that there has been no change in our affairs since the date of this offering circular. This offering circular will be updated and made available for delivery to the extent required by the federal securities laws.

This offering circular follows the disclosure format of Form S-1, pursuant to the General Instructions of Part II(a)(1)(ii) of Form 1-A.

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
| **[About This Offering circular](#ABOUTTHISOFFERINGCIRCULAR)** | **1** |
| **[Information Regarding Forward-Looking Statements](#INFORMATIONREGARDING)** | **2** |
| **[Offering Circular Summary](#OFFERINGCIRCULARSUMMARY)** | **4** |
| **[The Offering](#THEOFFERING)** | **12** |
| **[Selected Financial Data](#SELECTEDFINANCIALDATA)** | **14** |
| **[Risk Factors](#RISKFACTORS)** | **16** |
| **[Use of Proceeds](#USEOFPROCEEDS)** | **52** |
| **[Dividend Policy](#DIVIDENDPOLICY)** | **53** |
| **[Capitalization](#CAPITALIZATION)** | **53** |
| **[Dilution](#DILUTION)** | **54** |
| **[Management s Discussion and Analysis of Financial Condition and Results of Operations](#MDA)** | **55** |
| **[Business](#BUSINESS)** | **65** |
| **[Management](#MANAGEMENT)** | **102** |
| **[Executive and Director Compensation](#EXECUTIVEANDDIRECTORCOMPENSATION)** | **107** |
| **[Certain Relationships and Related Person Transactions](#CERTAINRELATIONSHIPSAND)** | **110** |
| **[Indemnification of Directors and Officers](#INDEMNIFICATIONOFDIRECTORS)** | **111** |
| **[Principal Stockholders](#PRINCIPALSTOCKHOLDERS)** | **113** |
| **[Description of Capital Stock](#DESCRIPTIONOFCAPITALSTOCK)** | **115** |
| **[Shares Eligible For Future Sale](#SHARESELIGIBLEFORFUTURESALE)** | **119** |
| **[Plan of Distribution](#PLANOFDISTRIBUTION)** | **121** |
| **[Expenses of this Offering](#EXPENSESOFTHISOFFERING)** | **126** |
| **[Experts and Legal Matters](#EXPERTSANDLEGALMATTERS)** | **126** |
| **[Where You Can Find More Information](#EXPERTSANDLEGALMATTERS)** | **127** |
| **[Index to Financial Statements](#IFS)** | **128** |

---

*[**Table of Contents**](#TOC)*

**ABOUT THIS OFFERING CIRCULAR**

No dealer, salesperson or other individual has been authorized to give any information or to make any representation other than those contained in this offering circular in connection with the offer made by this offering circular and, if given or made, such information or representations must not be relied upon as having been authorized by us. This offering circular does not constitute an offer to sell or a solicitation of an offer to buy any securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not qualified to do so, or to any person to whom it is unlawful to make such offer or solicitation. Neither the delivery of this offering circular nor any sale made hereunder shall, under any circumstances, create any implication that there has been no change in our affairs or that information contained herein is correct as of any time subsequent to the date hereof.

For investors outside the United States: We and the placement agents have not done anything that would permit this offering or possession or distribution of this offering circular in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this offering circular must inform themselves, and observe any restrictions relating to, the offering of the Shares of our common stock and the distribution of this offering circular outside the United States.

Our logo and some of our trademarks and tradenames are used in this offering circular. This offering circular also includes trademarks, tradenames and service marks that are the property of others. Solely for convenience, trademarks, tradenames, and service marks referred to in this offering circular may appear without the®,™ and SM symbols. References to our trademarks, tradenames and service marks are not intended to indicate in any way that we will not assert to the fullest extent under applicable law our rights or the rights of the applicable licensors if any, nor that respective owners to other intellectual property rights will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.

The market data and certain other statistical information used throughout this offering circular are based on independent industry publications, reports by market research firms or other independent sources that we believe to be reliable sources; however, we have not commissioned any of the market or survey data that is presented in this offering circular. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosures contained in this offering circular, and we believe these industry publications and third-party research, surveys and studies are reliable. While we are not aware of any misstatements regarding any third-party information presented in this offering circular, their estimates, in particular, as they relate to projections, involve numerous assumptions, are subject to risks and uncertainties, and are subject to change based on various factors, including those discussed under the section entitled "<u>Risk Factors</u>" beginning on page 16 of this offering circular. These and other factors could cause our future performance to differ materially from our assumptions and estimates. Some market and other data included herein, as well as the data of competitors as they relate to WUND Healing BioPharmaceuticals, Inc., is also based on our good faith estimates.

The timelines, expected dates, and milestones discussed in this document, including anticipated investigational new drug filings, clinical studies, and other future events, are preliminary and subject to change. These timelines may be affected by numerous factors, including, without limitation, costs, economic conditions, outcomes of prior studies, feedback from regulatory authorities, and other factors outside our control and the control of Zhittya Genesis Medicine, Inc., who we have contracted with as discussed below. All information regarding such timelines, filings, and studies has been provided to us by Zhittya Genesis Medicine, Inc. and we have no control over such timelines or whether or not Zhittya Genesis Medicine, Inc. moves forward with any such currently planned filings, activities or studies. To the extent circumstances change, the projected timelines and expected dates described herein may not be met and may change significantly. Expected filings, including investigational new drug filings and other regulatory submissions, as well as clinical studies, may not occur as anticipated, and Zhittya Genesis Medicine, Inc. may experience delays or may be unable to obtain regulatory approval for its drug candidates. Such changes could have a material adverse effect on our business, financial condition, cash flows, prospects, and operations. Investors should not place undue reliance on any forward-looking information regarding expected timelines or future events described in this document.

---

| |
|:---|
| 1 |
| *[**Table of Contents**](#TOC)* |

---

Unless the context otherwise requires, references in this offering circular to "<u>we,</u>" "<u>us,</u>" "<u>our,</u>" the "<u>Registrant</u>", the "<u>Company,</u>" "<u>WUND</u>" and "<u>WUND Healing BioPharmaceuticals, Inc.</u>" refer to WUND Healing BioPharmaceuticals, Inc.

In addition, unless the context otherwise requires and for the purposes of this offering circular:

· " <u>Exchange Act</u> " refers to the Securities Exchange Act of 1934, as amended;

· " <u>SEC</u> " or the " <u>Commission</u> " refers to the United States Securities and Exchange Commission; and

· " <u>Securities Act</u> " refers to the Securities Act of 1933, as amended.

**INFORMATION REGARDING FORWARD-LOOKING STATEMENTS**

We make forward-looking statements under the "<u>Offering Circular Summary</u>," "<u>Risk Factors</u>," "<u>Business</u>," "<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>" and in other sections of this offering circular. In some cases, you can identify these statements by forward-looking words such as "may," "might," "should," "would," "could," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "potential" or "continue," and the negative of these terms and other comparable terminology. These forward-looking statements, which are subject to known and unknown risks, uncertainties and assumptions about us, may include projections of our future financial performance based on our growth strategies and anticipated trends in our business. These statements are only predictions based on our current expectations and projections about future events. There are important factors that could cause our actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. In particular, you should consider the numerous risks and uncertainties described under "<u>Risk Factors</u>."

While we believe we have identified material risks, these risks and uncertainties are not exhaustive. Other sections of this offering circular describe additional factors that could adversely impact our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible to predict all risks and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

Although we believe the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, level of activity, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Except as required by U.S. federal securities law, we are under no duty to update any of these forward-looking statements after the date of this offering circular to conform our prior statements to actual results or revised expectations, and we do not intend to do so.

Forward-looking statements include, but are not limited to, statements about:

· Our ability to raise capital and the availability of future financing;

· Our ability to implement a sound business plan;

· Our ability to comply with the provisions of our License Agreement (as defined below) with Zhittya Genesis Medicine, Inc. ("Zhittya");

· Zhittya's ability to obtain regulatory approval for the products covered by the License Agreement;

· Our ability to obtain market acceptance of the products we market;

· Zhittya's and our ability to protect our intellectual property and to develop, maintain and enhance a strong brand;

---

| |
|:---|
| 2 |
| *[**Table of Contents**](#TOC)* |

---

· Zhittya's ability to successfully develop and clinically test product candidates;

· Zhittya's ability to file for, and obtain, United States Food and Drug Administration ("FDA") approval of its product candidates through the new drug application ("NDA") regulatory pathway;

· Our ability to compete and succeed in a highly competitive and evolving industry;

· Our intentions, expectations and beliefs regarding anticipated growth, market penetration and trends in our business;

· Our lack of operating history on which to judge our business prospects and management;

· Our future financial and operating results;

· Zhittya's ability to manage its research and development expenses;

· Our ability to manage our growth and operating expenses;

· Zhittya's reliance on third parties to conduct its research and expected clinical trials;

· Anticipated timing, costs and success of Zhittya's plan of commercialization;

· Our ability to react to general economic conditions and events and the impact they may have on us and our potential customers;

· Our ability to use the proceeds from this offering as discussed in the section entitled "*Use of Proceeds*;"

· Our ability to achieve quotation, and maintain compliance with the quotation requirements of the OTCQB Market maintained by OTC Markets; and

· Other factors discussed in this offering circular.

These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including those described in "*Risk Factors*." Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this offering circular may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this offering circular to conform these statements to actual results or to changes in our expectations.

You should read this offering circular and the documents that we reference in this offering circular and have filed with the Securities and Exchange Commission as exhibits to this offering circular with the understanding that our actual future results, levels of activity, performance and events and circumstances may be materially different from what we expect.

---

| |
|:---|
| 3 |
| *[**Table of Contents**](#TOC)* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> **OFFERING CIRCULAR SUMMARY**<br>*The following summary highlights selected information contained elsewhere in this offering circular and is qualified in its entirety by the more detailed information and financial statements included elsewhere in this offering circular. It does not contain all the information that may be important to you and your investment decision. You should carefully read this entire offering circular, including the matters set forth under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Plan of Operations," and our financial statements and related notes included elsewhere in this offering circular.* <br>**Overview**<br>We are a sales and marketing company which has the exclusive right to sell the drugs developed by Zhittya Genesis Medicine, Inc. ("Zhittya") in the United States and Canada. The Company is party to a product licensing and commercialization agreement with Zhittya, as discussed in further detail below. Zhittya holds seven million shares of the Company's Preferred Stock (which are convertible into shares of common stock of the Company on a one-for-one basis, subject to certain time-based and event-based restrictions, as well as a 4.99% ownership limitation, certain anti-dilution rights and pari passu liquidation rights with the holders of common stock, on an as-converted basis), which together make Zhittya a related party and give Zhittya significant influence over the Company. Zhittya's current sole drug candidate, Fibroblast Growth Factor 1 ("FGF-1"), has been shown in certain studies to stimulate the growth of new blood vessels (a biological process termed "angiogenesis") in tissues or organs that have perfusion defects (i.e., areas of reduced blood flow). Zhittya is developing these biological drug candidates to attempt to treat Parkinson's disease, coronary artery disease, type 2 diabetes, diabetic foot ulcers and many other diseases. FGF-1 is still in the early stages of study and Zhittya will need to initiate and complete clinical trials before the FDA, or another foreign regulatory body, can assess whether the drug is safe and effective to treat one or more indications. The Company was incorporated in the State of Nevada on May 16, 2016, and our headquarters are located in Las Vegas, Nevada.<br>**Our Business** <br>We entered into a product license and commercialization agreement with Zhittya on May 17, 2016, which was amended and restated on December 21, 2022, which grants us the exclusive right to market and sell drugs from Zhittya's portfolio in the United States and Canada (as amended and restated from time to time, the "<u>License Agreement</u>"). <br>Our right to market and sell Zhittya's drugs is subject to Zhittya's drug candidates first being granted regulatory approval for sale by the FDA or Health Canada, and we believe that the earliest possible timeframe in which FDA approval could be obtained, if at all, is approximately three to seven years. Health Canada approval is not expected to be sought until after FDA approval is received, if at all, and the timeline for such future approval, if any, cannot be estimated at this time. This estimate for FDA approval reflects a minimum projected period based on current assumptions and is subject to substantial uncertainty and numerous factors beyond the Company's control, including the scope and outcomes of clinical trials, regulatory review timelines, requests for additional data, and changes in regulatory requirements. The actual time required to obtain FDA approval, if ever obtained, may be significantly longer than three to seven years or may not occur at all. The Company is planning its operations and capital needs accordingly, recognizing that FDA approval may be delayed for an extended period or may never be achieved. <br>In discussions with Zhittya, Zhittya expects to initiate its first animal studies for diabetic foot ulcers in the fourth quarter of 2026. Zhittya also plans to submit one or more investigational new drug applications ("INDs") to the FDA for multiple potential indications, when the timing and resources are appropriate, including type 2 diabetes, coronary artery disease, venous ulcers and several neurodegenerative diseases. Zhittya expects to file an IND for diabetic foot ulcers in the first quarter of 2028 and to conduct animal studies for the other indications in 2028, followed by the filings of INDs for those indications, assuming favorable results of the studies, which timing may change in the future for numerous reasons.<br>

---

| |
|:---|
| 4 |
| *[**Table of Contents**](#TOC)* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> Zhittya's portfolio is divided into two groups: (1) injectable/infusion/intranasal candidate drugs and (2) wound healing candidate drugs. The injectable/infusion/intranasal candidate drugs are being developed for use in the potential treatment of Parkinson's disease, stroke, multi-infarct dementia (a type of vascular dementia, is caused by a series of small strokes or transient ischemic attacks (TIAs), leading to brain damage and cognitive decline), coronary heart disease, peripheral artery disease, chronic traumatic encephalopathy (CTE, a progressive, degenerative brain disease linked to repeated head trauma, often seen in athletes and military veterans, characterized by symptoms like memory loss, behavioral changes, and dementia), traumatic brain injury, Alzheimer's disease, amyotrophic lateral sclerosis ("ALS"), type 2 diabetes, chronic depression, post-traumatic stress disorder, multiple sclerosis, and multiple systems atrophy. The wound healing candidate drugs are being developed for use in the potential treatment of diabetic foot ulcers ("DFUs"), venous ulcers, burns, male pattern baldness, topical surgical wounds (C-sections, cosmetic surgeries), pressure wounds (or bedsores), internal surgical wounds (or anastomoses), and punctures/deep lacerations (for trauma/military).<br>The Company's sole source of income is the other income received from Zhittya. We currently receive other income from Zhittya's cross-border operations in the British Virgin Islands and the Bahamas, in which Zhittya's patients from the United States and Canada are treated using drugs covered by our License Agreement in another territory. Additionally, starting in September 2025, the Company began receiving other income from Zhittya's use of investigational drugs that are covered by our License Agreement for use in research studies for Type 2 diabetes. Zhittya is studying FGF-1 and Type 2 diabetes to attempt to determine the appropriate dosing amount in order to submit an IND in the future. These research studies are investor funded and are taking place in Las Vegas, Nevada. The Company and Zhittya agreed, pursuant to the terms of a Letter Agreement dated October 13, 2025, that Zhittya would pay the Company the price of $15,000 per patient treated in these studies for the use of FGF-1. As of December 31, 2025, the Company had received $300,000 from Zhittya for these investor-funded research studies. This income is part of the cross-border operations discussed below. The Company is not conducting the sales and marketing for the sales in the British Virgin Islands or other countries.<br>Pursuant to the License Agreement, Zhittya undertakes all of the drug development risk and is responsible for 100% of the cost of all clinical trials, general drug development and application for regulatory approval. Our primary business responsibility under the License Agreement is to market and sell the drugs in Zhittya's portfolio, assuming they receive requisite regulatory approvals. Zhittya is developing treatment candidates for over 22 diseases that are caused from the lack of blood flow to an organ or tissue. Through the License Agreement, we hope to achieve commercial success from generating revenues under the License Agreement, by marketing and selling Zhittya's drugs, subject to such drugs receiving regulatory approvals, while committing proportionately small amounts of capital toward drug development and regulatory approvals, as compared to the development expenses that would be necessary if we were to develop such drugs ourselves. <br>We do not currently plan to use any of the funds raised in this offering to pay clinical progress and regulatory milestone payments to Zhittya under the License Agreement. No milestones are expected in the next year. If clinical progress and regulatory milestone payments are required to be made to Zhittya under the License Agreement, such milestone payments would be made in stock of the Company or from the Company's cash flow, at our option, following this offering. Milestone payments made in the Company's stock would be calculated using the average closing price over the prior 20 trading days prior to issuance, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, we are required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock. We will only make milestone payments to Zhittya upon Zhittya's achievement of the applicable clinical progress and regulatory milestones, which are based on certain recognizable achievements in the development and approval of the injectable/infusion/intranasal drugs and topical drugs with the following applications: coronary heart disease, Parkinson's disease, stroke, diabetic foot ulcers and venous ulcers, as discussed in greater detail below under "Business—License Agreement with Zhittya". The milestone payments for wound healing drugs range from $100,000 to $10,000,000 and will not exceed $75,000,000 in total for the entire class of wound healing drugs. The milestone payments for injectable/infusion/intranasal drugs range from $100,000 to $25,000,000 and will not exceed $300,000,000 in total for the entire class of injectable/infusion/intranasal drugs. <br>The License Agreement contemplates the different availability of products in various licensed territories because of the timing of, or differences in, government approvals and that there may be the opportunity for study participation or treatment elsewhere, for patients who otherwise would be accommodated in licensed territories or vice-versa ("cross-border operation"). <br>

---

| |
|:---|
| 5 |
| *[**Table of Contents**](#TOC)* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> As a result, the net revenues generated from Zhittya patients who live in a Company licensed territory, who receive treatment outside that territory by Zhittya relating to the licensed products, will be shared 50/50 between Zhittya and the Company (or the Company and any other licensees who are due a portion of such amount). These net revenues do not count toward milestone payments set forth in the agreements.<br>Fees from cross-border operations are based on "Operating Profit", which is defined as net revenues (gross revenues minus returns) minus all direct costs of commercialization, such as direct sales, marketing, product costs, and product support. Operating Profit does not include executive salaries or general corporate overhead that is not directly related to commercialization. Fees are payable upon receipt.<br>Under the License Agreement, Zhittya's net revenues from such cross-border operations are shared equally between all licensees (currently just us) and Zhittya, are excluded from the milestone payments, and are subject to a tiered fee structure under which (a) no fee is due on the first $3 million of cross-border Operating Profit; (b) a fee equal to 50% of the Company's portion of Operating Profit is due on cross-border Operating Profit from $3 million to $10 million; and (c) a fee equal to 80% of the Company's portion of cross-border Operating Profit above $10 million is due.<br>All cross-border treatments will be organized and coordinated by Zhittya, with participation subject to product availability and patient capacity. Zhittya is responsible for the operating expenses relating to the cross-border operation and servicing the patients seeking to participate in the clinical studies.<br>As such, the Company is currently receiving Operating Profit generated by U.S. and Canadian patients in the Company's licensed territories that enroll in clinical study participation or treatment in other Zhittya licensed territories (British Virgin Islands and the Bahamas). Additionally, as discussed above, beginning in September 2025, the Company began receiving consideration in connection with Zhittya's investor-funded research studies into FGF-1 which are taking place in Las Vegas, Nevada.<br>During 2025, the Company recognized $1,192,000 of clinic revenue and $473,250 of advertising and promotion expenses for a net of $718,750 as other income from participation in future revenues. During 2024, the Company recognized $1,266,000 of clinic revenue and $825,000 of advertising and promotion expenses for a net of $441,000, as other income from participation in future revenues. At December 31, 2025 and 2024, the Company had a related net receivable from Zhittya of $0 and $31,750, recorded in other receivables on the accompanying balance sheets, with payment terms of due upon receipt. As of December 31, 2025 and 2024, all other income from participation in future revenues was generated from Zhittya.<br>See also "Business—License Agreement with Zhittya", for more information regarding our License Agreement and amounts due thereunder.<br>In connection with its injection/infusion/intranasal drug candidates and topical drug candidates, Zhittya is currently conducting studies with FGF-1.<br>Zhittya is currently the only company with which we have a licensing and sales agreement. Our viability is directly tied to the development, regulatory approval, and market adoption of the candidate drugs in Zhittya's portfolio. Though we are optimistic for Zhittya's success of its drug candidates, there is considerable risk that Zhittya will not meet expectations (including, but not limited to, the risk that Zhittya will not obtain regulatory approvals for its drug candidates) and, consequently, we may fail to meet expectations absent new licensing and sales agreements with other companies, and/or the termination of our Licensing Agreement with Zhittya. We recognize that even strong drug candidates face long odds of being approved by the FDA, as required for their marketing and sale in the United States and Canada, provided that Zhittya currently anticipates seeking Canadian approval only after it obtains U.S. approval, and as such, the process, timing, costs and steps to seek Canadian approval are not discussed in detail throughout this offering circular, as we do not anticipate Zhittya obtaining Canadian regulatory approval for some time, and we do not expect FDA approval for a minimum of three to seven years, if at all, as discussed above. Despite these challenges, we remain optimistic about Zhittya's ability to develop successful products and our ability to deliver those products to the market. <br>

---

| |
|:---|
| 6 |
| *[**Table of Contents**](#TOC)* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> Zhittya was approved in the British Virgin Islands in 2022 to conduct human research studies for Parkinson's disease and has treated over 200 patients without any reported severe adverse events being reported by such patients. The studies were open-label unblinded studies in which the participants and researchers know which treatment is administered. The Parkinson's disease studies are "patient supported," in which the patients pay a fee to be in the studies. Zhittya does not know if the data from the open-label studies could be replicated or could have material differences from well-controlled clinical trials of the Parkinson's disease patient population in the U.S. or Canada.<br>The treatment has also been shown to help increase patients' motor scores— a total of over 240 patients have been treated as of December 2025. As of May 2025, Zhittya disclosed that, of a total of 200 patients who had been treated as of such date, the average patient reported a 53% improvement in motor scores as measured on the Unified Parkinson's Disease Rating Scale (UPDRS), which is a standard clinical tool used by doctors and researchers to measure the severity and progression of Parkinson's disease (PD), assessing mentation, daily activities, motor function (tremor, rigidity, gait), and treatment complications. These studies are human studies which are designed to gather information and could materially differ from well-controlled clinical trials conducted in the U.S. <br>Zhittya has also received two study approvals by The Bahamas National Medical Ethics Committee. The first one is for the "Intranasal FGF-1 for Parkinson's Disease Clinical Trial". The second study approved was for the "Open Label, Two Dose Escalation Study to Evaluate the Safety, Tolerability and Effectiveness of Recombinant Human Fibroblast Growth Factor 1 (FGF-1) Administered by Intramyocardial Injection For the Treatment of Coronary Heart Disease." These studies are seeking additional data on the use of FGF-1 and are expected to have 100 patients each, but currently are waiting for patient enrollment. Zhittya is developing a patient recruitment plan and expects to have the first patients in the fourth quarter of 2026. Zhittya has also filed applications for research studies in Mexico and Panama and is waiting to hear back regarding the potential approval. <br>Under the License Agreement we receive revenues generated from patients from the United States and Canada who are treated with Zhittya's drugs covered by the License Agreement in other countries where such drugs are approved (cross-border operations), which are set forth under other income in our statement of operations included in the financial statements contained in this offering circular. Zhittya has only been approved to use FGF-1 to treat patients in two countries: The British Virgin Islands and The Bahamas, each as part of research studies. <br>**Going Concern Analysis**<br>The Company was incorporated on May 16, 2016 and has generated $2,047,793 in income from participation in future revenues through March 31, 2026 (which relate solely to other income from our relationship with Zhittya, as discussed above). As of March 31, 2026, we had a total stockholders' deficit of $(814712), an accumulated deficit of $125,144,816, and negative working capital of $1,010,091. As of December 31, 2025, we had a total stockholders' deficit of $(1125680), an accumulated deficit of $125,452,659, and negative working capital of $1,272,377. The large accumulated deficit is mainly the result of the original 2016 license agreement with Zhittya valued at $76.5 million, as discussed in greater detail below under "Business—License Agreement with Zhittya", that was fully written off by 2022 under a revised valuation. Another $46.5 million in expenses related to the value of the preferred stock issued to Zhittya pursuant to the terms of the License Agreement. These two items, combined, equal $123 million of the accumulated deficit and do not reflect the results of ongoing operations. From 2023 to 2025, the Company has generated net income every year, with cumulative income of $251,597 over these three years, and net income for the three months ended March 31, 2026 of $307,844. The Company will require significant additional capital in order to operate in the normal course of business and fund clinical progress and regulatory milestone payments. In February 2023, the Company began receiving other income from Zhittya's clinic in the British Virgin Islands, which is treating U.S. and Canadian patients pursuant to the cross-border provisions of the License Agreement as discussed above. In October, 2025, the Company began receiving income from Zhittya's treatments in the United State. The Company expects that those funds should cover the Company's operating expenses for the foreseeable future. While we believe in the viability of management's strategy to generate sufficient revenue, control costs, and the ability to raise additional funds, if necessary, additional funding may not be available on favorable terms, if at all. Our ability to continue as a going concern is dependent upon Zhittya's ability to continue to conduct patient-supported research studies in the United States or the British Virgin Islands and the Bahamas, to complete clinical studies, and obtain regulatory approvals for its drug candidates, and our ability to implement our business plan, to generate sufficient other income/revenues, and to control operating expenses.<br>

---

| |
|:---|
| 7 |
| *[**Table of Contents**](#TOC)* |

---

---

| | |
|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Competitive Strengths** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Competitive Strengths** |
| ·  | The Company has the exclusive market rights to Zhittya's portfolio of drugs in the U.S. and Canada. |
| · | Zhittya's drug candidate, FGF-1, could have therapeutic applications to treat multiple conditions. |
| ·  | Newly licensed biologics have 12 years of market exclusivity. |
| ·  | FGF-1 is easy to deliver. In most cases, it is administered with a nasal inhaler or applied topically. |
| ·  | FGF-1 may have the potential to address several unmet medical needs. |
| ·  | The Company does not pay for the research. It only pays on clinical progress and regulatory milestones reached, through certain cross-border payments once a total of $3 million in cross-border operating income has been received, and owes royalties on a percentage of product sales sold (50% for the sale of topical drugs and 80% for the sale of injection/infusion/intranasal drugs). |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Market Opportunity** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Market Opportunity** |
| ·  | No-option heart disease is estimated to affect between 600,000 and 1.8 million in the U.S. |
| ·  | Parkinson's disease affects nearly 1 million in the U.S. |
| ·  | Type 2 diabetes affects over 37 million Americans. |
| ·  | Stroke affects nearly 800,000 people annually in the U.S. |
| ·  | Diabetic foot ulcers affect 2-3 million patients annually in the U.S. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Growth Strategy**<br>If FGF-1 is approved for use in the U.S., which we believe will take a minimum of three to seven years to complete (however, the actual time required to obtain FDA approval, if ever obtained, may be significantly longer than three to seven years or may not occur at all), the Company hopes to partner with one of the three major U.S. pharmaceutical distribution companies, though there is no assurance that such a partnership will be obtained: McKesson, Cardinal Health, or Cencora (formerly AmerisourceBergen) to: | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Growth Strategy**<br>If FGF-1 is approved for use in the U.S., which we believe will take a minimum of three to seven years to complete (however, the actual time required to obtain FDA approval, if ever obtained, may be significantly longer than three to seven years or may not occur at all), the Company hopes to partner with one of the three major U.S. pharmaceutical distribution companies, though there is no assurance that such a partnership will be obtained: McKesson, Cardinal Health, or Cencora (formerly AmerisourceBergen) to: |
| ◊ | Leverage their distribution network for market penetration; |
| ◊ | Drive physician and patient adoption through their system; |
| ◊ | Optimize supply chain and logistics; and |
| ◊ | Monitor and optimize performance. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Summary Risk Factors**<br>Our business and our ability to execute our business strategy are subject to a number of risks as more fully described in the section titled "*Risk Factors*" beginning on page 16. These risks include, among others:<br><u>Risks Related to our Business</u> | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Summary Risk Factors**<br>Our business and our ability to execute our business strategy are subject to a number of risks as more fully described in the section titled "*Risk Factors*" beginning on page 16. These risks include, among others:<br><u>Risks Related to our Business</u> |
| ·  | We will need to raise substantial additional investment capital, which may be unavailable to us or, if raised, will cause dilution of our existing investors and could place significant restrictions on our ability to operate. Our financial situation creates doubt about whether we will continue as a going concern. |
| ·  | Our business is dependent on Zhittya's success in developing the drug candidates which we plan to sell, and we are restricted from undertaking any other business activities other than the marketing, and distribution of Zhittya's products during the term of the License Agreement, and Zhittya's failure to develop those drug candidates would materially and adversely affect our business. We depend entirely on the successful and timely regulatory approval and development of Zhittya's product candidates, and if Zhittya's product candidates are unable to be successfully developed and/or fail to obtain regulatory approval, it would significantly harm our business. |

---

---

| |
|:---|
| 8 |
| *[**Table of Contents**](#TOC)* |

---

· Our business is dependent on our License Agreement with Zhittya, which provides us with the exclusive rights to commercialize and market Zhittya's product candidates in the United States and Canada. Any breach, including non-payment of milestone payments when due, could lead to termination of the License Agreement. Any termination or loss of significant rights under the License Agreement would materially and adversely affect our business. The License Agreement is not assignable by us without Zhittya's consent. We are currently dependent on revenues derived from U.S. and Canadian patients traveling to foreign clinics to be treated with Zhittya's drugs and in the event the number of such patients declines in the future or stops, our other income and revenues will be materially affected. Amounts payable to us through cross-border operations may decline over time due in part to the contractual obligations of the License Agreement.

· We may not be able to satisfy certain contractual clinical progress and regulatory milestone obligations and the satisfaction of such milestone obligations may have a material adverse effect on our cash flows and ability to support our operations. Our results of operations will be affected by the level of milestone payments that we are required to pay to Zhittya or other royalty payments to third parties.

· Having only recently commenced operations, we are a development stage business and subject to the many risks associated with new businesses.

· Zhittya faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than Zhittya does.

· There are no substantial barriers to entry into the industry and Zhittya has not obtained intellectual property protection for its product candidates. There is no guarantee someone else will not duplicate its ideas and bring them to market before Zhittya does, which could severely limit our anticipated sales and other income/revenues. If we cannot generate sales and other income/revenues, it could result in the loss of your investment.

· We will need to license new modifications to the products and treatments that Zhittya develops under substantially the same terms as the License Agreement.

· If Zhittya's product candidates or any of our future product candidates are approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse the products we sell or use the products off-label, we may become subject to prohibitions on the sale or marketing of products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed.

· The significant level of competition for the product candidates that we market may result in pricing pressure, reduced margins, or the inability of our future product to achieve market acceptance.

· The loss of our management team or other key personnel would have an adverse impact on our future development and impair our ability to succeed.

· We plan to rely on third-party distribution partners for the distribution of Zhittya's products, product candidates, and services, which could delay or limit our ability to generate revenue.

· Security breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.

---

| |
|:---|
| 9 |
| *[**Table of Contents**](#TOC)* |

---

---

| | |
|:---|:---|
| <u>Risks Related to Government Regulation</u> | <u>Risks Related to Government Regulation</u> |
| ·  | The use of the product candidates we market may be limited by regulations, and we may be exposed to product liability and remediation claims. |
| ·  | We may be held liable for, or incur costs to settle, liability and remediation claims if any products we market cause injury or are found unsuitable during product testing, manufacturing, sale, or use. These risks exist even with respect to product candidates that have received, or may in the future receive, regulatory approval, registration, or clearance for commercial use. We cannot guarantee that we will be able to avoid product liability exposure. Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain. |
| ·  | The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if Zhittya is unable to obtain timely regulatory approval for its product candidates, our business will be substantially harmed. |
| ·  | We may be involved in lawsuits related to Zhittya's efforts to protect or enforce its intellectual property rights, which could be expensive, time-consuming, and ultimately unsuccessful. |
| <u>Risks Related to Our Securities and this Offering</u> | <u>Risks Related to Our Securities and this Offering</u> |
| ·  | There is no assurance that a market in our common stock will develop. If a market does develop and our stock price fluctuates after the offering, you could lose a significant part of your investment. Our common stock prices may be volatile and could decline substantially following this offering, and purchasers in this offering will experience immediate and substantial dilution in net tangible book value. In the event no market develops for our common stock you may be required to hold our common stock indefinitely. |
| ·  | We have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations and cause our common stock price to decline. |
| ·  | Certain recent initial public offerings of companies with public floats comparable to the anticipated public float of the Company have experienced extreme volatility that was seemingly unrelated to the underlying performance of the respective company. We may experience similar volatility, which may make it difficult for prospective investors to assess the value of our common stock. |
| ·  | The issuance of common stock upon conversion of our outstanding Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock will cause immediate and substantial dilution to existing stockholders and the sale of common stock upon conversion of our outstanding Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock may depress the market price of our common stock. |
| ·  | There is no guarantee that our common stock will be approved for quotation on the OTCQB Market or any market or that we will be able to comply with the OTCQB's continued listing standards in the future. |
| ·  | Stockholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of securities. |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Going Concern**<br>Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our future viability is largely dependent upon our ability to raise additional capital to finance our operations. Our management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Disruptions in the financial markets may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. Although our management continues to pursue these plans, there is no assurance that we will be successful with this offering or in obtaining sufficient financing on terms acceptable to us to continue to finance our operations, if at all. These circumstances raise substantial doubt on our ability to continue as a going concern, and our financial statements do not include any adjustments that might result from the outcome of these uncertainties. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **Going Concern**<br>Our financial statements have been prepared assuming we will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. Our future viability is largely dependent upon our ability to raise additional capital to finance our operations. Our management expects that future sources of funding may include sales of equity, obtaining loans, or other strategic transactions. Disruptions in the financial markets may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. Although our management continues to pursue these plans, there is no assurance that we will be successful with this offering or in obtaining sufficient financing on terms acceptable to us to continue to finance our operations, if at all. These circumstances raise substantial doubt on our ability to continue as a going concern, and our financial statements do not include any adjustments that might result from the outcome of these uncertainties. |

---

---

| |
|:---|
| 10 |
| *[**Table of Contents**](#TOC)* |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> **Corporate Information**<br>Our principal executive offices are located at 8683 W. Sahara Avenue, Suite 280, Las Vegas, NV 89117, and our telephone number is (702) 800-0030. Our website address is www.wundbio.com. The information contained on our website is not incorporated by reference into this offering circular, and you should not consider any information contained on, or that can be accessed through, our website as part of this offering circular or in deciding whether to purchase our common stock.<br>**Implications of Being an Emerging Growth Company**<br>We are not subject to the ongoing reporting requirements of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>") because we are not registering our securities under the Exchange Act. Rather, we will be subject to the more limited reporting requirements under Regulation A, including the obligation to electronically file: annual reports (including disclosure relating to our business operations for the preceding two fiscal years, or, if in existence for less than two years, since inception, related party transactions, beneficial ownership of the issuer's securities, executive officers and directors and certain executive compensation information, management's discussion and analysis ("MD&A") of the issuer's liquidity, capital resources, and results of operations, and two years of audited financial statements), semiannual reports (including disclosure primarily relating to the issuer's interim financial statements and MD&A), and current reports for certain material events.<br>In addition, at any time after completing reporting for the fiscal year in which our offering statement was qualified, if the securities of each class to which this offering statement relates are held of record by fewer than 300 persons and offers or sales are not ongoing, we may immediately suspend our ongoing reporting obligations under Regulation A. <br>While we have no current plans to, in the future we may become subject to the reporting requirements of the Exchange Act, and we expect to qualify as an "emerging growth company" under the Jumpstart Our Business Startups Act of 2012 (the "JOBS Act") at that time, provided we continue to satisfy the applicable eligibility requirements. As an emerging growth company, we may take advantage of certain reduced reporting and disclosure requirements, including: (i) exemption from the auditor attestation requirement for internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act; (ii) reduced executive compensation disclosure requirements; (iii) exemption from advisory shareholder votes on executive compensation; (iv) exemption from certain pay-versus-performance and CEO pay ratio disclosures; (v) the ability to provide only two years of audited financial statements and related MD&A; and (vi) extended transition periods for complying with new or revised accounting standards. We intend to take advantage of these accommodations to the extent available. In addition, if we qualify as a "smaller reporting company" under SEC rules, we may be eligible for certain additional scaled disclosure requirements, many of which overlap with the accommodations available to emerging growth companies.<br>

---

| |
|:---|
| 11 |
| *[**Table of Contents**](#TOC)* |

---

---

| | |
|:---|:---|
| <br> **THE OFFERING** | <br> **THE OFFERING** |
| ***Issuer*** | WUND Healing BioPharmaceuticals, Inc. |
| ***Common stock offered by us*** | 1,000,000 Shares  |
| ***Common stock outstanding prior to this offering*** | 2,632,000 shares |
| ***Public offering price*** | $10.00 per share |
| ***Common stock expected to be outstanding immediately after this offering***  | 3,632,000 shares  |
| ***Use of proceeds*** | We estimate that the net proceeds from the sale of Shares of our common stock in this offering will be approximately $8,820,000, assuming that all Shares of common stock offered herein are sold, after deducting estimated commissions, and estimated offering expenses payable by us.<br>The principal purposes of this offering are to strengthen our capitalization, enhance our financial flexibility, establish a public market for our common stock, and provide us and our stockholders with future access to the public equity markets. We believe that becoming a public company at this time will allow us to develop the operational infrastructure, internal controls, governance processes, and management experience necessary to operate effectively as a public reporting company. In addition, we believe a public listing will increase transparency for investors and provide greater potential liquidity for our existing stockholders over time. While we do not currently intend to use the net proceeds of this offering to fund significant clinical milestone payments, we believe that establishing our presence in the public markets now will better position us to raise additional capital in future periods, if needed, to support milestone payments and other development-related expenditures as Zhittya hopefully advances through its clinical trials and achieves key regulatory and clinical milestones.<br>We intend to use the net proceeds from this offering for general corporate purposes, which may include, but are not limited to, funding our working capital needs, supporting ongoing operations, and paying certain accrued expenses, including amounts owed to former officers and consultants for prior services rendered (see "Use of Proceeds", below). The actual allocation of proceeds will be determined at our discretion and will depend on various factors, including our operational requirements and the timing and availability of other sources of capital. |
| ***Benjamin Securities' warrants*** | We have agreed to issue to Benjamin Securities, Inc., one of the Placement Agents, and/or its affiliates, warrants to purchase 7% of the number of shares of common stock sold in this offering (up to 70,000 warrants), issuable following each closing of Shares. Benjamin Securities' warrants will be exercisable at any time, and from time to time, in whole or in part, commencing six months from the grant date of such warrants, will have a cashless exercise provision, and will expire five years from the grant date of such warrants, at an exercise price of $12.50 (125% of the public offering price of the common stock). Benjamin Securities' warrants will also provide for customary anti-dilution provisions and registration rights (including a one-time demand registration right and unlimited "piggyback" registration rights) with respect to the registration of the shares of our common stock underlying Benjamin Securities' warrants, which registration rights shall terminate on the fifth anniversary of the commencement date of sales in this offering. For additional information regarding our arrangement with Benjamin Securities, please see "*Plan of Distribution*."<br>|

---

---

| |
|:---|
| 12 |
| *[**Table of Contents**](#TOC)* |

---

---

| | | |
|:---|:---|:---|
| ***Risk factors*** | ***Risk factors*** | The Shares of our common stock issued hereby are speculative securities. Investing in Shares of our common stock involves significant risks. You should invest in them only if you can afford a complete loss of your investment. See "*Risk Factors*" starting on page 16 for a discussion of factors you should carefully consider before deciding whether to invest. |
| **No Liquidity** | **No Liquidity** | There is no current public market for the Shares being offered by the Company pursuant to this offering circular. See "*Risk Factors*" below for a further discussion. While we plan to apply for quotation on the OTCQB Market maintained by OTC Markets following this offering, there can be no assurance that we will obtain such quotation, or as to the level of trading that might occur if we do. The Company may facilitate or otherwise participate in the secondary transfer of any Shares on a limited basis at its discretion. Prospective Investors are urged to consult their own legal advisors with respect to secondary trading of the Shares.  |
| ***Lock-ups*** | ***Lock-ups*** | We, all of our directors and officers, and holders of greater than 5% of our outstanding securities (or securities convertible into our common stock) have agreed not to offer for sale, issue, sell, contract to sell, pledge or otherwise dispose of any of our common shares or securities convertible into common stock without the prior written consent of Benjamin Securities for a period of 180 days from [from the date of this offering circular], subject to certain limited exceptions. See "*Plan of Distribution—Lock-Up Agreements*." |
| Except as otherwise indicated herein, all information in this offering circular: | Except as otherwise indicated herein, all information in this offering circular: | Except as otherwise indicated herein, all information in this offering circular: |
| ·  | is based on 2,632,000 shares of common stock outstanding as of June 26, 2026; | is based on 2,632,000 shares of common stock outstanding as of June 26, 2026; |
| ·  | excludes up to an maximum of 70,000 shares of common stock underlying warrants which may be issued to Benjamin Securities and/or its affiliates in connection with this offering; and | excludes up to an maximum of 70,000 shares of common stock underlying warrants which may be issued to Benjamin Securities and/or its affiliates in connection with this offering; and |
| ·  | assumes no vesting of 50,000 outstanding restricted stock units. | assumes no vesting of 50,000 outstanding restricted stock units. |

---

---

| |
|:---|
| 13 |
| *[**Table of Contents**](#TOC)* |

---

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> **SELECTED FINANCIAL DATA**<br>The following table sets forth our selected financial data as of the dates and for the periods indicated. We have derived the statement of operations data for the years ending December 31, 2025 and 2024, from our audited financial statements and for the three months ended March 31, 2026 and 2025, from our unaudited financial statements, each included elsewhere in this offering circular. The financial statements, and the related notes thereto, have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").<br>The following summary financial data should be read with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and related notes and other information included elsewhere in this offering circular. Our historical results are not necessarily indicative of the results to be expected in future periods. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> **SELECTED FINANCIAL DATA**<br>The following table sets forth our selected financial data as of the dates and for the periods indicated. We have derived the statement of operations data for the years ending December 31, 2025 and 2024, from our audited financial statements and for the three months ended March 31, 2026 and 2025, from our unaudited financial statements, each included elsewhere in this offering circular. The financial statements, and the related notes thereto, have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").<br>The following summary financial data should be read with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and related notes and other information included elsewhere in this offering circular. Our historical results are not necessarily indicative of the results to be expected in future periods. | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br> **SELECTED FINANCIAL DATA**<br>The following table sets forth our selected financial data as of the dates and for the periods indicated. We have derived the statement of operations data for the years ending December 31, 2025 and 2024, from our audited financial statements and for the three months ended March 31, 2026 and 2025, from our unaudited financial statements, each included elsewhere in this offering circular. The financial statements, and the related notes thereto, have been prepared in accordance with generally accepted accounting principles in the United States ("U.S. GAAP").<br>The following summary financial data should be read with "Management's Discussion and Analysis of Financial Condition and Results of Operations" and our financial statements and related notes and other information included elsewhere in this offering circular. Our historical results are not necessarily indicative of the results to be expected in future periods. |
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp; Professional fees | $62772 | $62545 |
| &nbsp;&nbsp;&nbsp; Consulting fees | 99125 | 79104 |
| &nbsp;&nbsp;&nbsp; Lease expense | 8044 | 14991 |
| &nbsp;&nbsp;&nbsp; General and administrative expenses | 4564 | 2630 |
| **Total operating expenses** | 174505 | 159270 |
| Loss from operations | (174505) | (159270) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp; Income from participation in future revenues – related party | 484293 | 85750 |
| &nbsp;&nbsp;&nbsp; Interest expense | (1113) | (1595) |
| &nbsp;&nbsp;&nbsp; Other expense | (830) | - |
| **Net income (loss)** | $307844 | $(75115) |
| Basic and diluted net income per common share  | $0.12 | $(0.03) |
| Weighted average number of common shares outstanding, basic and diluted | 2632000 | 2632000 |

---

---

| |
|:---|
| 14 |
| *[**Table of Contents**](#TOC)* |

---

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **2024** |
| **Operating Expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Professional fees | $220852 | $114256 |
| &nbsp;&nbsp;&nbsp;&nbsp; Consulting | 352479 | 127000 |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease expense | 36013 | 89888 |
| &nbsp;&nbsp;&nbsp;&nbsp; Marketing expense | 995 |  |
| &nbsp;&nbsp;&nbsp;&nbsp; General and administrative expenses | 10227 | 10475 |
| **Total operating expenses** | 620566 | 341619 |
| Loss from operations | (620566) | (341619) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Income from participation in future revenues – related party | 718750 | 441000 |
| &nbsp;&nbsp;&nbsp;&nbsp; Interest expense | (6674) | (2342) |
| **Net income** | $91510 | $97039 |
| Basic and diluted net income per common share | $0.04 | $0.04 |
| Weighted average number of common shares outstanding, basic and diluted | 2632000 | 2632000 |
|  | **March 31,**<br> **2026** | **December 31,**<br> **2025** |
| **Balance Sheet Data:** |  |  |
| Cash and cash equivalents | $159906 | $176337 |
| Working capital deficit <sup>(1)</sup> | (1010091) | (1272377) |
| Total assets | 379161 | 356699 |
| Additional paid-in capital | 124320472 | 124317347 |
| Preferred stock | 7000 | 7000 |
| Accumulated deficit | (125144816) | (125452659) |
| Total stockholders' deficit | $(814712) | $(1125680) |
| (1) We define working capital as current assets, less current liabilities. See our financial statements for further details regarding our current assets and current liabilities. | (1) We define working capital as current assets, less current liabilities. See our financial statements for further details regarding our current assets and current liabilities. | (1) We define working capital as current assets, less current liabilities. See our financial statements for further details regarding our current assets and current liabilities. |

---

---

| |
|:---|
| 15 |
| *[**Table of Contents**](#TOC)* |

---

**RISK FACTORS**

*An investment in our common stock involves a high degree of risk. Before making an investment decision, you should give careful consideration to the following risk factors, in addition to the other information included in this offering circular, including our financial statements and related notes, before deciding whether to invest in our securities. The occurrence of any of the adverse developments described in the following risk factors could materially and adversely harm our business, financial condition, results of operations or prospects. You may lose all or part of your investment.*

**<u>Risks Related to our Business</u>**

***We will need to raise substantial additional investment capital, which may be unavailable to us or, if raised, will cause dilution of our existing investors and could place significant restrictions on our ability to operate.***

Even upon the completion of this offering, we will still need to raise substantial additional equity or debt financing to provide sufficient capital required to fully execute our business plan and expand our operations. Disruptions in the financial markets in general and more recently due to trade wars and tariffs may make equity and debt financing more difficult to obtain and may have a material adverse effect on our ability to meet our fundraising needs. We do not currently have any arrangements or credit facilities in place as a source of funds, and there can be no assurance that we will be able to raise sufficient capital in this offering or additional capital on acceptable terms, if at all. If such financing is not available on satisfactory terms, or is not available, we may be required to delay, scale back, or eliminate the development of business opportunities and our operations and financial condition may be materially adversely affected. If we raise additional capital by issuing equity securities, the percentage ownership of our existing stockholders will be reduced, and these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences, and privileges senior to those of our common stock. Debt financing, if obtained, may involve agreements that include liens on our assets and covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, would increase our expenses and could require that our assets be provided as security for such debt. Debt financing would also be required to be repaid regardless of our operating results. There are no assurances that we will have sufficient funds to pay the debt off, or that we will not default on its debt. If we raise additional funds through collaborations and licensing arrangements, we may be required to relinquish some rights to our technologies or product candidates, or to grant licenses on terms that are not favorable to us. Funding from any source may be unavailable to us on acceptable terms, if at all. If we do not have sufficient capital to fund our operations and expenses, this could lead to the failure of our business and the loss of your investment.

***Our business is dependent on Zhittya's success in developing the drug candidates which we plan to sell, and we are restricted from undertaking any other business activities other than the marketing, and distribution of Zhittya's products in the United States and Canada during the term of the License Agreement, and Zhittya's failure to develop those drug candidates would materially and adversely affect our business.***

Pursuant to the License Agreement with Zhittya, we may not engage in any business other than the promotion, marketing, and distribution of Zhittya's products in the United States and Canada from the date of FDA approval of Zhittya's first product through the end of the term of the License Agreement (through January 1, 2053, along with an additional automatic 30 year renewal term), subject to certain early termination rights in the License Agreement. In addition, we may not thereafter commercialize, promote, or support any third-party drug, treatment, or device that competes with any licensed use of Zhittya's drugs. As a result, we will be solely dependent on Zhittya and Zhittya's efforts to obtain FDA approval of its drug candidates for our other income/revenues and operations, and we will not have any control over such efforts.

We are entirely dependent on the success of Zhittya's drug candidates, which are still under clinical development, and if any such drug candidates do not receive regulatory approval for any reason (including Zhittya's inability to obtain the funding necessary for clinical trials or otherwise), our business may be materially adversely affected. Zhittya does not have any products that have gained regulatory approval in the U.S. and Canada. Zhittya plans to seek approval of its drug candidates with the U.S. FDA before pursuing approval in Canada. We cannot market and sell any of Zhittya's products in the United States or Canada without Zhittya first obtaining regulatory approval from the FDA and Health Canada. The Company believes that the earliest possible timeframe in which FDA approval could be obtained, if at all, is approximately three to seven years. This estimate reflects a minimum projected period based on current assumptions and is subject to substantial uncertainty and numerous factors beyond the Company's control, including the scope and outcomes of clinical trials, regulatory review timelines, requests for additional data, and changes in regulatory requirements. The actual time required to obtain FDA approval, if ever obtained, may be significantly longer than three to seven years or may not occur at all. As a result, our business is dependent on Zhittya's ability to successfully complete clinical development of and obtain regulatory approval in a timely manner and we are planning our operations and capital needs accordingly, recognizing that FDA approval may be delayed for an extended period or may never be achieved. Before obtaining regulatory approvals for the commercial sale of Zhittya's drug candidates for a target indication, Zhittya must demonstrate with substantial evidence gathered in clinical trials, generally including adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that Zhittya's drug candidates are safe and effective for use for that target indication and that the manufacturing facilities, processes and controls are adequate. Even if Zhittya's drug candidates were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements, which may further materially adversely affect our business and other income/revenues, and may cause any investment in the Company to become worthless.

---

| |
|:---|
| 16 |
| *[**Table of Contents**](#TOC)* |

---

***Zhittya has conducted, and may continue to conduct, human studies relating to neurological indications without first obtaining an IND authorization from the FDA.***

Although Zhittya obtained Institutional Review Board approval, physician approval of the study protocol, and informed consent from participating patients, the FDA may determine that such studies that Zhittya has conducted without first obtaining an IND authorization from the FDA, should not have been conducted without an effective IND.

If the FDA were to conclude that Zhittya's prior or future human studies violated applicable regulatory requirements, the FDA could refuse to accept, place a clinical hold on, delay, limit, or otherwise adversely affect one or more of Zhittya's future IND applications. Any such action could significantly delay or prevent the development, regulatory approval, or commercialization of products based on Zhittya's technology. In addition, the FDA could require additional preclinical or clinical studies, impose other regulatory sanctions, or take enforcement action against Zhittya.

If Zhittya is unable to obtain or maintain the regulatory approvals necessary to continue development of its products, the Company may be required to modify its business strategy, including seeking alternative development, licensing, marketing, or commercialization partners. Suitable alternative partners may not be available on acceptable terms, or at all, which could materially and adversely affect the Company's business, prospects, financial condition, and results of operations.

***We are dependent on Zhittya's ability to conduct clinical trials, which could delay or prevent development of certain licensed product candidates.***

Our License Agreement with Zhittya provides that Zhittya is responsible for conducting development activities, including filing investigational new drug applications and conducting clinical trials for certain licensed product candidates.

However, the FDA has broad discretion in determining whether the data submitted in support of an IND are sufficient to permit a sponsor to proceed directly to a particular phase of clinical development. Zhittya may not have the right to reference all relevant third-party data, and publicly available information may be insufficient for FDA purposes. The FDA may require Zhittya to conduct additional Phase I clinical trials before permitting Phase II trials to begin, even if Zhittya believes such studies are unnecessary.

If the FDA requires additional studies, or if Zhittya is unable to successfully navigate the regulatory process, development of these product candidates could be significantly delayed, incur substantial additional costs, or be abandoned. Any such outcomes could materially and adversely affect our business, financial condition, results of operations, and prospects, including our ability to realize the potential value of our License Agreement with Zhittya.

---

| |
|:---|
| 17 |
| *[**Table of Contents**](#TOC)* |

---

***Clinical development timelines are uncertain, and regulatory requirements could delay or prevent approval of licensed product candidates.***

The timelines, expected dates, and milestones discussed in this offering circular, including anticipated IND filings, clinical studies, and other future events, are preliminary and subject to change. These timelines may be affected by numerous factors, including, without limitation, costs, economic conditions, outcomes of prior studies, feedback from regulatory authorities, and other factors outside our control and the control of Zhittya, who we have contracted with as discussed below. All information regarding such timelines, filings, and studies has been provided to us by Zhittya and we have no control over such timelines or whether or not Zhittya moves forward with any such currently planned filings, activities or studies. To the extent circumstances change, the projected timelines and expected dates described herein may not be met and may change significantly. Expected filings, including IND filings and other regulatory submissions, as well as clinical studies, may not occur as anticipated, and Zhittya may experience delays or may be unable to obtain regulatory approval for its drug candidates. Such changes could have a material adverse effect on our business, financial condition, cash flows, prospects, and operations. Investors should not place undue reliance on any forward-looking information regarding expected timelines or future events described in this offering circular.

Even if Zhittya successfully files INDs, the FDA may require additional data, including Phase I clinical trials, before allowing Phase II trials to commence. Regulatory review processes are inherently unpredictable, and the timing and outcome of FDA decisions cannot be assured. Any delays or additional requirements imposed by the FDA could increase development costs, slow the progress of clinical programs, or prevent the commercialization of certain licensed product candidates. Such delays or failures could materially and adversely affect our business, financial condition, results of operations, and prospects.

***We depend entirely on the successful and timely production by Zhittya of its drug candidates.***

We rely exclusively on Zhittya for the manufacture of its drug candidates, and our ability to generate other income/revenues depends on Zhittya's ability to produce these drugs in sufficient quantities, on a timely basis, and in compliance with regulatory requirements. Zhittya currently manufactures its drug candidates through both a contract manufacturing organization ("CMO") and its laboratory facilities in Reno, Nevada. The manufacture of biologics is inherently complex and involves specialized processes, including fermentation and purification steps, that are difficult to scale consistently and are subject to variability, contamination, and other technical challenges. Even minor deviations in the manufacturing process can result in production failures, batch losses, delays, or increased costs.

Furthermore, all facilities engaged in the manufacture of drug products must adhere to current good manufacturing practices ("cGMP") and are subject to ongoing inspection and approval by the FDA and comparable foreign regulatory authorities. If Zhittya or its CMO fails to maintain compliance with cGMP requirements, experiences regulatory enforcement actions, or is unable to pass inspections, drug supply could be delayed, interrupted, or halted entirely. In addition, Zhittya's reliance on a CMO exposes it to risks outside of its direct control, including the potential for supply chain disruptions, capacity constraints, quality failures, or termination of the manufacturing relationship.

Any further delay or inability by Zhittya to manufacture its drug candidates to appropriate quality standards, at sufficient scale, or in compliance with regulatory requirements could prevent or delay preclinical or clinical studies, regulatory submissions, and commercialization efforts, and would negatively affect our ability to generate revenue through the sale of Zhittya's products. If Zhittya cannot produce its drug candidates in the quantities required and on acceptable terms, our business, financial condition, and results of operations could be materially and adversely affected.

***We depend entirely on the successful and timely regulatory approval and development of Zhittya's product candidates, and if Zhittya's product candidates are unable to be successfully developed and/or fail to obtain regulatory approval, it would significantly harm our business.***

We are currently dependent on Zhittya's success in developing its product candidates and receiving regulatory approval. We have no control over the development of Zhittya's product candidates or its ability to obtain regulatory approval. We entered into the License Agreement with Zhittya in 2016, knowing that it would take Zhittya some time to put its manufacturing capabilities in place, to submit INDs and hopefully obtain FDA approval of its drugs in development. However, since 2026, Zhittya has faced numerous unavoidable delays due to failures of its contracted manufacturers of FGF-1, and later in order to set up its own manufacturing facility, and, after much work, successfully producing its own FGF-1. In addition, COVID-19 slowed Zhittya's development progress as well. We have no products currently approved for sale, and if Zhittya's product candidates are unable to be successfully developed and/or fail to obtain regulatory approval or experience significant delays in doing so, we will not have available products to commercialize, which will significantly harm our business and other income/revenues, and may cause any investment in the Company to become worthless. Additionally, in the event Zhittya is further delayed in producing FGF-1, performing studies, submitting INDs, obtaining approval from the FDA of such INDs, and/or otherwise delayed further from obtaining FDA approval for FGF-1, which it anticipates will take at least three to seven years, our ability to generate cash flow and support our operations will be negatively affected, we may need to raise additional funds, and we may never be able to generate sufficient funds to support our operations.

---

| |
|:---|
| 18 |
| *[**Table of Contents**](#TOC)* |

---

***Our revenue from operations may be lower than expected due to the tiered payment structure and other factors.***

Under our License Agreement with Zhittya, revenues from certain clinical study or treatment operations are shared according to a tiered "waterfall" of Operating Profits. Operating Profit is defined as net revenues (gross revenues minus returns) minus all direct costs of commercialization, such as direct sales, marketing, product costs, and product support. Operating Profit does not include executive salaries or general corporate overhead that is not directly related to commercialization. The Company receives all of the fees generated on the first $3 million of Operating Profit (which totaled $2,047,793 as of March 31, 2026), 50% of Operating Profit between $3 million and $10 million, and only 20% of Operating Profit above $10 million. As operations grow and Operating Profit increases, the Company's share of revenue decreases, which may result in lower-than-expected revenue over time, even if total activity increases.

In addition, the amount of revenue the Company receives depends on factors outside its control, including Zhittya's management of operations, product availability, patient demand, and the timing and volume of participation from patients outside licensed territories. Any reductions in payments, whether due to the tiered structure or other factors, could materially and adversely affect the Company's business, financial condition, results of operations, and prospects.

***We will be required to purchase certain minimum quantities of drugs from Zhittya under the License Agreement. Zhittya may set certain minimum prices for products which we will not be able to exceed.***

The License Agreement requires us to purchase certain minimum quantities of drugs from Zhittya and provides Zhittya the right to set the minimum sales price of products we sell under the License Agreement. In the event such minimum quantities are greater than the demand for the products purchased, or such minimum prices are greater than the amount customers are willing to pay, we may be unable to sell such products, such products may expire or become worthless, and we may not have sufficient funds to pay Zhittya for such purchased products. The occurrence of any of the above may have a material adverse effect on our operations and stock price.

***Our business is dependent on our License Agreement with Zhittya, which provides us with the exclusive rights to commercialize and market Zhittya's product candidates in the United States and Canada. Any breach, including non-payment of clinical progress and regulatory milestone payments when due, could lead to termination of the License Agreement. Any termination or loss of significant rights under the License Agreement would materially and adversely affect our business.***

On May 17, 2016, we entered into the License Agreement with Zhittya which was amended on February 24, 2022 and amended and restated on December 21, 2022. Pursuant to the License Agreement, we obtained the exclusive right to market and sell drugs from Zhittya's portfolio in the United States and Canada if the requisite regulatory approval is obtained, if ever. Zhittya plans to seek approval of its drug candidates with the U.S. FDA before pursuing approval in Canada. The Company believes that the earliest possible timeframe in which FDA approval could be obtained, if at all, is approximately three to seven years. This estimate reflects a minimum projected period based on current assumptions and is subject to substantial uncertainty and numerous factors beyond the Company's control, including the scope and outcomes of clinical trials, regulatory review timelines, requests for additional data, and changes in regulatory requirements. The actual time required to obtain FDA approval, if ever obtained, may be significantly longer than three to seven years or may not occur at all. The Company is planning its operations and capital needs accordingly, recognizing that FDA approval may be delayed for an extended period or may never be achieved. The License Agreement may be terminated by Zhittya in the event a breach by us, including non-payment of clinical progress and regulatory milestone payments when due, is not cured within thirty days, and/or if we seek bankruptcy protection or are brought into involuntary bankruptcy proceedings, subject to certain limited cure rights. If the License Agreement were to be terminated by Zhittya upon a breach by us, we would lose our most significant asset and would no longer be able to commercialize and market Zhittya's product candidates, which would have a material adverse effect on our operations as we do not anticipate having any additional method of generating revenue at that time, and would likely force us to cease operations and possibly seek bankruptcy protection. The termination of the License Agreement could also cause the value of our common stock to become worthless.

---

| |
|:---|
| 19 |
| *[**Table of Contents**](#TOC)* |

---

***The License Agreement is not assignable by us without Zhittya's consent.***

The License Agreement provides that it is not assignable without Zhittya's written consent. Such prohibition on assignment may prohibit our ability to monetize the license provided by the License Agreement, prevent a change of control or business combination which would otherwise be favorable to stockholders.

***We are currently dependent on revenues derived from U.S. and Canadian patients traveling to foreign clinics to be treated with Zhittya's drug candidates and on patient sponsored studies relating to Type 2 Diabetes taking place in the United States and in the event the number of such patients declines in the future or stops, our other income/revenues will be materially affected.***

Currently, and until such time, if ever, as Zhittya's drug candidates obtain FDA and/or Canada Health approval in the United States and Canada, respectively, our sole income comes from, and is expected to come from, U.S. and Canadian patients traveling to foreign clinics to be treated with Zhittya's drug candidates and on a patient sponsored study relating to Type 2 diabetes taking place in Las Vegas, Nevada. Any decline in the number U.S. or Canadian patients willing or able to travel to other jurisdictions to be treated with Zhittya's drug candidates, whether due to (1) increases in the cost of travel; (2) travel restrictions, including as a result of pandemics or epidemics, terrorism or immigration policies; (3) inflation; (4) trade wars; (5) reduction in the volume of, or effectiveness of, Zhittya's marketing efforts; (6) alternative and more widely available drugs, or other events, or any declines in the number of patients in the U.S. who are willing to pay to participate in Zhittya's Type 2 diabetes study, whether due to the cost of such study, alternative available drugs or otherwise, could cause our other income/revenues to decline significantly. Currently, Zhittya primarily uses Google to market its services to patients and in the event Google prohibited the use of its services by Zhittya, raised its pricing significantly or ceased or modified such services, it could have a material adverse effect on the number of U.S. and Canadian citizens travelling to other jurisdictions to be treated with Zhittya's drug candidates and/or who are willing to pay to participate in Zhittya's Type 2 diabetes study taking place in Las Vegas, Nevada, and in turn our other income/revenues. Additionally, we and Zhittya are reliant on such alternative jurisdictions continuing to allow Zhittya to treat patients using its drug candidates, and in the future such jurisdictions could limit or prevent Zhittya's ability to treat patients, which in turn would reduce our other income/revenues and ability to generate other income/revenues. We have no control over Zhittya's marketing efforts or expenditures.

***We may not be able to satisfy certain contractual clinical progress and regulatory milestone obligations and the satisfaction of such milestone obligations may have a material adverse effect on our cash flows and ability to support our operations.***

Pursuant to the License Agreement with Zhittya, we are contractually obligated to remit certain clinical progress and regulatory milestone payments to Zhittya upon the occurrence of various events during clinical development and the FDA approval process of Zhittya's products. The milestone payments for wound healing drugs range from $100,000 to $10,000,000 and will not exceed $75,000,000 in total for the entire class of wound healing drugs. The milestone payments for injectable and infusion drugs range from $100,000 to $25,000,000 and will not exceed $300,000,000 in total for the entire class of injectable/infusion/intranasal drugs. No milestone payments are currently due, and it is anticipated that it will be over 18 months before a milestone is reached and it will be paid out of profits or we will need to raise significant additional capital to make such milestone payments. There can be no assurance that we will raise sufficient capital to pay the milestone payments, or complete the offering at all, thus potentially causing a material adverse effect on our business.

---

| |
|:---|
| 20 |
| *[**Table of Contents**](#TOC)* |

---

***Our results of operations will be affected by the level of clinical progress and regulatory milestone payments that we are required to pay to Zhittya, the royalty and other payments we are required to pay to Zhittya or other royalty payments to third parties.***

We are a party to the License Agreement which requires us to remit milestone payments related to certain Zhittya product candidates that we may decide to market and sell. The milestone payments for wound healing drug candidates range from $100,000 to $10,000,000 and will not exceed $75,000,000 in aggregate for the entire class of wound healing drugs. The clinical progress and regulatory milestone payments for injectable and infusion drug candidates range from $100,000 to $25,000,000 and will not exceed $300,000,000 in aggregate for the entire class of injectable/infusion/intranasal drugs. Any cross-border operations are also subject to the payment of the following fees for such use of the products; (a) no fee on the first $3 million of cross-border Operating Profit; (b) A fee equal to 50% of the Company's portion of Operating Profit from $3 million to $10 million; and (c) a fee equal to 80% of the Company's fee on Operating Profit above $10 million. We have also agreed to pay Zhittya royalties based on the future sale of licensed products of 50% for topical drugs and 80% for injection/infusion/intranasal drugs. Any failure on our part to pay milestone payments, of which none are currently due, or other amounts due to Zhittya could lead to us losing rights under our license and could thereby adversely affect our business. If product sales increase, we may, from time-to-time, disagree with Zhittya as to the appropriate royalties owed and the resolution of such disputes may be costly and may consume management's time. Furthermore, we may enter into additional license agreements in the future once the term of the License Agreement has expired, which may also include royalty payments.

***The regulatory history of the Chief Executive Officer of Zhittya, with whom we rely substantially for our revenues and prospects, may adversely affect our business, reputation, and ability to execute our business plan.***

From 1981 until 2004, Mr. Daniel C. Montano, the Chief Executive Officer of Zhittya, was a member of the Board of Directors of Helen of Troy, Ltd, a corporation whose shares are publicly traded. Mr. Montano also ran Montano Securities and was its president from 1985 to 1995. In 1992, Mr. Montano agreed to the SEC issuing an order against him and Gold Properties Restoration Co., a company which he served as Chairman of the Board and Chief Executive Officer of ("Gold Properties"), providing for Mr. Montano and the entity to cease-and-desist from violating Sections 5(b)(1) and 17(a)(2) and (3) of the Securities Act. The order contained findings that Gold Properties and Mr. Montano violated Section 17(a)(2) and (3) by disseminating materially false and misleading statements contained in promotional materials that were used in connection with Gold Properties' private placement during the fall of 1990 through the spring of 1991 and an initial public offering of securities filed with the Commission on February 1, 1991. The Order also contained findings that Gold Properties and Montano violated Section 5(b) (1) of the Securities Act by engaging in various activities, which constituted offers to sell Gold Properties common stock, that were undertaken in connection with Gold Properties' initial public offering. Mr. Montano was also sanctioned by the Massachusetts Securities Division in 1993 and the Missouri Secretary of State in 1996. In connection with matters that occurred in 1994, Mr. Montano agreed in 1997 to a settlement with the National Association of Securities Dealers, Inc. (NASD) pursuant to which he was fined $102,500 and suspended by the NASD from associating with any NASD members for a period of two years. Mr. Montano consented to the findings that he had engaged in a course of conduct that resulted in the mishandling or misuse by his firm, Montano Securities Corporation, of funds entrusted to it by applicants to the company. Montano Securities Corporation was also found to have carried out securities transactions without maintaining sufficient net capital. In May 1998, the NASD suspended Mr. Montano's registration as a registered securities broker for an unspecified time due to his failure to pay an arbitration award. In July 1998, the SEC entered an order affirming a decision by the NASD that Mr. Montano was found to have violated certain rules of the NASD, including not accurately and sufficiently discussing the mechanism of short-selling or the risks associated with implementing the strategy using a particular stock, making improper references to prior recommendations, making exaggerated and inappropriate presentations of prior recommendations and making improper projections.

Although the enforcement actions did not involve Zhittya or our Company and occurred prior to our relationship with Zhittya, investors, business partners, regulators, prospective customers, and other stakeholders may nevertheless view these matters negatively. Such perceptions could adversely affect the reputation and credibility of Zhittya and, by extension, our Company, impair our ability to attract investors, strategic partners, customers, or financing, increase regulatory scrutiny, and negatively impact the market's perception of our business. Because we are substantially dependent on the License Agreement and Zhittya, any adverse impact on Zhittya or its management could materially and adversely affect our business, financial condition, results of operations, and prospects.

---

| |
|:---|
| 21 |
| *[**Table of Contents**](#TOC)* |

---

***Having only recently commenced operations, we are a development stage business and subject to the many risks associated with new businesses.***

The Company was incorporated in May 2016. Accordingly, we have only a limited history by which you can assess our prospects. Consequently, any predictions about our future success, performance or viability may not be as accurate as they could be if we had a longer operating history or an approved product on the market. In addition, we have limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in the drug development and marketing field. We are, and expect for the foreseeable future to be, subject to all the same risks and uncertainties inherent in a new business enterprise and in the further development of our technology. No assurances can be given as to our ability to operate profitably. If we do not generate positive cash flow in the future and hence become profitable, we may not be able to remain in business.

Having only recently commenced operations, our ability to operate successfully is materially uncertain and our operations and prospects are subject to all risks inherent in a developing business enterprise. In investing in this offering, potential investors should be aware of the difficulties normally encountered by early-revenue, development stage companies and the high rate of failure of such enterprises. The likelihood of our viability and potential for revenue and profit generation must be considered in light of the significant problems, expenses, difficulties, complications, and delays that may be encountered. These potential problems and uncertainties include, but are not limited to:

· we may have difficulty implementing a sound business plan;

· customers may not adopt the products we sell quickly, or at all;

· operating costs may exceed our expectations;

· we may not be able to adequately protect our intellectual property, trademarks, and trade secrets;

· we may be exposed to product liability and remediation claims;

· we may not be able to generate significant sales;

· we may not attract and retain high quality personnel for management, executive, and board positions;

· more established and better capitalized companies may compete with us and be more successful than us;

· we may not be able to raise capital when needed to advance our business plans; and

· we may be exposed to economic downturns, political and economic events, and technological developments.

There can be no assurance that we will be able to successfully address these and other challenges with which we may be confronted. If our efforts are unsuccessful, our business, financial condition, and operating results could be materially and adversely affected, in which case our value could be negatively impacted and you could lose all or a part of your investment.

---

| |
|:---|
| 22 |
| *[**Table of Contents**](#TOC)* |

---

***Our financial situation creates doubt about whether we will continue as a going concern.***

The Company was incorporated on May 16, 2016. The Company's sole source of income is the other income received from Zhittya. As of March 31, 2026, we had a total stockholders' deficit of $(814,712), an accumulated deficit of $125,144,816, and negative working capital of $1,010,091. As of December 31, 2025, we had a total stockholders' deficit of $(1,125,680), an accumulated deficit of $125,452,659, and negative working capital of $1,272,378. The large accumulated deficit is mainly the result of the original 2016 license agreement with Zhittya valued at $76.5 million, as discussed in greater detail below under "Business—License Agreement with Zhittya", that was fully written off by 2022 under a revised valuation. Another $46.5 million in expenses is related to the value of the preferred stock issued to Zhittya pursuant to the terms of the License Agreement. These two items, combined, equal $123 million of the accumulated deficit and do not reflect the results of ongoing operations. From 2023 to 2025, the Company has generated net income every year, with cumulative income of $251,597 over these three years, and net income for the three months ended March 31, 2026 of $307,844.

There can be no assurance that we will be able to achieve a level of income adequate to generate sufficient cash flow from operations or obtain funding from this offering or additional financing through private placements, public offerings, and/or bank financing necessary to support our working capital requirements. To the extent that funds generated from any private placements, public offerings, and/or bank financing are insufficient, we will have to raise additional working capital. No assurance can be given that additional financing will be available, or if available, will be on acceptable terms. These conditions raise substantial doubt about our ability to continue as a going concern. If adequate working capital is not available, we may be forced to discontinue operations, which would cause investors to lose their entire investment. These conditions raise substantial doubt about our ability to continue as a going concern.

***Zhittya faces substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than Zhittya does.***

The commercialization of drugs is highly competitive. More established companies may have a competitive advantage over Zhittya due to their greater size, cash flows, and institutional experience. Compared to Zhittya, many of Zhittya's competitors may have significantly greater financial, technical, and human resources. As a result of these factors, Zhittya's competitors may have an advantage in marketing their approved products and may obtain regulatory approval of their product candidates before Zhittya is able to, which may limit Zhittya's ability to develop or commercialize product candidates, and in turn limit our ability to sell such products under the License Agreement. Our competitors may also be more successful than us in marketing their products.

Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of Zhittya's and our competitors. Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These companies compete with Zhittya in recruiting and retaining qualified scientific, management, and commercial personnel, complementary to, or necessary for, Zhittya's operations.

***Zhittya's product candidates for which it intends to seek approval may face competition sooner than anticipated.***

The enactment of the Biologics Price Competition and Innovation Act of 2009 ("BPCIA") created an abbreviated regulatory pathway for the approval of products demonstrated to be biosimilar, or "highly similar," to or "interchangeable" with an FDA-approved innovator (original) biologic product. The abbreviated regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as "interchangeable" based on its similarity to an existing reference product. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the original branded product is approved under a biologics license application ("BLA"). Although the FDA has approved 86 biosimilar products as of May 15, 2026 (according to fda.gov), complex provisions of the law are still being interpreted and implemented by the FDA. As a result, the ultimate impact, implementation, and meaning of the BPCIA are still subject to some uncertainty and FDA actions and court decisions concerning the law could have a material adverse effect on the future commercial prospects for Zhittya's biological products.

---

| |
|:---|
| 23 |
| *[**Table of Contents**](#TOC)* |

---

We believe that, if any of Zhittya's product candidates are approved as a biological product under a BLA, it should qualify for the 12-year period of exclusivity. However, there is a risk that the FDA could approve biosimilar applicants for other reference products that no longer have such exclusivity, thus potentially creating the opportunity for greater competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of Zhittya's referenced product candidates in a way that is similar to traditional generic substitution for non-biological products is not yet clear and will depend on a number of marketplace and regulatory factors that are still developing.

***There are no substantial barriers to entry into the industry and Zhittya has not obtained any registered intellectual property protection for its product candidates. There is no guarantee someone else will not duplicate its ideas and bring them to market before Zhittya does, which could severely limit our anticipated sales and other income/revenues. If we cannot generate sales and other income/revenues, it could result in the loss of your investment.***

Since Zhittya's product candidates have no registered intellectual property protection, unauthorized persons may attempt to copy aspects of its business, including its product design, functionality or marketing materials. Any encroachment upon Zhittya's corporate information, including the unauthorized use of its brand name, the use of a similar name by a competing company or a lawsuit initiated against it for infringement upon another company's proprietary information or improper use of their copyright, may affect its ability to create brand name recognition, cause customer confusion, and/or have a detrimental effect on its business. Litigation or proceedings before the U.S. or international patent and trademark offices may be necessary in the future to enforce Zhittya's registered intellectual property rights, to protect its trade secrets and domain name and/or to determine the validity and scope of the proprietary rights of others. Any such infringement, litigation, or adverse proceeding could result in substantial costs and diversion of resources and could seriously harm its and our business operations and/or results of operations. As a result, an investor could lose his or her entire investment.

***Our ability to sell and market licensed product candidates depends on Zhittya's intellectual property, which is currently limited to provisional patents and has not been registered with any governmental authority.***

Zhittya initially filed five provisional patent applications with the U.S. Patent and Trademark Office in 2025 relating to the use of FGF-1 to treat various diseases, including Parkinson's disease, neurodegenerative diseases of the brain, Type 2 diabetes, lung damage, and neuropathy. Zhittya subsequently filed corresponding non-provisional patent applications based on those provisional filings. The patent applications are intended to protect Zhittya's intellectual property relating to the therapeutic use of FGF-1 and, if issued as patents, may provide the Company with exclusive rights to the claimed inventions for the applicable patent term, subject to the requirements and limitations of U.S. patent law.

Because we rely on our license from Zhittya to sell and market these products, our ability to protect the licensed products from competition depends entirely on Zhittya's decisions regarding patent filings and prosecution. If Zhittya does not file non-provisional patent applications, or if such applications are not granted, competitors could make, use, sell, or market the same or similar products, which could materially and adversely affect our business, financial condition, results of operations, and prospects.

---

| |
|:---|
| 24 |
| *[**Table of Contents**](#TOC)* |

---

***The product candidates that we plan to market may fail if Zhittya is not able to successfully commercialize them and we may not ultimately generate significant other income/revenues as a result.***

Difficulties often encountered in scaling up production include problems involving production yields, quality control and assurance, shortage of qualified personnel, production costs, and process controls. In addition, the drugs we plan to market under the License Agreement will be subject to inherent risks associated with new technologies and products. These risks include the possibility that any of the product candidates we market may:

· be found unsafe;

· be ineffective or less effective than anticipated;

· fail to receive necessary regulatory approvals;

· be difficult to competitively price relative to alternative solutions;

· be harmful to consumers or the environment;

· fail to be developed and accepted by the market prior to the successful marketing of alternative products by competitors;

· be difficult or impossible to market because of infringement on the proprietary rights of third parties; or

· be too expensive for commercial use.

***We will need to license new modifications to the products and treatments that Zhittya develops under substantially the same terms as the License Agreement.***

In the event that Zhittya develops or otherwise acquires any modification of its drug candidate, FGF-1, which has been shown in a clinical trial to grow small blood vessels in the ischemic areas of the heart and has been shown in trials to reduce anginal pain, or updates the formulation of the products that are licensed to us, such modifications will be the sole and exclusive property of Zhittya. The License Agreement grants us the right to become Zhittya's exclusive licensee in the United States and Canada for such modifications under a new license agreement, which is expected to have substantially the same terms as the current License Agreement. There can be no assurance that those terms will be favorable to us under the circumstances. We estimate that with respect to any future modifications to the FGF-1 molecule it will take Zhittya at least seven years, if not longer, to develop and acquire all necessary regulatory approval to go to market, which regulatory approvals may not be received, and as such, we do not anticipate a new product release to overlap with the term of the License Agreement during which substantially same terms are required for modifications. However, our estimation may not be accurate and we may need to enter into such additional license agreements sooner.

***We are generating revenue, but it may not be sustainable or enough to cover operating losses and may not be at the volume that we expect in the future.***

We are generating revenue from patients who live in our licensed territory (the United States and Canda) and are traveling to other territories to be treated by Zhittya and from a patient supported study on Type 2 diabetes taking place in Las Vegas, Nevada; however, that revenue may not be sustainable in the long term. Zhittya's efforts to find patients might become ineffective or the governments where the clinics reside might revoke their approval. We are a sales and marketing company with a limited operating history. To date, we have invested substantially all of our efforts in the commercial planning for Zhittya's drug candidates. We have not generated any revenue from sales in the U.S. and Canadian markets to date, as Zhittya's drug candidates are still in development. We have a limited operating history upon which to evaluate our business and prospects. Consequently, any predictions about our future success, performance, or viability may not be as accurate as they could be if we had a longer operating history or approved products on the market. Because of the various risks and uncertainties associated with developing, obtaining regulatory approvals for, and marketing new products, we are unable to predict with any certainty the extent of any future other income/revenues, cash flows, profits, or losses.

We hope to continue generating enough other income to cover our operating expenses, as our activities have consisted primarily of developing our marketing strategies. As a result, for the years ended December 31, 2025, and 2024, we recorded net income of $91,510 and $97,039, respectively, and for the three months ended March 31, 2026, we generated net income of $307,844. To date, we have financed our operations primarily through preferred stock financings, loans from related parties, sales of common stock and other income generated through our agreement with Zhittya. We have devoted substantially all of our financial resources to general and administrative expenses associated with our operations.

---

| |
|:---|
| 25 |
| *[**Table of Contents**](#TOC)* |

---

Following this offering, we expect that our operating expenses will continue to increase as we (i) build our commercial infrastructure, (ii) develop, enhance, and begin to commercialize, if FDA approved, Zhittya's product candidates in the United States and Canada thereafter, (iii) make clinical progress and regulatory milestone payments to Zhittya, and (iv) incur additional operational costs associated with being a public company. For example, in anticipation of Zhittya potentially receiving FDA approval to support the commercial launch of its product candidates in the United States (not expected for 3 to 7 years) and later in Canada as Zhittya uses the data from the U.S. approval to seek approval in that market, we might need to grow our sales force over time and the number of our sales representatives at commercial launch will vary and may be higher depending on the duration of the pre-market approval review process. If Zhittya is delayed in obtaining approval of its product candidates by the FDA, we may be required to offer increased compensation to our U.S. sales team to retain them, which would further increase our operational costs. As a result, we expect to continue to incur operating losses for the foreseeable future. Our expected future operating losses, combined with our prior operating losses, may adversely affect the market price of our common stock and our ability to raise capital and continue operations.

If approved by the FDA, we expect that sales of Zhittya's product candidates will account for the substantial majority of our future revenue. If Zhittya's product candidates do not achieve an adequate level of acceptance by physicians, health care payors, and patients, and does not receive adequate reimbursement from third party payors, we may not generate sufficient revenue and we may not be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability in subsequent periods or on an ongoing basis. If we do not achieve or sustain profitability, it will be more difficult for us to finance our business and accomplish our strategic objectives, either of which would have a material and adverse effect on our business, financial condition, and results of operations and cause the market price of our common stock to decline.

***Customers may not adopt the products we market quickly or at all.***

Customers in the sector in which we operate can be generally cautious in their adoption of new products. In addition, given the relative novelty of our future planned products to be marketed, customers of those products may require education regarding their utility and use, which may delay their adoption. There can be no assurance that customers will adopt the products we sell in the future quickly, or at all.

***If Zhittya's product candidates or any of our future product candidates are approved for marketing, and we are found to have improperly promoted off-label uses, or if physicians misuse the products we sell or use the products off-label, we may become subject to prohibitions on the sale or marketing of its products, significant fines, penalties, sanctions, or product liability claims, and our image and reputation within the industry and marketplace could be harmed.***

The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about pharmaceutical products, such as Zhittya's product candidates, if approved. In particular, a product may not be promoted for uses or indications that are not approved by the FDA or other similar regulatory authorities as reflected in the product's approved labeling. If Zhittya receives marketing approval for Zhittya's product candidates such as for the treatment of foot ulcers, which is one indication that Zhittya is pursuing, physicians could use Zhittya's product candidates on their patients in a manner that is inconsistent with the approved label, potentially including for the treatment of other aesthetic or therapeutic indications. If we are found to have promoted such off-label uses, we may receive warning letters and be subject to other enforcement actions from the FDA, Health Canada and other regulatory agencies, and become subject to significant liability, which would materially harm our business. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or prosecution based on our marketing and promotional practices, we could face similar sanctions, which would materially harm our business. In addition, management's attention could be diverted from our business operations, significant legal expenses could be incurred, and our reputation could be damaged. The FDA has also required that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed in order to resolve FDA enforcement actions. If we are deemed by the FDA to have engaged in the promotion of products for off-label use, we could be subject to FDA prohibitions or other restrictions on the sale or marketing of products and other operations or significant fines and penalties, and the imposition of these sanctions could also affect our reputation and position within the industry.

---

| |
|:---|
| 26 |
| *[**Table of Contents**](#TOC)* |

---

Physicians may also misuse Zhittya's product candidates or any future product candidates, if approved, or use improper techniques, potentially leading to adverse results, side effects or injury, which may lead to product liability claims. If Zhittya's product candidates or any future product candidates, if approved, are misused or used with improper techniques or are determined to cause or contribute to consumer harm, we may become subject to costly litigation by our customers or their patients. Product liability claims could divert management's attention from our core business, be expensive to defend, result in sizable damage awards against us that may not be covered by insurance and subject us to negative publicity resulting in reduced sales of our marketed products. Furthermore, the use of Zhittya's product candidates or any future product candidates, if approved, for indications other than those cleared by the FDA may not effectively treat such conditions, which could harm our reputation in the marketplace among physicians and consumers. Any of these events could harm our business and results of operations and cause our stock price to decline.

***Zhittya's product candidates or any of its future product candidates may cause serious or undesirable side effects or possess other unexpected properties that could delay or prevent their regulatory approval, limit the commercial profile of approved labeling, or result in post-approval regulatory action.***

Unforeseen side effects from Zhittya's product candidates or future product candidates marketed by us could arise either during clinical development or, if approved, after marketing such product. Undesirable side effects caused by product candidates could cause us or regulatory authorities to interrupt, modify, delay, or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA, Health Canada, or similar regulatory authorities. Results of clinical trials could reveal a high and unacceptable severity and prevalence of side effects. In such an event, trials could be suspended or terminated and the FDA, Health Canada, or similar regulatory authorities could order us to cease further development of or deny approval of product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in product liability claims. Any of these occurrences may harm our business, financial condition, operating results, and prospects.

Additionally, if we or others identify undesirable side effects, or other previously unknown problems, caused by Zhittya's product candidates, or any of our future product candidates, after obtaining regulatory approval in the United States, Canada or other jurisdictions, a number of potentially negative consequences could result, including:

· regulatory authorities may withdraw their approval of the product candidate;

· regulatory authorities may require a recall of the product candidate or a product candidate may be voluntarily recalled;

· regulatory authorities may require the addition of warnings or contraindications in the product labeling, narrowing of the indication in the product label or issuance of field alerts to physicians and pharmacies;

· regulatory authorities may require the creation of a medication guide outlining the risks of such side effects for distribution to patients or institute risk evaluation and mitigation strategies;

· we may be subject to limitations as to how we market or promote the product;

· the way the product is administered may be required to be changed or modified in some way;

· regulatory authorities may require additional clinical trials or costly post-marketing testing and surveillance to monitor the safety or efficacy of the product;

· sales of the product may decrease significantly;

· we could be sued and held liable for harm caused to patients; and

· Zhittya's or our brand and reputation may suffer.

---

| |
|:---|
| 27 |
| *[**Table of Contents**](#TOC)* |

---

Any of the above events could prevent us from achieving or maintaining market acceptance of the affected product and could substantially increase the costs of commercializing such products. The demand for any such product candidates could also be negatively impacted by any adverse effects of a competitor's product or treatment.

***The significant level of competition for the product candidates that we market may result in pricing pressure, reduced margins, or the inability of our future product to achieve market acceptance.***

The industry for the products we plan to market and sell is intensely competitive and rapidly changing. We may be unable to compete successfully, which may result in price reductions, reduced margins, and the inability to achieve market acceptance for the Zhittya's products that we sell.

Our competitors may have longer operating histories, significantly greater resources, greater brand recognition than we do, and large customer bases. As a result, they may be able to devote greater resources to the manufacture, promotion, or sale of their products, receive greater resources and support from market partners and independent distributors, initiate or withstand substantial price competition, or more readily take advantage of acquisition or other opportunities.

***Unsuccessful pre-clinical development and future Clinical Phase I/II studies for the product candidates for which we plan to market will have a material adverse effect on our business.***

The successful completion of pre-clinical development and multiple clinical trials is critical to the success of the product candidates we plan to market and sell. If the pre-clinical development and clinical trials are unsuccessful or produce inconsistent results or unanticipated adverse side effects, such product candidates could be delayed and as a result Zhittya may be unable to successfully commercialize them.

***The loss of our management team or other key personnel would have an adverse impact on our future development and impair our ability to succeed.***

In the early stages of development, our business will be significantly dependent on our management team and other key personnel. Our success will be particularly dependent upon John Laub, our Chief Executive Officer. The loss of Mr. Laub or any other future key personnel could have a material adverse effect on us and our ability to further execute our intended business. The replacement of any of our key personnel would likely involve significant time and costs and may significantly delay or prevent the achievement of our business objectives, which could have an adverse effect on our business. In addition, we do not carry any "key person" insurance policies that could offset potential loss of service under applicable circumstances.

***Our independent contractors, consultants, commercial collaborators, principal investigators, vendors, and other agents may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements.***

We are exposed to the risk that our independent contractors, consultants, commercial collaborators, principal investigators, vendors, and other agents may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless, and/or negligent conduct or disclosure of unauthorized activities to us that violates applicable regulations, including those laws requiring the reporting of true, complete, and accurate information to regulatory agencies, manufacturing standards, and federal and state healthcare laws and regulations. In particular, sales, marketing, and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, kickbacks, self-dealing, and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing, and promotion, sales commissions, referrals, customer incentive programs, and other business arrangements. Misconduct by these parties could also involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. The precautions we take to detect and prevent misconduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant civil, criminal, and administrative penalties, including, without limitation, damages, fines, disgorgement, imprisonment, and the curtailment or restructuring of our operations.

---

| |
|:---|
| 28 |
| *[**Table of Contents**](#TOC)* |

---

***We plan to rely on third-party distribution partners for the distribution of Zhittya's products, product candidates, and services, which could delay or limit our ability to generate revenue.***

With respect to certain markets for Zhittya's product candidates and services, we plan to retain third-party service providers to perform functions related to the marketing, distribution, and sale of Zhittya's product candidates and any future product candidates. Key aspects of those functions may be out of our direct control, including regulatory compliance, warehousing, and inventory management, distribution, contract administration, accounts receivable management, and call center management. Any future distribution partners may hold significant control over important aspects of the commercialization of Zhittya's product candidates, including market identification, regulatory compliance, marketing methods, pricing, composition of sales force, and promotional activities.

We may not be able to control the amount and timing of resources that any future third-party distribution partners may devote to Zhittya's product candidates, or prevent any third-party from pursuing the development of alternative technologies or products that compete with Zhittya's products, except to the extent our contractual arrangements protect us against such activities. Also, we may not be able to prevent any other third-party from withdrawing its support of Zhittya's products.

If third-party service providers fail to comply with applicable laws and regulations, fail to meet expected deadlines, encounter natural or other disasters at their facilities, or otherwise fail to perform their services to us in a satisfactory or predicted manner, or at all, our ability to deliver products to meet commercial demand could be significantly impaired. In addition, we may use third parties to perform various other services for us relating to sample accountability and regulatory monitoring, including adverse event reporting, safety database management, and other product maintenance services. If the quality or accuracy of the data maintained by these service providers is insufficient, our ability to continue to market Zhittya's products could be jeopardized or we could be subject to regulatory sanctions, and any indemnity we may receive from such third-party service providers could be limited by such provider's ability to pay and otherwise may not be sufficient to cover all losses we may experience.

***We will need to increase the size of our organization, and we may experience difficulties in managing this growth.***

As of June 1, 2026, we had no employees. Our chief executive officer (CEO) and chief financial officer (CFO) are independent contractors, who work approximately 40 hours per week for us. We will need to expand our managerial, operational, finance, and other resources to manage our operations and to commercialize Zhittya's product candidates. Our management and personnel, systems, and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our growth strategy requires that we:

· identify, recruit, retain, incentivize, and integrate employees, once we begin hiring employees;

· manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and

· continue to improve our operational, financial, and management controls, reporting systems, and procedures.

Due to our limited financial resources and our limited experience in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our development and strategic objectives or disrupt our operations.

---

| |
|:---|
| 29 |
| *[**Table of Contents**](#TOC)* |

---

***If we are not able to attract and retain highly skilled employees and contractors, we may not be able to implement our business model successfully.***

We will rely upon consultants/contractors to effectively establish, manage, and grow our business, until such time as we begin hiring employees. We currently rely upon our management team, who work for us as independent contractors. Consequently, we believe that our future viability will depend largely on our ability to attract and retain highly skilled personnel. In order to do so, we may need to pay higher compensation, fees, and/or other incentives to our employees or consultants than we currently expect and such higher compensation payments would have a negative effect on our operating results. Competition for experienced, high-quality employees, consultants, and contractors is intense and we cannot assure that we will be able to recruit and retain such personnel. We may not be able to hire or retain the necessary personnel to implement our business strategy. Our failure to hire and retain such personnel could impair our ability to develop new products and manage our business effectively.

***Security breaches, loss of data and other disruptions could compromise sensitive information related to our business, prevent us from accessing critical information or expose us to liability, which could adversely affect our business and our reputation.***

In the ordinary course of business, we expect to collect and store sensitive data, including legally protected patient health information, credit card information, personally identifiable information about our employees, intellectual property, and proprietary business information. The secure processing, storage, maintenance and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we plan to take measures to protect sensitive information from unauthorized access or disclosure, our information technology and infrastructure may be vulnerable to attacks by hackers, or viruses, breaches or interruptions due to employee error, malfeasance or other disruptions, or lapses in compliance with privacy and security mandates. Any such virus, breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. We have measures in place that are designed to prevent, and if necessary, to detect and respond to such security incidents and breaches of privacy and security mandates. However, in the future, any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, such as the Health Insurance Portability and Accountability Act ("HIPAA") and European Union General Data Protection Regulation ("GDPR"), government enforcement actions and regulatory penalties. Unauthorized access, loss or dissemination could also disrupt our operations, including our ability to process samples, provide test results, share and monitor safety data, bill payors or patients, provide customer support services, conduct research and development activities, process and prepare company financial information, manage various general and administrative aspects of our business and may damage our reputation, any of which could adversely affect our business, financial condition and results of operations.

**<u>Risks Related to Government Regulation</u>**

***The use of the product candidates we market may be limited by regulations, and we may be exposed to product liability and remediation claims.***

The use of the product candidates we market may be regulated by various local, state, federal, and foreign regulators. Even if we are able to comply with all such regulations and obtain all necessary registrations, we cannot provide assurance that our future products will not cause injury to the environment, people or animals, and/or otherwise have unintended adverse consequences, under all circumstances. For example, the product candidates may be improperly combined with other chemicals or, even when properly combined, Zhittya's product candidates may be blamed for damage caused by those other chemicals. The costs of remediation or products liability could materially adversely affect our results, financial condition, and operations.

---

| |
|:---|
| 30 |
| *[**Table of Contents**](#TOC)* |

---

***We may be held liable for, or incur costs to settle, liability and remediation claims if any products we market cause injury or are found unsuitable during product testing, manufacturing, sale, or use. These risks exist even with respect to product candidates that have received, or may in the future receive, regulatory approval, registration, or clearance for commercial use. We cannot guarantee that we will be able to avoid product liability exposure.***

When at the stage customary to do so, we expect to maintain product liability insurance at levels we believe are sufficient and consistent with industry standards for like companies and products. However, we cannot guarantee that our product liability insurance will be sufficient to help us avoid product liability-related losses. In the future, it is possible that meaningful insurance coverage may not be available on commercially reasonable terms or at all. In addition, a product liability claim could result in liability to us greater than our assets or insurance coverage. Moreover, even if we have adequate insurance coverage, product liability claims or recalls could result in negative publicity or force us to devote significant time and attention to these matters, which could harm our business.

Product liability claims may be brought against us by patients, healthcare providers, or others selling or otherwise coming into contact with the products we market and commercialize. If we cannot successfully defend ourselves against product liability claims, we will incur substantial liabilities and reputational harm. In addition, regardless of merit or eventual outcome, product liability claims may result in:

· costs of litigation;

· distraction of management's attention from our primary business;

· the inability to commercialize certain products;

· decreased demand for certain products;

· damage to our business reputation;

· product recalls or withdrawals from the market;

· withdrawal of clinical study participants;

· substantial monetary awards to patients or other claimants; or

· loss of sales.

While we may attempt to manage our product liability exposure by proactively recalling or withdrawing from the market any defective products, any recall or market withdrawal of Zhittya's products may delay the supply to our customers and may impact our reputation. We may not be successful in initiating appropriate market recall or market withdrawal efforts that may be required in the future and these efforts may not have the intended effect of preventing product malfunctions and the accompanying product liability that may result. Such recalls and withdrawals may also be used by our competitors to harm our reputation for safety or be perceived by patients as a safety risk when considering the use of the products we market, either of which could have a material adverse effect on our business, financial condition, and results of operations.

Although we plan to have product liability insurance that we believe is appropriate, this insurance is subject to deductibles and coverage limitations. Product liability insurance may not be available to us on acceptable terms, if at all, and, if available, coverage may not be adequate to protect us against any future product liability claims. If we are unable to obtain insurance at an acceptable cost or on acceptable terms or otherwise protect against potential product liability claims, we could be exposed to significant liabilities. A product liability claim, recall, or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could have a material adverse effect on our business, financial condition, and results of operations.

---

| |
|:---|
| 31 |
| *[**Table of Contents**](#TOC)* |

---

***Our inability to comply with ongoing and changing regulatory requirements could delay or prevent sales of the product candidates we are marketing.***

The testing, manufacture, sale, and use of the product candidates we market will be regulated by government agencies in the United States, and abroad. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our business and the products we plan to market. Any new statutes, regulations, or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of or make it more difficult to obtain approval to, manufacture, market, or distribute products we plan to market. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: additional testing prior to obtaining clearance or approval for future product candidates, changes to manufacturing methods, recall, replacement, or discontinuance of future product candidates, or additional record keeping. These regulations substantially increase the time and cost associated with bringing future products to market. If the third-party manufacturers who develop the products that we market do not receive the necessary governmental approvals to test, or manufacture the products we plan to market, or if regulatory authorities revoke their approvals, do not grant approvals in a timely manner or grant approvals subject to restrictions on their use, we may be unable to sell these products in the United States or other jurisdictions, which could adversely affect our results and operations.

There can be no assurance that Zhittya will be able to obtain regulatory approval for marketing technologies, products, and applications it may develop. Because many of the products that may be sold by us must be registered with one or more government agencies, the registration process can be time consuming and expensive, and there is no guarantee that the product will obtain all needed registrations.

Even if Zhittya obtains all necessary regulatory approvals to market and sell products we license, they will be subject to continuing review and extensive regulatory requirements, including periodic re-registrations. Regulatory authorities could withdraw a previously approved product from the market upon receipt of newly discovered information, including an inability to comply with regulatory requirements or the occurrence of unanticipated problems with Zhittya's products, or for other reasons.

***The regulatory approval process is expensive, time-consuming, and uncertain and may prevent us from obtaining approvals for the commercialization of our future product candidates, if any.***

The labeling, approval, selling, marketing and distribution of health and life-science related product candidates are subject to extensive regulation, which regulations differ from country to country.

In connection with the development of any marketing and distribution for product candidates that qualify as biopharmaceuticals, we will not be permitted to market them in the United States or other regions until Zhittya receives approval to do so by the appropriate regulatory agencies in the United States (which we don't expect for 3-7 years) and later in Canada, of which Zhittya is under no obligation to have products approved in the United States or Canada. We have not submitted an application or premarket notification for or received marketing clearance or approval for any of Zhittya's product candidates. Obtaining approval of any premarket approval can be a lengthy, expensive, and uncertain process. There is no guarantee that Zhittya's products will receive regulatory approval for marketing and distribution. If the FDA or other relevant regulatory agencies do not approve our applications for marketing our biopharmaceutical product(s), then we cannot market the product(s). The regulatory agencies may seek additional information or additional data, which would further delay our ability to market the product. Furthermore, failure to comply with FDA, non-U.S. regulatory authorities, or other applicable U.S. and non-U.S. regulatory requirements may, either before or after product clearance or approval, if any, subject us to administrative or judicially imposed sanctions, including:

· civil and criminal penalties;

· injunctions;

· suspension or withdrawal of regulatory clearances or approvals;

· voluntary or mandatory product recalls and publicity requirements;

· total or partial suspension of production;

· imposition of restrictions on operations; and

· refusal to clear or approve pending applications or premarket notifications.

---

| |
|:---|
| 32 |
| *[**Table of Contents**](#TOC)* |

---

The FDA and/or other regulatory agencies can delay, limit, or deny clearance or approval of a biopharmaceutical product candidate for many reasons, including:

· a biopharmaceutical product may not be deemed safe or effective;

· regulatory officials may not find the data from pre-clinical studies and clinical trials sufficient;

· the regulatory agency may not approve our third-party manufacturer's processes or facilities; or

· the regulatory may change its clearance or approval policies or adopt new regulations.

***Our future revenue from the sale of Zhittya's licensed drugs in the U.S. and Canada depends on Zhittya obtaining regulatory approval in the United States and Canada, which may never occur.***

We currently receive revenue from the Zhittya's sales of its drugs to U.S. and Canadian residents who travel to certain countries outside the United States and Canada in order to use Zhittya's drugs, and which we record as other income. Under our License Agreement, if and when the Zhittya's drugs are approved for use by the FDA or Health Canada, we will be obligated to pay Zhittya 50% of our operating profits derived from such sales of topical drugs and 80% of our operating profits derived from such sales of injection/infusion/intranasal drugs. However, Zhittya is under no obligation to seek, obtain, or maintain FDA or Health Canada approval for its drugs and the process of obtaining such regulatory approvals is time-consuming, expensive, and uncertain.

As a result, Zhittya may choose not to pursue FDA or Health Canada approval, may delay such approval for extended periods, or may abandon the approval process entirely because of costs, regulatory challenges, or strategic business considerations. If Zhittya does not obtain regulatory approval in the United States or Canada for its drugs, we may never generate revenue from sales of the drugs in these markets, which could have a material adverse effect on our financial condition and results of operations.

***The regulatory approval processes of the FDA and other comparable foreign regulatory authorities are lengthy, time-consuming and inherently unpredictable, and if Zhittya is unable to obtain timely regulatory approval for its product candidates, our business will be substantially harmed.***

We will not be permitted to market product candidates in the United States until Zhittya is able to receive approval of a new drug application, or NDA, from the FDA, or in any foreign countries until Zhittya receives the requisite approval from such countries. Prior to submitting an NDA to the FDA for approval of Zhittya's product candidates, Zhittya will be required to have its product candidates complete initiate and complete clinical trials. Successfully completing its clinical program and obtaining approval of an NDA is a complex, lengthy, expensive, and uncertain process, and the FDA may delay, limit, or deny approval of product candidates for many reasons. This could increase costs and jeopardize Zhittya's ability to obtain regulatory approval for and successfully market product candidates, which would in turn jeopardize our ability to generate product revenue.

***Zhittya's clinical studies are subject to numerous risks.***

Zhittya is in the process of conducting, and may in the future conduct, studies evaluating our licensed product candidates, and we do not control their design, conduct, timing or interpretation. Certain studies conducted by Zhittya have been, or may be, patient-supported, open-label or otherwise not randomized, double-blind or well-controlled, which may limit the reliability, interpretability and regulatory acceptability of the resulting data.

Pre-clinical data generated by Zhittya may not be predictive of safety or efficacy in humans, and any positive signals observed in non-clinical models may not translate to clinical studies. Similarly, open-label or patient-supported clinical studies may lack appropriate control arms and blinding, increasing the risk of bias (including selection bias) and making it difficult to determine whether observed outcomes are attributable to the investigational product rather than placebo effects, disease variability or other confounding factors. Patients in such studies may also self-select for participation, resulting in study populations that are not representative of the broader disease population (Parkinson's disease or otherwise) in the United States or Canada.

---

| |
|:---|
| 33 |
| *[**Table of Contents**](#TOC)* |

---

Results from Zhittya's studies may not be replicated in future randomized, double-blind, well-controlled clinical trials, and future trials could produce materially different or less favorable results. Regulatory authorities, including the FDA and Health Canada, may determine that data from studies or from patient-supported or open-label clinical studies are insufficient, unreliable or biased, and may require additional, more rigorous studies, resulting in increased costs, delays or uncertainty regarding regulatory approval. Any such outcomes could materially adversely affect our ability to develop, obtain approval for or commercialize Zhittya's product candidates.

***We expect the product candidates Zhittya develops will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.***

The Biologics Price Competition and Innovation Act (the "BPCI Act") was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as "interchangeable" based on its similarity to an approved biologic. Under the BPCI Act, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain whether such processes intended to implement the BPCI Act may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for Zhittya's biological products.

Notwithstanding the above, we believe that any of the product candidates Zhittya develops that are approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this 12 year period of exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider the subject product candidates to be reference products for competing products, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.

***Zhittya will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense to us, and we may be subject to penalties if Zhittya fails to comply with regulatory requirements or experience unanticipated problems with its product candidates.***

Any regulatory approvals that Zhittya's product candidates receive will require surveillance to monitor the safety and efficacy of such product candidate. The FDA may also require a risk evaluation and mitigation strategy in order to approve Zhittya's product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves Zhittya's product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for the product candidates will be subject to extensive and ongoing regulatory requirements, some of which are expected to be undertaken by us. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that Zhittya conducts post-approval. As such, Zhittya and we will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, Zhittya must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require Zhittya to conduct another study to obtain additional safety or biomarker information. Further, we will be required to comply with FDA promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product's approved uses (known as "off-label use"), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. Later discovery of previously unknown problems with Zhittya's product candidates, including adverse events of unanticipated severity or frequency, or with third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a risk evaluation and mitigation strategy program. Other potential consequences include, among other things:

---

| |
|:---|
| 34 |
| *[**Table of Contents**](#TOC)* |

---

· restrictions on the marketing or manufacturing of product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;

· fines, warning letters or holds on clinical trials;

· refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;

· product seizure or detention, or refusal to permit the import or export of Zhittya's product candidates; and

· injunctions or the imposition of civil or criminal penalties.

The FDA's and other regulatory authorities' policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of Zhittya's product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current U.S. President's administration may impact Zhittya's and our business and industry. Namely, the current U.S. President's administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA's ability to engage in routine oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these orders will be implemented, and the extent to which they will impact the FDA's ability to exercise its regulatory authority. If these executive actions impose restrictions on the FDA's ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. If we or Zhittya are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or Zhittya are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.

***Negative public opinion and increased regulatory scrutiny of Zhittya's product candidates and treatments may damage public perception of such product candidates or adversely affect our ability to conduct our business or Zhittya's ability to obtain regulatory approvals for its product candidates.***

The technologies that Zhittya uses are novel. Public perception may be influenced by claims that such technology is unsafe, and Zhittya's products may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians specializing in targeted diseases prescribing the product candidates we license from Zhittya as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of the products we sell and/or Zhittya's product candidates may result in fewer physicians prescribing such treatments or may reduce the willingness of patients to utilize such treatments or participate in clinical trials for Zhittya's product candidates. Increased negative public opinion or more restrictive government regulations in response thereto, would have a negative effect on our business or financial condition and may delay or impair the development and commercialization of Zhittya's product candidates or demand for such product candidates.

---

| |
|:---|
| 35 |
| *[**Table of Contents**](#TOC)* |

---

***Even if Zhittya obtains regulatory approval of its product candidates, the products may not gain market acceptance among physicians, patients, hospitals, treatment centers and others in the medical community.***

Zhittya and its technologies may not become broadly accepted by physicians, patients, hospitals, and others in the medical community. It is possible that the product candidates may result in unforeseen and unintended outcomes, which may result in unacceptable side effects, including death. Additional factors will influence whether the product candidates are accepted in the market, including:

· the clinical indications for which the product candidates are approved;

· physicians, hospitals, treatment centers and patients considering Zhittya's product candidates as a safe and effective treatment;

· the potential and perceived advantages of Zhittya's product candidates over alternative treatments;

· the prevalence and severity of any side effects;

· product labeling or product insert requirements of the FDA or other regulatory authorities;

· limitations or warnings contained in the labeling approved by the FDA;

· the timing of market introduction of Zhittya's product candidates as well as competitive products;

· the cost of treatment in relation to alternative treatments;

· the availability of coverage and adequate reimbursement by third-party payors and government authorities;

· the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;

· relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and

· the effectiveness of our sales and marketing efforts.

If Zhittya's product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if the products achieve market acceptance, they may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than Zhittya's products, are more cost effective or render Zhittya's products obsolete.

***Pre-clinical data is uncertain and may not be replicated in future clinical studies.***

We discuss the results of certain pre-clinical and clinical studies in this offering circular, all of which are inherently preliminary and may not be predictive of the results of future clinical trials. Findings from pre-clinical studies, including observations of biological activity, tissue response, or other potential therapeutic effects, are subject to significant limitations, including small sample sizes, limited controls, differences in study design, and the absence of the statistical rigor typically associated with well-designed randomized clinical trials. In addition, certain prior studies may not have reported adverse events, statistical analyses, or p-values, which further limits the ability to assess the significance, reproducibility, and clinical relevance of the reported findings. As a result, there can be no assurance that any positive pre-clinical observations will be replicated in future human studies or larger, controlled clinical trials, or that such trials will demonstrate comparable safety, efficacy, biological activity, or therapeutic benefit. Failure to reproduce favorable pre-clinical results in subsequent clinical development could materially harm our business, prospects, financial condition, and the market price of our securities.

---

| |
|:---|
| 36 |
| *[**Table of Contents**](#TOC)* |

---

**<u>Risks Related to Intellectual Property</u>**

***We may be involved in lawsuits related to Zhittya's efforts to protect or enforce its intellectual property rights, which could be expensive, time-consuming, and ultimately unsuccessful.***

Zhittya does not have any patents, trademarks, or registered intellectual property. Any encroachment upon its proprietary information, including the unauthorized use of its brand name, the use of a similar name by a competing company or a lawsuit initiated either by Zhittya or against Zhittya for infringement upon proprietary information or improper use of a trademark, may affect its ability to create brand name recognition, cause customer confusion, and/or have a detrimental effect on its business due to the cost of defending any potential litigation related to infringement. If Zhittya, in the future, obtains any of such intellectual property, litigation, or proceedings before the U.S. or international patent and trademark offices may be necessary to enforce its intellectual property rights, to protect its trade secrets and domain name, and/or to determine the validity and scope of the proprietary rights of others. Any such litigation or adverse proceeding could result in substantial costs and diversion of resources and could seriously harm our business, operations, and/or results of operations.

***Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain.***

Our commercial success depends upon our ability to market and sell Zhittya's products without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the life sciences industry. We cannot guarantee that Zhittya's product candidates will not infringe third-party patents or other proprietary rights. We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to Zhittya's products and technology, including *inter partes* review, interference, or derivation proceedings before the United States Patent and Trademark Office ("USPTO") and similar bodies in other countries. Third parties may assert infringement claims against us based on existing intellectual property rights and intellectual property rights that may be granted in the future.

If we are found to infringe on a third party's intellectual property rights, we or Zhittya could be required to obtain a license from such a third party to continue developing and marketing such products. However, neither Zhittya nor we may be able to obtain any required license on commercially reasonable terms or at all. Even if Zhittya or we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We or Zhittya could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, Zhittya or we could be found liable for monetary damages, including treble damages and attorneys' fees if we are found to have willfully infringed a patent. A finding of infringement could prevent Zhittya from commercializing its product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business.

**<u>Risks Related to Our Securities and this Offering</u>**

***There is no existing public market for our common stock, and an active trading market may never develop or be sustained.***

Prior to this offering, there has been no public market for our common stock. We cannot predict whether investor interest in our Company generated by this offering will lead to the development of a trading market, or how liquid any such market might become. Even if a trading market develops following this offering, it may not be maintained, and investors may find it difficult or impossible to sell their Shares at any price. If an active trading market does not develop or is not sustained, the value of your investment could be adversely affected, and you may be required to hold your Shares for an indefinite period of time.

---

| |
|:---|
| 37 |
| *[**Table of Contents**](#TOC)* |

---

***This is a "best efforts" offering; no minimum amount of Securities is required to be sold, and we may not raise the amount of capital we believe is required for our business.***

There is no required minimum number of Securities that must be sold as a condition to completion of this offering. Because there is no minimum offering amount required as a condition to each closing of this offering, the actual offering amount, and proceeds to us are not presently determinable and may be substantially less than the maximum amounts set forth in this offering circular. We may sell fewer than all of the Shares offered hereby, which may significantly reduce the amount of proceeds received by us, and investors in this offering will not receive a refund in the event that we do not sell an amount of Shares sufficient to pursue the business goals outlined in this offering circular. Thus, we may not raise the amount of capital we believe is required for our business and may need to raise additional funds, which may not be available or available on terms acceptable to us. Despite this, any proceeds from the sale of the Shares offered by us will be available for our immediate use, and because there is no escrow account and no minimum offering amount in this offering, investors could be in a position where they have invested in us, but we are unable to fulfill our objectives due to a lack of interest in this offering.

***There can be no assurance that our common stock will be approved for quotation on the OTCQB Market or that we will maintain such quotation.***

Following this offering, we intend to apply for quotation of our common stock on the OTCQB Market operated by OTC Markets Group Inc. However, quotation on the OTCQB is subject to a number of eligibility requirements, including, among others, a minimum bid price requirement, current SEC reporting obligations, payment of applicable fees, and compliance with OTC Markets Group's corporate governance standards. We cannot assure you that we will satisfy all applicable requirements, that our application will be approved, or that we will be able to locate a broker-dealer willing to sponsor our quotation application. Even if our common stock is quoted on the OTCQB, we may fail to maintain continued eligibility, in which case our shares may be downgraded to the OTC Pink Market or may not be quoted on any public market at all. Any failure to obtain or maintain OTCQB quotation could significantly impair the liquidity of our common stock and your ability to sell your Shares.

***We will need a broker-dealer to sponsor our application for quotation on the OTC Markets, and there is no assurance that we will secure such a sponsor.***

In order to have our common stock quoted on the OTCQB or any other tier of the OTC Markets, we must have a registered broker-dealer submit an application on our behalf through the Financial Industry Regulatory Authority (FINRA). We have not yet secured a broker-dealer sponsorship commitment, and there can be no assurance that we will be able to do so on acceptable terms, or at all. If we are unable to find a broker-dealer willing to sponsor our quotation application, our common stock may not be quoted on any public market following this offering, which could render your investment illiquid.

***Our common stock may be subject to the SEC'S penny stock rules, which could make transactions in our common stock more difficult and reduce the trading market for our shares.***

Our common stock may be subject to the SEC's "penny stock" rules if it trades below $5.00 per share and we do not qualify for an applicable exemption. Under these rules, broker-dealers effecting transactions in penny stocks are subject to heightened disclosure obligations and customer suitability requirements, including the delivery of standardized risk disclosure documents and the preparation of suitability determinations prior to any transaction. These requirements may discourage broker-dealers from recommending or handling our common stock, reduce the trading market for our shares, and make it significantly more difficult for investors to purchase or sell our common stock in the secondary market.

***The offering price has been determined arbitrarily by us and may not reflect the market value of our common stock.***

The offering price of our common stock has been determined by us and does not necessarily bear any relationship to our assets, net tangible book value, earnings, financial condition, prospects, or any other established criterion of value. The offering price should not be regarded as an indicator of the future market price of our common stock. The market price of our common stock following this offering, if a trading market develops at all, may be substantially lower than the offering price, and investors purchasing Shares in this offering may lose some or all of their investment.

---

| |
|:---|
| 38 |
| *[**Table of Contents**](#TOC)* |

---

***We intend to become a reporting company under Tier 2 of Regulation A, and there can be no assurance that we will successfully complete or maintain that status.***

Following the qualification of this offering, we will become subject to the periodic and current reporting requirements of Regulation A. We cannot assure you that we will be able to satisfy our ongoing reporting obligations once this offering is qualified. As discussed herein, there is no public market for the Shares, provided that following the closing of this offering, the Company currently plans to apply for quotation on the OTCQB Market maintained by OTC Markets; however, there can be no assurance that we will obtain such quotation, or as to the level of trading that might occur if we do. Failure to timely file required reports with the SEC could result in the loss of our ability to quote our common stock on the OTCQB (if such quotation is approved in the future), which could adversely affect the liquidity and marketability of our common stock and the ability of holders of restricted shares to rely on resale exemptions under the securities laws.

***Holders of restricted shares may be unable to rely on Rule 144 if we do not become and remain a reporting company.***

Shares of our common stock sold in prior exempt transactions, and shares issued to our founders, officers, directors, and employees, are "restricted securities" within the meaning of Rule 144 under the Securities Act. Rule 144 permits holders of restricted securities to resell shares in the open market without registration, subject to compliance with certain conditions, including a requirement that the issuer has been subject to the reporting requirements of the Exchange Act for at least 90 days and is current in its reporting obligations. If we fail to become or remain a reporting company, holders of restricted shares may be unable to avail themselves of the Rule 144 resale exemption and may have no other means of selling their shares absent a registered offering or another applicable exemption.

***The market price of our common stock may be volatile, and you could lose all or a significant portion of your investment.***

If a trading market for our common stock develops following this offering, the market price of our common stock may be subject to wide fluctuations in response to numerous factors, many of which are beyond our control. These factors may include, among others, our actual or anticipated operating results, changes in our business or prospects, developments in our industry, market conditions generally, investor perceptions, trading volume, and broad economic, political, or market conditions such as recessions or changes in interest rates. Volatility in our stock price could cause you to lose all or a significant part of the value of your investment. In addition, companies with publicly traded securities that experience significant stock price volatility are sometimes subject to securities class action litigation. Even if such litigation is without merit, it could result in substantial costs and divert management's attention and resources from our business.

***Becoming a public reporting company will significantly increase our operating costs and place demands on our management.***

Upon the qualification of this offering and the effectiveness of our Exchange Act registration, we will become subject to the reporting, disclosure, and governance requirements applicable to public companies. We expect to incur significant additional costs related to legal counsel, independent audit services, financial reporting systems, investor relations, and directors' and officers' liability insurance that we did not incur as a private company. In addition, our management team will be required to devote substantial time and attention to our SEC reporting obligations, which may divert their focus from the operation and growth of our business. These increased costs and demands on management may adversely affect our financial condition and results of operations.

---

| |
|:---|
| 39 |
| *[**Table of Contents**](#TOC)* |

---

***As an emerging growth company and smaller reporting company, we will be subject to reduced disclosure requirements, which may make our common stock less attractive to investors.***

We expect to qualify as both an "emerging growth company" and "smaller reporting company" under SEC rules following the effectiveness of our Exchange Act registration. As an emerging growth company and smaller reporting company, we will be permitted to provide less extensive disclosures in our SEC filings than those required of larger public companies, including scaled executive compensation disclosures and relief from certain other disclosure requirements. These reduced disclosures may make it more difficult for investors to fully evaluate our business, financial condition, and prospects, and may make our common stock less attractive to institutional investors or analysts who cover public companies, which could adversely affect the trading market for our shares.

***We do not expect to pay dividends in the foreseeable future.***

We do not intend to declare dividends for the foreseeable future, as we anticipate that we will reinvest any and all future earnings in the development and growth of our business. Therefore, investors will not receive any funds unless they sell their securities, and holders may be unable to sell their securities on favorable terms or at all. We cannot assure you of a positive return on your investment or that you will not lose the entire amount of your investment.

***Upon our dissolution, you may not recoup all or any portion of your investment.***

In the event of our liquidation, dissolution or winding-up, whether voluntary or involuntary, our assets would be used to pay all of our debts and liabilities, and only thereafter would any remaining assets be distributed to our stockholders, subject to rights of the holders of our preferred stock, if any, on a *pro rata* basis. There can be no assurance that we will have assets available from which to pay any amounts to our stockholders upon such a liquidation, dissolution or winding-up. In such an event, you would lose all of your investment.

***Purchasers in this offering will experience immediate and substantial dilution in net tangible book value.***

Because the price per share of our common stock being offered is higher than the book value per share of our common stock, you will suffer substantial dilution in the net tangible book value of the common stock you purchase in this offering. Based on the public offering price of $10.00 per share, if you purchase common stock in this offering, you will suffer dilution per share in the net tangible book value of the common stock. See "<u>Dilution</u>" below for a more detailed discussion of the dilution you will incur if you purchase our common stock in the offering.

***We have broad discretion in how we use the proceeds of this offering and may not use these proceeds effectively, which could affect our results of operations and cause our common stock price to decline.***

We will have considerable discretion in the application of the net proceeds of this offering. We intend to use the net proceeds from this offering to fund our business strategy, including without limitation, new and ongoing research and development expenses, offering expenses, working capital and other general corporate purposes, which may include funding for the hiring of additional personnel. As a result, investors will be relying upon management's judgment with only limited information about our specific intentions for the use of the balance of the net proceeds of this offering. We may use the net proceeds for purposes that do not yield a significant return or any return at all for our stockholders. In addition, pending their use, we may invest the net proceeds from this offering in a manner that does not produce income or that loses value.

***A significant number of our outstanding shares will not be subject to lock-up agreements in connection with this offering. The sale of a significant number of our shares may cause the market price of our common stock to drop significantly.***

Upon completion of this offering all of our directors and officers and the holders of 5% our capital stock will have signed lock-up agreements that prevent them from selling any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, subject to certain exceptions, for a period of not less 180 days [from the date of this offering circular] without the prior written consent of Benjamin Securities. Benjamin Securities may in its sole discretion and at any time without notice release some or all of the shares subject to lock-up agreements prior to the expiration of the period. When determining whether or not to release shares from the lock-up agreements, Benjamin Securities will consider, among other factors, the stockholder's reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time.

---

| |
|:---|
| 40 |
| *[**Table of Contents**](#TOC)* |

---

If a public market exists for our securities and our stockholders sell substantial amounts of our common stock in the public market, the market price of our common stock could decrease significantly. The perception in the public market that our stockholders might sell shares of our common stock could also depress the market price of our common stock. We cannot predict the effect, if any, of future sales of our common stock on the value of our common stock. Sales of substantial amounts of our common stock by large stockholders, or the perception that such sales could occur, may adversely affect the market price of our common stock.

The market price for shares of our common stock may drop significantly when such securities are sold in the public markets. A decline in the price of shares of our common stock might impede our ability to raise capital through the issuance of additional shares of our common stock or other equity securities.

***If a public market exists for our common stock in the future, our common stock price may be volatile and could decline substantially following this offering.***

If a public market exists for our common stock in the future, our common stock may be highly volatile and subject to wide fluctuations. Our financial performance, government regulatory action, tariffs, tax laws, interest rates, and market conditions in general could have a significant impact on the future market price of our common stock.

Some of the factors that could negatively affect or result in fluctuations in the future market price of our common stock include:

· actual or anticipated variations in our quarterly operating results;

· changes in market valuations of similar companies;

· adverse market reaction to the level of our indebtedness;

· additions or departures of key personnel;

· actions by stockholders;

· Prices of, and the supply and demand for, pharmaceutical products;

· speculation in the press or investment community;

· general market, economic, and political conditions, including an economic slowdown or dislocation in the global credit markets;

· our operating performance and the performance of other similar companies;

· changes in accounting principles; and

· passage of legislation or other regulatory developments that adversely affect us or the pharmaceutical industry.

---

| |
|:---|
| 41 |
| *[**Table of Contents**](#TOC)* |

---

Other factors unrelated to our performance that may affect the price of the Company's securities include the following: (i) the extent of analytical coverage available to investors concerning our business may be limited if investment banks with research capabilities do not follow the Company; (ii) lessening in trading volume and general market interest in the Company's securities may affect an investor's ability to trade significant numbers of the Company's securities; (iii) the size of our public float may limit the ability of some institutions to invest in the Company's securities; and (iv) a substantial decline in the price of the Company's securities that persists for a significant period of time could cause the Company's securities, if listed on an exchange, to be delisted from such exchange further reducing market liquidity. As a result of any of these factors, the market price of the Company's securities at any given point in time may not accurately reflect our long-term value. Class action litigation often has been brought against companies following periods of volatility in the market price of their securities. We may in the future be the target of similar litigation. Securities litigation could result in substantial costs and damages and divert management's attention and resources.

The fact that no market currently exists for the Company's securities may affect the pricing of the Company's securities in the secondary market, the transparency and availability of trading prices and the liquidity of the Company's securities. The market price of the Company's securities is affected by many other variables which are not directly related to our success and are therefore not within our control. These include other developments that affect the market for pharmaceutical products, the breadth of the public market for our Company's securities and the attractiveness of alternative investments. The effect of these and other factors on the market price of the Company's securities is expected to make the price of the Company's securities volatile in the future, which may result in losses to investors.

***The offering price per share of common stock offered under this offering circular may not accurately reflect the value of your investment.***

The offering price per common stock share offered by this offering circular was negotiated between us and the Placement Agents. Factors considered in determining the price of our common stock include:

· the information set forth in this offering circular and otherwise available to the Placement Agents;

· the prospects for our Company and the industry in which we operate;

· an assessment of our management;

· our past and present financial and operating performance;

· our prospects for future earnings;

· financial and operating information and market valuations of publicly-traded companies engaged in activities similar to ours;

· the prevailing conditions of United States securities markets at the time of this offering; and

· other factors deemed relevant.

The offering price may not accurately reflect the value of our common stock and may not be realized upon any subsequent disposition of the common stock.

***After the completion of this offering, we may be at an increased risk of securities class action litigation.***

Historically, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and pharmaceutical companies have experienced significant stock price volatility in recent years. If we were to be sued, it could result in substantial costs and a diversion of management's attention and resources, which could harm our business.

***We could issue "blank check" preferred stock without stockholder approval with the effect of diluting the interests of then-current stockholders and impairing their voting rights, and provisions in our charter documents and under Nevada law could discourage a takeover that stockholders may consider favorable.***

Our Amended and Restated Articles of Incorporation provides for the authorization to issue up to 25,000,000 shares of "blank check" preferred stock with designations, rights, and preferences as may be determined from time to time by our Board of Directors (the "Board"), of which 3,500,000 shares have been designated as Series A-1 Convertible Preferred Stock and 3,500,000 shares have been designated as Series A-2 Convertible Preferred Stock.

---

| |
|:---|
| 42 |
| *[**Table of Contents**](#TOC)* |

---

Our Board is empowered, without stockholder approval, to issue one or more series of preferred stock with dividend, liquidation, conversion, voting or other rights which could dilute the interest of, or impair the voting power of, our common stockholders. The issuance of a series of preferred stock could be used as a method of discouraging, delaying, or preventing a change in control. For example, it would be possible for our Board to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company. In addition, advance notice is required prior to stockholder proposals, which might further delay a change of control.

***The issuance of common stock upon conversion of our outstanding Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock will cause immediate and substantial dilution to existing stockholders and the sale of common stock upon conversion of our outstanding Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock may depress the market price of our common stock.***

As of the date of this offering circular, there are 3,500,000 shares designated and 3,500,000 outstanding shares of Series A-1 Convertible Preferred Stock ("Series A-1 preferred stock")and 3,500,000 shares designated and 3,500,000 outstanding shares of Series A-2 Convertible Preferred Stock ("Series A-2 preferred stock")(each as discussed and with certain terms related thereto), defined below under "Description of Capital Stock—Preferred Stock— Series A-1 Convertible Preferred Stock and Series A-2 Convertible Preferred Stock".

Each share of Series A-1 preferred stock is convertible at the option of the holders of Series A-1 preferred stock into one share of our common stock, subject to anti-dilution protections and other adjustments upon certain events. Until twenty-four (24) months have elapsed from the first underwritten public offering of the Company's common stock, holders of our Series A-1 preferred stock are prohibited from effecting a conversion. Holders of our Series A-1 preferred stock are also prohibited from effecting a conversion that would result in a holder beneficially owning more than 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the issuance of shares of common stock upon a conversion of Series A-1 preferred stock. Upon a sale of the Company, if not converted earlier, all shares of Series A-1 preferred stock will automatically convert into shares of our common stock.

Each share of Series A-2 preferred stock is convertible at the option of the holders of Series A-2 preferred stock into one share of our common stock, subject to anti-dilution protections and other adjustments upon certain events. Holders of our Series A-2 preferred stock are prohibited from effecting a conversion until (a) twenty-four (24) months have elapsed from the first underwritten public offering of the Company's common stock and (b) the 30-day volume-weighted average price for our common stock exceeds $20.00. Holders of our Series A-2 preferred stock are also prohibited from effecting a conversion that would result in a holder beneficially owning more than 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the issuance of shares of common stock upon a conversion of Series A-2 preferred stock which includes their holding of Series A-1 preferred stock together the conversion could not result in the holder of the Series A-1 and A-2 together owning more than 4.99% of the shares of our common stock outstanding immediately after giving effect to the issuance of shares of the common stock outstanding. Upon a sale of the Company, if not converted earlier, all shares of Series A-2 preferred stock will automatically convert into shares of our common stock if the sales price exceeds $20 per share.

The conversion of the Series A-1 and Series A-2 preferred stock into common stock of the Company will cause significant dilution to the then holders of our common stock.

Additionally, if conversions of our outstanding Series A-1 and Series A-2 preferred stock and sales of such converted shares take place, the price of our common stock may decline. In addition, the common stock issuable upon conversion of our outstanding Series A-1 and Series A-2 preferred stock may represent overhang that may also adversely affect the market price of our common stock. Overhang occurs when there is a greater supply of a company's stock in the market than there is demand for that stock. When this happens the price of the Company's stock will decrease, and any additional shares which stockholders attempt to sell in the market will only further decrease the share price. If the share volume of our common stock cannot absorb converted shares sold by the holder of the Series A Preferred Stock, then the value of our common stock will likely decrease.

---

| |
|:---|
| 43 |
| *[**Table of Contents**](#TOC)* |

---

***Because of the speculative nature of investment risk, you may lose your entire investment.***

An investment in the Company's securities carries a high degree of risk and should be considered as a speculative investment. The Company has no history of earnings, limited cash reserves, a limited operating history, has not paid dividends and is highly unlikely to pay dividends in the immediate or near future. The likelihood of success of the Company must be considered in light of the problems, expenses, difficulties, complications and delays frequently encountered in connection with the establishment of any business. An investment in the Company's securities may result in the loss of an investor's entire investment. Only potential investors who are experienced in high-risk investments and who can afford to lose their entire investment should consider an investment in the Company.

***If paid in shares of our common stock, in our discretion, the clinical progress and regulatory milestone payments owed to Zhittya will cause significant dilution to existing stockholders.***

Pursuant to our License Agreement with Zhittya, we are required to make certain milestone payments to Zhittya, upon Zhittya's achievement of applicable clinical progress and regulatory milestones, which are based on certain recognizable achievements in the development and approval of the injectable/infusion/intranasal drug candidates and topical drug candidates with the following applications: coronary heart disease, Parkinson's disease, stroke, diabetic foot ulcers and venous ulcers, as discussed in greater detail below under "Business—License Agreement with Zhittya".

The clinical progress and regulatory milestone payments for wound healing drug candidates range from $100,000 to $10,000,000 and will not exceed $75,000,000 in total for the entire class of wound healing drugs. The milestone payments for injectable and infusion drug candidates range from $100,000 to $25,000,000 and will not exceed $300,000,000 in total for the entire class of injectable/infusion/intranasal drugs.

At our discretion, such clinical progress and regulatory milestone payments may be paid in the form of cash or shares of our common stock, calculated using the average closing price over the prior 20 trading days prior to issuance, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, we are required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock.

Additionally, these clinical progress and regulatory milestone payments obligations will not begin to accrue until 90 days after the closing of our initial public offering or public sale of shares. To date, no clinical progress and regulatory milestone payments are due.

The issuance of shares of common stock in satisfaction of clinical progress and regulatory milestone payments due pursuant to the terms of the License Agreement will cause significant dilution to existing stockholders.

***Future sales of our common stock, other securities convertible into our common stock, or preferred stock could cause the market value of our common stock to decline and could result in dilution of your shares.***

Our Board of Directors is authorized, without your approval, to cause us to issue additional shares of our common stock or to raise capital through the creation and issuance of preferred stock, other debt securities convertible into common stock, options, warrants and other rights, on terms and for consideration as our Board of Directors in its sole discretion may determine.

If our stockholders sell substantial amounts of our common stock in the public market, the market price of our common stock could decrease significantly. The perception in the public market that our stockholders might sell shares of our common stock could also depress the market price of our common stock. If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the trading price of our common stock could decline significantly. Benjamin Securities may waive the lock-up agreements entered into in connection with this offering. If the lock-up agreements entered into in connection with this offering are waived, shares of our common stock will become available for sale into the market, subject to applicable law, which could reduce the market price for our common stock.

---

| |
|:---|
| 44 |
| *[**Table of Contents**](#TOC)* |

---

We cannot predict the effect, if any, of future sales of our common stock, or the availability of our common stock for future sales, on the value of our common stock. Sales of substantial amounts of our common stock by large stockholders, or the perception that such sales could occur, may adversely affect the market price of our common stock.

The market price for shares of our common stock may drop significantly when such securities are sold in the public markets. A decline in the price of shares of our common stock might impede our ability to raise capital through the issuance of additional shares of our common stock or other equity securities.

***We have no intention of declaring dividends in the foreseeable future.***

The decision to pay cash dividends on our common stock rests with our Board of Directors and will depend on our earnings, unencumbered cash, capital requirements and financial condition. We do not anticipate declaring any dividends in the foreseeable future, as we intend to use any excess cash to fund our operations. Investors in our common stock should not expect to receive dividend income on their investment, and investors will be dependent on the appreciation of our common stock to earn a return on their investment.

**<u>Risk Factors Relating to Our Organizational Documents</u>**

***Your investment in us may be adversely affected by the limitation of liability and indemnification of management under the Nevada Revised Statutes and our Amended and Restated Articles of Incorporation.***

The Nevada Revised Statutes and our Amended and Restated Articles of Incorporation provide for the limitation of the liability of directors for monetary damages. Such provisions may discourage stockholders from bringing a lawsuit against directors for breaches of fiduciary duty and may also have the effect of reducing the likelihood of derivative litigation against directors and officers even though such action, if successful, might otherwise be a benefit to our stockholders. In addition, a stockholder's investment in us may be adversely affected to the extent that costs of settlement and damage awards against our officers or directors are paid by us pursuant to such provisions. Additionally, in accordance with Nevada Revised Statutes, our Amended and Restated Articles of Incorporation and our Bylaws, we will indemnify, hold harmless and provide advancement of expenses, to the fullest extent permitted by applicable law, directors, officers, employees, and agents that are made a party or threatened to be made a party to legal proceedings by reason of the fact that such parties were working at our request. We direct you to our Amended and Restated Articles of Incorporation and our Bylaws for more information.

***Our Bylaws provide that the Eighth Judicial District Court of Clark County, Nevada, will be the sole and exclusive forum for certain disputes which could limit stockholders' ability to obtain a favorable judicial forum for disputes with us or our directors, officers, future employees or agents.***

Our Bylaws, to be effective immediately prior to the start of this offering, provide that unless we consent in writing to the selection of an alternative forum, the Eighth Judicial District Court of Clark County, Nevada shall be the sole and exclusive forum for state law claims with respect to: (i) any derivative action or proceeding brought in our name or right or on our behalf, (ii) any action asserting a claim for breach of any fiduciary duty owed by any of our directors, officers, future employees, or agents to us or our stockholders, (iii) any action arising or asserting a claim arising pursuant to any provision of Nevada Revised Statutes Chapters 78 or 92A or any provision of our Amended and Restated Articles of Incorporation or Bylaws, or (iv) any action asserting a claim governed by the internal affairs doctrine, including, without limitation, any action to interpret, apply, enforce, or determine the validity of our Amended and Restated Articles of Incorporation or Bylaws.

---

| |
|:---|
| 45 |
| *[**Table of Contents**](#TOC)* |

---

This choice of forum provision may limit a stockholder's ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our or its directors, officers, other future employees, or agents, which may discourage such lawsuits against us and our directors, officers, other future employees, and agents. Alternatively, if a court were to find the choice of forum provision contained in our Bylaws to be inapplicable or unenforceable in an action, that we may incur additional costs associated with resolving such action in other jurisdictions, which could have a material adverse effect on our business, results of operations, and financial condition.

**<u>General Risk Factors</u>**

***We have a short operating history in an evolving industry and, as a result, our past results may not be indicative of future operating performance.***

We have a short operating history in a rapidly evolving industry that may not develop in a manner favorable to our business. Our relatively short operating history makes it difficult to assess our future performance. You should consider our business and prospects in light of the risks and difficulties we may encounter.

Our future success will depend in large part upon our ability to, among other things:

· increase our market share;

· increase consumer awareness of our brand and maintain our reputation;

· anticipate and respond to macroeconomic changes;

· compete effectively;

· avoid interruptions in our business from information technology downtime, cybersecurity breaches, or labor stoppages;

· effectively manage our growth; and

· hire, integrate, and retain talented people at all levels of our organization.

If we fail to address the risks and difficulties that we face, including those associated with the challenges listed above as well as those described elsewhere in this "<u>Risk Factors</u>" section, our business and our operating results will be adversely affected.

***Failure to adequately manage our planned aggressive growth strategy may harm our business or increase our risk of failure.***

For the foreseeable future, we intend to pursue an aggressive growth strategy for the expansion of our operations. Our ability to rapidly expand our operations will depend upon many factors, including our ability to work in a regulated environment, establish and maintain strategic relationships with suppliers, and obtain adequate capital resources on acceptable terms. Any restrictions on our ability to expand may have a materially adverse effect on our business, results of operations, and financial condition. Accordingly, we may be unable to achieve our targets for growth, and our operations may not be successful or achieve anticipated operating results.

---

| |
|:---|
| 46 |
| *[**Table of Contents**](#TOC)* |

---

Additionally, our growth may place a significant strain on our managerial, administrative, operational, and financial resources and our infrastructure. Our future success will depend, in part, upon the ability of our senior management to manage growth effectively. This will require us to, among other things:

· implement additional management information systems;

· further develop our operating, administrative, legal, financial, and accounting systems and controls;

· hire additional personnel;

· develop additional levels of management within our company;

· locate additional office space; and

· maintain close coordination among our operations, legal, finance, sales and marketing, and client service and support personnel.

As a result, we may lack the resources to deploy our services on a timely and cost-effective basis. Failure to accomplish any of these requirements could have an adverse effect on future operating results.

***If we make any acquisitions, they may disrupt or have a negative impact on our business.***

If we make acquisitions in the future, we could have difficulty integrating the acquired company's assets, personnel and operations with our own. We do not anticipate that any acquisitions or mergers we may enter into in the future would result in a change of control of the Company. In addition, the key personnel of the acquired business may not be willing to work for us. We cannot predict the effect expansion may have on our core business. Regardless of whether we are successful in making an acquisition, the negotiations could disrupt our ongoing business, distract our management and employees and increase our expenses. In addition to the risks described above, acquisitions are accompanied by a number of inherent risks, including, without limitation, the following:

· the difficulty of integrating acquired assets or operations;

· the potential disruption of the ongoing businesses and distraction of our management and the management of acquired companies;

· difficulties in maintaining uniform standards, controls, procedures and policies;

· the potential impairment of relationships with employees and members and customers as a result of any integration of new management personnel;

· liability associated with acquired assets;

· the effect of any government regulations which relate to the business acquired;

· potential unknown liabilities associated with acquired businesses, or the defense of any litigation, whether or not successful, resulting from actions of the acquired company prior to our acquisition; and

· potential expenses under the labor, environmental and other laws of various jurisdictions.

Our business could be severely impaired if and to the extent that we are unable to succeed in addressing any of these risks or other problems encountered in connection with an acquisition, many of which cannot be presently identified. These risks and problems could disrupt our ongoing business, distract our management and employees, increase our expenses and adversely affect our results of operations.

---

| |
|:---|
| 47 |
| *[**Table of Contents**](#TOC)* |

---

***We may apply working capital and future funding to uses that ultimately do not improve our operating results or increase the value of our securities.***

In general, we have complete discretion over the use of our working capital and any new investment capital we may obtain in the future. Because of the number and variety of factors that could determine our use of funds, our ultimate expenditure of funds (and their uses) may vary substantially from our current intended operating plan for such funds. Our management has broad discretion to use any or all of our available capital reserves. Our capital could be applied in ways that do not improve our operating results or otherwise increase the value of a stockholder's investment.

***Claims, litigation, government investigations, and other proceedings may adversely affect our business and results of operations.***

We may be subject to actual and threatened claims, litigation, reviews, investigations, and other proceedings, including proceedings relating to our operations or those of third parties, and other matters. Any of these types of proceedings, may have an adverse effect on us because of legal costs, disruption of our operations, diversion of management resources, negative publicity, and other factors. The outcomes of these matters are inherently unpredictable and subject to significant uncertainties. Determining legal reserves and possible losses from such matters involves judgment and may not reflect the full range of uncertainties and unpredictable outcomes. Until the final resolution of such matters, we may be exposed to losses in excess of the amount recorded, and such amounts could be material. Should any of our estimates and assumptions change or prove to have been incorrect, it could have a material effect on our business, financial position, results of operations, or cash flows. In addition, it is possible that a resolution of one or more such proceedings, including as a result of a settlement, could require us to make substantial future payments, prevent us from offering certain products or services, require us to change our business practices in a manner materially adverse to our business, requiring development of non-infringing or otherwise altered technologies, damaging our reputation, or otherwise having a material effect on our operations.

***We may incur indebtedness in the future which could reduce our financial flexibility, increase interest expense and adversely impact our operations and our costs.***

As of March 31, 2026, we had $1,193,873 of liabilities. However, we may incur significant amounts of indebtedness in the future. Our level of indebtedness could affect our operations in several ways, including the following:

· a significant portion of our cash flows is required to be used to service our indebtedness;

· a high level of debt increases our vulnerability to general adverse economic and industry conditions;

· covenants contained in the agreements governing our outstanding indebtedness limit our ability to borrow additional funds and provide additional security interests, dispose of assets, pay dividends and make certain investments;

· a high level of debt may place us at a competitive disadvantage compared to our competitors that are less leveraged and, therefore, may be able to take advantage of opportunities that our indebtedness may prevent us from pursuing; and

· debt covenants may affect our flexibility in planning for, and reacting to, changes in the economy and in our industry.

A high level of indebtedness increases the risk that we may default on our debt obligations. We may not be able to generate sufficient cash flows to pay the principal or interest on our debt, and future working capital, borrowings or equity financing may not be available to pay or refinance such debt. If we do not have sufficient funds and are otherwise unable to arrange financing, we may have to sell significant assets or have a portion of our assets foreclosed upon which could have a material adverse effect on our business, financial condition and results of operations.

---

| |
|:---|
| 48 |
| *[**Table of Contents**](#TOC)* |

---

***Our business could be adversely affected by security threats, including cybersecurity threats.***

We face various security threats, including cybersecurity threats to gain unauthorized access to our sensitive information, to seek initiation of unauthorized fund transfers, or to render our information or systems unusable, and threats to the security of our facilities and infrastructure or third-party facilities and infrastructure. The potential for such security threats subjects our operations to increased risks that could have a material adverse effect on our business, financial condition and results of operations. For example, unauthorized access to our seismic data, reserves information or other proprietary information could lead to data corruption, communication interruptions, or other disruptions to our operations.

Our implementation of various procedures and controls to monitor and mitigate such security threats and to increase security for our information, systems, facilities and infrastructure may result in increased capital and operating costs. Moreover, there can be no assurance that such procedures and controls will be sufficient to prevent security breaches from occurring. If any of these security breaches were to occur, they could lead to losses of, or damage to, sensitive information or facilities, infrastructure and systems essential to our business and operations, as well as data corruption, reputational damage, communication interruptions or other disruptions to our operations, which, in turn, could have a material adverse effect on our business, financial position and results of operations.

***The threat and impact of terrorist attacks, cyber-attacks or similar hostilities may adversely impact our operations.***

We cannot assess the extent of either the threat or the potential impact of future terrorist attacks on the energy industry in general, and on us in particular, either in the short-term or in the long-term. Uncertainty surrounding such hostilities may affect our operations in unpredictable ways, including that our facilities or those of our counterparties, could be targets of, or indirect casualties of, an act of terror, a cyber-attack or electronic security breach, or an act of war.

***We may have difficulty managing growth in our business, which could have a material adverse effect on our business, financial condition and results of operations and our ability to execute our business plan in a timely fashion.***

Because of our small size, growth in accordance with our business plans, if achieved, will place a significant strain on our financial, technical, operational and management resources. As we expand our activities, including our planned pharmaceutical marketing efforts, there will be additional demands on our financial, technical and management resources. The failure to continue to upgrade our technical, administrative, operating and financial control systems or the occurrence of unexpected expansion difficulties could have a material adverse effect on our business, financial condition and results of operations and our ability to execute our business plan in a timely fashion.

***Failure to adequately protect critical data and technology systems could materially affect our operations.***

Information technology solution failures, network disruptions and breaches of data security could disrupt our operations by causing delays or cancellation of customer orders, impeding processing of transactions and reporting financial results, resulting in the unintentional disclosure of customer, employee or our information, or damage to our reputation. There can be no assurance that a system failure or data security breach will not have a material adverse effect on our financial condition, results of operations or cash flows.

***Stockholders may be diluted significantly through our efforts to obtain financing and satisfy obligations through the issuance of securities.***

Wherever possible, our board of directors will attempt to use non-cash consideration to satisfy obligations. In many instances, we believe that the non-cash consideration will consist of shares of our common stock, preferred stock (which may be similar to or different than the Series A-1 and A-2 preferred stock) or warrants to purchase shares of our common stock. Our board of directors has authority, without action or vote of the stockholders, subject to the requirements of any national exchange on which our common stock is eventually traded, if any (which generally require stockholder approval for any transactions which would result in the issuance of more than 20% of our then outstanding shares of common stock or voting rights representing over 20% of our then outstanding shares of stock, subject to certain exceptions, including sales in a public offering and/or sales which are undertaken at or above the lower of the closing price immediately preceding the signing of the binding agreement or the average closing price for the five trading days immediately preceding the signing of the binding agreement), to issue all or part of the authorized but unissued shares of common stock, preferred stock or warrants to purchase such shares of common stock. In addition, we may attempt to raise capital by selling shares of our common stock, possibly at a discount to market in the future. These actions will result in dilution of the ownership interests of existing stockholders and may further dilute common stock book value, and that dilution may be material. Such issuances may also serve to enhance existing management's ability to maintain control of us, because the shares may be issued to parties or entities committed to supporting existing management.

---

| |
|:---|
| 49 |
| *[**Table of Contents**](#TOC)* |

---

***Securities analysts may not cover, or continue to cover, our common stock and this may have a negative impact on the market price of our securities.***

The trading market for our common stock will depend, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over independent analysts (provided that we have engaged various non-independent analysts). We do not have any independent analysts that cover our common stock, and any future analysts which cover our common stock may discontinue coverage of our common stock at any time. If no independent securities or industry analysts cover us, the trading price for our common stock could be negatively impacted. If one or more of the future analysts who cover us, if any, downgrades our common stock, changes their opinion of our shares or publishes inaccurate or unfavorable research about our business, our stock price could decline. If one or more of these analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease and we could lose visibility in the financial markets, which could cause our stock price and trading volume to decline.

***There may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud may materially harm us.***

We do not expect that internal control over financial accounting and disclosure, even if timely and well-established, will prevent all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system's objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected. Failure of our control systems to prevent error or fraud could materially adversely affect our business.

***Failure to develop our internal controls over financial reporting as we grow could have an adverse impact on us.***

As we mature, we will need to develop our current internal control systems and procedures to manage our growth. We are required to establish and maintain appropriate internal controls over financial reporting. Failure to establish appropriate controls, or any failure of those controls once established, could adversely impact our public disclosures regarding our business, financial condition, or results of operations. In addition, management's assessment of internal controls over financial reporting may identify weaknesses and conditions that need to be addressed in our internal controls over financial reporting or other matters that may raise concerns for investors. Any actual or perceived weaknesses and conditions that need to be addressed in our internal control over financial reporting, disclosure of management's assessment of our internal controls over financial reporting, or disclosure of our public accounting firm's attestation to or report on management's assessment of our internal controls over financial reporting may have an adverse impact on the price of our common stock.

***The Company does not insure against all potential losses, which could result in significant financial exposure.***

The Company does not have commercial insurance or third-party indemnities to fully cover all operational risks or potential liability in the event of a significant incident or series of incidents causing catastrophic loss. As a result, the Company is, to a substantial extent, self-insured for such events. The Company relies on existing liquidity, financial resources and borrowing capacity to meet short-term obligations that would arise from such an event or series of events. The occurrence of a significant incident, series of events, or unforeseen liability for which the Company is self-insured, not fully insured or for which insurance recovery is significantly delayed could have a material adverse effect on the Company's results of operations or financial condition.

---

| |
|:---|
| 50 |
| *[**Table of Contents**](#TOC)* |

---

***Global economic conditions could materially adversely affect our business, results of operations, financial condition and growth.***

Adverse macroeconomic conditions, including inflation, slower growth or recession, new or increased tariffs, changes to fiscal and monetary policy, tighter credit, higher interest rates, high unemployment and currency fluctuations could materially adversely affect our operations, expenses, access to capital and the market for pharmaceutical products. In addition, uncertainty about, or a decline in, global or regional economic conditions could have a significant impact on our expected funding sources, suppliers and partners. A downturn in the economic environment could also lead to limitations on our ability to issue new debt; reduced liquidity; and declines in the fair value of our financial instruments. These and other economic factors could materially adversely affect our business, results of operations, financial condition and growth.

***We may be adversely affected by climate change or by legal, regulatory or market responses to such change.***

The long-term effects of climate change are difficult to predict; however, such effects may be widespread. Impacts from climate change may include physical risks (such as rising sea levels or frequency and severity of extreme weather conditions), social and human effects (such as population dislocations or harm to health and well-being), compliance costs and transition risks (such as regulatory or technology changes) and other adverse effects. The effects of climate change could increase the cost of certain products, commodities and energy (including utilities), which in turn may impact our ability to procure goods or services required for the operation of our business. Climate change could also lead to increased costs as a result of physical damage to or destruction of our facilities, equipment and business interruption due to weather events that may be attributable to climate change. These events and impacts could materially adversely affect our business operations, financial position or results of operation.

***We might be adversely impacted by changes in accounting standards.***

Our financial statements are subject to the application of U.S. GAAP, which periodically is revised or reinterpreted. From time to time, we are required to adopt new or revised accounting standards issued by recognized authoritative bodies, including the Financial Accounting Standards Board ("<u>FASB</u>") and the SEC. It is possible that future accounting standards may require changes to the accounting treatment in our financial statements and may require us to make significant changes to our financial systems. Such changes might have a materially adverse impact on our financial position or results of operations.

\* \* \* \* \*

**For all of the foregoing reasons and others set forth herein, an investment in our securities involves a high degree of risk.**

---

| |
|:---|
| 51 |
| *[**Table of Contents**](#TOC)* |

---

**USE OF PROCEEDS**

If we sell all of the Shares being offered, our net proceeds (after our estimated offering expenses of $980,000) will be $9,020,000. We will use these net proceeds for the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Shares Offered (% Sold)** | **Shares Sold** <br> **(100%)** | **Shares Sold** <br> **(75%)** | **Shares Sold** <br> **(50%)** | **Shares Sold** <br> **(25%)** |
| **Gross Offering Proceeds** | $**10000000** | $**7500000** | $**5000000** | $**2500000** |
| *Approximate Offering Expenses* |  |  |  |  |
| Misc. Expenses | 250000 | 200000 | 150000 | 100.000 |
| Legal and Accounting | 230000 | 230000 | 230000 | 230000 |
| Placement Agent Fees <sup>(1)</sup> | 700000 | 525000 | 350000 | 175000 |
| **Total Offering Expenses** | **980000** | **955000** | **730000** | **555000** |
| **Total Net Offering Proceeds** | **8820000** | **6545000** | **4270000** | **1995000** |
| *Principal Uses of Net Proceeds <sup>(2)</sup>* |  |  |  |  |
| Payment of Accrued Compensation <sup>(3)</sup> | 485836 | 485836 | 485836 | 485836 |
| Accounts Payable | 425287 | 425287 | 425287 | 425287 |
| Working Capital | 7.908877 | 5633877 | 3358877 | 1083877 |
| **Total Principal Uses of Net Proceeds** | **8.820000** | **6545000** | **4270000** | **1995000** |

---

________________

(1) Placement Agent Fees are 7%.

(2) Any line item amounts not expended completely shall be held in reserve as working capital and subject to reallocation to other line-item expenditures as required for ongoing operations.

(3) Accrued amounts owed to our former chief financial officer of $262,198, accounting consultant of $148,637 and former vice president of $75,000, total $485,836. Such amounts do not accrue interest.

The precise amounts that we will devote to each of the foregoing items, and the timing of expenditures, will vary depending on numerous factors.

The expected use of net proceeds from this offering represents our intentions based upon our current plans and business conditions, which could change in the future as our plans and business conditions evolve and change. The amounts and timing of our actual expenditures, specifically with respect to working capital, may vary significantly depending on numerous factors. The precise amounts that we will devote to each of the foregoing items, and the timing of expenditures, will vary depending on numerous factors. As a result, our management will retain broad discretion over the allocation of the net proceeds from this offering.

In the event we do not sell all of the Shares being offered, we may seek additional financing from other sources in order to support the intended use of proceeds indicated above. If we secure additional equity funding, investors in this offering would be diluted. In all events, there can be no assurance that additional financing would be available to us when wanted or needed and, if available, on terms acceptable to us.

We intend to pay our early regulatory milestone payments, such as completing animal toxicity studies and filing an IND from the cash flow from operations and not from these proceeds. The actual allocation of proceeds will be determined at our discretion and will depend on various factors, including our operational requirements and the timing and availability of other sources of capital.

The principal purposes of this offering are to strengthen our capitalization, enhance our financial flexibility, establish a public market for our common stock, and provide us and our stockholders with future access to the public equity markets. We believe that becoming a public company at this time will allow us to develop the operational infrastructure, internal controls, governance processes, and management experience necessary to operate effectively as a public reporting company. In addition, we believe that in the event we are able to obtain a public listing for our common stock, that will increase transparency for investors and provide greater potential liquidity for our existing stockholders over time. While we do not currently intend to use the net proceeds of this offering to fund significant clinical milestone payments, we believe that establishing our presence in the public markets now will better position us to raise additional capital in future periods, if needed, to support milestone payments and other development-related expenditures as Zhittya hopefully advances through its clinical trials and achieves key regulatory and clinical milestones.

We have based this estimate on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect. Additionally, our management will retain broad discretion over the allocation of the net proceeds from this offering and our existing cash and cash equivalents.

In the ordinary course of our business, we expect to from time to time evaluate the acquisition of, investment in, or in-license of complementary products, technologies, or businesses, and we could use a portion of the net proceeds from this offering for such activities. We currently do not have any agreements, arrangements, or commitments with respect to any potential acquisition, investment, or license.

Pending our use of the net proceeds from this offering, we intend to invest the net proceeds in a variety of capital preservation investments, including short-term, investment-grade, interest-bearing instruments and government securities.

---

| |
|:---|
| 52 |
| *[**Table of Contents**](#TOC)* |

---

**DIVIDEND POLICY**

We plan to retain any earnings for the foreseeable future for our operations. We have never paid any dividends on our common stock and do not anticipate paying any cash dividends in the foreseeable future. Any future determination to pay cash dividends will be at the sole discretion of our Board and will depend on our financial condition, operating results, capital requirements and such other factors as our Board deems relevant.

**CAPITALIZATION**

The following table sets forth our cash and cash equivalents and capitalization as of March 31, 2026:

· on an actual basis;

· on a pro forma as adjusted basis to give further effect to our issuance and sale of 1,000,000 Shares of our common stock being offered as part of this offering at a public offering price of $10.00 per share, after deducting the estimated placement agent fees and commissions and our estimated offering expenses.

You should read this capitalization table together with "*Use of Proceeds*," "*Management's Discussion and Analysis of Financial Condition and Results of Operations*," and our financial statements and the related notes appearing elsewhere in this offering circular.

---

| | | |
|:---|:---|:---|
|  | **March 31, 2026** | **March 31, 2026** |
|  | **Actual** | **Pro Forma**<br> **As Adjusted** |
| Cash | $159906 | $8068783 |
| Shareholders' equity |  |  |
| Series A-1 Preferred Stock, par value $0.001, 3,500,000 shares designated; 3,500,000 shares issued and outstanding, actual and as adjusted | 3500 | 3500 |
| Series A-2 Preferred Stock par value $0.001, 3,500,000 shares designated; 3,500,000 shares issued and outstanding, actual and as adjusted | 3500 | 3500 |
| &nbsp;&nbsp;&nbsp;&nbsp; Common Stock, par value $0.001 per share, 50,000,000 shares authorized; 2,632,000 shares issued and outstanding, actual; 3,632,000 shares issued and outstanding, as adjusted | 2632 | 3632 |
| Additional paid-in capital | 124320472 | 133170542 |
| Accumulated deficit | (125144816) | (125144816) |
| Total stockholders' equity (deficit) | (814712) | 7836358 |

---

Each increase (decrease) of 0.25 million Shares in the number of Shares of common stock offered by us would increase (decrease) each of our pro forma, as adjusted cash, additional paid-in capital, total stockholders' equity and total capitalization by approximately $2.5 million, after deducting estimated placement agent discounts and commissions.

The number of shares of common stock to be outstanding after this offering is based on 2,632,000 shares outstanding as of March 31, 2026 and 3,632,000 shares outstanding on a pro forma, as adjusted basis, including the 1,000,000 maximum number of Shares of common stock offered in the offering, and does not give effect to:

· the conversion of any Series A-1 Preferred Stock or Series A-2 Preferred Stock into common stock pursuant to the terms thereof;

· the exercise of Benjamin Securities' warrants; and

· no vesting of 50,000 outstanding restricted stock units.

---

| |
|:---|
| 53 |
| *[**Table of Contents**](#TOC)* |

---

**DILUTION**

If you invest in our common stock, your ownership interest will be diluted to the extent of the difference between the initial public offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering.

An early-stage company typically sells its shares (or grants options over its shares) to its founders and early employees at a very low cash cost, because they are, in effect, putting their "sweat equity" into the company. When the company seeks cash investments from outside investors, like you, the new investors typically pay a much larger sum for their shares than the founders or earlier investors, which means that the cash value of your stake is diluted because all the shares are worth the same amount, and you paid more than earlier investors for your shares.

As of March 31, 2026, we had a net tangible book value of $(1,026,663), or $(0.39) per share of common stock, based on shares of common stock outstanding at March 31, 2026. Our net tangible book value per share is the amount of our total tangible assets less our total liabilities at March 31, 2026, divided by the number of shares of common stock outstanding at March 31, 2026.

The following table illustrates dilution to new investors assuming the sale of 25%, 50%, 75% and 100% of the maximum number of Shares offered in this offering. This table is solely for illustration. Actual dilution will depend on the final number of Shares sold.

The following table illustrates this dilution on a per share basis based on the net tangible book value.

---

| | | | | |
|:---|:---|:---|:---|:---|
| **Percentage of Shares offered that are sold** | **100%** | **75%** | **50%** | **25%** |
| Public offering price per share | $10.00 | $10.00 | $10.00 | $10.00 |
| Historical net tangible book value per share as of March 31, 2026 | (0.39) | (0.39) | (0.39) | (0.39) |
| Increase in as adjusted net tangible book value per share attributable to new investors in this offering | 2.54 | 2.02 | 1.43 | 0.73 |
| As adjusted net tangible book value per share immediately after this offering | 2.15 | 1.63 | 1.04 | 0.34 |
| Dilution per share to new investors in this offering | $7.85 | $8.37 | $8.96 | $9.66 |

---

*Future dilution*

Another important way of looking at dilution is the dilution that happens due to future actions by the company. The investor's stake in a company could be diluted due to the company issuing additional shares. In other words, when the company issues more shares, the percentage of the company that you own will go down, even though the value of the company may go up. You will own a smaller piece of a larger company. This increase in number of shares outstanding could result from a stock offering (such as an initial public offering, another crowdfunding round, a venture capital round, angel investment), employees exercising stock options, or by conversion of certain instruments (e.g. convertible bonds, preferred shares or warrants) into stock.

---

| |
|:---|
| 54 |
| *[**Table of Contents**](#TOC)* |

---

If the Company decides to issue more shares, an investor could experience value dilution, with each share being worth less than before, and control dilution, with the total percentage an investor owns being less than before. There may also be earnings dilution, with a reduction in the amount earned per share (though this typically occurs only if a company offers dividends, and most early-stage companies are unlikely to offer dividends, preferring to invest any earnings into the company).

If you are making an investment expecting to own a certain percentage of the company or expecting each share to hold a certain amount of value, it's important to realize how the value of those shares can decrease by actions taken by the company. Dilution can make drastic changes to the value of each share, ownership percentage, voting control, and earnings per share.

**MANAGEMENT'S DISCUSSION AND ANALYSIS** 

**OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

*The following discussion and analysis summarizes the significant factors affecting our operating results, financial condition, liquidity and cash flows as of and for the periods presented below. The following discussion and analysis should be read in conjunction with the financial statements and the related notes thereto included elsewhere in this offering circular. The discussion contains forward-looking statements that are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. Actual results could differ materially from those discussed in or implied by forward-looking statements as a result of various factors, including those discussed below and elsewhere in this offering circular, particularly in the sections titled "Risk Factors" and "Information Regarding Forward-Looking Statements.*

**Going Concern Analysis**

Our ability to become profitable depends on our ability to generate revenue. We are currently generating revenue as Zhittya Genesis Medicine, Inc. (Zittya) treats patients in its foreign clinics. We do not expect to generate significant revenue until our strategic partner, Zhittya, obtains FDA approval for its drug candidates and we successfully commercialize one of the product candidates in the U.S. and Canada.

The Company's sole source of income is the other income received from Zhittya pursuant to our License Agreement with Zhittya. As of March 31, 2026, we had a total stockholders' deficit of $(814,712), an accumulated deficit of $125,144,816, and negative working capital of $1,010,091. As of December 31, 2025, we had a total stockholders' deficit of $(1,125,680), an accumulated deficit of $125,452,659, and negative working capital of $1,272,378. The large accumulated deficit is mainly the result of the original 2016 license agreement with Zhittya valued at $76.5 million, as discussed in greater detail under "Business—License Agreement with Zhittya", that was fully written off by 2022 under a revised valuation. Another $46.5 million in expenses related to the value of the preferred stock issued to Zhittya pursuant to the terms of the License Agreement. These two items, combined, equal $123 million of the accumulated deficit and do not reflect the results of ongoing operations. From 2023 to 2025, the Company has generated net income every year, with cumulative income of $251,597 over these three years, and net income for the three months ended March 31, 2026 of $307,844.

In the event Zhittya is further delayed in producing FGF-1, performing studies, submitting INDs, obtaining approval from the FDA of such INDs, and/or otherwise delayed further from obtaining FDA approval for FGF-1, which it anticipates will take at least three to seven years, our ability to generate cash flow and support our operations will be negatively affected, we may need to raise additional funds, and we may never be able to generate sufficient funds to support our operations.

We expect to incur significant expenses for the foreseeable future. We expect our expenses to increase in connection with our ongoing activities. Further, we expect to incur additional costs associated with operating as a reporting company. Accordingly, we will need additional financing to support our continuing operations. We plan to seek to fund our operations through public or private equity, debt financings, or other sources. Adequate additional financing may not be available to us on acceptable terms, or at all, or if such funding comes through the form of equity, may cause significant dilution to existing stockholders. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenue to achieve profitability, and we may never do so.

---

| |
|:---|
| 55 |
| *[**Table of Contents**](#TOC)* |

---

The Company was incorporated on May 16, 2016 and will require significant additional capital in order to operate in the normal course of business and fund clinical progress and regulatory milestone payments related to approvals and clinical studies. As a result, these conditions have raised substantial doubt regarding our ability to continue as a going concern beyond one year. While we believe in the viability of management's strategy to generate sufficient revenue, control costs, and the ability to raise additional funds, if necessary, there can be no assurances to that effect. Our ability to continue as a going concern is dependent upon the ability to complete clinical studies and implement the business plan, raise additional capital, generate sufficient other income/revenues, and to control operating expenses. The Company's ability to realize its assets and discharge its liabilities is dependent upon the Company obtaining the necessary financing and ultimately upon its ability to achieve profitable operations. These material uncertainties may cast significant doubt on the Company's ability to continue as a going concern. Failure to arrange adequate financing on acceptable terms and/or achieve profitability may have an adverse effect on the financial position, results of operations, cash flows and prospects of the Company. The financial statements do not give effect to adjustments to assets or liabilities that would be necessary should the Company be unable to continue as a going concern. These adjustments could be material.

**Results of Operations**

We have a limited operating history. Therefore, there is limited historical financial information upon which to base an evaluation of our performance. Our prospects must be considered in light of the uncertainties, risks, expenses, and difficulties frequently encountered by companies in their early stages of operations. We have incurred significant net losses since inception. We have, however, generated net income of $91,510 and $97,039 for the years ended December 31, 2025 and 2024, respectively and net income for the three months ended March 31, 2026 of $307,844. As of March 31, 2026, we had a total stockholders' deficit of $(814,712), an accumulated deficit of $125,144,816, and negative working capital of $1,010,091. As of December 31, 2025, we had a total stockholders' deficit of $(1,125,680), an accumulated deficit of $125,452,659, and negative working capital of $1,272,378. The large accumulated deficit is mainly the result of the original 2016 license agreement with Zhittya valued at $76.5 million, as discussed in greater detail under "Business—License Agreement with Zhittya", that was fully written off by 2022 under a revised valuation. Another $46.5 million in expenses related to the value of the preferred stock issued to Zhittya pursuant to the terms of the License Agreement. These two items, combined, equal $123 million of the accumulated deficit and do not reflect the results of ongoing operations. From 2023 to 2025, the Company has generated net income every year, with cumulative income of $251,597 over these three years, and net income for the three months ended March 31, 2026 of $307,844. We expect to incur additional net expenses over the next several years as we continue to maintain and expand our existing operations. The amount of future income we will achieve is uncertain.

*Financial Overview*

**Revenue**

We are generating other income from Zhittya's cross-border operations and from a patient sponsored Type 2 diabetes research study taking place in Las Vegas, Nevada, and we expect the cross-border operations to continue and to grow, and future patient-funded studies to potentially become available in the United States. However, for the Company to make significant revenue, Zhittya, our strategic partner, needs to complete the development of its product candidates in a timely manner and obtain regulatory approval for them; otherwise, our ability to generate future revenue, and our results of operations and financial position, would be materially and adversely affected.

If our development efforts for Zhittya's current or future product candidates are successful and result in regulatory approval, we may generate revenue in the future from product sales of such licensed products. Because of the numerous risks and uncertainties associated with product development, regulatory approval, and market acceptance, we are unable to predict the amount or timing of product revenue.

**Operating Expenses**

Operating expenses consist primarily of professional fees, consulting fees, office lease expenses, marketing costs, and general and administrative expenses. Operating expenses are expensed when incurred.

---

| |
|:---|
| 56 |
| *[**Table of Contents**](#TOC)* |

---

Professional fees include audit, legal, and outside accounting costs. Consulting fees primarily include the outsourced CEO and CFO, as well as general and business development consulting. General and administrative expenses include insurance, technology, banking, and other administrative costs.

We anticipate that our operating expenses will increase in the future to support our efforts to promote and raise awareness of the Company and to operate as a reporting company. These expenses will likely include costs related to the fees to outside consultants, lawyers, accountants, and investor relations firms.

**Other income (expense)**

Other income (expense) primarily consists of Income from participation in future revenues from a related party.

**Income Taxes** 

As of December 31, 2025, and 2024 we had net operating loss (NOL) carry forwards of approximately $2,100,000. Net operating loss carryforwards of $32, and $35,310 will expire in 2036 and 2037, respectively. The remaining $2.07 million of the Company's net operating losses have an indefinite carryforward period, but utilization for any tax year is limited to 80% of taxable income. After weighing all available and positive and negative evidence for the period, the Company determined a full valuation allowance is necessary against all net operating losses. As of March 31, 2026, the Company's net operating loss carryforwards and related valuation allowance were not materially changed from December 31, 2025. The Company recorded no income tax expense for the three months ended March 31, 2026.

We have not recorded any net tax benefit due to uncertainty around utilizing these tax attributes within their respective carryforward periods.

Utilization of the net operating losses may be subject to a substantial annual limitation due to ownership change limitations provided by the Internal Revenue Code of 1986, as amended (the "Internal Revenue Code").

**RESULTS OF OPERATIONS**

***Comparison of the three months ended March 31, 2026, and 2025***

---

| | | | |
|:---|:---|:---|:---|
|  | **For the Three Months** <br> **Ended March 31,** | **For the Three Months** <br> **Ended March 31,** | **For the Three Months** <br> **Ended March 31,** |
|  | **2026** | **2025** | **Change** |
| **Operating expenses:** |  |  |  |
| &nbsp;&nbsp;&nbsp; Professional fees | $62772 | $62545 | $227 |
| &nbsp;&nbsp;&nbsp; Consulting fees | 99125 | 79104 | 20021 |
| &nbsp;&nbsp;&nbsp; Lease expense | 8044 | 14991 | (6947) |
| &nbsp;&nbsp;&nbsp; General and administrative expenses | 4564 | 2630 | 1934 |
| **Total operating expenses** | 174505 | 159270 | 15235 |
| Loss from operations | (174505) | (159270) | (15235) |
| Other income (expense): |  |  |  |
| &nbsp;&nbsp;&nbsp; Income from participation in future revenues – related party | 484293 | 85750 | $398543 |
| &nbsp;&nbsp;&nbsp; Interest expense | (1113) | (1595) | $482 |
| &nbsp;&nbsp;&nbsp; Income tax expense | (830) | - | $(830) |
| **Net income (loss)** | $307844 | $(75115) | $382959 |

---

---

| |
|:---|
| 57 |
| *[**Table of Contents**](#TOC)* |

---

***Professional fees***

These fees increased $227 for the three months ended March 31, 2026, due to $28,151 in additional audit fees in preparation for a potential public offering and $1,079 in legal fees, offset mostly by $29,003 in lower accounting costs with the financials now being initially prepared by the Company's CFO.

***Consulting fees***

Consulting fees increased $20,021 for the three months ended March 31, 2026, as a result of the Company hiring a business development consultant for $12,000 ($4,000 over three months) and the CFO being paid $8,021 more for working a full quarter versus 75 days during the three months ended March 31, 2025.

***Lease expense***

Lease expense decreased $6,947 in the three months ended March 31, 2026 as the Company relocated to a less expensive office lease in mid- January 2025.

***General and administrative expenses***

General and administrative expenses increased $1,934 in the three months ended March 31, 2026, primarily from insurance and automobile expenses relating to the Company's business development consultant engaged in 2026.

***Income from participation in future revenues* – related party**

This income increased $398,543 for the three months ended March 31, 2026, due to $603,250 more in patient fees offset by $204,707 more in advertising costs and referral fees. Zhittya launched type 2 diabetes treatments in September 2025, for which the Company receives $15,000 per patient, resulting in $480,000 in new fees paid in the three months ended March 31, 2026. The Company also received $123,250 in additional fees from other treatments from Zhittya in the three months ended March 31, 2026, compared to the three months ended March 31, 2025.

***Interest expense***

Interest expense was $482 less in the three months ended March 31, 2026 due to $12,000 in prior related party loans that were repaid after March 31, 2025.

***Income tax expense***

The Company incurred $830 in income tax expense for the three months ended March 31, 2026.

***Net Income (Loss)***

The Company had net income of $307,844 for the three months ended March 31, 2026, compared to a net loss of $(75,115) in the three months ended March 31, 2025, primarily due to $398,543 in additional income from participation in future revenues, offset slightly by $15,236 more in operating expenses, each as discussed in greater detail above.

---

| |
|:---|
| 58 |
| *[**Table of Contents**](#TOC)* |

---

***Comparison of the years ended December 31, 2025, and 2024:***

---

| | | | |
|:---|:---|:---|:---|
|  | **For the Years Ended,** | **For the Years Ended,** | **For the Years Ended,** |
|  | **2025** | **2024** | **Change** |
| **Operating expenses:** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Professional fees | $220852 | $114256 | $106596 |
| &nbsp;&nbsp;&nbsp;&nbsp; Consulting fees | 352479 | 127000 | 225479 |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease expense | 36013 | 89888 | (53875) |
| Marketing expense | 995 |  | 995 |
| &nbsp;&nbsp;&nbsp;&nbsp; General and administrative expenses | 10227 | 10475 | (247) |
| **Total operating expenses** | 620566 | 341619 | 278948 |
| Loss from operations | (620566) | (341619) | (278948) |
| Other income (expense): |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Income from participation in future revenues – related party | 718750 | 441000 | 277750 |
| &nbsp;&nbsp;&nbsp;&nbsp; Interest expense | (6674) | (2342) | (4332) |
| **Net income** | $91510 | $97039 | $(5530) |

---

**Professional fees**

These fees increased by $106,596 for the year ended 2025 versus the year ended 2024, driven by $107,133 in additional audit expenses and $16,806 in extra legal fees incurred in preparation for the anticipated public offering, offset by $(17,343) in lower accounting fees due to more efficient external support.

**Consulting fees** 

The increase of $225,479 for the year ended December 31, 2025 versus the year ended December 31, 2024, is due to the engagement of an outsourced CFO for $184,479 in the year ended 2025, and a $41,000 increase in the remuneration of other consultants.

**Lease expense**

The Company relocated to a less expensive office lease in mid-January 2025. The year ended December 31, 2025 included $6,775 in final costs on the old lease in January 2025 and $29,238 in costs on the new lease. The year ended December 31, 2024 consists of twelve months on the old lease at $22,472 per quarter.

**Income from participation in future revenues – related party**

For the year ended December 31, 2025, this income increased over the year ended December 31, 2024, due to $300,000 in income from diabetes studies launched by Zhittya in September 2025, offset by $22,250 less income from ongoing studies.

**Interest expense**

Interest expense was $6,674 for the year ended December 31, 2025, versus $2,342 for the year ended December 31, 2024, was due to related party loans that averaged nearly $30,000 higher during the current year.

**Net income**

For the year ended December 31, 2025, the Company generated $5,530 less net income than in the year ended December 31, 2024. Higher other income of $277,750 was offset by $278,948 more in operating expenses, largely in preparation for an anticipated public offering in 2026.

---

| |
|:---|
| 59 |
| *[**Table of Contents**](#TOC)* |

---

**LIQUIDITY, FINANCING, AND CAPITAL RESOURCES**

As of March 31, 2026, we had approximately $159,906 in unrestricted cash. We believe our current unrestricted cash will not be sufficient to fund our currently anticipated operating expenses. We plan on funding this shortfall through additional borrowings from related parties, and if necessary, the sale of additional common shares of stock, including through the offering contemplated by this offering circular.

We have incurred significant operating losses and negative cash flows from operations since our inception, and we anticipate that we will incur significant losses for at least the next several years. As of March 31, 2026 and December 31, 2025, we had cash and cash equivalents of $159,906 and $176,337, respectively. For the three months ended March 31, 2026 and 2025, our net income (loss) was $307,844 and $(75,115), respectively, and our net cash provided by operating activities was $483,373 and $16,792, respectively. As of December 31, 2025 and December 31, 2024, we had cash of $176,337 and $67,434, respectively. For the years ended December 31, 2025 and 2024, our net income was $91,510 and $97,039, respectively, and our net cash provided by operating activities was $176,477 and $66,149, respectively.

We believe that funds from this offering, as well as revenues that the Company expects to receive from the ongoing Parkinson's disease and Type 2 diabetes studies, will support our operations until such time as Zhittya obtains FDA approval for one or more of its drug candidates, and milestone payments are due. We believe that the earliest possible timeframe in which FDA approval could be obtained, if at all, is approximately three to seven years. Health Canada approval is not expected to be sought until after FDA approval is received, if at all, and the timeline for such future approval, if any, cannot be estimated at this time.

Our future liquidity and capital funding requirements are expected to depend on numerous factors, including:

· our need to make clinical progress and regulatory milestone payments to Zhittya;

· our ability to handle any delays in approval of the drug candidates that the Company is planning to sell;

· the costs of commercialization activities, including product sales, marketing, manufacturing, and distribution;

· our need to implement additional infrastructure and internal systems;

· our ability to hire additional personnel to support our operations as a reporting company; and

· the emergence of competing drugs, technologies, or other adverse market developments.

We believe that our existing cash resources will not be sufficient to meet our forecasted requirements for operating liquidity, capital expenditures, and debt services for at least the next 12 months. We expect that over the next 12 months, our liquidity needs could range from none to $1 million, in the worst case. The Company does not currently have, and does not expect to have during the next 12 months, any capital expenditures or any debt service. The Company plans to address its financing requirements relating to the financial challenges as follows:

· plans to raise capital of up to $10 million through the offering described in this offering circular,

· receive funds from Zhittya's U.S. operations,

· borrowing additional funds, and

· manage cash outlays.

There is no certainty that the Company will be successful in raising capital and the Company currently has no committed source for borrowings. If we raise additional funds by issuing equity securities, our shareholders will experience dilution. Debt financing, if available, may involve covenants further restricting our operations or our ability to incur additional debt. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. Additional financing may not be available at all, or in amounts or on terms that we do not deem to be favorable. If we are unable to obtain additional financing when needed to satisfy our liquidity requirements, we may be required to delay the marketing of Zhittya's drugs.

The following table provides detailed information about our net cash flows from continuing operations for the periods indicated:

---

| |
|:---|
| 60 |
| *[**Table of Contents**](#TOC)* |

---

**CASH FLOWS**

***For the three months ended March 31, 2026 and 2025***

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Net cash provided by operating activities | 43373 | 16792 |
| Net cash used in investing activities |  | (5336) |
| Net cash provided by (used in) financing activities | (59804) | 7334 |
| Net increase (decrease) in cash and cash equivalents | (16431) | 18790 |

---

*Net Cash used in operating activities*

In the three months ended March 31, 2026, net cash provided by operating activities was mainly the result of the Company generating $307,844 of net income, incurring $3,125 in non-cash stock-based consulting expenses, and a $156,908 increase in accounts payable, offset by a $440,000 decrease in other receivables, related party. Net cash provided by operating activities for the three months ended March 31, 2025 was mainly due to $75,115 of net loss, offset by $31,750 of increase in other receivables, related party, $28,214 of increase in accounts payable and $19,320 of increase in accrued expenses.

*Net Cash used in investing activities*

The Company paid a security deposit on a less expensive new office lease entered in January 2025 of $5,336, which made up the entire net cash used in investing activities for the three months ended March 2025.

*Net Cash provided by financing activities*

Net cash provided by financing activities for the three months ended March 31, 2026, was mainly due to the Company reducing loans payable to related parties by $12,000 and incurring $47,804 in deferred offering costs. Net cash provided by financing activities for the three months ended March 31, 2025, was mainly due to the Company borrowing a net of $33,000 from related parties in March 2025 to fund operating needs, offset by the repayment of a $916 loan and the Company incurring $25,000 in deferred offering costs.

***For the years ended December 31, 2025 and 2024***

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **2024** |
| Net cash provided by operating activities | $176477 | $66150 |
| Net cash (used in) investing activities | (5336) |  |
| Net cash (used in) financing activities | (62238) | (21665) |
| Net increase in cash | $108903 | $44485 |

---

*Net cash provided by operating activities*

For the year ended December 31, 2025, the Company had $176,477 of cash provided by operating activities, which mainly consisted of net income of $91,510, $1,360 in non-cash lease expenses, $7,722 in lease payments applied against a security deposit, and $11,979 in stock consulting expenses. The Company also collected the remaining $31,750 related party receivable, and increased accounts payable/accrued expenses by $37,776 to conserve cash, offset slightly by prepaid insurance for $5,620 for the year ended December 31, 2025. For the year ended December 31, 2024, net cash provided by operating activities was due to net income of $97,039, offset by $9,027 in non-cash lease expenses, together $37,909 in lease payments applied against a security deposit, collected $24,000 in related party receivables, and used this cash flow to reduce accounts payable/accrued expenses by $83,771.

*Net Cash used in investing activities*

Net cash used in investing activities for the year ended December 31, 2025 was solely due to $5,336 paid on a security deposit for a less expensive new office lease deposit.

---

| |
|:---|
| 61 |
| *[**Table of Contents**](#TOC)* |

---

*Net Cash used in financing activities*

For the year ended December 31, 2025, net cash used in financing activities was $62,238 and related to $86,126 in deferred offering costs, $916 in external loans and a net of $24,804 received from related parties to fund operating needs. For the year ended December 31, 2024, net cash used in financing activities was $21,665 and related to $35,000 incurred in deferred offering costs, a net of $13,390 received from related-party loans, and $55 repaid on an external loan.

**OFF-BALANCE SHEET ARRANGEMENTS**

We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have any off-balance sheet arrangements, as defined by applicable regulations of the SEC, which are reasonably likely to have a current or future material effect on our financial condition, results of operations, liquidity, capital expenditures, or capital resources.

**CRITICAL ACCOUNTING POLICIES AND ESTIMATES**

Our discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States, or US GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised, if the revision affects only that period, or in the period of the revision and future periods, if the revision affects both current and future periods.

Significant judgments, estimates and assumptions that have the most significant effect on the amounts recognized in the financial statements relate to the stock-based compensation, other receivables, and income from participation in future revenues. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management's estimates.

Accounting for past equity issuances has been based on the estimated fair value at the time of issuance. Share-based compensation was based on the value of equity transactions over the past three years prior to the issuance of the Restricted Stock Units.

**Recently Issued Accounting Pronouncements**

In July 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets (ASU 2025-05). The ASU 2025-05 relates to estimating credit losses under the calculation of current expected credit losses (CECL) for current accounts receivable and current contract assets arising from revenue transactions accounted for under ASC 606, Revenue from Contracts with Customers. The provisions of ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company early adopted ASU 2025-05 on January 1, 2025 on a prospective basis and elected to apply the practical expedient for accounts receivable, however, since the Company does not have any accounts receivable at December 31, 2025, there was no impact of this adoption on the accompanying financial statements or operations.

In November 2024, the FASB issued ASU 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures" to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its financial statements and related disclosures. The adoption of this pronouncement is not expected to have a material impact on the Company's financial statements.

---

| |
|:---|
| 62 |
| *[**Table of Contents**](#TOC)* |

---

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures related to improvements to income tax disclosures. The amendments in this update require enhanced jurisdictional and other disaggregated disclosures for the effective tax rate reconciliation and income taxes paid. The amendments in this update are effective for fiscal years beginning after December 15, 2024. The adoption of this pronouncement had no impact on the Company's financial statements.

In November 2023, the FASB issued ASU 2023-07 "Segment Reporting: Improvements to Reportable Segment Disclosures". This guidance expands public entities' segment disclosures primarily by requiring disclosure of significant segment expenses that are regularly provided to the chief operating decision maker and included within each reported measure of segment profit or loss, an amount and description of its composition for other segment items, and interim disclosures of a reportable segment's profit or loss and assets. The guidance is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The amendments are required to be applied retrospectively to all prior periods presented in an entity's financial statements. The Company adopted the ASU on January 1, 2024 and has expanded its disclosure.

In October 2023, the FASB issued ASU 2023-06 "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative," which incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification ("Codification"). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification topics, allow investors to more easily compare entities subject to the SEC's existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SEC's regulations. The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this ASU should be applied prospectively. The Company does not expect ASU 2023-06 will have a material impact to its financial statements or related disclosures.

**Implications of Being an Emerging Growth Company**

We are not subject to the ongoing reporting requirements of the Exchange Act because we are not registering our securities under the Exchange Act. Rather, we will be subject to the more limited reporting requirements under Regulation A, including the obligation to electronically file:

· annual reports (including disclosure relating to our business operations for the preceding two fiscal years, or, if in existence for less than two years, since inception, related party transactions, beneficial ownership of the issuer's securities, executive officers and directors and certain executive compensation information, <u>MD&A</u> of the issuer's liquidity, capital resources, and results of operations, and two years of audited financial statements),

· semiannual reports (including disclosure primarily relating to the issuer's interim financial statements and MD&A) and

· current reports for certain material events.

In addition, at any time after completing reporting for the fiscal year in which our offering statement was qualified, if the securities of each class to which this offering statement relates are held of record by fewer than 300 persons and offers or sales are not ongoing, we may immediately suspend our ongoing reporting obligations under Regulation A.

---

| |
|:---|
| 63 |
| *[**Table of Contents**](#TOC)* |

---

If we become subject to the ongoing reporting requirements of the Exchange Act in the future, as an issuer with less than $1.235 billion in total annual gross revenues during our last fiscal year, we will qualify as an "emerging growth company" under the Jumpstart Our Business Startups Act of 2012 (the "<u>JOBS Act</u>") and this status will be significant. An emerging growth company may take advantage of certain reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. In particular, as an emerging growth company we:

· will not be required to obtain an auditor attestation on our internal controls over financial reporting pursuant to the Sarbanes-Oxley Act of 2002;

· will not be required to provide a detailed narrative disclosure discussing our compensation principles, objectives and elements and analyzing how those elements fit with our principles and objectives (commonly referred to as " <u>compensation discussion and analysis</u> ");

· will not be required to obtain a non-binding advisory vote from our shareholders on executive compensation or golden parachute arrangements (commonly referred to as the " <u>say-on-pay</u>," " <u>say-on-frequency</u> " and " <u>say-on-golden-parachute</u> " votes);

· will be exempt from certain executive compensation disclosure provisions requiring a pay-for-performance graph and CEO pay ratio disclosure;

· may present only two years of audited financial statements and only two years of related Management's Discussion and Analysis of Financial Condition and Results of Operations, or MD&A; and

· will be eligible to claim longer phase-in periods for the adoption of new or revised financial accounting standards.

To the extent we register our common stock under the Exchange Act in the future, we intend to take advantage of all of these reduced reporting requirements and exemptions, including the longer phase-in periods for the adoption of new or revised financial accounting standards under Section 107 of the JOBS Act. Our election to use the phase-in periods may make it difficult to compare our financial statements to those of non-emerging growth companies and other emerging growth companies that have opted out of the phase-in periods under Section 107 of the JOBS Act.

Under the JOBS Act, we may take advantage of the above-described reduced reporting requirements and exemptions for up to five years after our initial sale of common equity pursuant to a registration statement declared effective under the Securities Act, or such earlier time that we no longer meet the definition of an emerging growth company. Note that this offering, while a public offering, is not a sale of common equity pursuant to a registration statement, since the offering is conducted pursuant to an exemption from the registration requirements. In this regard, the JOBS Act provides that we would cease to be an "<u>emerging growth company</u>" if we have more than $1.235 billion in annual revenues, have more than $700 million in market value of our common stock held by non-affiliates, or issue more than $1 billion in principal amount of non-convertible debt over a three-year period.

Certain of these reduced reporting requirements and exemptions are also available to us due to the fact that we may also qualify, once listed, as a "<u>smaller reporting company</u>" under the Commission's rules. For instance, smaller reporting companies are not generally required to obtain an auditor attestation on their assessment of internal control over financial reporting; are not required to provide a compensation discussion and analysis; are not required to provide a pay-for-performance graph or CEO pay ratio disclosure; and may present only two years of audited financial statements and related MD&A disclosure.

---

| |
|:---|
| 64 |
| *[**Table of Contents**](#TOC)* |

---

**BUSINESS**

**Overview**

We are a sales and marketing company which has the exclusive right to sell the drugs developed by Zhittya Genesis Medicine, Inc. ("Zhittya") in the United States and Canada. The Company is party to a product licensing and commercialization agreement with Zhittya, as discussed in further detail below. Zhittya holds seven million shares of the Company's preferred stock (which are convertible into shares of common stock of the Company on a one-for-one basis, subject to certain time-based and event-based restrictions, as well as a 4.99% ownership limitation, certain anti-dilution rights and pari passu liquidation rights with the holders of common stock, on an as converted basis), which together make Zhittya a related party and give Zhittya significant influence over the Company. Zhittya's current sole drug candidate, Fibroblast Growth Factor 1 ("FGF-1"), has been shown in certain studies, to stimulate the growth of new blood vessels (a biological process termed "angiogenesis") in tissues or organs that have perfusion defects (i.e., areas of reduced blood flow). Zhittya is developing these biological drug candidates to attempt to treat Parkinson's disease, coronary artery disease, type 2 diabetes, diabetic foot ulcers and many other diseases. FGF-1 is still in the early stages of study and Zhittya will need to initiate and complete clinical trials before the FDA, or another foreign regulatory body, can assess whether the drug is safe and effective to treat one or more indications. The Company was incorporated in the State of Nevada on May 16, 2016, and our headquarters are located in Las Vegas, Nevada.

**Our Business** 

We have entered into a License Agreement with Zhittya (described in greater detail below) which grants us the exclusive right to market and sell drugs from Zhittya's portfolio in the United States and Canada. Our right to market and sell Zhittya's drugs is subject to Zhittya's drug candidates first being granted regulatory approval for sale by the FDA or Health Canada, and we believe that the earliest possible timeframe in which FDA approval could be obtained, if at all, is approximately three to seven years. Health Canada approval is not expected to be sought until after FDA approval is received, if at all, and the timeline for such future approval, if any, cannot be estimated at this time. This estimate for FDA approval reflects a minimum projected period based on current assumptions and is subject to substantial uncertainty and numerous factors beyond the Company's control, including the scope and outcomes of clinical trials, regulatory review timelines, requests for additional data, and changes in regulatory requirements. The actual time required to obtain FDA approval, if ever obtained, may be significantly longer than three to seven years or may not occur at all. The Company is planning its operations and capital needs accordingly, recognizing that FDA approval may be delayed for an extended period or may never be achieved.

Zhittya expects to initiate its first animal studies in the fourth quarter of 2026. Zhittya expects to file an IND for diabetic foot ulcers in the first quarter of 2028. Zhittya plans to focus on diabetic foot ulcers as its first indication for FDA approval for a number of reasons. Merck & Co., Inc. ("Mereck") began work on FGF-1 for diabetic foot ulcers in the late 1980s and advanced to a Phase II study before the then new Merck management closed all biological-drug activities in 1997. Venturis Therapeutics Inc., then Cardiovascular Biotherapeutics, Inc. ("<u>Cardiovascular Biotherapeutics</u>") acquired all of that data, and certain of the personnel who had managed the Merck program joined Cardiovascular Biotherapeutics. Cardiovascular Biotherapeutics also advanced the indication for diabetic foot ulcers. Daniel C. Montano, CEO of Zhittya and Jack Jacobs, PhD, have access to this data. Other reasons that Zhittya plans to focus on diabetic foot ulcers include that the medicine is topical, and wound closure can be observed and measured by conventional clinical means. We have been advised that Zhittya believes that the treatment of diabetic foot ulcers is the easiest and fastest path to market and plans to conduct animal studies for the other indications in 2028, followed by the filings of INDs for those indications, in the event the outcome of the studies are favorable.

We entered into the License Agreement with Zhittya in 2016, knowing that it would take Zhittya some time to put its manufacturing capabilities in place, to submit INDs and hopefully obtain FDA approval of its drugs in development. However, since 2016, Zhittya has faced numerous unavoidable delays due to failures of its contracted manufacturers of FGF-1, and later in order to set up its own manufacturing facility, and, after much work, successfully producing its own FGF-1. In addition, COVID-19 slowed Zhittya's development progress as well. In the event Zhittya is further delayed in producing FGF-1, performing studies, submitting INDs, obtaining approval from the FDA of such INDs, and/or otherwise delayed further from obtaining FDA approval for FGF-1, which it anticipates will take at least three to seven years, our ability to generate cash flow and support our operations will be negatively affected, we may need to raise additional funds, and we may never be able to generate sufficient funds to support our operations.

Zhittya has also received two study approvals by The Bahamas National Medical Ethics Committee. The first one is for the "Intranasal FGF-1 for Parkinson's Disease Clinical Trial". The second study approved was for the "Open Label, Two Dose Escalation Study to Evaluate the Safety, Tolerability and Effectiveness of Recombinant Human Fibroblast Growth Factor 1 (FGF-1) Administered by Intramyocardial Injection For the Treatment of Coronary Heart Disease." These studies are seeking additional data on the use of FGF-1 and are expected to have 100 patients each but currently are waiting for patient enrollment. Zhittya is developing a patient recruitment plan and expects to have the first patients in the fourth quarter of 2026. Zhittya has also filed applications for research studies in Mexico and Panama and is waiting to hear back regarding this potential approval.

---

| |
|:---|
| 65 |
| *[**Table of Contents**](#TOC)* |

---

Zhittya's portfolio is divided into two groups: (1) injectable/infusion/intranasal candidate drugs and (2) wound healing candidate drugs. The injectable/infusion/intranasal candidate drugs are being developed for use in the potential treatment of Parkinson's disease, stroke, multi-infarct dementia (a type of vascular dementia, is caused by a series of small strokes or transient ischemic attacks (TIAs), leading to brain damage and cognitive decline), coronary heart disease, peripheral artery disease, chronic traumatic encephalopathy (CTE, a progressive, degenerative brain disease linked to repeated head trauma, often seen in athletes and military veterans, characterized by symptoms like memory loss, behavioral changes, and dementia), traumatic brain injury, Alzheimer's disease, amyotrophic lateral sclerosis ("ALS"), type 2 diabetes, chronic depression, post-traumatic stress disorder, multiple sclerosis, and multiple systems atrophy. The wound healing candidate drugs are being developed for use in the potential treatment of diabetic foot ulcers ("DFUs"), venous ulcers, burns, male pattern baldness, topical surgical wounds (C-sections, cosmetic surgeries), pressure wounds (or bedsores), internal surgical wounds (or anastomoses), and punctures/deep lacerations (for trauma/military).

The Company's sole source of income is the other income received from Zhittya pursuant to the terms of the License Agreement. We currently receive other income from Zhittya's cross-border operations in the British Virgin Islands and the Bahamas, in which Zhittya's patients from the United States and Canada are treated using drugs covered by our License Agreement, in another territory. Additionally, starting in September 2025, the Company began receiving other income from Zhittya's use of licensed drugs in the United States for Type 2 diabetes research studies. Zhittya is studying FGF-1 and Type 2 diabetes to attempt to determine the appropriate dosing amount in order to submit an IND in the future. These research studies are investor funded and are taking place in Las Vegas, Nevada. The Company and Zhittya agreed, pursuant to the terms of a Letter Agreement dated October 13, 2025, that Zhittya would pay the Company the price of $15,000 per patient treated in these studies for the use of FGF-1. As of December 31, 2025, the Company had received $300,000 from Zhittya for these investor-funded research studies. During the three months ended March 31, 2026, the Company received $510,000 from Zhittya for these Investor-Funded research studies. This income is part of the cross-border operations. Zhittya has advised us that it has Institutional Review Board and doctor approval for Neurological studies in Nevada which would include Parkinson's disease, type 2 diabetes, cerebral palsy, aphasia, and dementia. The Company is not conducting the sales and marketing for the sales in the British Virgin Islands or other countries.

Pursuant to the License Agreement, Zhittya undertakes all of the drug development risk and is responsible for 100% of the cost of all clinical trials, general drug development and application for regulatory approval. Our primary business responsibility under the License Agreement is to market and sell the drugs in Zhittya's portfolio, assuming they receive requisite regulatory approvals. Zhittya is developing treatment candidates for over 22 diseases that are caused from the lack of blood flow to an organ or tissue. Through the License Agreement, we hope to achieve commercial success from generating revenues under the License Agreement, by marketing and selling Zhittya's drugs, subject to such drugs receiving regulatory approvals, while committing proportionately small amounts of capital toward drug development and regulatory approvals, as compared to the development expenses that would be necessary if we were to develop such drugs ourselves.

We do not currently plan to use any of the funds raised in this offering to pay clinical progress and regulatory milestone payments to Zhittya under the License Agreement. The Company does not plan on using the proceeds to make milestone payments. No milestones are expected in the next year. If clinical progress and regulatory milestone payments are required to be made to Zhittya under the License Agreement, such milestone payments would be made in stock of the Company or from the Company's cash flow, at our option, following this offering. Milestone payments made in the Company's stock would be calculated using the average closing price over the prior 20 trading days prior to issuance, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, we are required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock. We will only make milestone payments to Zhittya upon Zhittya's achievement of the applicable clinical progress and regulatory milestones, which are based on certain recognizable achievements in the development and approval of the injectable/infusion/intranasal drugs and topical drugs with the following applications: coronary heart disease, Parkinson's disease, stroke, diabetic foot ulcers and venous ulcers, as discussed in greater detail below under "Business—License Agreement with Zhittya". The milestone payments for wound healing drugs range from $100,000 to $10,000,000 and will not exceed $75,000,000 in total for the entire class of wound healing drugs. The milestone payments for injectable/infusion/intranasal drugs range from $100,000 to $25,000,000 and will not exceed $300,000,000 in total for the entire class of injectable/infusion/intranasal drugs.

---

| |
|:---|
| 66 |
| *[**Table of Contents**](#TOC)* |

---

The License Agreement contemplates the different availability of products in various licensed territories because of the timing of, or differences in, government approvals and that there may be the opportunity for study participation or treatment elsewhere, for patients who otherwise would be accommodated in licensed territories or vice-versa.

As a result, the net revenues generated from Zhittya patients who live in a Company licensed territory, who receive treatment outside that territory by Zhittya relating to the licensed products, will be shared 50/50 between Zhittya and the Company (or the Company and any other licensees who are due a portion of such amount). These net revenues do not count toward milestone payments set forth in the agreements.

Fees from cross-border operations are based on "Operating Profit", which is defined as net revenues (gross revenues minus returns) minus all direct costs of commercialization, such as direct sales, marketing, product costs, and product support. Operating Profit does not include executive salaries or general corporate overhead that is not directly related to commercialization. Fees are payable upon receipt.

Under the License Agreement, Zhittya's net revenues from such cross-border operations are shared equally between all licensees (currently just us) and Zhittya, are excluded from the milestone payments, and are subject to a tiered fee structure under which (a) no fee is due on the first $3 million of cross-border Operating Profit; (b) a fee equal to 50% of the Company's portion of Operating Profit is due on cross-border Operating Profit from $3 million to $10 million; and (c) a fee equal to 80% of the Company's portion of cross-border Operating Profit above $10 million is due.

All cross-border treatments will be organized and coordinated by Zhittya, with participation subject to product availability and patient capacity. Zhittya is responsible for the operating expenses relating to the cross-border operation and servicing the patients seeking to participate in the clinical studies.

As such, the Company is currently receiving Operating Profit generated by U.S. and Canadian patients in the Company's licensed territories that enroll in clinical study participation or treatment in other Zhittya licensed territories (British Virgin Islands and the Bahamas). Additionally, as discussed above, beginning in September 2025, the Company began receiving consideration in connection with Zhittya's investor-funded research studies into FGF-1 which are taking place in Las Vegas, Nevada.

During the year ended December 31, 2025 the Company recognized $1,192,000 of clinic revenue and $473,250 of advertising and promotion expenses for $718,750 as other income from participation in future revenues. During the year ended 2024, the Company recognized $1,266,000 of clinic revenue and $825,000 of advertising and promotion expenses for a net of $441,000, as other income from participation in future revenues. At December 31, 2025 and December 31, 2024, the Company had a related net receivable from Zhittya of $0 and $31,750, recorded in other receivables on the accompanying balance sheets, with payment terms of due upon receipt. As of December 31, 2025 and December 31, 2024, all of its other income from participation in future revenues was generated from Zhittya.

During the three months ended March 31, 2026, the Company recognized $820,000 of clinic revenue and $335,707 of advertising and promotion expenses and referral fees for a net of $484,293 as income from participation in future revenues. During the three months ended March 31, 2025, the Company recognized $216,750 of clinic revenue and $131,000 of advertising and promotion expenses for a net of $85,750 as income from participation in future revenues. At March 31, 2026 and March 31, 2025, the Company had a related net receivable from Zhittya of $0 and $0. During the three months ended March 31, 2026, the Company offset $440,000 of related net receivables against a related party loan from Zhittya. As of March 31, 2026 and March 31, 2025, all of the Company's other income from participation in future revenues was generated from Zhittya.

See also "—License Agreement with Zhittya", for more information regarding our License Agreement and amounts due thereunder.

---

| |
|:---|
| 67 |
| *[**Table of Contents**](#TOC)* |

---

**Zhittya's Management History With FGF-1**

Zhittya's management, Daniel C. Montano, Chief Executive Officer and Dr. Jack Jacobs, President and Chief Science Officer, were previously the Chief Executive Officer and Chief Science Officer, respectively, of Cardiovascular Biotherapeutics from 1998 and 2000, respectively, to 2014. At Cardiovascular Biotherapeutics they oversaw four FDA authorized clinical trials:

---

| | | |
|:---|:---|:---|
| Drug Candidate | Drug Candidate | Indication |
| 1 | CVBT-141A | Severe Coronary Heart Disease (CHD) surgical delivery |
| 2 | CVBT-141B | Dermal Ulcers (Wound Healing) |
| 3 | CVBT-141C | Peripheral Arterial Disease (PAD) |
| 4 | CVBT-141H | Severe Coronary Heart Disease (CHD) injection catheter delivery |

---

According to Cardiovascular Biotherapeutics' filings with the SEC:

· The Phase I Severe Coronary Heart Disease trial was completed and the surgically-delivered FGF-1 resulted in statistically significant improvement (p < 0.05) in 3 clinical parameters, including angina class, angina scores and time on treadmill until angina started. No serious adverse events could be directly attributable to FGF-1. Tumor markers remained within normal limits and there were no significant changes in eye exams. For the Phase II heart trial, it was decided in consultation with the FDA, to switch to a cardiac catheter delivery system.

· The Phase I Dermal Ulcer trial was completed and the following safety data was obtained: Topically applied FGF-1 was well tolerated with no adverse events seen. Utilizing a sensitive FGF-1 ELISA assay, FGF-1 was undetectable in the circulation after topical application. The Phase I trial was not powered to detect efficacy. A Phase Ib/II Clinical Protocol to examine safety and efficacy was prepared, but not submitted to the FDA.

· The Phase I Peripheral Arterial Disease trial was allowed by the FDA, but it was not started and no patients were enrolled.

· The Phase II Severe Coronary Heart Disease trial was started utilizing the Johnson & Johnson Myostar cardiac injection catheter. Nine patients were enrolled before the trial was halted due to a change in internal resource allocations at Cardiovascular Biotherapeutics. No adverse events were seen in the first 9 patients treated. The trial was not unblinded after it was halted, so efficacy data was not obtained.

To our knowledge, (a) Cardiovascular Biotherapeutics began interacting with the FDA in 1999; and (b) since 2007, has had no publicly unresolved issues with the FDA. However, in 2003, while preparing a Phase II trial using mini-thoracotomy (surgical) access, the FDA raised an issue regarding the requirement for a placebo control group. In clinical trials, a placebo control typically requires one arm of the study to receive an inactive treatment (or sham procedure) to properly isolate the drug's true biological effects from placebo effects or other variables. For an invasive surgical delivery method like mini-thoracotomy, this would have necessitated performing sham surgery on control patients, which raises significant ethical and practical concerns and is generally not permissible due to the unnecessary risk to participants. This issue was resolved by switching to a less invasive percutaneous injection catheter delivery system, which allowed for proper blinding and placebo controls without sham surgery. The change was made in consultation with the FDA. However, by 2010, no suitable injection catheter was commercially available (Johnson & Johnson had discontinued support for its catheter system), which caused the placebo-control challenge to re-emerge if the company were to revert to a surgical approach. Zhittya plans to work with the FDA to resolve this issue when it begins applying for its IND for Severe Coronary Heart Disease.

---

| |
|:---|
| 68 |
| *[**Table of Contents**](#TOC)* |

---

Daniel Montano and Dr. Jack Jacobs resigned from Cardiovascular Biotherapeutics in 2014. Cardiovascular Biotherapeutics fell out of compliance with its SEC filing requirements beginning in 2007, because it lacked the funds to pay the personnel and service providers required to prepare and file its periodic reports. In May of 2012, the SEC issued an order pursuant to Section 12(j) of the Exchange Act, revoking the registration of Cardiovascular Biotherapeutics' securities under the Exchange Act. The SEC noted in the filing that Cardio Biotherapeutics had not filed any periodic reports since the period ended September 30, 2008. In September 2018, a group of Cardio Biotherapeutic's creditors filed an involuntary bankruptcy petition under Chapter 7 of the Bankruptcy code, against Cardio Biotherapeutics, but it was later dismissed voluntarily by the creditors in June 2019.

The Company's President, John Laub, met Daniel Montano, president of Zhittya in the early 2000s, when Mr. Montano was the president of Cardiovascular Biotherapeutics. Mr. Laub was the former President of the Regenerative Medicine Organization, and had worked with Cardiovascular Biotherapeutics. In 2010, Mr. Laub and Mr. Montano first discussed the idea of a sales and marketing company that was separate from Zhittya's research and development activities. This was an outgrowth of similar discussions that Mr. Montano had with other pharmaceutical companies, in which the pharmaceutical company would pay upfront capital to acquire the marketing rights and pay milestones tied to the regulatory progress, with a royalty back to the developer. The discussions with pharmaceutical companies had not advanced because the pharmaceutical companies noted that the native FGF-1 was not patentable. Merck, the original developer of FGF-1, had held the composition-of-matter patent, which expired in 1997. When Mr. Montano resigned as CEO of Cardiovascular Biotherapeutics, in late 2014, he started Zhittya. In 2016, Mr. Laub and Mr. Montano renewed their discussion. In 2016, they worked out a model in which the sales and marketing company would make an upfront payment for the marketing rights and pay Zhittya milestone payments on progress toward FDA approval of its drugs. In 2016, Mr. Laub founded the Company and the parties agreed that the Company would only pay on milestones achieved on progress toward FDA approval.

**Market Opportunity**

**<u>I. Cardiovascular Disease</u>**

Heart disease is the number one cause of death in the U.S., according to the Centers for Disease Control and Prevention (CDC) and according to the National Heart, Lung, and Blood Institute, one in every three deaths in the U.S. are attributable to cardiovascular disease, or CVD, each year. According to a 2025 fact sheet by the National Heart, Lung, and Blood Institute, more than 900,000 people die of cardiovascular disease every year in the United States. Heart disease and stroke claim more lives each year in the United States than all forms of cancer and Chronic Lower Respiratory Disease (CLRD) combined. Between 2017 and 2020, 127.9 million US adults had some form of cardiovascular disease.

Cardiovascular disease is the term for all types of diseases that affect the heart or blood vessels, including coronary heart disease, stroke, heart failure and peripheral artery disease. Coronary artery disease (CAD) is primarily caused by a lack of blood flow to the heart due to atherosclerosis, a buildup of plaque in the arteries that can reduce the blood flow to the heart. Atherosclerosis can also rupture and form blood clots which then can obstruct blood flow and result in a heart attack.

Current treatments for CAD include angioplasty, stents, lithotripsy, and open-heart surgery, also known as coronary artery bypass graft (CABG) surgery. These procedures focus on the large coronary arteries where a catheter can be inserted. The blood vessels below the large arteries can also become blocked due to atherosclerosis but are too small to insert a catheter. The blockages in these small vessels can lead to ischemic areas which can lead to heart failure due to lack of blood to the heart muscle. It can also lead to a painful condition called refractory angina (RA), which is a chronic and persistent form of angina caused by reduced blood flow to the heart, which a combination of medical therapy, angioplasty, or coronary artery bypass grafting cannot adequately control. RA patients are often referred to as "no option" patients because they have exhausted conventional revascularization options and continue to experience debilitating symptoms.

---

| |
|:---|
| 69 |
| *[**Table of Contents**](#TOC)* |

---

**Zhittya's Proposed Treatment**

Zhittya's drug candidate, FGF-1, has been shown in a clinical trial to grow small blood vessels in the ischemic areas of the heart. *Schumacher et al. (1998) "Induction of Neoangiogenesis in Ischemic Myocardium by Human Growth Factors. First Clinical Results of a New Treatment of Coronary Heart Disease", Circulation 97:645-650.* The non-blinded study took place at the Philipps University in Marburg, Germany. Twenty patients without any history of infarction or cardiac surgery (14 men and 6 women; minimum age, 50 years), were subjected to an elective bypass operation for multivessel coronary heart disease and were treated with an injection of FGF-1 (0.01 mg/kg body weight) which was applied directly during the operations. An additional 20 patients who underwent the same procedure were treated with denatured FGF-1 as a control group. The endpoint was the formation of capillaries in the ischemic human myocardium, which was demonstrated in all cases around the site of injection.

No adverse events and no p-values were noted in the research paper. This study involved a limited number of cases, and the observed findings should be interpreted cautiously. These results are preliminary, are not subject to the same controls and statistical rigor as well-designed randomized clinical trials, and may not be predictive of future clinical outcomes in humans. Accordingly, there can be no assurance that these results will be replicated in larger, controlled clinical studies, or that any future trial will demonstrate similar safety, biological activity, or therapeutic benefit.

![](wund_1aimg2.jpg)

***Figure 1:*** *Coronary angiogram in a patient with severe CAD before and 12 weeks after the local administration of human FGF-1 into the ischemic heart wall. A "blush" of new blood vessels can be seen around the site of FGF-1 administration (from Schumacher et.al.; ref 13), whereas the control does not include a "blush" of new blood vessels, which helps show that the endpoint of the study was met, i.e., that the injection of injection of FGF-1, led to the formation of capillaries in the ischemic human myocardium.*

Clinical trials routinely use "p-values" to report statistical probability. A p-value is a statistical measure that helps determine whether an observed result in a study is likely due to chance. The p-value is not however to be confused with the probability that the drug works, instead it is the probability that the observed difference in the study (typically between those using the applicable drug and placebo) could occur by random variation alone. A p-value < 0.05 is conventionally used to indicate statistical significance. This means there is less than a 5% probability that the observed result occurred by chance assuming no true effect exists. P-value is important because under the Federal Food, Drug, and Cosmetic Act, the FDA generally requires: "substantial evidence" of effectiveness, demonstrated by adequate and well-controlled investigations, for drug approval. Typically, statistical significance is a key component of, but not the sole determinant of, "substantial evidence." The FDA also looks for clinical significance when determining whether to approve a drug. That is, even if there is "substantial evidence" of effectiveness, if the drug's effects are minimal the FDA may not approve the drug candidate.

Because the study discussed above did not report a p-value, it cannot be ruled out that the results are due to chance; it cannot be assumed that the results generalize to a broader population; and causality cannot be concluded.

A Phase 1 study was conducted at the University of Cincinnati and Hershey Medical Center and was discussed in an October 16, 2007 abstract disclosed in *Circulation*, 116:II-443, titled "*Angiogenesis Protein Therapy with Human Fibroblast Growth Factor (FGF-1): Results of a Phase I open label, Dose Escalation Study in Subjects with CAD not Eligible for PCI or CABG*". The trial was sponsored by Cardiovascular BioTherapeutics, Inc. (CVBT), and in 2014 Zhittya was given access to CVBT's data. The primary endpoints were a) safety and tolerability of FGF-1, b) pharmacokinetics of FGF-1, c) efficacy, d) improved perfusion via SPECT SCAN, Stress Echo and Angiography, e) change in Canadian Cardiovascular Society (CCS) and angina score, f) and change in Seattle Angina Questionnaire (SAQ). The secondary endpoints were the change in ophthalmologic exam and the change in laboratory values.

---

| |
|:---|
| 70 |
| *[**Table of Contents**](#TOC)* |

---

Twenty-one patients were assigned to one of three different groups, each receiving a different dose of FGF-1 solution: 1, 3, or 10 microgram/kilogram (ug/kg) body weight per injection. The study was a Phase I open label study with no placebo group. The drug was administered via mini-thoracotomy for the treatment of "no option" coronary heart disease. Effectiveness was assessed by measuring the impact of FGF-1 treatment on myocardial perfusion, exercise tolerance, CCS angina class, and Seattle Angina Questionnaire scores (Figure 8 below). Efficacy results from that trial done 12 weeks after the FGF-1 injections showed statistically significant improvement in three clinical parameters, including angina pain class (see Figure 8 below), Seattle Angina Score (a second assay of angina pain) and the treadmill test. The Single Photon Emission Computed Tomography (SPECT) scans and angiograms showed indications of improvement in myocardial perfusion in groups 2 and 3. Mean exercise time improved from 4.64 ± 2.37(SD) minutes at baseline to 5.80 ± 2.74(SD) minutes at 12 weeks. Based on the SAQ, all groups had a decrease in anginal frequency and improvement in anginal stability.

![](wund_1aimg3.jpg)

*Figure 8. Canadian Cardiovascular Society Angina Scores (CCSAS), SAQ and Treadmill Waling Time show improvements after treatment with FGF-1.*

With the CCSAS, Class IV angina is the most severe form with angina at rest. Class I is the mildest with angina only with strenuous exercise. The SAQ Scores were \*p<0.05 and +p=0.06. These symbols indicate the threshold of significance for different data points. The Asterisk which is for Frequency and Exertional Capacity is \*P < 0.05 which is statistically significant. The Plus Sign was for stability +P = 0.06. This is referred to as "Trend Toward Significance" or the result did not quite meet the strict 0.05 cutoff, but it came very close. We believe this is a strong signal that the treatment is working, likely requiring a larger group of patients (Phase 2) to prove it. Exercise performance as determined by time on the treadmill before a patient has to stop due to angina or evidence on an electrocardiogram that ischemia is occurring. The improvement in patients had a p=0.035 (paired 2 tailed, t-test), indicating that improvement was likely due to the FGF-1 treatment rather than random chance, is statistically significant. A paired test means the researchers compared the same group of people to themselves at two different times. Point A: Baseline (before the FGF-1 injection). Point B: Follow-up (6 or 12 weeks after the injection). This is the most accurate way to measure the effect of a treatment in a small group because it accounts for individual variations in health. The two-tailed test is a more rigorous "conservative" approach. It tests for a change in either direction. By using a two-tailed test and still achieving p=0.035, the evidence for the treatment's positive effect is considered stronger.

Pharmacokinetic data is presented in Figure 9 below which looks at plots of circulating levels of FGF-1 at different time points for individual patients. It can be seen that FGF-1 concentrations reach peak levels very rapidly within minutes of injection and then decrease rapidly within the first hour post-injection. FGF-1 levels reach near pre-treatment baseline concentrations within 12-24 hours. No patients in any of the dosing groups demonstrated any detectable increase in levels of FGF-1 specific antibodies at either 6 or 12 weeks.

.

---

| |
|:---|
| 71 |
| *[**Table of Contents**](#TOC)* |

---

![](wund_1aimg4.jpg)

*Figure 9: Pharmacokinetics of FGF-1141 in Patients with Severe Coronary Heart Disease Following Intramyocardial Injections of FGF-1. On the left-hand panel the serum levels of FGF-1 are plotted versus time after injection into the heart. On the right-hand panel the two elimination phases of FGF-1 from the circulation are apparent and include a rapid and a slower (terminal) elimination phase seen for each dose of FGF-1 administered.*

On July 10, 2007, Cardiovascular Biotherapeutics was authorized for a Phase II Clinical Protocol for its protein drug candidate, human fibroblast growth factor-1 (FGF-1) for the treatment of severe coronary heart disease. Per discussions with Daniel C. Montano who was president of Cardiovascular Biotherapeutics at the time, Cardiovascular Biotherapeutics advanced the FGF-1 candidate into a Phase II trial, which was in progress when Cardiovascular Biotherapeutics lost its funding during the Great Recession (December 2007 to June 2009). In addition, Cardiovascular Biotherapeutics was hit by the closure of its injection catheter manufacturer (a Johnson & Johnson subsidiary) in 2010, and the bankruptcy of Phage Biotechnology Corporation (its FGF-1 manufacturer) in 2010. Collectively, the three events halted further enrollment.

Per discussion with the President and Chief Science Officer of Zhittya, Jack Jacobs, PhD, Dr. Jacobs said Zhittya will not be able to reference Cardiovascular Biotherapeutics Phase 1 trial data because Zhittya would have to prove that the FGF-1 used in the Cardiovascular Biotherapeutics trial is the same FGF-1 to be used in Zhittya's trials. Zhittya cannot prove this because Zhittya is using a different method to make FGF-1.

In the paper, *Coronary Microvascular Dysfunction Across the Spectrum of Cardiovascular Diseases: JACC State-of-the-Art Review*", published in the Journal of the American College of Cardiology in 2021, the authors state that these conditions are collectively called Coronary Microvascular Dysfunction (CMD), which encompasses several pathogenetic mechanisms involving coronary microcirculation and plays a major role in determining myocardial ischemia in patients with angina without obstructive coronary artery disease, as well as in several other conditions, including obstructive coronary artery disease, nonischemic cardiomyopathies, takotsubo syndrome, and heart failure, especially the phenotype associated with preserved ejection fraction. Unfortunately, despite the identified pathophysiological and prognostic role of CMD in several conditions, to date, there is no specific treatment for CMD. Zhittya believes that its drug candidates can treat CMD by growing small blood vessels in the ischemic areas, although there can be no assurance that such results will be achieved.

***Size of the Market***

The estimated market size for "no-option" heart patients—those with CAD and/or refractory angina, who are not eligible for PCI or coronary artery bypass grafting (CABG)—in the United States is growing due to an aging population and improved survival from coronary artery disease. According to an article published by the European Heart Journal in 2025 titled "Refractory angina: mechanisms and stratified treatment in obstructive and non-obstructive chronic myocardial ischemic syndromes" the US has between 600,000 and 1.8 million patients who suffer from RA, with 75,000 new patients diagnosed each year. Refractory angina is defined in this article as "chronic angina-type chest pain in the presence of myocardial ischemia that persists despite optimal medical, interventional and surgical treatment," for which "current therapies are limited and new approaches to treatment are needed."

---

| |
|:---|
| 72 |
| *[**Table of Contents**](#TOC)* |

---

Although according to "*Coronary Microvascular Dysfunction: Consideration for Diagnosis and Treatment*" published in the Cleveland Clinic Journal of Medicine in 2021, this market could be considerably larger, because one-half to two-thirds of women with angina symptoms who undergo coronary angiography for suspected ischemic heart disease have no obstructive coronary artery disease (CAD), according to some estimates. This condition, characterized by signs and symptoms of ischemia in the setting of nonobstructive CAD, is termed "ischemia and no obstructive coronary artery disease" (INOCA). The same article estimates that there are at least three million to four million patients with stable INOCA in the United States, and it is more prevalent in women than in men. Coronary microvascular dysfunction (CMD), or the abnormal dilation and constriction of the small vessels of the heart, is the underlying cause of INOCA in one-half of cases. The overall prevalence of INOCA has been increasing as clinical recognition grows, along with expanded use of diagnostic tests to assess microvascular dysfunction.

We estimate that the price of Zhittya's heart drug candidate to treat no-option heart patients could be $40,000 per treatment. With one million potential patients, we estimate the total United States market for such a drug candidate could be $40 billion. We are unaware of any competitors to Zhittya's FGF-1 drug candidate for no-option heart disease.

**<u>II. Brain Disorders</u>**

***<u>Stroke</u>***

A stroke is a serious medical condition that occurs when the blood supply to part of the brain is interrupted or reduced, depriving brain tissue of oxygen and nutrients. When a stroke occurs, the brain is suddenly deprived of its normal blood supply—either because a blood vessel is blocked (ischemic stroke) or bursts (hemorrhagic stroke). This interruption prevents oxygen and glucose from reaching brain cells, which are highly sensitive to even brief shortages in blood supply. This leads to the rapid death of brain cells and can cause lasting brain damage, disability, or even death if not treated promptly.

**Zhittya's Proposed Treatment**

Zhittya has reported that as of December 2025 it has treated five stroke patients with FGF-1 who were treated with a nasal inhaler. The treatment consisted of two doses daily for six days. According to Zhittya, each patient improved from their current state, some faster, some slower. Improvements were reported in walking, cognition and memory. The patients are being monitored every three months with a Zoom interview and a review of their motor skills. The endpoints were safety and improvements in walking, cognition, and memory. No adverse events were noted. The studies were open-label unblinded studies which occurred in the British Virgin Islands in which the participants and researchers knew which treatment was administered. Zhittya does not know if the data from the open-label studies could be replicated or could have material differences from well-controlled clinical trials of stroke patient population in the U.S. or Canada.

**Size of the Market**

The Centers for Disease Control and Prevention in 2024 noted that each year more than 795,000 people have a stroke in the U.S., all of whom, we anticipate, will be the target market for Zhittya's FGF-1 nasal inhaler. According to the Stroke Awareness Foundation, stroke is the leading cause of serious long-term disability. There are over seven million stroke survivors that live in the United States, and two-thirds of them are currently disabled. Approximately 25% of people who recover from their first stroke will have another within five years.

***<u>Parkinson's Disease</u>***

Parkinson's disease is a progressive neurological disorder characterized by a gradual loss of nerve cells in the brain, specifically those that produce dopamine. This loss of dopamine leads to a variety of symptoms, primarily affecting movement but also impacting other areas like cognition, mood, and sleep.

---

| |
|:---|
| 73 |
| *[**Table of Contents**](#TOC)* |

---

Zhittya was cleared in 2022 to conduct human research studies using FGF-1 in the British Virgin Islands. Since then, Zhittya has reported that it has treated over 240 Parkinson's disease patients as of December 2025, using a nasal inhaler to deliver the drug into the brain across the blood-brain barrier. Zhittya has further publicly reported (in a press release dated February 27, 2025), that Parkinson's disease patients who were enrolled in a two and one-half year study in which they received intranasal FGF-1 therapy exhibited an average 53% improvement in motor skills using the Unified Parkinson's Disease Rating Scale within six months of treatment. These studies were to gather information to design clinical trials. The results from these studies might not be replicated and are not indicative of a well-controlled clinical trial.

Research published in 2020 titled, "Vascular, flow and perfusion abnormalities in Parkinson's disease" in the journal "Parkinson and Related Disorders", noted that Parkinson's disease patients have shown less blood flow to the part of the brain that has the dopamine-producing neurons.

Studies have also shown positive data with FGF-1 in several animal models, including peer-reviewed publications in rodent and primate models of Parkinson's disease, as described below. In the publication *Neurotoxicity Research*, the article by McLay et.al, "*Administration of FGF-1 Through Transfected Cells Alleviates MPTP Toxicity in Mice*", demonstrated that the implantation of fibroblasts genetically modified to secrete fibroblast growth factor-1 (FGF-1) increased striatal dopamine concentrations in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mouse model of Parkinson's disease. In addition, in the *American Journal of Translational Research,* the article by Wei et.al., "*Fibroblast Growth Factor 1 Attenuates 6-Hydroxydopamine-Induced Neurotoxicity: An In Vitro and In Vivo Investigation in Experimental Models of Parkinson's Disease*", demonstrated that FGF-1 administration improved the motor function recovery, increased the tyrosine hydroxylase-positive neurons (TH) survival and up-regulated the levels of neurotransmitters in rats with experimental Parkinson's disease. In another peer-reviewed publication by deYebenes et. al., appearing in the journal *Parkinsonism and Related Disorders,* human fibroblast growth factors (FGF-1 and FGF-2) were able to reverse the motor skill decline seen in monkeys with experimentally induced Parkinson's disease. Placebo-treated animals continued to see a decline in their motor skills scores. Of particular importance was the finding that in the FGF-1 treated monkeys, there was a regeneration of new dopamine-secreting neurons in the brains of those animals. In addition, a reduction of toxic plaque was noted in the brain and no serious adverse events were reported. The authors concluded that these two human FGFs, by stimulating the growth of new dopamine neurons, led to the reversal of the classical Parkinson's disease motor skill deficits (such as tremors, jerkiness, and gait disturbances) seen in this primate model.

![](wund_1aimg5.jpg)

*The above graph is from data from "Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys" by deYebenes, et.al, that appeared in the journal, Parkinsonism and Related Disorders. The graph shows two groups of monkeys. Both groups were given MPTP toxin which induces Parkinson's-like symptoms in animals. After nine months, one group (blue boxes) were given FGF-1, which showed steady improvement in motor skills over the next seven months, whereas the placebo group (red triangles) continued to decline in motor skills.*

---

| |
|:---|
| 74 |
| *[**Table of Contents**](#TOC)* |

---

![](wund_1aimg8.jpg)

*The above image is from "Long-term intracerebral infusion of fibroblast growth factors restores motility and enhances F-DOPA uptake in parkinsonian monkeys" by deYebenes, et.al, that appeared in the journal, Parkinsonism and Related Disorders and shows more dopamine in the brains of monkeys with FGF-1. The above image shows slices of brains from monkeys given FGF-1, and a placebo. The FGF-1 treated monkeys show increased dopamine which is shown by the brown color.*

![](wund_1aimg9.jpg)

*The above image is from "Fibroblast Growth Factor 1 Attenuates 6-Hydroxydopamine-Induced Neurotoxicity: An In Vitro and In Vivo Investigation in Experimental Models of Parkinson's Disease," by Wei et al., which appeared in the American Journal of Translational Research, shows the reduction of alpha synuclein plaques with FGF-1. The above image shows comparative images of brain slices, including (1) a sham (an inactive control), as compared to (2) an image with Parkinson's (PD), as compared to (3) an animal with Parkinson's disease treated with FGF-1, which shows less alpha synuclein in the animals treated with FGF-1.*

**Zhittya's Treatment**

Zhittya's planned treatment is to treat the patients with twice-a-day doses of FGF-1 with a nasal inhaler for six days, and then re-dose those patients every three months for two years. As noted on Zhittya's website, Zhittya has been conducting medical research studies with humans in the British Virgin Islands and Zhittya has disclosed that it has dosed over 240 patients as of December 2025. The patients have reported on average, as of May 2025 when a total of 200 Parkinson's disease patients had been treated, a 53% improvement in motor scores as measured on the UPDRS. These studies were performed for the purpose of gathering information to use in designing clinical trials. The information from these studies is expected to assist with determining the dosing and frequency in a well-controlled clinical trial. The results of these studies might not be replicated in a clinical trial.

---

| |
|:---|
| 75 |
| *[**Table of Contents**](#TOC)* |

---

**Size of the Market**

Pursuant to a July 2018 press release from the Parkinson's Foundation, it is estimated that as of 2020, at least 930,000 people in the United States suffer from Parkinson's disease, and according to a December 2022 press release from the Parkinson's Foundation, an estimated 90,000 people are diagnosed with Parkinson's disease each year in the U.S. Parkinson's disease is second only to Alzheimer's disease as the most prevalent neurodegenerative disease. Currently, there is no treatment to reverse Parkinson's disease. There are treatments that improve some of the motor symptoms (tremors, gait disturbances) of Parkinson's disease, including medications such as levodopa and levodopa in combination with carbidopa, which is the most commonly prescribed drug for Parkinson's disease according to the Michael J. Fox Foundation.

***<u>Vascular Dementia</u>***

Vascular dementia is a common type of dementia caused by reduced or blocked blood flow to the brain, which deprives brain cells of oxygen and nutrients and leads to their damage or death. This disruption in blood supply is most often the result of conditions such as strokes (both major and "silent" strokes), small vessel disease, or a series of mini-strokes (transient ischemic attacks, or TIAs). According to the U.S. Centers for Disease Control and Prevention, vascular dementia is the second most common form of dementia after Alzheimer's disease. Symptoms of vascular dementia can vary depending on the part of the brain affected and the extent of blood vessel damage. Generally, symptoms of vascular dementia can affect memory, thinking, language, problem-solving, and behavior to a degree that interferes with daily life and activities

**Zhittya's Proposed Treatment**

Zhittya's planned treatment is to treat vascular dementia patients with FGF-1 via a nasal inhaler for six days and then re-dose those patients every three months for two years. Every three months the patients will be given memory and cognition tests. Zhittya anticipates that it will see improvement in their short-term memory and cognition, depending on the severity of the condition, within 18 months to two years, although there can be no assurance that such results will be achieved. Zhittya has not yet treated any patients.

**Size of the Market**

According to the article "Epidemiology of Vascular Dementia: Nosology in a Time of Epiomics" published in July 2019 journal of *Arteriosclerosis, Thrombosis and Vascular Biology,* the estimates indicate that vascular dementia accounts for approximately 15% to 20% of all dementia cases in the United States. The overall prevalence of dementia among adults age 65 and older in the U.S. is about 10%, according to the Columbia University Irving Medical Center. Applying these proportions, it is estimated that vascular dementia affects roughly 1.5% to 2% of adults age 65 and older in the U.S. Given that according to the U.S. Census Bureau, the U.S. population age 65 and older is approximately 55.8 million as of 2020, this suggests that between 837,000 and 1.1 million older Americans are living with vascular dementia.

***<u>Alzheimer's Disease as a Vascular Disorder</u>***

Alzheimer disease ("AD") is an insidious disorder that progressively ravages the brain, destroying its memory and intellect. According to the Alzheimer's Associate, Alzheimer's disease is a progressive brain disorder and the most common cause of dementia, accounting for 60–80% of dementia cases. It slowly destroys memory, thinking skills, and eventually the ability to carry out even simple daily tasks. The disease is characterized by the buildup of abnormal proteins in the brain—amyloid plaques and tau tangles—which disrupt communication between nerve cells and ultimately lead to their death. Early symptoms often include memory loss, especially of recent events, difficulty finding words, confusion, poor judgment, and changes in mood or behavior. As the disease progresses, individuals may experience severe memory loss, disorientation, difficulty speaking or swallowing, and a loss of independence. We believe that the main stumbling block in the clinical management and in the search for a cure of AD is that the cause of this disorder has remained uncertain. For more than 30 years, AD has been classified and managed as a neurodegenerative disorder, distinct from vascular forms of dementia, such as multi-infarct dementia, based on the characteristic huge loss of brain tissue.

---

| |
|:---|
| 76 |
| *[**Table of Contents**](#TOC)* |

---

Many investigators in the field have supported the notion that AD and the dementing processes may be the result of changes in brain structure, most notably brain atrophy, brought about by the inexorable neurodegenerative process that characterizes AD. Dramatic loss of brain volume is often readily apparent in autopsies of patients suffering from late-stage Alzheimer's disease (according to the National Institute on Aging). Neuronal death in AD is thought to be caused by the toxic accumulation of a naturally occurring protein, tau, inside the neuron. This protein becomes over-phosphorylated and accumulates inside the neuron leading to the development of "neurofibrillary tangles" and cell death. In addition, another hallmark of AD is the accumulation of plaques, composed of the beta-amyloid protein, that occurs outside the neuron and disrupts neuron-neuron communication in the brain. It is the current conventional wisdom that these two processes combine to destroy memory and cognition in selected areas of the brain (such as the hippocampus and frontal brain regions involved in reasoning and logic). More recently, however, a substantial and ever-growing amount of evidence indicates that AD is initiated by vascular factors that precede the neurodegenerative process.

The question of whether AD is first provoked by a neurodegenerative process, as the prevailing paradigm maintains, or by vascular-related events, which then propel neurodegenerative changes, is of crucial importance. Establishing the correct pathogenesis for this dementia could help to unravel the exact mechanisms responsible for the cognitive failure and, in so doing, target specific therapy to overcome or treat this disorder more effectively. If AD is a vascular disorder that initiates its pathology through cerebral microvascular abnormalities, then its origin, clinical signs, diagnosis, and potential treatment should revolve around a vascular-centered view.

Researchers from McGill University in Montreal completed a study reported in the journal "Nature" in June 2016, that studied the disease progression in 1,171 patients with AD. The researchers analyzed close to 8,000 brain imaging studies and examined a number of biomarkers for AD, including brain hypo-perfusion, brain atrophy, cognitive decline, glucose under-utilization and the accumulation of beta amyloid protein and tau protein. They then developed an algorithm to look at the 30-year trajectory of each of these markers in AD, which showed that the very first change seen in AD was a deterioration of the microvasculature leading to under-perfusion of brain neurons.

These vasculature changes occurred before any of the symptomatic changes in AD occurred, including structural changes in the brain, accumulation of beta amyloid plaques or cognitive decline.

In the journal "Frontiers in Cellular Neuroscience," in an article published in 2021 titled, "Microvascular Alterations in Alzheimer's Disease," it was noted that the microvasculature is commonly viewed as secondary to neuronal death and inflammation. However, the paper noted recent microscopy studies that suggested a critical role of the microvasculature in disease progression. Cruz Hernández et al. (2019) demonstrated via vascular and neutrophil imaging with 2-photon microscopy in AD mice and mathematical blood flow modeling (in mouse, human, and synthetic microvascular networks) that capillary flow blockage via neutrophils reduces cerebral blood flow (CBF). CBF was restored through antibody targeting of neutrophils, which improved short-term memory function up to 16-months of age in APP/PS1 mice (Bracko et al., 2020). Nortley et al. (2019) demonstrated capillary compression by pericytes induced by amyloid-triggered release of endothelin could lead to widespread reductions in blood flow. These findings suggest the microvasculature could contribute to damage of brain cells and synapses (Nortley et al., 2019).

In paper titled, "Development of Capillary Dysfunction in Alzheimer's Disease", published in 2024 in the journal "Frontiers in Aging Neuroscience", the authors noted that one of the factors initiating neurodegeneration may be a local microcirculatory impairment occurring in capillaries of the hippocampus and mediobasal structures of the temporal lobes of the brain. A morphological study of hippocampal tissue samples from middle-aged individuals (up to 60 years old) revealed changes indicating ischemic cell damage along with impaired blood circulation in the vessels of the microcirculatory bed.

Cerebral capillary degeneration has been shown to be present in practically all AD brains examined postmortem and in cortical biopsy material from pathologically confirmed AD, according to an April 2002 study published in the journal "Stroke", titled "*Alzheimer Disease as a Vascular Disorder: Nosological Evidence*". These cerebral micro-vessel aberrations have been consistently observed in AD brain tissue by a large number of investigators using a variety of histological techniques.

The degenerate capillaries appear more prevalent in the hippocampus, a region that is linked to memory and learning and is an initial target for neurofibrillary tangle formation in AD. Microvessel changes in AD brains show no correlation to the stage of the disease, a finding that suggests that such capillary anomalies are not a consequence of AD pathology. In addition, brain capillary distortions do not appear to be significantly targeted by amyloid deposition.

---

| |
|:---|
| 77 |
| *[**Table of Contents**](#TOC)* |

---

Jack Jacob, PhD, President and Chief Scientific Officer of Zhittya, believes that it is both a reduction in the number of brain micro-vessels and a decrease in their vascular functions that leads to a decline in cerebral blood flow, apoptosis or cell death of neurons and the reduced clearance of beta amyloid deposits.

**Zhittya's Proposed Treatment**

Zhittya's planned treatment is to treat Alzheimer's patients with FGF-1 via a nasal inhaler for six days and then re-dose those patients every three months for two years. Every three months the patients will be evaluated for short term memory and cognition. Zhittya anticipates that it will see improvement in their memory and cognition within 18 months to two years, depending on the severity of their condition, although there can be no assurance that such results will be achieved. Zhittya has not yet treated any Alzheimer's patients.

**Size of the Market**

According to the journal, *Alzheimer's & Dementia,* it was reported in an article titled, "2024 Alzheimer's Disease Facts and Figures", an estimated 6.9 million Americans age 65 and older are living with Alzheimer's dementia. According to Alzheimer's San Diego, nearly 500,000 Americans are diagnosed with Alzheimer's each year.

***<u>Autism</u>***

Autism spectrum disorder ("ASD"), or often referred to simply as autism, is a highly variable, neurodevelopmental disorder whose symptoms first appear during infancy or childhood, and generally follows a steady course without improvement. The three classical symptoms of autism include impairments in social interaction, impairments in communication, and repetitive behavior. People with autism may be severely impaired in some respects, but average, or even superior, in others, as seen with autistic savants.

**Vascular Dysfunction in Autism** 

Recently, there have been a number of reports in both animal models of autism and in autistic patients which show that there is vascular dysfunction evident in this disease.

Cerebral hypoperfusion (reduced blood flow) has been shown in a number of people diagnosed with autism. As reduced blood flow impacts the delivery of oxygen and nutrients to neurons, hypoperfusion in autistic children has been associated with key autism-related behaviors, including language deficits, impaired executive function and abnormal responses to sensory stimuli, as well as difficulty in facial perception.

In work from the University of Utah, researchers used functional MRI to examine metabolic activity in the brains of normal individuals and those with autism. We believe that a plausible explanation for this reduced activity could be diminished blood flow to those areas of the brain, brought about by decreased angiogenesis (the growth of new blood vessels). A research study, "Vascular contributions to 16p11.2 deletion autism syndrome modeled in mice" published in Nature Neuroscience in 2020 showed significant decrease in angiogenesis in the brains of autistic individuals and in a mouse model of autism.

A Canadian study from 2020 has undertaken the first ever in-depth study of vasculature in the autistic brain. The product of four years of work, a paper published in the July 13, 2020 issue of the prestigious peer-reviewed journal, *Nature Neuroscience*, lays out several lines of novel evidence that strongly implicate defects in endothelial cells—the lining of blood vessels—in autism.

In this study, human endothelial cells obtained from autistic individuals were unable to sprout the extensions that normally connect blood vessels to each other, allowing the vascular network to expand and grow. Endothelial cells in the brains of newborn autistic mice had the same problem. The endothelial cells obtained from autistic individuals were not leaky, but lacked the ability to undergo normal angiogenesis or growth of new blood vessels to provide proper blood perfusion in the brain.

---

| |
|:---|
| 78 |
| *[**Table of Contents**](#TOC)* |

---

By adolescence, both humans and mice still showed reduced vascular density in their brains. This defective "angiogenesis response" seen in autism places a possible therapy for this disorder squarely in the sights of the FGF-1 molecule, because FGF-1 is a potent stimulator of angiogenesis in our bodies.

Numerous lines of evidence, both in humans and animals, indicate that there is a problem with the brain's blood vessels in individuals with autism. This problem appears focused on the autistic brain's inability to grow new blood vessels (angiogenesis) when additional demands for a ramped-up blood supply is needed. This leads to a decrease in capillary and arteriole density in areas of the brain that control important activities, including social interactions, communication and impulse control, activities that become disrupted in autism.

**Zhittya's Planned Treatment**

Zhittya's planned treatment is to treat its ASD patients with FGF-1 via a nasal inhaler for six days and then re-dose those patients every three months for two years. Zhittya believes that each autistic patient is unique; therefore, Zhittya plans to assess each patient individually and establish a personalized baseline assessment. Zhittya anticipates that it will see improvement from each patient's base in their memory, cognition, concentration and autonomic conditions, although there can be no assurance that such results will be achieved.

**Size of the Market**

Autism affects an estimated 8.1 million people in the U.S., according to two studies, one by the U.S. Centers for Disease Contril and Prevention (CDC) published in 2025, and one published in 2020 in the Journal of Autism and Developmental Disorders. The 2025 data disclosed by the CDC reflects that 1 in 31 children, or 3.2%, have autism in the U.S. With approximately 73 million children (ages 0–17) in the U.S., this equates to roughly 2.3 million children with autism. From the Journal of Autism and Development Disorders, the article titled "National and State Estimates of Adults with Autism Spectrum Disorder" reports that 1 in 45 adults, or about 2.2% of U.S. adults, ages 18-84 years, are living with ASD (Autism Spectrum Disorder). With about 260 million adults in the U.S., this equates to approximately 5.8 million adults with autism.

***<u>Traumatic Brain Injuries</u>***

Traumatic brain injuries ("TBIs") are among the most devastating health issues in the United States, with profound and far-reaching effects on individuals, families, and society as a whole. According to the Brain Trauma Foundation, TBIs are a major cause of death and disability across all age groups, especially among people under 45, where they surpass other causes such as cancer and spinal cord injury.

TBIs can have wide-ranging and serious consequences, affecting nearly every aspect of a person's life. The effects depend on the severity, location, and type of injury, but can be immediate, long-term, or even permanent. Immediate and short-term consequences include headaches, dizziness, fatigue, nausea, vomiting, loss of consciousness, and seizures. Injuries at the base of the skull can cause cranial nerve damage, leading to facial paralysis, loss of sensation, vision or hearing problems, swallowing difficulties, and altered senses of smell or taste. In addition, there can be cognitive (confusion, memory loss), emotional (mood swings, depression), and motor deficits (paralysis, balance problems) from TBIs.

TBIs can also impact daily living, creating a situation where persons with a TBI are not able to live on their own. Many survivors require help with daily activities and may not be able to return to work or school. Studies reported in 2024 show that at least three in 10 people hospitalized for a TBI have a history of substance abuse, according to the U.S. Department of Veterans Affairs. The effects of a TBI can place significant emotional, financial, and caregiving burdens on families and society.

---

| |
|:---|
| 79 |
| *[**Table of Contents**](#TOC)* |

---

The pathology behind TBIs has been well studied and multiple animal models of TBIs have been developed to examine the pathophysiology of this type of trauma. In general, rapid acceleration, deceleration, or rotational forces cause the brain to elongate and deform, stretching individual cells and blood vessels and altering membrane permeability. Although all cell compartments can be affected by the injury, axons are especially vulnerable to shear injury, given their relatively long length. Striking microvascular disordering has also been consistently observed in animal models of TBI. Rodents that have been subjected to experimental TBIs and then allowed to recover showed a microvasculature that is less dense and more disordered. In these experiments, rodents were subjected to pressure-induced fluid percussion TBI, allowed 24 hours post-injury injury. Upon recovery at 14 days, the microvascular has shown to be reestablished, but it is less dense and more disordered than in the control animals. From the above results, we believe it is possible that neurons would most likely be under-perfused in those areas of recovery that display disordered microvasculature. This condition has been termed traumatic cerebral vascular injury.

**Zhittya's Planned Treatment**

Zhittya's planned treatment is to treat patients with TBIs with FGF-1 via a nasal inhaler for six days and then re-dose those patients every three months for two years. Zhittya anticipates that it will see improvement in their memory and cognition, although there can be no assurance that such results will be achieved.

**Size of the Market**

According to the Brain Injury Alliance Connecticut, each year, an estimated 2.8 million Americans suffer some form of traumatic brain injury (TBI) and approximately 5.3 million Americans are living with a disability that resulted from a TBI.

The Brain Injury Association of America reported in December of 2024 that approximately 67% of military veterans in the U.S. have experienced at least one traumatic brain injury. The Defense and Veterans Brain Injury Center (DVBIC) reported nearly 414,000 TBIs among U.S. service members worldwide between 2000 and late 2019 and more than 185,000 Veterans who use VA for their health care have been diagnosed with at least one TBI.

**<u>III. Type 2 Diabetes Mellitus</u>**

Type 2 diabetes mellitus, commonly known as type 2 diabetes, is a chronic condition in which the body either does not use insulin properly (insulin resistance) or does not produce enough insulin, in each case leading to persistently high levels of glucose (sugar) in the blood. Insulin is a hormone produced by the pancreas that helps move glucose from the bloodstream into the body's cells, where it is used for energy. In type 2 diabetes, the cells in muscles, fat, and the liver become less responsive to insulin, and over time, the pancreas may not be able to produce enough insulin to keep blood sugar levels normal. If left untreated or poorly managed, type 2 diabetes can lead to serious health problems, including heart disease and stroke, kidney damage, nerve damage (neuropathy), eye damage (retinopathy), and foot problems, sometimes leading to amputation and increased risk of infections.

In 2014, the Salk Institute conducted an animal study by injecting FGF-1 in the brains of rodents with type 2 diabetes. The rodents' blood glucose levels dropped to a normal level. In 2017, another study was conducted in association with the Howard Hughes Medical Institute to explore why the rodent's blood glucose levels were returned to normal. And in 2022, another study using mice injected with FGF-1 with the Salk Institute and in collaboration with the National Institute of Health (NIH), confirmed that FGF-1 could be a potential treatment for type 2 diabetes. Zhittya's scientist, Jack Jacobs, PhD, President and Chief Scientific Officer of Zhittya, believes that FGF-1 helps reset the glucose set point in the brain.

**Size of the Market**

More than 38 million Americans have diabetes (about 1 in 10), and about 90% to 95% of them have type 2 diabetes, according to the CDC as of May 2025, which would mean that there are about 35.2 million in the U.S. with type 2. According to the American Diabetes Association report in 2023, national healthcare costs attributable to diabetes have increased by $80 billion in the past 10 years, from $227 billion in 2012 to $307 billion in 2022.

**Zhittya's Planned Treatment**

In 2023, Zhittya dosed 20 type-2 diabetes patients in the British Virgin Islands, and thus far all have remained free from abnormal blood glucose levels. Zhittya's planned treatment for type 2 diabetes is to treat the patients with FGF-1via a nasal inhaler for six days. Zhittya anticipates that it will see a drop in the fasting glucose levels of these patients by the end of six days, although there can be no assurance that such results will be achieved.

---

| |
|:---|
| 80 |
| *[**Table of Contents**](#TOC)* |

---

**<u>IV. Diabetic Foot Ulcers</u>**

Diabetic foot ulcers, or DFUs, are a serious and common complication of diabetes, presenting significant medical, personal, and societal problems. Diabetic foot ulcers are dangerous because they are slow to heal, prone to severe infection, frequently lead to amputation, cause high rates of disability and death, and impose a major economic and healthcare burden. Early detection, prevention, and aggressive treatment are critical to improving outcomes for people with diabetic foot ulcers.

The main issues with diabetic foot ulcers include high risk of infection because diabetes impairs immune function and blood flow, making it harder for the body to fight bacteria and heal wounds. Infections can spread from the skin to deeper tissues, bones (osteomyelitis), and even into the bloodstream (sepsis), which can be life-threatening.

Diabetic foot ulcers can lead to amputation and disability. Non-healing or severe infections often require partial or complete amputation of toes, feet, or even the lower leg to save the patient's life. About 20% of moderate or severe diabetic foot ulcers can lead to some level of amputation. Amputation results in permanent disability, and can lead to a loss of independence, and a dramatic decline in quality of life.

Diabetic foot ulcers are associated with a high risk of death—the five-year mortality rate after a foot ulcer can be as high as 50–70%, which is comparable to many cancers. Mortality is even higher after amputation. Even after healing, foot ulcers often recur; up to 65% of patients experience another ulcer within three to five years. Chronic ulcers and repeated infections can lead to ongoing pain, immobility, and further complications.

Diabetic foot ulcers are dangerous because they are slow to heal, prone to severe infection, frequently lead to amputation, cause high rates of disability and death, and impose a major economic and healthcare burden.

**Zhittya's Planned Treatment**

Zhittya plans to prepare and file an IND application to the FDA to conduct a Phase I clinical trial to treat patients with diabetic foot ulcers with a topical formulation of human FGF-1 in 2028.

 **Size of the Market**

According to an article in the Journal of the American Medical Association published in 2023, titled "What Are Diabetic Foot Ulcers?" Diabetic foot ulcers affect about 1.6 million in the US annually. One-third of people with diabetes will develop a foot ulcer during their lifetime. Approximately half of diabetic foot ulcers become infected, and about 20% of these infections result in amputation of part of the foot or the whole foot.

**<u>V. Venous Ulcers</u>**

Venous ulcers, also known as venous leg ulcers or venous stasis ulcers, are open sores that most commonly develop on the lower legs, especially around the ankles, due to problems with blood flow in the leg veins. They are the most common type of chronic leg ulcer. Venous ulcers occur when the valves in the leg veins become damaged or do not work properly, a condition known as chronic venous insufficiency. Normally, these valves help blood flow back up to the heart. When they fail, blood pools in the lower legs, increasing pressure inside the veins (venous hypertension). Over time, this high pressure and pooling of blood can damage the skin and underlying tissue, eventually causing an open sore to form.

Venous ulcers can be slow to heal and are prone to infection. Without proper treatment, they may persist for weeks, months, or even longer, and can recur after healing. Infections can become serious, sometimes spreading to deeper tissues or the bloodstream.

---

| |
|:---|
| 81 |
| *[**Table of Contents**](#TOC)* |

---

**Market Size**

Venous leg ulcers are extremely common in the United States and affect between 500,000 to 2 million people annually as noted in the "Chronic Venous Ulcers: A Comparative Effectiveness Review of Treatment Modalities, published by the Agency for Health Research and Quality in 2014. According to a 2013 article published in Cureus entitled, "*Venous, Arterial, and Neuropathic Leg Ulcers With Emphasis on the Geriatric Population*", in individuals 65 years and older, venous leg ulcers affect up to 5% of the 65 or older population in the United States. Based on a report from the Population Reference Bureau, there are 59 million Americans in 2023 that are 65 and older. If 4% of older Americans have venous ulcers, that figure could be 2.3 million annually.

These painful leg wounds are generally not life-threatening, but they are very debilitating and keep a number of patients from sleeping well. We believe the market for Zhittya's venous ulcer drug candidate, assuming it is approved for use in the U.S., could be $1 billion per year based on the number of wounds annually.

**Zhittya's Proposed Treatment**

Zhittya plans to submit an IND application to the FDA for a Phase I clinical trial to treat patients suffering from venous leg ulcers with FGF-1 in 2028.

**<u>VII. Multiple Sclerosis</u>**

Multiple sclerosis (MS) is a chronic, unpredictable disease of the central nervous system—specifically the brain, spinal cord, and optic nerves. It is considered an autoimmune disorder, meaning the body's immune system mistakenly attacks its own tissues. With MS, the immune system targets and damages myelin, the protective sheath that surrounds nerve fibers. The immune system attack leads to inflammation and destruction of myelin, resulting in scar tissue (sclerosis or plaques) in multiple areas of the central nervous system. Damaged myelin and nerve fibers disrupt the transmission of electrical impulses between the brain and the rest of the body, causing a wide range of symptoms.

MS symptoms vary widely from person to person and can change over time. Common symptoms include numbness, tingling, or weakness in limbs; vision problems (blurred or double vision, pain with eye movement); muscle stiffness, spasms, or weakness; trouble walking, loss of balance or coordination; bladder or bowel problems; and cognitive changes (difficulty with memory, attention, or thinking). The most common type of MS is relapsing-remitting MS, which is characterized by clear attacks of symptoms (relapses) followed by partial or complete recovery (remissions). Other types are primary progressive MS, with which symptoms gradually worsen from the onset without clear relapses, and secondary progressive MS, which begins as relapsing-remitting MS, then transitions to a steadily progressive phase.

**Zhittya's Proposed Treatment**

In a paper written for the Columbia University Irving Medical Center in 2017 titled, "*Fixing Leady Blood-Brain Barrier May Help Treat Multiple Sclerosis*" the author noted that in the healthy central nervous system, the blood-brain barrier is constructed from a tightly packed layer of endothelial cells that line blood vessels, keeping viruses and toxins that are circulating in the bloodstream from slipping into the brain and/or spinal cord. However, in people with MS, this barrier becomes more porous, and immune cells slip past and attack the myelin that surrounds nerve cells. As noted, multiple sclerosis could be the result of leaky blood vessels that suffer from a process known as "endothelial cell dysfunction." In this process, the endothelial cells that line blood vessels in the body become dysfunctional and disordered and permit the leakage of immune cells and toxic proteins from the vasculature. As FGF-1 is a potent endothelial cell mitogen as reviewed in "*The FGF family: biology, pathophysiology and therapy*" published in *Nature Reviews of Drug Discovery*, Zhittya believes that FGF-1 would be an attractive candidate to test in patients with multiple sclerosis. Zhittya's proposed treatment would be FGF-1 delivered by nasal inhaler twice a day for six days and a follow-up dosing every three months for two years. Zhittya anticipates that this would repair the leaky blood vessels in the brain, although there can be no assurance that such results will be achieved.

---

| |
|:---|
| 82 |
| *[**Table of Contents**](#TOC)* |

---

**Market Size**

According to Healthline.com, nearly 1 million people in the United States are living with Multiple Sclerosis (MS). MS is more common in women than men (about two to three times higher in women), and prevalence is highest among adults aged 45–64.

**<u>VIII. Peripheral Artery Disease & Critical Leg Ischemia</u>**

Peripheral arterial disease (PAD) is typically caused by diminished perfusion of the muscles involved in walking, a result of atherosclerosis leading to decreased patency of one or more arteries supplying the legs. This disease results from blockages in the major arteries involved in perfusing the legs with blood. Approximately 60% of individuals with PAD are symptomatic, typically exhibiting either pain on walking (but not rest) or pain that persists even during rest, denoted intermittent claudication (IC) and critical limb ischemia (CLI), respectively. The majority of symptomatic patients present with IC. Patients with IC are often limited to walking short distances before experiencing pain, thereby limiting their mobility and diminishing their quality of life

**Zhittya's Proposed Treatment**

Induction of collateral arteriogenesis and microvascular angiogenesis would improve leg blood inflow and perfusion. As FGF-1 has been shown to induce arteriogenesis and angiogenesis in animal models of leg ischemia and Zhittya believes that this potent endothelial cell mitogen offers the prospect of improving flow and function in the ischemic legs of patients with PAD, although there can be no assurance that such results will be achieved.

Zhittya sponsored a preclinical animal study at Comparative Bioscience in Sunnyvale, California in 2016 to evaluate effects of intramuscular injection of FGF-1 on collateral vessel formation, blood perfusion and microvascular density in the ischemic hindlimb of rabbits. The study was similar in design to a study previously published by Hershey et al.20. In the Zhittya study, 30 animals received FGF-1 every other day over an approximately 2 week period, with each dose given as a series of six injections into the ischemic leg muscle.

---

| |
|:---|
| 83 |
| *[**Table of Contents**](#TOC)* |

---

FGF-1 was well tolerated by animals in both the low and high dose groups. Both FGF-1 low and high doses increased the density of angiographically visible collateral vessels compared to control-treated animals at the final evaluation (see image below).

![](wund_1aimg10.jpg)

*This image shows X-rays of rabbits hind legs in which an ischemic condition is induced. The placebo-controlled animals are on the top and the FGF-1 treated animals are on the bottom. The FGF-1 treated animals showed an increased collateral vessel density after 20 days.*

The increase in collateral vessel density in response to FGF-1 treatment was greater than in control-treated animals at day 20 as shown in the image above. This effect was statistically significant (p = 0.04). The low dose group had significantly more collateral vessels in the ischemic hind limb than the control (p = 0.049); there was also a tendency for the high dose group to have more collateral vessels than controls (p = 0.098). In animal research studies, unexpected events or deviations form the protocol are reported. This study reported that there were a number of minor deviations from the protocol during the course of the study, none of which were judged to have any substantial impact on study integrity. In animal studies, the scientific endpoint is the pre-defined moment the data collection stops; the conclusion is the final interpretation of what that data actually means. This study's conclusion stated that, compared to a sham control injection, treatment with FGF-1 at both high and low doses improved indices and correlates of blood perfusion and collateral blood flow in the affected hindlimb, including angiographic score index and blood flow in the common iliac artery. Administration of FGF-1 also enhanced microvascular density in the hindlimb musculature in a dose-dependent fashion. This agent shows potential for clinical application to treat ischemic diseases such as critical limb ischemia and intermittent claudication; further investigation in animal models of chronic myocardial ischemia is also warranted.

Zhittya intends to initiate a research and development effort to test FGF-1 in a patient population with PAD and intermittent claudication. If this effort is successful, additional medical indications are expected to be pursued, including clinical studies in patients with both critical limb ischemia and Berger's disease, because all three conditions result in significantly diminished blood flow to the legs, causing symptoms such as pain, tissue damage, sores, ulcers, and—in severe cases—gangrene.

**Market Size – Peripheral Artery Disease**

The most current and comprehensive estimates indicate that between 21 million and 26 million people in the United States have peripheral artery disease ("PAD") as of 2025, as noted in the Journal of Vascular Disease Management in an article titled, "*The Current U.S. Prevalence of Peripheral Arterial Disease*." This range reflects updated analyses that account for the aging U.S. population and the rising prevalence of diabetes—both major risk factors for PAD.

**Market Size – Critical Leg Ischemia**

According to an article in the journal "Circulation" titled "*Contemporary Trends in Hospital Admissions and Outcomes in Patients with Critical Limb Ischemia*", published in February 2021, approximately 2 million people in the United States suffer from an advanced form of PAD, known as critical limb ischemia. These patients are at a much higher risk of suffering a lower limb amputation from their disease.

**<u>IX. Lung Diseases Including "Long COVID"</u>**

The fifth leading cause of death in the United States is respiratory disorders. The emergence and rapid spread of the COVID-19 virus has dramatically raised the awareness of respiratory distress and lung damage. The principal cells in the lung that is damaged by respiratory disorders, including COVID-19, are the epithelial cells that line the air sacs of the lung.

An estimated 30% of individuals who become infected with the coronavirus and have symptoms will sustain long-term lung damage. Experts on lung diseases at Johns Hopkins Medical Center who see patients with COVID-19 lung damage state: "It will be important, for all patients who have survived severe COVID-19 — and experienced severe ARDS (acute respiratory distress syndrome) requiring mechanical ventilation or high levels of oxygen — to schedule regular follow-up visits with their primary care physician or a pulmonary specialist so they can be evaluated for potential long-term problems. If necessary, treatment options, including a lung transplant, can be recommended."

---

| |
|:---|
| 84 |
| *[**Table of Contents**](#TOC)* |

---

**Zhittya's Proposed Treatment**

Fibroblast growth factors ("FGFs") are involved in a diverse array of physiological and pathological conditions. FGFs play pivotal roles in the development and maintenance of many tissues and organs derived from all of the three main cell types (germ cells) in the body, including the ectoderm (e.g., brain, skin), mesoderm (e.g., cartilage, bone, muscle, adipose tissue), and endoderm (e.g., lung, gastrointestinal tract, liver, pancreas). The involvement of specific FGFs in early lung development has been firmly established. At embryonic day 8 in the mouse, FGF-1 and FGF-2 are critically involved in the initial specification of which embryonic cells will ultimately differentiate into lung tissue. These two FGFs, along with FGF-10, are then the prime drivers for the subsequent growth and development of the mature embryonic lung.

Based on the potential ability of FGFs to stimulate the growth of lung epithelial cells, researchers have examined the effect of these growth factors in animal models of lung injury. Numerous studies support the activity of FGFs in protecting and stimulating the growth of lung epithelial cells and in lung repair. Based on the excellent safety profile that has been established in humans with FGF-1, it is appropriate to move forward on clinical testing of this FGF in COVID-19 survivors with lung damage.

The following are several lung diseases in which FGFs, including FGF-1, could play a major role and may benefit from treatment with inhaled FGF-1:

· Emphysema

· Asthma

· Chronic Obstructive Pulmonary Disease ("COPD")

· Idiopathic Pulmonary Fibrosis

Zhittya believes that FGF-1 could be used to treat individuals who suffer from scarring or damage in their lungs by using an inhaler to grow new blood vessels and repair the epithelial cells in the lungs of those patients. Zhittya also believes that FGF-1 could be an effective treatment to reverse lung damage and lung scarring to potentially treat the common symptoms of severe lung damage, although there can be no assurance that such results will be achieved.

**Market Size**

More than 34 million adults in the United States were living with chronic lung disease as of 2023, according to the American Lung Association. This figure includes major conditions such as chronic obstructive pulmonary disease (COPD), asthma, and other chronic lower respiratory diseases. According to an article by Statista analyzing certain data published by the U.S. Centers for Disease Control and Prevention based on studies from August and September 2024, 17.9% of adults in the United States have experienced long COVID-19 symptoms.

**Intellectual Property**

We currently have no registered intellectual property with any governmental authority. Zhittya has granted us permission under the License Agreement to use its trademarks in our business activities. Our commercial success is currently dependent on Zhittya maintaining control of the intellectual property of its drug candidates.

Zhittya initially filed five provisional patent applications with the U.S. Patent and Trademark Office in 2025 relating to the use of FGF-1 to treat various diseases, including Parkinson's disease, neurodegenerative diseases of the brain, Type 2 diabetes, lung damage, and neuropathy. Zhittya subsequently filed corresponding non-provisional patent applications based on those provisional filings. The patent applications are intended to protect Zhittya's intellectual property relating to the therapeutic use of FGF-1 and, if issued as patents, may provide the Company with exclusive rights to the claimed inventions for the applicable patent term, subject to the requirements and limitations of U.S. patent law. Zhittya's patent applications do not conflict with previous patents filed by Cardiovascular Biotherapeutics because Cardiovascular Biotherapeutics filed its patents based on using phage technology to make proteins, whereas Zhittya's patents are based on drug delivery. A provisional patent application gives a filer one full year to assess an invention's commercial potential before committing to the higher cost of filing and prosecuting a non-provisional application for a patent. Zhittya made its full patent applications before the one year deadline. Currently, Zhittya does not have any registered intellectual property with any governmental authority.

---

| |
|:---|
| 85 |
| *[**Table of Contents**](#TOC)* |

---

**License Agreement with Zhittya**

On May 17, 2016, we entered into a License Agreement with Zhittya (the "<u>Original License Agreement</u>"). Pursuant to the Original License Agreement, we obtained the exclusive right to market and sell drugs from Zhittya's portfolio in the United States and Canada. Our right to market and sell Zhittya's drugs is subject to Zhittya's drug candidates first being granted regulatory approval for sale by the FDA or Health Canada. The Company believes that the earliest possible timeframe in which FDA approval could be obtained, if at all, is approximately three to seven years. This estimate reflects a minimum projected period based on current assumptions and is subject to substantial uncertainty and numerous factors beyond the Company's control, including the scope and outcomes of clinical trials, regulatory review timelines, requests for additional data, and changes in regulatory requirements. The actual time required to obtain FDA approval, if ever obtained, may be significantly longer than three to seven years or may not occur at all. The Company is planning its operations and capital needs accordingly, recognizing that FDA approval may be delayed for an extended period or may never be achieved. Zhittya plans to apply for approval in Canada after the FDA has approved the use of Zhittya's drug candidates in the U.S., if ever. The License Agreement includes our marketing and sale of Zhittya's topical drug candidates and injection/infusion/intranasal drug candidates for a term of 30 years. We also acquired the right to use Zhittya's trademarks to identify products in Zhittya's portfolio in connection with our marketing and commercialization efforts. In addition, Zhittya has also granted the Company full information rights with respect to the status of Zhittya's development of FGF-1, including access to all development data (pre-clinical and clinical trial results, regulatory communications and chemistry, manufacturing, and controls), has agreed to provide the Company regular written progress reports, and to grant the Company rights to inspect Zhittya's facilities and records, and is required to provide the Company 48 hours' notice of any material development.

In exchange for the exclusive license from Zhittya, we agreed to pay $1,500,000 in cash (of which $890,000 has been paid to date) and granted Zhittya $75,500,000 worth of our dividend participating, non-voting convertible preferred stock (the preferred stock, our Series A-1 and Series A-2 preferred stock, together with the cash payment, the "License Payment"). Each share of Zhittya's preferred stock is convertible into one share of our common stock. On October 19, 2019, we and Zhittya amended the Original License Agreement and revised the consideration payable to Zhittya to consist of 3,500,000 shares of our Series A-1 preferred stock and 3,500,000 shares of our Series A-2 preferred stock. We refer you to "*Description of Capital Stock—Preferred Stock*" for a summary of the preferred stock issued to Zhittya in connection with the License Agreement.

On February 24, 2022, the Company entered into a second amendment to the Original License Agreement. This amendment primarily clarified the fee due to Zhittya on the sale or distribution of injectable, and infusion treatments licensed pursuant to the Original License Agreement. The amendment also clarified the net revenue sharing arrangement with licensees in different geographic regions.

On December 21, 2022, the Company entered into a restated and amended product license and commercialization agreement with Zhittya, which replaced the Original License Agreement, as amended, as described above. Pursuant to the License Agreement, the Company acquired the rights to sell the injectable/infusion/intranasal drugs for an additional $500,000 cash payment, up to $300 million in clinical progress and regulatory milestone payments and an 80% royalty.

The rights to the License Agreement were originally recorded at $75.0 million, and revised to $75.6 million, and were being amortized over the sixteen-year life of the original License Agreement; however, an updated valuation for December 31, 2022, valued the rights at zero and the rights were written off at that time.

Pursuant to the License Agreement, Zhittya will undertake all of the drug candidate development risk and will be responsible for 100% of the cost of all clinical trials, general drug candidate development and application for regulatory approval. Our primary business responsibility under the License Agreement is to market and sell the drugs in Zhittya's portfolio in our exclusive territory (the United States and Canada). Zhittya is developing treatment candidates for over 22 diseases that are caused from the lack of blood flow to an organ or tissue. Through the License Agreement, we hope to achieve commercial success by marketing and selling Zhittya's drugs while committing proportionately small amounts of capital toward drug development and regulatory approvals as compared to the development expenses that would be necessary if we were to develop such drugs ourselves.

---

| |
|:---|
| 86 |
| *[**Table of Contents**](#TOC)* |

---

We expect to keep a majority of the proceeds from this offering in the form of cash until clinical progress and regulatory milestone payments are required to be made to Zhittya under the License Agreement. No clinical progress and regulatory milestone payments are expected until 12 months after the date of this offering circular. We will only make milestone payments to Zhittya upon Zhittya's achievement of the applicable clinical progress and regulatory milestones, which are based on recognizable achievements in the development and approval of eight wound healing drug candidates, i.e., drugs to treat (1) diabetic foot ulcers; (2) venous ulcers; (3) burns; (4) male pattern baldness; (5) topical surgical wounds; (6) pressure wounds; (7) internal surgical wounds; and (8) second generation FGFs.

The clinical progress and regulatory milestones for the topical drug candidates are as follows:

---

| | |
|:---|:---|
| **Clinical Progress and Regulatory Milestones – Topical Drugs** | **Payment** |
| Complete animal toxicity studies | $200000 |
| Submit Phase I clinical protocol to the regulatory body (RB) | 100000 |
| Phase I protocol accepted by RB | 100000 |
| First patient treated in Phase I clinical trial | 100000 |
| Final patient treated in Phase I clinical trial | 500000 |
| Phase I study safety endpoints met | 1000000 |
| Submit Phase II clinical protocol to RB | 100000 |
| Phase II protocol accepted by RB | 250000 |
| First patient treated in Phase II clinical trial | 500000 |
| 1/3 patients treated in Phase II clinical trial | 1000000 |
| 2/3 patients treated in Phase II clinical trial | 1000000 |
| Submit "Breakthrough Drug Designation" application to RB | 500000 |
| Final patient treated in Phase II clinical trial | 2000000 |
| Phase II study unblinded and efficacy endpoints met | 5000000 |
|  | $**12350000** |
| **(If Breakthrough Drug Designation Obtained)** |  |
| "Breakthrough Drug Designation" approved by RB | 5000000 |
| Submit Biologics License Application to RB | 10000000 |
| FDA approval | 10000000 |
|  | $**25000000** |
| **(If Breakthrough Drug Designation Not Obtained)** |  |
| End of Phase II meeting with RB | 500000 |
| Submit Phase III clinical protocol to RB | 250000 |
| Phase III protocol accepted by RB | 500000 |
| 1/3 patients treated in Phase III clinical trial | 2000000 |
| 2/3 patients treated in Phase III clinical trial | 2000000 |
| Final patient treated in Phase III clinical trial | 2000000 |
| Phase III study unblinded and efficacy endpoints met | 5000000 |
| Submit BLA to RB | 10000000 |
| RB approval | 10000000 |
|  | $**32250000** |

---

---

| |
|:---|
| 87 |
| *[**Table of Contents**](#TOC)* |

---

The Company will pay the above clinical progress and regulatory milestone payments on the progress of each topical drug candidate not to exceed $75,000,000 in aggregate, payable in installments, in cash or shares of our stock (at our discretion), calculated using the average closing price over the prior 20 trading days prior to issuance, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, we are required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock. Once the milestone payments reach an aggregate of $75,000,000, no additional clinical progress and regulatory milestone payments for topical drug candidates would be required. As of the date of this offering circular, the Company has made no milestone payments relating to topical drug candidates, as none have become due. Additionally, the Company's obligation to pay clinical progress and regulatory milestone payments to Zhittya are not required to begin until the earliest, 90 days after our initial public offering or public sale of shares.

The Company will pay Zhittya 50% of the Company's operating profits from the sale of the topical drugs when the Company begins selling its drugs in the U.S.

We also have the exclusive marketing rights to Zhittya's injection/infusion/intranasal drug candidates in the United States and Canada, which may include drugs for the treatment of (1) Parkinson's disease; (2) stroke; (3) multi-infarct dementia; (4) coronary heart disease; (5) peripheral artery disease; (6) lumbar ischemia; (7) chronic traumatic encephalopathy (CTE); (8) traumatic brain injury (TBI); (9) Alzheimer's disease; (10) Huntington's disease; (11) amyotrophic lateral sclerosis (ALS); (12) chronic depression; (13) post-traumatic stress disorder (PTSD); (14) multiple sclerosis (MS); and (15) multiple systems atrophy (MSA).

---

| |
|:---|
| 88 |
| *[**Table of Contents**](#TOC)* |

---

The Company will pay clinical progress and regulatory milestone payments to Zhittya in connection with the infusion/injection/intranasal drug candidates in an amount not to exceed $300 million in the aggregate, payable in installments, in cash or shares of our stock (at our discretion), calculated using the average closing price over the prior 20 trading days prior to issuance, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, we are required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock. The royalty for injection/infusion/intranasal drug candidates will be 80% of the Company's operating profits from the sale of such drugs. In addition, the clinical progress and regulatory milestone payments listed below for each injection/ infusion/intranasal drug candidate, in an amount not to exceed $300,000,000 in the aggregate. Once the clinical progress and regulatory milestone payments reach an aggregate of $300,000,000, no additional clinical milestone payments for injection/infusion/intranasal drugs would be required.

---

| | |
|:---|:---|
| **Clinical Progress and Regulatory Milestones – Injectable and Infusion Drugs** | **Payment** |
| Complete animal toxicity studies | $200000 |
| Submit Phase I clinical protocol to RB | 100000 |
| Phase I protocol accepted by RB | 500000 |
| First patient treated in Phase I clinical trial | 500000 |
| Final patient treated in Phase I clinical trial | 1000000 |
| Phase I study safety endpoints met | 2000000 |
| Submit Phase II clinical protocol to RB | 200000 |
| Phase II protocol accepted by RB | 500000 |
| First patient treated in Phase II clinical trial | 1000000 |
| 1/3 patients treated in Phase II clinical trial | 1000000 |
| 2/3 patients treated in Phase II clinical trial | 1000000 |
| Submit "Breakthrough Drug Designation" application to RB | 500000 |
| Final patient treated in Phase II clinical trial | 4000000 |
| Phase II study unblinded and efficacy endpoints met | 15000000 |
|  | $27500000 |
| **(If Breakthrough Drug Designation Obtained)** |  |
| "Breakthrough Drug Designation" approved by RB | 25000000 |
| Submit Biologics License Application to RB | 5000000 |
| FDA approval | 25000000 |
|  | $**55000000** |
| **(If Breakthrough Drug Designation Not Obtained)** |  |
| End of Phase II meeting with RB | 500000 |
| Submit Phase III clinical protocol to RB | 500000 |
| Phase III protocol accepted by RB | 1000000 |
| 1/3 patients treated in Phase III clinical trial | 2000000 |
| 2/3 patients treated in Phase III clinical trial | 2000000 |
| Final patient treated in Phase III clinical trial | 2000000 |
| Phase III study unblinded and efficacy endpoints met | 25000000 |
| Submit BLA to RB | 5000000 |
| RB approval | 25000000 |
|  | $**63000000** |

---

---

| |
|:---|
| 89 |
| *[**Table of Contents**](#TOC)* |

---

As of the date of this offering circular the Company has made no clinical progress and regulatory milestone payments relating to injection/infusion/intranasal drug candidates, as none have become due. Additionally, the Company's obligation to pay clinical progress and regulatory milestone payments to Zhittya are not required to begin until, at the earliest, 90 days following our initial public offering or public sale of shares.

Zhittya is currently the only company with which we have a licensing and sales agreement. Pursuant to the License Agreement, beginning on the date of the first governmental approval of a product covered by the License Agreement, we are restricted from engaging in any business other than the promotion, marketing, and distribution of Zhittya's products under the License Agreement in the United States and Canada. As a result, our viability is directly tied to the development, regulatory approval, and market adoption of the candidate drugs in Zhittya's portfolio. Though we are optimistic about Zhittya's success with its drug candidates, there is considerable risk that Zhittya will not meet expectations and, consequently, we may fail to meet expectations absent new agreements with other companies. Currently, there are no such agreements. We recognize that even strong drug candidates face long odds of being approved by the FDA, as required for their marketing and sale in the United States. Despite these challenges, we remain optimistic about Zhittya's ability to develop successful products and our ability to deliver them to the market.

Our License Agreement with Zhittya is structured to incentivize Zhittya to meet the goals of obtaining drug approval. We are only required to make clinical milestone payments to Zhittya when progress has been made as measured by the achievement of certain clinical progress and regulatory milestones. Our cost of drug development is capped at the amount of the clinical progress and regulatory milestone payments.

Zhittya has signed territorial license agreements in five areas of the world: United States/Canada, Europe, Middle East, Latin America and Southeast Asia. There will be different availability of products for treatment in various territories for which Zhittya licenses its drug candidates because of the timing of or differences in government approvals. Thus, there may be an opportunity for treatment of patients elsewhere who otherwise would be treated in our exclusive territory (United States and Canada) or vice-versa. In such event our patients may receive approved treatment outside of our territory or we may treat patients from outside of our territory. In such event the net revenues of any such operations will be divided equally between the two licensees involved or with Zhittya if only one licensee is involved.

In addition, the License Agreement states that the net revenues of any such joint cross-border operations shall be divided equally between the two licensees that are involved or with Zhittya if only one licensee is involved for clinical study or testing of the product in the territory. The revenue from these cross-border operations shall not apply towards the clinical progress and regulatory milestone requirements. Any cross-border operations shall also be subject to the payment of the following fees for such use of the product:

a) There shall be no fee payable by us as licensee from the first $3 million of our cross-border operating profits (revenues less marketing and cross border costs), which total $2,047,793 as of March 31, 2026.

b) We are required to pay Zhittya a fee of 50% of our cross-border operating profits from $3 million to $10 million.

c) We are required to pay Zhittya a fee of 80% of our cross-border operating profits after operating profits of $10 million have been reached.

---

| |
|:---|
| 90 |
| *[**Table of Contents**](#TOC)* |

---

Under the License Agreement, at no point prior to three years from the date of this offering shall Zhittya own more than 4.99% of our issued and outstanding common stock and for the first two years after this offering, Zhittya cannot convert any of its shares of convertible preferred stock into our common stock. Additionally, following two years from the date of this offering but prior to three years from the date of this offering, Zhittya may not convert preferred stock if and to the extent that such conversion would result in Zhittya holding more than 4.99% of our common stock.

If the drug candidates produced by Zhittya receive FDA approval and we begin selling them, we will be responsible for collecting the proceeds from all sales. In such circumstances, we will then remit a portion of our operating profits (gross sales less direct costs) to Zhittya on a monthly basis. Direct costs include costs associated with direct sales and marketing costs, and exclude costs such as salaries and corporate overhead. We will pay Zhittya 50% of our operating profits from the sale of topical drugs and 80% of our operating profits from the sale of injectable/infusion/intranasal drugs.

We currently receive other income from Zhittya's cross-border operations in the British Virgin Islands and the Bahamas, in which Zhittya's patients from the United States and Canada are treated in another territory using drugs covered by our License Agreement. Additionally, starting in September 2025, the Company began receiving other income from Zhittya's use of licensed drugs in the United States for Type 2 diabetes research studies. These research studies are investor funded and are taking place in Las Vegas, Nevada. The Company and Zhittya agreed, pursuant to the terms of a Letter Agreement dated October 13, 2025, that Zhittya would pay the Company the price of $15,000 per patient treated in these studies for the use of FGF-1. As of December 31, 2025, the Company had received $300,000 from Zhittya for the investor-funded research studies. For the three months ended March 31, 2026, the Company received $510,000 from Zhittya for these Investor-Funded research studies. This income is part of the cross-border operations discussed below. The Company is not conducting the sales and marketing for the sales in the British Virgin Islands or other countries.

The cross-border revenue sharing applies throughout the world, to the extent that patients from the United States and Canada are treated using drugs covered by the License Agreement in a territory other than the United States and Canada.

Although the License Agreement does not specify payment terms or timing, to date Zhittya has been providing the Company a monthly statement and has been paying the amounts owed to the Company on a monthly basis.

**Clinical Progress and Regulatory Milestone Payments for Wound Healing Drugs**

In addition to the License Payment, we are also obligated to make payments to Zhittya if its topical drug candidates meet certain clinical progress and regulatory milestones as discussed above. As shown in the tables above, the milestone payments range from $100,000 to $10,000,000 and will not exceed $75,000,000 in total for the entire class of wound healing drugs. At our discretion, such milestone payments may be paid in the form of cash or shares of our common stock, calculated using the average closing price over the prior 20 trading days, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, we are required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock. Additionally, these milestone payment obligations will not begin to accrue until 90 days after our initial public offering or public sale of shares. To date, no milestone payments are due to Zhittya in connection with wound healing drug candidates.

**Clinical Progress And Regulatory Milestone Payments for Injectable and Infusion Drugs**

We are also obligated to make payments to Zhittya if its injection/infusion/intranasal drug candidates meet certain clinical progress and regulatory milestones. These milestone payments range from $100,000 to $25,000,000 and will not exceed $300,000,000 in total for the entire class of injectable/infusion/intranasal drugs. At our discretion, such milestone payments may be paid in the form of cash or shares of our common stock, calculated using the average closing price over the prior 20 trading days, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, we are required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock. Additionally, these milestone payment obligations will not begin to accrue until 90 days after our initial public offering or public sale of shares. To date, no milestone payments are due to Zhittya in connection with injection/infusion/intranasal drug candidates.

---

| |
|:---|
| 91 |
| *[**Table of Contents**](#TOC)* |

---

**Indemnification Obligations Under License Agreement**

Pursuant to the License Agreement, each party has agreed to indemnify and hold the other party harmless from and against certain third-party claims. Specifically:

· Zhittya has agreed to defend, indemnify, and hold the Company harmless from any losses or claims arising out of third-party actions relating to the product or the performance of the agreement, to the extent caused by Zhittya's negligence, willful misconduct, or breach of any representation or warranty set forth in the License Agreement.

· We have also similarly agreed to defend, indemnify, and hold Zhittya harmless from third-party claims arising from our negligence, willful misconduct, or breach of any representation or warranty set forth in the License Agreement.

In each case, the indemnifying party must be given prompt notice of the claim and retains the right to control the defense and settlement of such claims.

**Termination Rights Under the License Agreement**

The License Agreement includes provisions for termination under the following circumstances:

· Either party may terminate the License Agreement upon a material breach by the other party, following written notice and a 30-day cure period.

· The License Agreement may be terminated by either party with 30 days' notice if the other party becomes subject to bankruptcy, insolvency, or similar financial proceedings.

Upon termination or expiration of the License Agreement:

· All rights and licenses revert to Zhittya;

· We must cease all use and distribution of the products and associated technology or trademarks; and

· We are required to return or destroy relevant materials and pay any outstanding amounts due to Zhittya.

The License Agreement also provides that certain provisions, including those relating to indemnification, confidentiality, and post-termination obligations, survive the expiration or termination of the License Agreement.

**About Zhittya**

Zhittya (which means "life" in Ukrainian) is advancing a group of drug candidates intended to trigger the human body's natural regeneration process. Zhittya's regenerative drug candidates act by specifically stimulating the growth of new blood vessels (a biological process termed angiogenesis) in tissues or organs that have perfusion defects. Zhittya describes the physiological actions of its drug candidates as stimulating "therapeutic angiogenesis." According to the website of the Angiogenesis Foundation in Cambridge, MA, over 70 human diseases have been linked to a lack of angiogenesis and blood perfusion. The American Heart Association, in its 2023 "*Disease Statistics*" annual report, states that lack of blood perfusion to the heart (or coronary artery disease) and lack of blood perfusion to the brain (or stroke) are responsible for close to 41% and 17% of cardiovascular diseases in the United States, respectively. Zhittya has clinical development programs planned for 22 separate medical conditions, most of which are believed to be caused by a lack of blood perfusion. Zhittya's scientific management is led by Jack Jacobs, Ph.D., who is the president and chief science officer of Zhittya. Dr. Jacobs had previously worked for Merck & Co. and has twenty years of experience in overseeing the manufacturing of FGF-1 and supervising U.S. clinical trials.

---

| |
|:---|
| 92 |
| *[**Table of Contents**](#TOC)* |

---

The biological drug candidates being developed by Zhittya can be broadly categorized into two groups: (1) "injectable/infusion/intranasal drugs" and (2) "topical drugs."

**Injectable/Infusion/Intranasal Drug candidates**

Zhittya is also developing a portfolio of drug candidates that are intended to be either infused or injected or inhaled into the human body. Zhittya is developing the protein growth factor, human fibroblast growth factor-1, or FGF-1, which is a potent stimulator of new blood vessels growth (or angiogenesis). As reviewed in "*The FGF family: biology, pathophysiology and therapy*" published in *Nature Reviews of Drug Discovery*, the mechanism of action of FGF-1 in the medical indications listed below is primarily through the growth factor's activity in stimulating new blood vessel growth in damaged tissues or organs.

Zhittya is using a nasal inhaler device to deliver human FGF-1 directly into the brain in human research studies. Zhittya is using an off the shelf, third party nasal device. Similar devices have been approved by the FDA for use in humans. At a March 2024 inhalation conference, Bing Li of the FDA's Division of Bioequivalence in the Office of Generic Drugs of the Center for Drug Evaluation and Research (CDER) noted that in 2014 (the last publicly available data) 27 nasal sprays had been approved and 22 nasal sprays were still awaiting review.

As of June 2026, Zhittya is developing injectable/infusion/intranasal drug candidates for the treatment of the following medical indications: Parkinson's disease, stroke, type 2 diabetes, multi-infarct dementia, coronary heart disease, peripheral artery disease, chronic traumatic encephalopathy, traumatic brain injury, Alzheimer's disease, amyotrophic lateral sclerosis, or ALS, post-traumatic stress disorder, multiple sclerosis, and multiple systems atrophy.

**Topical Drug candidates**

In addition to the injectable/infusion/intranasal drug candidates discussed above, FGF-1 is also a potent mitogen for all of the principal cell types that make up skin, including dermal fibroblasts and keratinocytes. These combined biological activities of FGF-1 make it an attractive candidate to develop as a new agent for a number of wound healing indications.

As of June 2026, Zhittya is developing topical drug candidates for the following medical indications: diabetic foot ulcers, or DFUs, venous ulcers; burns, male pattern baldness, topical surgical wounds (c-sections, cosmetic surgeries), pressure wounds (or bedsores), internal surgical wounds (or anastomoses), and punctures/deep lacerations (from trauma/military). All the drug candidates being developed for the indications listed in the previous sentence contain human FGF-1 as their active pharmaceutical ingredient. The actual formulations for each indication may differ slightly, as well as their mode of application.

There are published reports on structurally altering the FGF-1 molecule. Zhittya is also contemplating generating a second generation of FGF-1 related drug candidates with the goal of creating drugs that have enhanced stability, biological activity, or a better side effect profile. In some cases, these second-generation products may afford Zhittya patent protection which could potentially provide a competitive marketplace advantage for these products. We may enter into subsequent agreements, in our discretion, to have the right to become Zhittya's exclusive licensee in the territory (the United States and Canada) with respect to those modifications, under substantially the same terms under the License Agreement.

**Goals**

Zhittya's goal (and, by extension, ours) is gaining FDA approval in the U.S. and Health Canada approval in Canada (Zhittya plans to apply for Health Canada approval in Canada after approval is obtained from the FDA in the U.S.) for all of its drug candidates, which can be expedited or enhanced by obtaining certain regulatory designations from the FDA. As explained in further detail in "*Government Regulation and Product Approval"* below, the following FDA designations are designed to expedite the review process, each as described below: (i) unmet medical need, (ii) disease-modifying agent, and (iii) breakthrough therapy.

---

| |
|:---|
| 93 |
| *[**Table of Contents**](#TOC)* |

---

**Progress**

According to Zhittya, as of December 2025, it has treated over 240 Parkinson's disease patients in the British Virgin Islands, where FGF-1 has been approved for use in research studies. The patients have reported on average, as of May 2025 when 200 Parkinson's disease patients had been treated, an improvement of 53% in their symptoms. This study involved a limited number of cases, and the observed findings should be interpreted cautiously. study results are inherently preliminary, are not subject to the same controls and statistical rigor as well-designed randomized clinical trials, and may not be predictive of future clinical outcomes in humans. Accordingly, there can be no assurance that these results will be replicated in larger, controlled clinical studies, or that any future trial will demonstrate similar safety, biological activity, or therapeutic benefit. Zhittya is using this information to design the appropriate dosing and the timing of the dosing of the patients for expected future clinical trials.

Zhittya expects to start its first animal studies in the fourth quarter of 2026 for diabetic foot ulcers ("DFUs"). In addition, the Company has no control over which INDs, if any, are submitted and/or the timing of such submissions, and the approval of such INDs will be in the sole discretion of the FDA. Zhittya expects to file an IND for DFUs in 2028 and in that same year to start additional animal studies for the other indications in order to file additional INDs, which timing may change in the future for numerous reasons.

We believe that type 2 diabetes, severe coronary artery disease, Parkinson's disease, diabetic foot ulcers, and venous ulcers are Zhittya's leading "therapeutic angiogenesis" drug candidates that are the farthest along in drug development. Based on our discussions with Zhittya, we believe the animal trials could start in the fourth quarter of 2026, and subsequent trials could start thereafter.

We believe that many of the diseases that Zhittya is targeting are considered to be unmet medical needs by the FDA. In addition, we believe that Zhittya's drug would be considered a "disease-modifying agent," which is an agent that corrects the underlying root cause of a disease.

Zhittya manufactures its own FGF-1. Zhittya had previously utilized several commercial cGMP contract manufacturers; however, Zhittya advised us that it had experienced production delays with one manufacturer and the other underwent foreclosure and liquidation of its assets. Zhittya manufactures FGF-1 from E.Ccoli bacteria using a plasmid-based recombinant expression method. The gene coding for the human FGF-1 protein is chemically synthesized in Zhittya's lab and then placed into an E. Coli DNA plasmid which is introduced into E. Coli cells. The human FGF-1 protein is then made in the bacterial cells and purified. The FGF-1 produced is the same molecule used across all applications, including both nasal and topical drug candidates. Zhittya's in-house laboratory began producing FGF-1 for both the nasal and topical drug candidates in the first quarter of 2026. Zhittya has utilized several commercial cGMP contract manufacturers and is currently in the process of bringing manufacturing in-house. Zhittya has set up its lab on the campus of the University of Reno and in the first quarter of 2026, began producing FGF-1 for research studies.

It is difficult to estimate the exact amount of time a drug will need to move through the clinical development process (see "*U.S. Government Regulation of Drug Products*" below for a more detailed explanation of this process). Many factors can affect this timeline, including the rate of patient enrollment into the clinical trials and any adverse events that may have to be addressed, as the patients undergo treatment. In addition, receiving certain designations from the FDA, such as "fast-track" or "breakthrough therapy", can significantly speed up the clinical development process. Taking a conservative approach, we estimate that once an IND is submitted and approval is given to initiate treatment of patients the following timetable will follow:

· *Phase I clinical trials*: Primarily safety study with efficacy readouts monitored that may take 9-12 months to complete in addition to time required to file reports with the FDA.

· *Phase II clinical trials*: Dose-ranging studies looking for the best dose of drug to treat the patients with the lowest side effect profile that may take 12-24 months to complete in addition to time required to file reports with the FDA.

· *Phase III clinical trials*: Taking a single dose of the drug and testing it in a large and diverse patient population that may take 2-4 years to complete in addition to time required to file reports with the FDA.

---

| |
|:---|
| 94 |
| *[**Table of Contents**](#TOC)* |

---

Many of Zhittya's drug candidates seek to address diseases with no current treatments that can reverse or stop the disease process (an "unmet medical need"), and thus it is conceivable that a number of Zhittya's drug candidates could obtain an FDA designation that would expedite the development and/or approval process. For example, if the FDA gave Zhittya's Parkinson's disease drug the designation of "breakthrough therapy", it is conceivable that this drug could be approved after successful completion of a Phase II clinical trial.

**Growth Strategy**

Many companies that intend to sell biological drugs such as Zhittya's need to raise large amounts of capital and have difficulty surviving the time-consuming and expensive process of developing their drugs. Our business is structured not to require large sums of capital. Instead, the Company only pays clinical progress and regulatory milestone payments which are fixed and are only payable upon Zhittya achieving steps toward drug approval (as discussed above). We also owe certain royalty payments to Zhittya as discussed above, which are payable out of revenues generated through the sale of products or cross-border operations. Additionally, we expect to continue receiving other income from Zhittya's foreign clinics, where patients from the United States and Canada are treated. Zhittya will continue to work towards approval for its drug candidates in the United States and later in Canada. Before the FDA approves its drug candidates in the U.S., which we don't expect to occur for three to seven years, if at all, we plan to discuss Zhittya's progress in pre-clinical and clinical trials in press releases, interviews, and articles. We believe that this awareness will encourage patients and investors to follow our progress.

While official marketing and sales of Zhittya's drug candidates by us cannot commence until the drug candidates receive FDA approval, which we do not expect to occur for at least three to seven years, if at all, our work is expected to begin when Zhittya's drug candidates are in Phase III studies. At that point, we plan to identify a drug distribution company. The Company hopes to partner with one of the three major U.S. pharmaceutical distribution companies in the future, though there is no assurance that such a partnership will be obtained: McKesson, Cardinal Health, or Cencora (formerly AmerisourceBergen) to:

· Leverage their distribution network for market penetration;

· Drive physician and patient adoption through their system;

· Optimize supply chain and logistics; and

· Monitor and optimize performance.

When Zhittya is close to filing its New Drug Application ("NDA"), we will prepare an overall marketing plan to raise awareness with potential patients, doctors, and medical community.

**Research**

In addition to our existing research into the market for Zhittya's drug candidates, we plan to conduct targeted research and outreach within communities affected by the diseases and conditions for which Zhittya's drug candidates are designed. We anticipate that this will provide us with valuable insights into how to engage with these communities, once the drug candidates become commercially available, in addition to gaining name recognition and goodwill.

**Awareness Campaigns**

Subject to the progression of Zhittya's various drug candidates and applications, we intend to conduct several awareness campaigns while the drug candidates are in their developmental and approval stages, targeting diseases and conditions with unmet medical needs. We plan to raise awareness of the drug candidates' progress with patients, the medical community, the public and investors through press releases, social media, influencers, newsletters, conferences and presentations over the next several years, subject to applicable laws. Our objective through this process will be to educate the medical and patient community about the possible applications of these drug candidates and the current status of their regulatory approval.

---

| |
|:---|
| 95 |
| *[**Table of Contents**](#TOC)* |

---

**Competition**

The drug discovery and development industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies, and public and private research institutions. Any product candidates that we license and which are successfully developed and commercialized, as we intend for FGF-1, may compete with existing therapies and new therapies that may become available in the future.

Our competitors may have significantly greater financial resources, an established presence in the market, greater expertise in research and development, manufacturing, preclinical and clinical testing, and may already be in the process of obtaining regulatory approvals and marketing of approved products. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Assuming Zhittya's drug candidates are approved by the FDA, of which there is no assurance, and are commercially marketed, we expect there to be competition from other drug companies for drugs addressing the unmet medical needs they treat, and some competition for drugs addressing other diseases and conditions.

Pursuant to the License Agreement, we will have the exclusive license to sell Zhittya's product candidates in the United States and Canada.

**U.S. Government Regulation of Drug Products**

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act and its implementing regulations. The procedure for obtaining regulatory approvals and the subsequent compliance with applicable federal, state, local, and foreign statutes and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA's refusal to approve a pending Biological License Application ("BLA") , withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or civil or criminal penalties.

The process required by the FDA before biological product candidates may be marketed in the United States generally involves the following:

· submission to the FDA of an IND application which must become effective before human clinical trials may begin and which must be updated annually;

· completion of extensive preclinical laboratory tests and preclinical animal studies, all performed in accordance with the FDA's Good Laboratory Practice regulations. Preclinical testing generally includes evaluation of products in the laboratory or in animals to characterize the product and determine safety and efficacy;

· approval by an independent institutional review board ("IRB") at each clinical site before each trial may be initiated;

· performance of adequate and well-controlled human clinical trials in accordance with good clinical practice ("GCP") requirements to establish the safety and efficacy of the product candidate for each proposed indication;

---

| |
|:---|
| 96 |
| *[**Table of Contents**](#TOC)* |

---

· submission to the FDA of an BLA after completion of all pivotal clinical trials;

· a determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review;

· satisfactory completion of an FDA advisory committee review, if applicable;

· satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the active pharmaceutical ingredient ("API"), and finished drug product are produced and tested to assess compliance with cGMP regulations and to assure that the facilities, methods and controls are adequate to preserve the drug's identity, strength, quality and purity;

· satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data;

· payment of user fees and securing FDA approval of the BLA; and

· compliance with any post-approval requirements, including the potential requirement to implement Risk Evaluation and Mitigation Strategies ("REMS") and the potential requirement to conduct post-approval studies.

Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on the general investigational plan and the protocol(s) for human studies. The IND also includes results of other human studies, as appropriate, as well as manufacturing information, analytical data and any available clinical data or literature to support the use of the investigational new drug. An IND must become effective before human clinical trials may begin. An IND will automatically become effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to the proposed clinical trials. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before clinical trials can begin. Accordingly, submission of an IND may or may not result in the FDA allowing clinical trials to commence.

Clinical trials involve the administration of the new investigational drug to human subjects under the supervision of qualified investigators in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the study, the parameters to be used in monitoring safety, and the efficacy criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND.

Additionally, approval must also be obtained from each clinical trial site's IRB before the trials may be initiated, and the IRB must monitor the study until completed. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.

The clinical investigation of a drug is generally divided into three phases. Although the phases are usually conducted sequentially, they may overlap or be combined. The three phases of an investigation are as follows:

· *Phase 1*. Phase 1 includes the initial introduction of an investigational new drug into humans. Phase 1 clinical trials are typically closely monitored and may be conducted in patients with the target disease or condition or in healthy volunteers. These studies are designed to evaluate the safety, dosage tolerance, metabolism, and pharmacologic actions of the investigational drug in humans, and the side effects associated with increasing doses, and if possible, to gain early evidence on effectiveness. During Phase 1 clinical trials, sufficient information about the investigational drug's pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials.

---

| |
|:---|
| 97 |
| *[**Table of Contents**](#TOC)* |

---

· *Phase 2*. Phase 2 includes controlled clinical trials conducted to preliminarily or further evaluate the effectiveness of the investigational drug for a particular indication(s) in patients with the disease or condition under study, to determine dosage tolerance and optimal dosage, and to identify possible adverse side effects and safety risks associated with the drug. Phase 2 clinical trials are typically well-controlled, closely monitored, and conducted in a limited patient population.

· *Phase 3*. Phase 3 clinical trials are generally controlled clinical trials conducted in an expanded patient population generally at geographically dispersed clinical trial sites. They are performed after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to further evaluate dosage, clinical effectiveness and safety, to establish the overall benefit-risk relationship of the investigational drug product, and to provide an adequate basis for product approval.

A registration study is any clinical study that adequately meets regulatory agency requirements for the evaluation of a product candidate's efficacy and safety such that it can be used to justify the approval of the product. Generally, pivotal studies are Phase 3 studies but may also be Phase 2 studies if the trial design provides a well-controlled and reliable assessment of clinical benefit, particularly in situations where there is an unmet medical need.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. Phase 1, Phase 2, and Phase 3 clinical trials may not be completed successfully within any specified period, or at all. The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the study. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate.

Assuming successful completion of all required testing in accordance with all applicable regulatory requirements, detailed investigational drug product information is submitted to the FDA in the form of a BLA requesting approval to market the product for one or more indications.

The application includes all relevant data available from pertinent preclinical and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product's chemistry, manufacturing, controls, and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and effectiveness of the investigational drug product to the satisfaction of the FDA.

In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act ("PDUFA") guidelines that are currently in effect, the FDA has a goal of ten months from the date of "filing" of an NDA to review and act on the submission, or if the application relates to an unmet medical need in a serious or life-threatening indication, six months from filing. For filings that do not relate to an unmet medical need in a serious or life-threatening indication, this review typically takes twelve months from the date the BLA is submitted to FDA because the FDA has approximately two months to make a "filing" decision.

In addition, under the Pediatric Research Equity Act of 2003, as amended and reauthorized, certain NDAs or supplements to an NDA must contain data that are adequate to assess the safety and effectiveness of the drug for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements.

---

| |
|:---|
| 98 |
| *[**Table of Contents**](#TOC)* |

---

The FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.

The FDA conducts a preliminary review of all BLAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. The FDA may request additional information rather than accept a BLA for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. Once the BLA submission has been accepted for filing, the FDA's goal is to review applications within ten months from filing or, if the application relates to an unmet medical need in a serious or life-threatening indication, six months from filing. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the application to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee but it typically follows such recommendations.

The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. Additionally, before approving an BLA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.

After the FDA evaluates the BLA and conducts inspections of manufacturing facilities where the drug product and/or its active pharmaceutical ingredient, or API, will be produced, it may issue an approval letter or a "Complete Response Letter." An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter may require additional clinical data and/or an additional pivotal Phase 3 clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials or manufacturing. Even if such additional information is submitted, the FDA may ultimately decide that the BLA does not satisfy the criteria for approval. The FDA could also approve the BLA with a REMS plan to mitigate risks, which could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. The FDA also may condition approval on, among other things, changes to proposed labeling, development of adequate controls and specifications, or a commitment to conduct one or more post-market studies or clinical trials. Such post-market testing may include Phase 4 clinical trials and surveillance to further assess and monitor the product's safety and effectiveness after commercialization. Regulatory approval of oncology products often requires that patients in clinical trials be followed for long periods to determine the overall survival benefit of the drug. The FDA may prevent or limit further marketing of a product based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes, and additional labeling claims, are subject to further testing requirements and FDA review and approval.

Newly discovered or developed safety or effectiveness data may require changes to a product's approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. The FDA strictly regulates marketing, labeling, advertising, and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability. Also, from time to time, legislation is drafted, introduced and passed in the United States Congress that could significantly change the statutory provisions governing the approval, manufacturing, and marketing of products regulated by the FDA. In addition, FDA regulations and guidance are often revised or reinterpreted by the agency in ways that may significantly affect our business and Zhittya's products. It is impossible to predict whether legislative changes will be enacted, or FDA regulations, guidance or interpretations changed or what the impact of such changes, if any, may be.

---

| |
|:---|
| 99 |
| *[**Table of Contents**](#TOC)* |

---

**Available Special Regulatory Procedures**

The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drug candidates that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drug candidates to patients earlier than under standard FDA review procedures.

**Fast Track Designation**

To be eligible for a fast track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the BLA for a fast track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.

**Priority Review**

The FDA may give a priority review designation to drug candidates that offer major advances in treatment, or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the PDUFA guidelines, these six and ten month review periods are measured from the "filing" date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast track designation are also likely to be considered appropriate to receive a priority review.

**Breakthrough Therapy Designation**

Under the provisions of the Food and Drug Administration Safety and Innovation Act passed in July 2012, a sponsor can request designation of a product candidate as a "breakthrough therapy." A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drug candidates, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drug candidates designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy.

**Accelerated Approval Pathway**

The FDA may grant accelerated approval to a drug for a serious or life-threatening condition that provides meaningful therapeutic advantage to patients over existing treatments based upon a determination that the drug has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit. The FDA may also grant accelerated approval for such a condition when the product has an effect on an intermediate clinical endpoint that can be measured earlier than an effect on irreversible morbidity or mortality ("IMM"), and that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. Drug candidates granted accelerated approval must meet the same statutory standards for safety and effectiveness as those granted traditional approval.

For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. Surrogate endpoints can often be measured more easily or more rapidly than clinical endpoints. An intermediate clinical endpoint is a measurement of a therapeutic effect that is considered reasonably likely to predict the clinical benefit of a drug, such as an effect on IMM. The FDA has limited experience with accelerated approvals based on intermediate clinical endpoints, but has indicated that such endpoints generally may support accelerated approval where the therapeutic effect measured by the endpoint is not itself a clinical benefit and basis for traditional approval, if there is a basis for concluding that the therapeutic effect is reasonably likely to predict the ultimate clinical benefit of a drug.

---

| |
|:---|
| 100 |
| *[**Table of Contents**](#TOC)* |

---

The accelerated approval pathway is most often used in settings in which the course of a disease is long and an extended period of time is required to measure the intended clinical benefit of a drug, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Thus, accelerated approval has been used extensively in the development and approval of drug candidates for treatment of a variety of cancers in which the goal of therapy is generally to improve survival or decrease morbidity and the duration of the typical disease course requires lengthy and sometimes large trials to demonstrate a clinical or survival benefit.

The accelerated approval pathway is usually contingent on a sponsor's agreement to conduct, in a diligent manner, additional post-approval confirmatory studies to verify and describe the drug's clinical benefit. As a result, a product candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase 4 or post-approval clinical trials to confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or confirm a clinical benefit during post-marketing studies, would allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA.

Even if a product qualifies for one or more of the foregoing programs which are intended to expedite or simplify the FDA process, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. Zhittya may explore some of these opportunities for its product candidates as appropriate.

**Properties and Facilities**

Our corporate headquarters and executive offices are located in Las Vegas, Nevada. We believe that our existing facilities are suitable and adequate to meet our current needs. We intend to add new facilities or expand existing facilities as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations.

On January 10, 2025, the Company entered into a 37-month lease agreement (from February 1, 2025 through February 29, 2028) for office space at 8683 W. Sahara Avenue, Suite 280, Las Vegas, NV 89117, which serves as the Company's headquarters. Under the terms of the lease, the Company leases 1,160 square feet of office space for $2,146 per month, plus operating expenses, subject to scheduled annual rent increases.

We believe our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.

**Legal Proceedings**

We may be involved from time to time in ordinary litigation, negotiation, and settlement matters that will not have a material effect on our operations or finances. We are not currently party to any material legal proceedings, and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results, or financial condition.

**Employees** 

We do not have any employees, and we are not a party to any collective bargaining agreements. At this time we have engaged our management team as independent contractors only. Following the completion of this offering, we anticipate having five employees.

---

| |
|:---|
| 101 |
| *[**Table of Contents**](#TOC)* |

---

**MANAGEMENT**

**Executive Officers and Directors**

The following table sets forth the name, age, and position of each of our executive officers, key employees, and directors as of the date of this offering circular.

---

| | | |
|:---|:---|:---|
| **Name** | **Age** | **Position(s)** |
| **Executive Officers** |  |  |
| John Laub | 68 | President, Chief Executive Officer, Chairman of the Board of Directors |
| Jon Paul | 73 | Chief Financial Officer  |
| **Non-Employee Directors** |  |  |
| Gregory Fey | 82 | Director |
| James Lamb | 75 | Director |

---

***Business Experience***

The following is a brief description of the education and business experience of directors and executive officers.

**John Laub** – *President, Chief Executive Officer, Treasurer and Chairman of the Board of Directors*

John Laub has been President, Chief Executive Officer and Chairman of the Board since the Company's inception in May 2016. With over 30 years of business experience and 15 years in the biotechnology field, Mr. Laub brings leadership and deep industry knowledge to the executive team. Since 2005, Mr. Laub has served as President of the Nevada Biotechnology & Health Sciences Consortium, a non-profit, membership organization promoting biotechnology, health sciences and whole-plant medicine. He has also served as the representative from Nevada for the national Biotechnology Innovation Organization (or BIO) since 2008. From June 2010 to September 2019, Mr. Laub was the Chairman of the Board of Advisors for the University of Nevada, Las Vegas College of Sciences. From September 2010 to December 2016, Mr. Laub was a partner of Mr. Lamb as principals of the consulting firm Laub & Lamb. On February 1, 2024, he joined the Board of Advisors for Touro University Nevada, a non-profit medical school. Previously, from April 2005 to June 2012, Mr. Laub served as Chief Executive Officer of the Regenerative Medicine Organization. Mr. Laub received a B.S. in Accounting from Oregon State University and has been a Certified Public Accountant in good standing with the Nevada State Board of Accountancy since 1992. We believe that Mr. Laub is qualified to serve as a member and Chairman of our Board due to his extensive leadership and deep industry knowledge and his experience as our President and Chief Executive Officer.

**Jon Paul** *– Chief Financial Officer*

Jon Paul is the Chief Financial Officer. Mr. Paul has approximately 40 years of senior financial experience with both public and private companies. He has built a strong track record in leading hypergrowth in fast-paced businesses, including the cannabis, consumer goods, wireless telecom, and generic pharmaceutical industries. Mr. Paul joined the Company as the Chief Financial Officer (CFO) in January 2025. Prior to joining WUND, Mr. Paul worked as a business consultant from August 2023 to December 2024. Previously, Mr. Paul served as Chief Financial Officer of Australis Capital Inc. (AUSA:CNX; AUSAF:OTCQB), a publicly traded global cannabis company from January 2021 to July 2023.

Mr. Paul was also previously CFO at PLUS Products, a CSE-listed hemp and cannabis edibles company operating in California and Nevada. While at PLUS, Mr. Paul oversaw the company's successful IPO and was a key member of the team responsible for its significant increase in revenues. Previously, Mr. Paul held several senior financial roles, helping companies in a variety of sectors achieve strong growth, profitability, as well as effected several successful transactions and exits. Mr. Paul holds an MBA from the Harvard Business School and a BSc in accounting from the University of Illinois, and holds or earned several financial and non-financial certificates and designations, including CPA (accounting), CMC (consulting), CM&AA (M&A) and Black Belt (sales).

---

| |
|:---|
| 102 |
| *[**Table of Contents**](#TOC)* |

---

**Gregory Fey –** *Director*

Gregory Fey has served as a member of the Board since May 2016. Mr. Fey spent over 30 years in orthopedic sales and management. The next 10 years he worked with tech and biotech startups. He was also a consultant to Fortune 500 pharma and biotech companies. He received a Bachelor of Arts degree from Long Island University. He is retired and lives in Gainesville, Florida. We believe that Mr. Fey is qualified to serve as a member of our Board due to his knowledge, understanding and belief in the underlying science and his extensive experience in most aspects of healthcare and biotechnology.

**James Lamb** – *Director*

James Lamb has served as a member of the Board since our inception in May 2016. Mr. Lamb has over 45 years of experience in politics as well as public relations and marketing. Since May 2014, Mr. Lamb has served as a director of the Nevada Biotechnology & Health Sciences Consortium with Mr. Laub. From September 2010 to December 2016, Mr. Lamb was a partner of Mr. Laub as principals of the consulting firm Laub & Lamb. Mr. Lamb has taught courses on public relations and marketing at the undergraduate and graduate levels. Mr. Lamb received a B.S. in International Studies from Bradley University, an M.B.A. from National University and an M.S. in Computer Information Management from Webster University. We believe that Mr. Lamb's experience in politics, public relations, and marketing as well as his director experience at the Nevada Biotechnology & Health Science Consortium directly apply to the business needs of the Company and that he will provide significant benefit to the Board and is qualified to serve as a director of the Company.

Each of Mr. Laub and Mr. Paul are independent contractors who work approximately 40 hours per week for the Company.

**Involvement in Certain Legal Proceedings**

To the best of our knowledge, during the past ten years, none of our directors, director nominee or executive officers were involved in any of the following: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being a named subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities or banking activities; (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law; (5) being the subject of, or a party to, any Federal or State judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of (i) any Federal or State securities or commodities law or regulation; (ii) any law or regulation respecting financial institutions or insurance companies including, but not limited to, a temporary or permanent injunction, order of disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or (iii) any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or (6) being the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

---

| |
|:---|
| 103 |
| *[**Table of Contents**](#TOC)* |

---

**Board Leadership Structure and Risk Oversight**

Our Board of Directors has the responsibility for selecting the appropriate leadership structure for the Company. In making leadership structure determinations, the Board of Directors considers many factors, including the specific needs of the business and what is in the best interests of the Company's stockholders. Our current leadership structure is comprised of a combined Chairman of the Board and Chief Executive Officer, Mr. John Laub. The Board of Directors believes that this leadership structure is the most effective and efficient for the Company at this time. Mr. Laub possesses detailed and in-depth knowledge of the issues, opportunities, and challenges facing the Company, and is thus best positioned to develop agendas that ensure that the Board of Directors' time and attention are focused on the most critical matters. Combining the Chairman of the Board and CEO roles promotes decisive leadership, fosters clear accountability and enhances the Company's ability to communicate its message and strategy clearly and consistently to our stockholders, particularly during periods of turbulent economic and industry conditions. The Board of Directors believes that its programs for overseeing risk, as described below, would be effective under a variety of leadership frameworks and therefore do not materially affect its choice of structure.

Effective risk oversight is an important priority of the Board of Directors. Because risks are considered in virtually every business decision, the Board of Directors discusses risk throughout the year, generally or in connection with specific proposed actions. The Board of Directors' approach to risk oversight includes understanding the critical risks in the Company's business and strategy, evaluating the Company's risk management processes, allocating responsibilities for risk oversight, and fostering an appropriate culture of integrity and compliance with legal responsibilities. The directors exercise direct oversight of strategic risks to the Company.

Board of Directors is tasked with reviewing and assessing the Company's processes to manage business and financial risk and financial reporting risk. It also reviews from time to time, the Company's policies for risk assessment and assess the steps management has taken to control significant risks.

**Term of Office**

Officers hold office until his or her successor is elected and qualified. The term of office of our directors will expire at the next annual meeting of stockholders, subject to re-nomination and reappointment to the board by our stockholders.

**Director Independence**

We use the definition of "independence" of the NYSE American listing rules to make this determination. The NYSE American listing rules provide that an "independent director" is one who the Board "affirmatively determines" has no "material relationship" with us either directly or as a partner, shareholder or officer of an organization that has a relationship with us. The NYSE American listing rules provide that a director cannot be considered independent if:

· the director is, or has been within the last three (3) years, an employee of ours or an immediate family member of director is, or has been within the last three (3) years, an executive officer of ours;

· the director has received, or has an immediate family member who is an executive officer of ours and has received, during any twelve-month period within the last three (3) years, more than $120,000 compensation directly from us (not including compensation received for director service, pension plan payments or deferred compensation for prior service not contingent on continued service);

· the director or an immediate family member is a current partner of our internal or external auditor; the director is a current employee of the auditor; an immediate family member is a current employee of the auditor and personally works on our audit; or the director or an immediate family member was within the last three (3) years a partner or employee of the auditor and personally worked on our audit within that time;

· the director or an immediate family member is, or has been within the last three (3) years, employed as an executive officer of another company where any of our present executive officers at the same time serves or served on that company's compensation committee; or

· the director is a current employee, or an immediate family member is a current executive officer, of an organization that has made to or received from our payments for property or services in an amount which, in any of the last three fiscal (3) years, exceeds greater of 2% of such other company's consolidated gross revenues or $1 million. Charitable contributions not considered "payments" for purposes of this prohibition, but contributions meeting these thresholds must be disclosed on our website or in its annual proxy statement or its Annual Report on Form 10-K.

---

| |
|:---|
| 104 |
| *[**Table of Contents**](#TOC)* |

---

Under such definitions, we consider Messrs. Fey and Lamb to be "independent."

**Committees of the Board**

Our Company currently does not have nominating, compensation or audit committees or committees performing similar functions, nor does our Company have a written nominating, compensation or audit committee charter. Our directors believe that it is not necessary to have such committees, at this time, because the functions of such committees can be adequately performed by our Board of Directors.

Our Company does not have any defined policy or procedural requirements for stockholders to submit recommendations or nominations for directors. Our directors believe that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our Company does not currently have any specific or minimum criteria for the election of nominees to the Board of Directors and we do not have any specific process or procedure for evaluating such nominees. The Board of Directors will assess all candidates, whether submitted by management or stockholders, and make recommendations for election or appointment.

**Code of Ethics**

We have adopted a written code of ethical business conduct, which applies to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. We intend to disclose any amendments to our Code of Ethical Business Conduct and any waivers with respect to our Code of Ethical Business Conduct granted to our principal executive officer, our principal financial officer, or any of our other employees performing similar functions on our corporate website within four business days after the amendment or waiver. In such case, the disclosure regarding the amendment or waiver will remain available on our website for at least 12 months after the initial disclosure. There have been no waivers granted with respect to our Code of Ethical Business Conduct to any such officers or employees to date.

**Conflicts of Interest**

We comply with applicable state law with respect to transactions (including business opportunities) involving potential conflicts. Applicable state corporate law requires that all transactions involving our company and any director or executive officer (or other entities with which they are affiliated) are subject to full disclosure and approval of the majority of the disinterested independent members of our Board, approval of the majority of our stockholders or the determination that the contract or transaction is intrinsically fair to us. More particularly, our policy is to have any related party transactions (i.e., transactions involving a director, an officer or an affiliate of our company) be approved solely by a majority of the disinterested independent directors serving on the Board.

**Family Relationships**

There are no family relationships among any of the directors or executive officers.

**Arrangements between Officers and Directors**

To our knowledge, there is no arrangement or understanding between any of our officers or directors and any other person, including directors, pursuant to which the officer was selected to serve as an officer or director.

**Other Directorships**

No director of the Company is also a director of an issuer with a class of securities registered under Section 12 of the Exchange Act (or which otherwise are required to file periodic reports under the Exchange Act).

---

| |
|:---|
| 105 |
| *[**Table of Contents**](#TOC)* |

---

**Stockholder Communications with the Board**

A stockholder who wishes to communicate with our Board of Directors may do so by directing a written request addressed to our Secretary, Yvonne Luell, who, upon receipt of any communication other than one that is clearly marked "<u>Confidential,</u>" will note the date the communication was received, open the communication, make a copy of it for our files and promptly forward the communication to the director(s) to whom it is addressed. Upon receipt of any communication that is clearly marked "<u>Confidential,</u>" our Secretary will not open the communication, but will note the date the communication was received and promptly forward the communication to the director(s) to whom it is addressed.

**Policy on Equity Ownership**

The Company does not have a policy on equity ownership at this time.

**Policy Against Hedging**

The Company recognizes that hedging against losses in Company shares may disturb the alignment between stockholders and executives that equity awards are intended to build; however, while 'short sales' are discouraged by the Company, the Company does not currently have a policy prohibiting such transactions. We plan to implement a policy prohibiting such transactions in the future.

**Compensation Recovery and Clawback Policy**

Under the Sarbanes-Oxley Act of 2002 (the "<u>Sarbanes-Oxley Act</u>"), in the event of misconduct that results in a financial restatement that would have reduced a previously paid incentive amount, we can recoup those improper payments from our Chief Executive Officer and Chief Financial Officer (if any). The SEC also recently adopted rules which direct national stock exchanges to require listed companies to implement policies intended to recoup bonuses paid to executives if the Company is found to have misstated its financial results.

On August 25, 2025, and effective on August 25, 2025, the Board of Directors of the Company adopted a Policy for the Recovery of Erroneously Awarded Incentive-Based Compensation (the "<u>Clawback Policy</u>"), to comply with the final clawback rules adopted by the U.S. Securities and Exchange Commission under Section 10D and Rule 10D-1 of the Exchange Act ("<u>Rule 10D-1</u>"), and NYSE American rules and, together with Rule 10D-1, the "<u>Final Clawback Rules</u>"). The Clawback Policy provides for the mandatory recovery of erroneously awarded incentive compensation from current and former officers of the Company as defined in Rule 10D-1 ("<u>Covered Officers</u>") in the event the Company is required to prepare an accounting restatement as specified in the Clawback Policy. Under the Clawback Policy, the Board may recoup from the Covered Officers erroneously awarded incentive compensation received within a lookback period of the three completed fiscal years preceding the date on which the Company is required to prepare an accounting restatement.

**Indemnification**

In accordance with the Nevada Revised Statutes and our Amended and Restated Articles of Incorporation, we will indemnify, hold harmless and provide advancement of expenses, to the fullest extent permitted by applicable law, directors, officers, employees, and agents that are made a party or threatened to be made a party to legal proceedings by reason of the fact that such parties were working at our request. For more information see the section of this offering circular titled "*Risk Factors*."

Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to directors, officers or persons controlling the registrant pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act, and is therefore unenforceable.

---

| |
|:---|
| 106 |
| *[**Table of Contents**](#TOC)* |

---

**EXECUTIVE AND DIRECTOR COMPENSATION**

**Summary Compensation Table**

The following table sets forth information concerning the compensation of (i) all individuals serving as our principal executive officer or acting in a similar capacity for the period from January 1, 2024 to December 31, 2025 ("PEO"), regardless of compensation level; (ii) our two most highly compensated executive officers other than the PEO who were serving as executive officers for the periods ended December 31, 2025 and 2024, if any (subject to the limitations below); and (iii) up to two additional individuals for whom disclosure would have been provided pursuant to paragraph (ii) but for the fact that the individual was not serving as an executive officer at December 31, 2025 or 2024 (collectively, the "Named Executive Officers"). Except as set forth below, we had no other executive officers from January 1, 2024 to December 31, 2025.

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Salary** | **Bonus** | **Option** <br> **Awards** | **Stock Awards** |  | **All Other** <br> **Compensation** | **Total** |
| **Name and Principal Position** | **Year** | **($)** | **($)** | **($)** | **($)\*** |  | **($)** | **($)** |
| John Laub | 2025 | 120000 |  |  |  |  |  | 120000 |
| President, Chief Executive Officer | 2024 | 110000 |  |  |  |  |  | 110000 |
| Jon Paul\*\* | 2025 | 172500 |  |  | 11979 | (1) |  | 184479 |
| Chief Financial Officer |  |  |  |  |  |  |  |  |

---

\*Stock Awards represent the aggregate grant date fair value of awards computed in accordance with Financial Accounting Standards Board Accounting Standard Codification Topic 718. These amounts do not correspond to the actual value that will be recognized by the named individuals from these awards. No executive officer serving as a director received any compensation for services on the Board of Directors separate from the compensation paid as an executive for the periods above.

\*\* Mr. Paul became an officer of the Company on January 15, 2025.

(1) Represents the value of 50,000 restricted stock units granted on August 26, 2025, and effective on January 15, 2025, which vest 40% after 2 years; 30% after three years; and 30% after four years, subject in each case to the terms of the WUND Healing BioPharmaceuticals, Inc. Restricted Stock Unit Plan, the award agreement evidencing such grant, and Mr. Paul's continued service to the Company on such vesting dates.

Does not include perquisites and other personal benefits or property, unless the aggregate amount of such compensation is more than $10,000. No executive officer earned non-equity incentive plan compensation or nonqualified deferred compensation during the periods reported above. No executive officer serving as a director received any compensation for services on the Board of Directors separate from the compensation paid as an executive for the periods above.

As of June 1, 2026, we had no employees. Our CEO and CFO are independent contractors, who work approximately 40 hours per week for us.

**Outstanding Equity Awards at Fiscal Year-End**

The Company: (i) did not grant any stock options to its executive officers or directors during the two years ended December 31, 2025; (ii) did not have any outstanding equity awards as of December 31, 2025, except for the RSUs discussed above; and (iii) had no options exercised by its Named Executive Officers during the two years ended December 31, 2025.

There are no outstanding options as of the date of this offering circular.

---

| |
|:---|
| 107 |
| *[**Table of Contents**](#TOC)* |

---

**Restricted Stock Unit Plan**

On August 26, 2025, the Board of Directors of the Company adopted the WUND Healing BioPharmaceuticals, Inc. Restricted Stock Unit Plan (the "<u>RSU Plan</u>"). Pursuant to the RSU Plan, employees, consultants and directors of the Company are eligible to receive restricted stock units. A total of 50,000 restricted stock units are authorized under the RSU Plan, of which all 50,000 have been granted as of the date of this offering circular.

On August 26, 2025, and effective on January 15, 2025, the Board of Directors approved the grant for Mr. Jon Paul for 50,000 restricted stock units that 40% after 2 years; 30% after three years; and 30% after four years, subject in each case to the terms of the RSU Plan, the award agreement evidencing such grant, and Mr. Paul's continued service to the Company on such vesting dates

**Director Compensation**

During the fiscal years ended December 31, 2025 and 2024, we did not pay cash or equity-based compensation to any of our non-executive directors for service on our Board. We have reimbursed and will continue to reimburse all of our non-executive directors for their reasonable out-of-pocket expenses incurred in attending Board and committee meetings.

John Laub, our President and Chief Executive Officer, did not receive any additional compensation for his service on the Board. His compensation as a named executive officer is set forth above under "*Summary Compensation Table*."

Under the non-executive director compensation policy, our non-executive directors will be eligible to receive the following compensation for service on our Board and committees of our Board following the completion of this offering: The Company will pay its independent Board members $48,000 for their annual service as Board members. Each Board member will receive $10,000 for each Board meeting attended. In addition, on an annual basis, the Audit Committee chair will earn an additional $20,000.

Board compensation will be reviewed annually, and changes will be recommended by the Compensation Committee and approved by our Board.

**Consulting Agreements**

On July 22, 2025, and effective January 1, 2025, the Company entered into a Consulting Agreement with John Laub, its Chief Executive Officer, to provide services to the Company as Chief Executive Officer. Pursuant to the Consulting Agreement, Mr. Laub is responsible for fulfilling duties as assigned by the Board of Directors and is prohibited from working with competitors during the term of the agreement. Mr. Laub will receive an annual base salary of $120,000, payable bi-weekly, with the potential for performance-based bonuses and eligibility for equity awards under the Company's equity incentive plans. The base salary began accruing on January 1, 2025 (such accrued amounts from time to time, the "<u>Accrued Base</u>"), and shall be payable, together with Accrued Base, beginning on such date as the Company has the cash flow to make the monthly payments and/or pay the Accrued Base, as determined in the sole discretion of the Board of Directors.

The Compensation Committee of the Board of Directors shall review the base annually and the Compensation Committee or the Board may adjust the base compensation at their discretion, provided any decrease requires the consent of Mr. Laub unless part of a company-wide reduction. Additionally, the Board of Directors or Compensation Committee of the Board of Directors may also pay bonuses to Mr. Laub from time to time in cash or equity in its discretion.

Under the agreement, Mr. Laub is entitled to standard employee benefits, including health insurance and retirement plans, and will be reimbursed for reasonable business expenses. The agreement is at-will, allowing either party to terminate it at any time, with or without cause. In the event of the termination of the Consulting Agreement without Cause or resignation by Mr. Laub for Good Reason (each as defined below), Mr. Laub will be entitled to severance pay equal to (i) one year of his base salary, (ii) any earned but unpaid bonus, (iii) accelerated vesting of 50% of his equity awards, and (iv) continuation of health benefits for six months. If a Change in Control (as defined below) occurs, Mr. Laub is entitled to (x) severance pay for 12 months, (y) full accelerated vesting of equity awards, and (z) continued health benefits for six months. No severance shall be payable if Mr. Laub is terminated for Cause or resigns without Good Reason or upon the death or disability of Mr. Laub. The agreement includes customary indemnification and dispute resolution provisions, requires that disputes will be resolved through binding arbitration, and includes a clawback provision to comply with applicable laws and Company policies.

---

| |
|:---|
| 108 |
| *[**Table of Contents**](#TOC)* |

---

For purposes of the Consulting Agreement, (1) "Cause" is defined as: (i) willful misconduct or gross negligence; (ii) fraud, embezzlement, or theft; (iii) material violation of Company policies or the terms of the Consulting Agreement; (iv) conviction of a felony or crime involving moral turpitude; (v) willful failure to perform duties after written notice and a reasonable opportunity to cure (if curable); or (vi) beach of any provision of the Consulting Agreement and failure to cure with 20 days prior notice; (2) "Good Reason" is defined as: (i) a material reduction in base compensation or targeted bonus opportunity without consent; (ii) a material diminution in duties or authority; or (iii) relocation of Mr. Laub's primary workplace by more than 50 miles without consent, provided he gives written notice within 30 days of the event, the Company fails to cure within 30 days, and he resigns within 60 days of the notice; and (c) a "Change in Control" occurs if, subject to certain customary exceptions, after the effective date of the Consulting Agreement, any of the following events take place: (a) the Company merges or consolidates with another entity and more than 50% of the voting power of the surviving entity is held by new stockholders; (b) the Company sells or otherwise disposes of all or substantially all of its assets or undergoes complete liquidation or dissolution; (c) the composition of the Board of Directors changes within a two-year period such that fewer than a majority are incumbent directors (defined as directors serving as of the effective date of the Consulting Agreement or elected with the support of a majority of such directors, excluding directors elected in connection with a proxy contest); or (d) any person or group acquires beneficial ownership of at least 30% of the Company's outstanding voting securities, subject to certain exclusions for employee benefit plan trustees or acquisitions that do not increase post-transaction ownership above 30%.

Also on August 11, 2025, and effective January 15, 2025, the Company formalized the engagement of its Chief Financial Officer, and entered into a Consulting Agreement with Jon Paul, its Chief Financial Officer. Mr. Paul's Consulting Agreement has substantially similar terms as Mr. Laub's, discussed above, except that:

(a) As additional consideration for entering into the agreement, the Company agreed to award Mr. Paul 50,000 RSUs that will vest at 2 years at 40%, 3 years at 30% and at 4 years at 30%, subject in each case to the terms of the equity plan pursuant to which they were awarded, the award agreement evidencing such award, and Mr. Paul's continued service to the Company on such vesting dates, which award was formally granted on August 26, 2025, to be effective January 15, 2025.

(b) Mr. Paul's agreement provides for base compensation of $180,000 per year; and

(c) Mr. Paul's agreement provides in the event of termination of the agreement without Cause or resignation for Good Reason (each as defined above), Mr. Paul will be entitled to severance pay equal to two months of his base salary, any earned but unpaid bonus, and continuation of health benefits for three months. If a Change in Control occurs, Mr. Paul is entitled to severance pay for three months, full accelerated vesting of equity awards, and continued health benefits for six months.

**Key Man Insurance**

We have no key man insurance on any of our executive officers, nor does the Company plan to obtain any keyman insurance on any of its executive officers.

---

| |
|:---|
| 109 |
| *[**Table of Contents**](#TOC)* |

---

**CERTAIN RELATIONSHIPS AND RELATED PERSON TRANSACTIONS**

**Transactions with Related Persons**

Except as discussed below or otherwise disclosed above under "Executive and Director Compensation", which information is incorporated by reference where applicable in this "Certain Relationships and Related Transactions" section, the following sets forth a summary of all transactions since January 1, 2024, or any currently proposed transaction, in which the Company was to be a participant and the amount involved exceeded or exceeds the lesser of $120,000 or one percent of the average of the Company's total assets at December 31, 2025 or 2024, and in which any officer, director, or any stockholder owning greater than five percent (5%) of our outstanding voting shares, nor any member of the above referenced individual's immediate family, had or will have a direct or indirect material interest. We believe the terms obtained or consideration that we paid or received, as applicable, in connection with the transactions described below were comparable to terms available or the amounts that would be paid or received, as applicable, in arm's-length transactions.

During the years ended December 31, 2025, 2024 and 2023, the Company received $24,750, $41,962 and $25,016, respectively as loans from companies under common ownership and management (related party loans). As of March 31, 2026, the Company had a balance of $47,960.

Zhittya is a strategic partner to the Company and owns seven million shares of the Company's preferred stock, giving Zhittya significant influence over the Company. The Company has a product license and commercialization agreement in place with the Company, discussed in greater detail above under "Business—License Agreement with Zhittya", which description is incorporated by reference herein.

In exchange for the exclusive license from Zhittya, we agreed to pay Zhittya, among other amounts, $1,500,000 in cash. The Company from 2016 to 2022 made payments against the payable totaling $890,000. The Company had made no payments to Zhittya for the years ended December 31, 2025 and 2024. The balance owed was not converted to a loan and has no interest rate or due date.

At December 31, 2025, 2024 and 2023, the Company had a remaining $610,000 payable to Zhittya relating to the acquisition of territorial rights under the License Agreement which is included in the related party loans and payables in the balance sheets included in the Company's financial statements as included herein. The Company plans on paying off the balance in 2026. The Company reduced its balance owed to Zhittya by $440,000 in the first quarter ending March 31, 2026. As of March 31, 2026, the balance due was $170,000.

The Company, until December 2022, had a consulting agreement in place with an individual for his services as the Company's Chief Financial Officer, Michael J. Rugen. At March 31, 2026, December 31, 2025, and December 31, 2024, the Company has a payable of $262,198 towards the agreement. These amounts are recorded in accrued expenses on the accompanying balance sheets.

The Company, until December 2022, had a consulting agreement in place with an individual who was serving as its Vice President of Marketing, Scott Laub. At March 31, 2026, December 31, 2025, and December 31, 2024, the Company has a payable of $75,000 payable towards the agreement. These amounts are recorded in accrued expenses on the accompanying balance sheets.

During the three months ended March 31, 2025, the Company received $3,250 from Zhittya and as of December 31, 2025, had a balance of $618,750 due to Zhittya. During the three months ended March 31, 2026, the Company offset $440,000 in accounts receivable from Zhittya against this loan, resulting in a balance of $178,750 on this loan.

During the year ended December 31, 2025, the Company received $55,554 and repaid $34,000, and during the year ended December 31, 2024, the Company received $25,000 and repaid $11,610, on loans from companies under common ownership and management (related party loans), resulting in a total balance of $68,960 as of December 31, 2025. During the three months ended March 31, 2026, the Company repaid $12,000, resulting in a total balance of $47,960 as of March 31, 2026.

---

| |
|:---|
| 110 |
| *[**Table of Contents**](#TOC)* |

---

As of March 31, 2026, December 31, 2025 and 2024, the Company has the following related party loan balances on its balance sheet:

---

| | | | |
|:---|:---|:---|:---|
|  | **March 31,**<br> **2026** | **December 31,** <br> **2025** | **December 31,** <br> **2024** |
| Zhittya Genesis Medicine | $178750 | $618750 | $615500 |
| Companies under common ownership and management | 47960 | 59960 | 38406 |
| **Related Party Loan Balance**  | $**226710** | $**678710** | $**653906** |

---

At December 31, 2025 and 2024, the Company had $0 and $31,750 in other receivables relating to income from participation in future revenues due from Zhittya. At March 31, 2026, the balance was $0.

**Review, Approval and Ratification of Related Party Transactions**

Given our small size and limited financial resources, we have not adopted formal policies and procedures for the review, approval, or ratification of transactions, such as those described above, with our executive officers, directors and significant stockholders. However, all of the transactions described above were approved and ratified by our directors. In connection with the approval of the transactions described above, our directors took into account various factors, including their fiduciary duties to the Company; the relationships of the related parties described above to the Company; the material facts underlying each transaction; the anticipated benefits to the Company and related costs associated with such benefits; whether comparable products or services were available; and the terms the Company could receive from an unrelated third party.

We intend to establish formal policies and procedures in the future, once we have sufficient resources and have appointed additional directors. On a moving forward basis, our directors will continue to approve any related party transaction based on the criteria set forth above.

In addition, our Code of Ethical Business Conduct (described above under "<u>Management—Code of Ethics</u>"), which is applicable to all of our employees, officers and directors, requires that all employees, officers and directors avoid any conflict, or the appearance of a conflict, between an individual's personal interests and our interests.

**INDEMNIFICATION OF DIRECTORS AND OFFICERS**

Section 78.7502(1) of the Nevada Revised Statutes provides that a corporation may indemnify any person who was or is a party, or is threatened to be made a party, to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (except in an action brought by or on behalf of the corporation) if that person is or was a director, officer, employee or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee or agent of another corporation or enterprise, against expenses, including attorneys' fees, judgments, fines and amounts paid in settlement actually and reasonably incurred by that person in connection with such action, suit or proceeding, if that person acted in good faith and in a manner which that person reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceedings, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon a plea of nolo contendere or its equivalent, alone, does not create a presumption that the person did not act in good faith or in a manner which the person reasonably believed to be in, or not opposed to, the best interests of the corporation, and that, with respect to any criminal action or proceeding, the person had reasonable cause to believe his action was unlawful.

Section 78.7502(2) of the Nevada Revised Statutes provides that a corporation may indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit brought by or on behalf of the corporation to procure a judgment in its favor because the person acted in any of the capacities set forth above, against expenses, including amounts paid in settlement and attorneys' fees, actually and reasonably incurred by that person in connection with the defense or settlement of such action or suit, if the person acted in accordance with the standard set forth above, except that no indemnification may be made in respect of any claim, issue or matter as to which such person shall have been adjudged liable by a court of competent jurisdiction after exhaustion of all appeals therefrom to be liable to the corporation or for amounts paid in settlement to the corporation unless and only to the extent that the court in which such action or suit was brought or other court of competent jurisdiction determines that, in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

---

| |
|:---|
| 111 |
| *[**Table of Contents**](#TOC)* |

---

Section 78.7502(3) of the Nevada Revised Statutes further provides that, to the extent a director or officer of a corporation has been successful on the merits or otherwise in the defense of any action, suit or proceeding referred to in subsections 1 and 2 thereof, or in the defense of any claim, issue or matter therein, that person shall be indemnified by the corporation against expenses (including attorneys' fees) actually and reasonably incurred by that person in connection therewith.

Section 78.751 of the Nevada Revised Statutes provides that unless indemnification is ordered by a court, the determination to provide indemnification must be made by the stockholders, by a majority vote of a quorum of the Board who were not parties to the action, suit or proceeding, or in specified circumstances by independent legal counsel in a written opinion. In addition, the articles of incorporation, bylaws or an agreement made by the corporation may provide for the payment of the expenses of a director or officer of the expenses of defending an action as incurred upon receipt of an undertaking to repay the amount if it is ultimately determined by a court of competent jurisdiction that the person is not entitled to indemnification. Section 78.751 of the Nevada Revised Statutes further provides that the indemnification provided for therein shall not be deemed exclusive of any other rights to which the indemnified party may be entitled and that the scope of indemnification shall continue as to directors, officers, employees or agents who have ceased to hold such positions, and to their heirs, executors and administrators.

Section 78.752 of the Nevada Revised Statutes provides that a corporation may purchase and maintain insurance on behalf of a director, officer, employee or agent of the corporation against any liability asserted against him or incurred by him in any such capacity or arising out of his status as such whether or not the corporation would have the authority to indemnify him against such liabilities and expenses.

The Company's Amended and Restated Articles of Incorporation limits the liability of the Company's directors and officers for monetary damages for breach of fiduciary duty as a director, save and except for acts or omissions which involve intentional misconduct, fraud or a knowing violation of law, to the fullest extent permitted by law. Consequently, the Company's directors and officers are not personally liable to the Company or the Company's stockholders for monetary damages for any breach of fiduciary duties as directors or officers, except liability for acts or omissions which involve intentional misconduct, fraud or a knowing violation of law. Any repeal or modification of these provisions will be prospective only and will not adversely affect any limitation on the personal liability of a director or officer of the Company for acts or omissions prior to that repeal or modification. If the Nevada Revised Statutes are amended to provide for further limitations on the personal liability of directors and officers of corporations, then the personal liability of the Company's directors and officers will be further limited to the greatest extent permitted by the Nevada Revised Statutes.

The Company's Amended and Restated Articles of Incorporation and Bylaws provide that the Company will, under certain circumstances, indemnify any director, officer, employee, fiduciary or agent of the Company or a person who is or was serving at the Company's request as a director, officer, employee, fiduciary or agent of another corporation, partnership, joint venture, trust or other enterprise, to the fullest extent permitted by applicable law, if such person is made a party or threatened to be made a party to legal proceedings by reason of the fact that such person was working at the Company's request, against expenses (including attorney fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by these persons in connection with the legal proceedings, subject to certain conditions.

In addition, the Company's Amended and Restated Articles of Incorporation and Bylaws provide that the Company must advance expenses incurred by or on behalf of a director, officer, employee, fiduciary or agent in advance of the final disposition of any action or proceeding, subject to certain exceptions.

The Company plans to enter into indemnification agreements with each of its directors and executive officers that may be broader than the specific indemnification provisions contained in the Nevada Revised Statutes. These indemnification agreements require the Company, among other things, to indemnify its directors and executive officers against liabilities that may arise by reason of their status or service. These indemnification agreements also require the Company to advance all expenses incurred by the directors and executive officers in investigating or defending any such action, suit or proceeding, subject to certain exceptions. The Company believes that these agreements are necessary to attract and retain qualified individuals to serve as directors and executive officers.

---

| |
|:---|
| 112 |
| *[**Table of Contents**](#TOC)* |

---

The limitation of liability and indemnification provisions that are included in the Company's Amended and Restated Articles of Incorporation, Bylaws and future indemnification agreements with its directors and executive officers may discourage stockholders from bringing a lawsuit against the Company's directors and executive officers for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against the Company's directors and executive officers even though an action, if successful, might benefit the Company and other stockholders. Further, a stockholder's investment may be adversely affected to the extent that the Company pays the costs of settlement and damage awards against directors and executive officers as required by these indemnification provisions. At present, the Company is not aware of any pending litigation or proceeding involving any person who is or was one of its directors, officers, employees, fiduciaries or other agents or is or was serving at its request as a director, officer, employee, fiduciary or agent of another corporation, partnership, joint venture, trust or other enterprise, for which indemnification is sought, and the Company is not aware of any threatened litigation that may result in claims for indemnification.

The Company's Bylaws provide that the Company may purchase and maintain insurance, at its expense, on behalf of any person who is or was a director or officer of the Company, or is or was a director or officer of the Company serving at the request of the Company as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the Company would have the power or the obligation to indemnify such person against such liability under the provisions of the Company's Bylaws. The Company maintains insurance under which, subject to the limitations of the insurance policies, coverage is provided to its directors and executive officers against loss arising from claims made by reason of breach of fiduciary duty or other wrongful acts as a director or executive officer, including claims relating to public securities matters, and to the Company with respect to payments that may be made by the Company to these directors and executive officers pursuant to the Company's indemnification obligations or otherwise as a matter of law.

**PRINCIPAL STOCKHOLDERS**

The following table sets forth certain information regarding the beneficial ownership of our common stock as of June 26, 2026 (the "<u>Date of Determination</u>") by (i) each Named Executive Officer, as such term is defined above under "<u>Executive and Director Compensation</u>", (ii) each member of our Board of Directors and director nominee, (iii) each person deemed to be the beneficial owner of more than five percent (5%) of our common stock, and (iv) all of our executive officers and directors as a group. Unless otherwise indicated, each person named in the following table is assumed to have sole voting power and investment power with respect to all shares of our common stock listed as owned by such person.

The column titled "<u>Beneficial Ownership- Common Stock Percent Prior to Offering</u>" is based on a total of 2,632,000 shares of our common stock outstanding as of the Date of Determination. The column titled "<u>Beneficial Ownership- Common Stock Percent After Offering</u>" is based on 3,632,000 shares of our common stock to be outstanding after this offering, which assumes that the Company sells all 1,000,000 shares of common stock included in this offering.

Beneficial ownership is determined in accordance with the rules of the SEC and includes voting and/or investing power with respect to securities. These rules generally provide that shares of common stock subject to options, warrants or other convertible securities that are currently exercisable or convertible, or exercisable or convertible within 60 days of the Date of Determination, are deemed to be outstanding and to be beneficially owned by the person or group holding such options, warrants or other convertible securities for the purpose of computing the percentage ownership of such person or group, but are not treated as outstanding for the purpose of computing the percentage ownership of any other person or group.

---

| |
|:---|
| 113 |
| *[**Table of Contents**](#TOC)* |

---

To our knowledge, except as indicated in the footnotes to this table and pursuant to applicable community property laws, as of the Date of Determination, (a) the persons named in the table have sole voting and investment power with respect to all shares of common stock shown as beneficially owned by them, subject to applicable community property laws; and (b) no person owns more than 5% of our common stock. Unless otherwise indicated, the address for each of the officers or directors listed in the table below is: c/o WUND Healing BioPharmaceuticals, Inc., 8683 W. Sahara Avenue, Suite 280, Las Vegas, NV 89117.

---

| | | | | |
|:---|:---|:---|:---|:---|
| | | | **Beneficial Ownership** | **Beneficial Ownership** |
| <br>**Class of Stock** | <br>**Name of Beneficial Owner** | **Number of**<br>**Common Stock** <br> **Shares**<br> **Beneficially**<br> **Owned** | **Common Stock**<br> **Percent**<br> **Prior to**<br> **Offering** | **Common Stock**<br> **Percent**<br> **After**<br> **Offering** |
| ***Directors, Executive Officers, and Director Nominees***  | ***Directors, Executive Officers, and Director Nominees***  | ***Directors, Executive Officers, and Director Nominees***  |  |  |
| Common Stock | John Laub | 360000 <br><sup>(1)</sup> | 13.9% | 9.9% |
| Common Stock | Jon Paul | <sup>—</sup><br><sup>(2)</sup> | <sup>—</sup> | <sup>—</sup>% |
| Common Stock | Gregory Fey | 25000  | 1.0% | \*% |
| Common Stock | James Lamb | 25000  | 1.0% | \*% |
| **Common Stock** | ***All executive officers, directors and director nominees, as a group (four persons)*** | **410000** | **15.9%** | **12.0%** |
|  | ***5% Stockholders*** |  |  |  |
| Common Stock | Wolfgang Rueck**<sup>(2)</sup>** | 150000 | 5.8% | 4.1% |

---

\* Less than 1%.

(1) Shares held in the name of the Laub Family Trust, dated 08/28/18, which shares Mr. Laub is deemed to beneficially own due to his status as Trustee of the Trust.

(2) Does not include 50,000 shares of common stock issuable upon the vesting of 50,000 restricted stock units that will vest to Mr. Paul, if at all, 40% on January 15, 2027; 30% on January 15, 2028; and 30% on January 15, 2029, subject to his continued services with the Company

(3) Address Kappel bergstr.9, 71394 Kernen Stetten, Germany.

Pursuant to Rule 13d-3, of the Securities Exchange Act of 1934, as amended, a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship, or otherwise has or shares: (1) voting power which includes the power to vote, or to direct the voting of, such security; and/or, (2) investment power which includes the power to dispose, or to direct the disposition of, such security. A person is deemed to be the beneficial owner of a security, if that person has the right to acquire beneficial ownership of such security, within sixty days from the date of determination.

Note that as described in greater detail under "Description of Capital Stock", each share of Series A-1 preferred stock is convertible at the option of the holders of Series A-1 preferred stock into one share of our common stock, subject to anti-dilution protections and other adjustments upon certain events, beginning twenty-four (24) months from the consummation of the offering. Holders of our Series A-1 preferred stock are also prohibited from effecting a conversion that would result in a holder beneficially owning more than 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the issuance of shares of common stock upon a conversion of Series A-1 preferred stock; and each share of Series A-2 preferred stock is convertible at the option of the holders of Series A-2 preferred stock into one share of our common stock, subject to anti-dilution protections and other adjustments upon certain events, provided that holders of our Series A-2 preferred stock are prohibited from effecting a conversion until (a) twenty-four (24) months from the consummation of the offering have elapsed and (b) the 30-day volume-weighted average price for the common stock prior to such conversion exceeds $20.00. Holders of our Series A-2 preferred stock are also prohibited from effecting a conversion that would result in a holder beneficially owning more than 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the issuance of shares of common stock upon a conversion of Series A-2 preferred stock which includes their holding of Series A-1 preferred stock together the conversion could not result in the holder of the Series A-1 and A-2 together owning more than 4.99% of the shares of our common stock outstanding immediately after giving effect to the issuance of shares of the common stock outstanding.

---

| |
|:---|
| 114 |
| *[**Table of Contents**](#TOC)* |

---

As a result, Zhittya, the holder of our outstanding Series A-1 and Series A-2 preferred stock, convertible into an aggregate of 7,000,000 shares of our common stock, subject to the conversion restrictions discussed above, is not included in the table above, as Zhittya does not have (1) the power to vote, or to direct the voting of, such common stock issuable upon conversion of the Series A-1 and A-2 preferred stock; and/or, (2) the power to dispose, or to direct the disposition of, such common stock issuable upon conversion of the Series A-1 and A-2 preferred stock as of the date of this offering circular, or within sixty days from such date, and is not deemed to beneficially own the common stock issuable upon conversion of the Series A-1 and A-2 preferred stock as of the date of this offering circular.

**Change of Control**

The Company is not aware of any arrangements which may at a subsequent date result in a change of control of the Company.

**DESCRIPTION OF CAPITAL STOCK**

The following summary is a description of the material terms of our capital stock and is not complete. You should also refer to the Amended and Restated Articles of Incorporation and Bylaws, which are included as exhibits to this offering circular, and the applicable provisions of the Nevada Revised Statutes (NRS).

***Authorized Capitalization***

We are authorized to issue a total of 75,000,000 shares of capital stock, consisting of 50,000,000 shares of common stock and 25,000,000 shares of preferred stock. As of the date of this offering circular, we have outstanding (a) 2,632,000 shares of common stock; (b) 3,500,000 shares of Series A-1 preferred stock; and (c) 3,500,000 shares of Series A-2 preferred stock.

**Common Stock**

*Voting*

Each share of our common stock is entitled to one vote on all stockholder matters. Shares of our common stock do not possess any cumulative voting rights.

Except for the election of directors, if a quorum is present (i.e., a majority of the voting stock), an action on a matter is approved if it receives the affirmative vote of the holders of a majority of the voting power of the shares of capital stock present in person or represented by proxy at the meeting and entitled to vote on the matter, unless otherwise required by applicable law. The election of directors will be determined by a plurality of the votes cast in respect of the shares present in person or represented by proxy at the meeting and entitled to vote, meaning that the nominees with the greatest number of votes cast, even if less than a majority, will be elected. The rights, preferences and privileges of holders of common stock are subject to, and may be impacted by, the rights of the holders of shares of any series of preferred stock that we have designated, or may designate and issue in the future.

*Dividends*

The holders of shares of our common stock are entitled to dividends when and as declared by the Board from funds legally available therefore if, as and when determined by our Board in their sole discretion, subject to provisions of law, and any provision of our Amended and Restated Articles of Incorporation, as amended from time to time. There are no preemptive, conversion or redemption privileges, nor sinking fund provisions with respect to the common stock.

*Liquidation*

In the event of any voluntary or involuntary liquidation, dissolution or winding up of our affairs, the holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities.

---

| |
|:---|
| 115 |
| *[**Table of Contents**](#TOC)* |

---

*Fully Paid and Non-assessable*

All outstanding shares of common stock are, and the common stock to be outstanding upon completion of this offering will be, duly authorized, validly issued, fully paid and non-assessable.

*No Preemptive, Conversion, or Redemption Rights.* 

Holders of our outstanding common stock have no preemptive, conversion, or redemption rights. Shares of our common stock are not assessable. To the extent that additional shares of our common stock may be issued in the future, the relative interests of the then existing stockholders may be diluted.

*Changes in Authorized Number*

The number of authorized shares of common stock may be increased or decreased subject to our legal commitments at any time and from time to time to issue them, by the affirmative vote of the holders of a majority of our stock entitled to vote.

**Preferred Stock**

We are authorized to issue up to 25,000,000 shares of preferred stock. This preferred stock may be issued in one or more series, the terms of which may be determined at the time of issuance by our Board without further action by stockholders. The terms of any series of preferred stock may include voting rights (including the right to vote as a series on particular matters), preferences as to dividend, liquidation, conversion and redemption rights, and sinking fund provisions. The issuance of any preferred stock could materially adversely affect the rights of the holders of our common stock, and therefore, reduce the value of our common stock. In particular, specific rights granted to future holders of preferred stock could be used to restrict our ability to merge with, or sell our assets to, a third party and thereby preserve control by the present management. The following summaries describe the classes and series of our preferred stock currently outstanding.

Pursuant to the License Agreement with Zhittya, the Company issued to Zhittya preferred stock convertible into 7,000,000 shares of Company common stock.

On December 1, 2019, the Board, through unanimous written consent designated 7,000,000 shares of preferred stock as Series A-1 and Series A-2 in the amount of 3,500,000 shares for each Series, each convertible into our common stock on a one to one basis, for a total of 7,000,000 shares of common stock. However, these preferred shares were not authorized to be issued until March 2020, as described below.

In March 2020, the Company solicited its stockholders and received written votes from holders representing 55% of the common stock to approve articles of incorporation that authorized 25,000,000 shares of preferred stock. The written vote representing approval of over 50% was received on March 21, 2020. The articles also stated that the Board could designate the shares in the manner they saw fit. This stockholder approval coupled with the December 2019 designation resulted in the Series A-1 and the Series A-2 preferred stock being authorized and issuable.

***Series A-1 Preferred Stock***

The holders of shares of Series A-1 preferred stock are entitled to receive dividends on shares of Series A-1 preferred stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually paid on shares of our common stock when, as and if such dividends are declared by our Board and paid on shares of the common stock.

*Liquidation Rights*

In the event of any liquidation, dissolution or winding up of the Company either voluntary or involuntary, the holders of Series A-1 preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series A-1 preferred stock were fully converted to common stock which amounts will be paid *pari passu* with all holders of our common stock.

---

| |
|:---|
| 116 |
| *[**Table of Contents**](#TOC)* |

---

*Conversion*

Each share of Series A-1 preferred stock is convertible at the option of the holders of Series A-1 preferred stock into one share of our common stock, subject to anti-dilution protections and other adjustments upon certain events. For a period of twenty-four (24) months after the first underwritten public offering of the Company's common stock, holders of our Series A-1 preferred stock are prohibited from effecting a conversion. Holders of our Series A-1 preferred stock are also prohibited from effecting a conversion that would result in a holder beneficially owning more than 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the issuance of shares of common stock upon a conversion of Series A-1 preferred stock. Upon a sale of the Company, if not converted earlier, all shares of Series A-1 preferred stock will automatically convert into shares of our common stock.

*Voting Rights*

Holders of the Series A-1 preferred stock have no voting rights.

***Series A-2 Preferred Stock***

The holders of shares of Series A-2 preferred stock are entitled to receive dividends on shares of Series A-2 preferred stock equal (on an as-if-converted-to-common-stock basis) to and in the same form as dividends actually paid on shares of our common stock when, as and if such dividends are declared by our Board and paid on shares of the common stock.

*Liquidation Rights*

In the event of any liquidation, dissolution or winding up of the Company either voluntary or involuntary, the holders of Series A-2 preferred stock will be entitled to receive out of our assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series A-2 preferred stock were fully converted to common stock which amounts will be paid pari passu with all holders of our common stock.

*Conversion*

Each share of Series A-2 preferred stock is convertible at the option of the holders of Series A-2 preferred stock into one share of our common stock, subject to anti-dilution protections and other adjustments upon certain events. Holders of our Series A-2 preferred stock are prohibited from effecting a conversion until (a) twenty-four (24) months after the first underwritten public offering of the Company's common stock have elapsed and (b) the 30-day volume-weighted average price for our common stock exceeds $20.00. Holders of our Series A-2 preferred stock are also prohibited from effecting a conversion that would result in a holder beneficially owning more than 4.99% of the number of shares of our common stock outstanding immediately after giving effect to the issuance of shares of common stock upon a conversion of Series A-2 preferred stock which includes their holding of Series A-1 preferred stock. Together the conversion cannot result in the holder of the Series A-1 and A-2 together owning more than 4.99% of the shares of our common stock outstanding immediately after giving effect to the issuance of shares of the common stock outstanding. Upon a sale of the Company, if not converted earlier, all shares of Series A-2 preferred stock will automatically convert into shares of our common stock if the sales price exceeds $20 per share.

*Voting Rights*

Holders of the Series A-2 preferred stock have no voting rights.

---

| |
|:---|
| 117 |
| *[**Table of Contents**](#TOC)* |

---

**Anti-Takeover Provisions our Bylaws**

*Board of Directors Vacancies*

Our Bylaws authorize only our Board to fill vacant directorships. In addition, the number of directors constituting our Board may be set only by resolution of the majority of the incumbent directors.

*Special Meeting of Stockholders*

Our Bylaws provide that special meetings of our stockholders may be called by our president, the Board or a committee of the Board that has been duly designated by the Board and whose powers and authority include the power to call such meetings.

*Advance Notice Requirements for Stockholder Proposals and Director Nominations*

Our Bylaws provide that a stockholder seeking to bring business before our annual meeting of stockholders, or to nominate candidates for election as directors at our annual meeting of stockholders, must provide timely notice of their intent in writing. To be timely, a stockholder's notice must be delivered to the secretary at our principal executive offices not later than the close of business on the 90<sup>th</sup> day nor earlier than the close of business on the 120<sup>th</sup> day prior to the first anniversary of the preceding year's annual meeting; provided, however, that in the event the date of the annual meeting is not within 25 days before or after such anniversary date, notice by the stockholder to be timely must be so delivered not later than the close of business on the 10<sup>th</sup> day following the day on which such notice of the date of annual meeting was mailed or public disclosure of the date of the annual meeting was made, whichever occurs first. These provisions may preclude our stockholders from bringing matters before our annual meeting of stockholders or from making nominations for directors at our annual meeting of stockholders.

*Exclusive Forum*

**Anti-Takeover Provisions Under The Nevada Revised Statutes**

<u>Business Combinations</u>

Sections 78.411 to 78.444 of the NRS prohibit a Nevada corporation from engaging in a "<u>combination</u>" with an "<u>interested stockholder</u>" for three years following the date that such person becomes an interested stockholder and place certain restrictions on such combinations even after the expiration of the three-year period. With certain exceptions, an interested stockholder is a person or group that owns 10% or more of the corporation's outstanding voting power (including stock with respect to which the person has voting rights and any rights to acquire stock pursuant to an option, warrant, agreement, arrangement, or understanding or upon the exercise of conversion or exchange rights) or is an affiliate or associate of the corporation and was the owner of 10% or more of such voting stock at any time within the previous three years.

---

| |
|:---|
| 118 |
| *[**Table of Contents**](#TOC)* |

---

A Nevada corporation may elect not to be governed by Sections 78.411 to 78.444 by a provision in its articles of incorporation. We have such a provision in our Articles of Incorporation, as amended, pursuant to which we have elected to opt out of Sections 78.411 to 78.444; therefore, these sections do not apply to us.

<u>Control Shares</u>

Nevada law also seeks to impede "<u>unfriendly</u>" corporate takeovers by providing in Sections 78.378 to 78.3793 of the NRS, commonly referred to as the "<u>Control Share Act</u>", that an "<u>acquiring person</u>" shall only obtain voting rights in the "<u>control shares</u>" purchased by such person to the extent approved by the other stockholders at a meeting. With certain exceptions, an acquiring person is one who acquires or offers to acquire a "<u>controlling interest</u>" in the corporation, defined as one-fifth or more of the voting power. Control shares include not only shares acquired or offered to be acquired in connection with the acquisition of a controlling interest, but also all shares acquired by the acquiring person within the preceding 90 days. The statute covers not only the acquiring person but also any persons acting in association with the acquiring person. The NRS control share statutes only apply to issuers that have 200 or more stockholders of record, at least 100 of whom have had addresses in Nevada appearing on the stock ledger of the corporation at all times during the 90 days immediately preceding such date; and whom do business in Nevada directly or through an affiliated corporation. At this time, we do not believe we have 100 stockholders of record who have addresses in Nevada and we do not conduct business in Nevada directly or through an affiliated corporation. Therefore, the provisions of the Control Share Act are believed not to apply to acquisitions of our shares and will not until such time as these requirements have been met. At such time as they may apply, the provisions of the Control Share Act may discourage companies or persons interested in acquiring a significant interest in or control of us, regardless of whether such acquisition may be in the interest of our stockholders.

A Nevada corporation may elect to opt out of the provisions of Sections 78.378 to 78.3793 of the NRS. We have a provision in our Articles of Incorporation pursuant to which we have elected to opt out of Sections 78.378 to 78.3793; therefore, these sections do not apply to us.

<u>Removal of Directors</u>

Section 78.335 of the NRS provides that 2/3rds of the voting power of the issued and outstanding shares of the Company are required to remove a Director from office. As such, it may be more difficult for stockholders to remove Directors due to the fact the NRS requires greater than majority approval of the stockholders for such removal.

**Warrants and Options**

As of the date of this offering circular, we have no outstanding warrants or options.

**Transfer Agent**

The transfer agent and registrar for our common stock is V Stock Transfer, LLC, 18 Lafayette Place, Woodmere, NY 11598.

**Quotation/Listing**

There is no public market for the Shares, provided that following the closing of this offering, the Company currently plans to apply for quotation on the OTCQB Market maintained by OTC Markets; however, there can be no assurance that we will obtain such quotation, or as to the level of trading that might occur if we do.

**SHARES ELIGIBLE FOR FUTURE SALE**

Prior to this offering, there has been no active market for our common stock. Future sales of substantial amounts of our common stock including shares issued upon the conversion of convertible notes, the exercise of outstanding options and warrants, in the public market after this offering, or the possibility of these sales occurring, could adversely affect market prices prevailing from time to time and could impair our ability to raise capital through the sale of our equity securities. We are unable to estimate the number of shares of our common stock that may be sold in the future.

---

| |
|:---|
| 119 |
| *[**Table of Contents**](#TOC)* |

---

Upon completion of this offering, assuming an offering size of 1,000,000 shares of common stock, we will have outstanding an aggregate of 3,632,000 shares of common stock. The Shares of common stock sold in this offering will be freely transferable without restriction or registration under the Securities Act, except for any Shares purchased by any of our existing "affiliates," as that term is defined in Rule 144 under the Securities Act.

Previously issued shares of common stock that were not offered and sold in this offering, as well as shares issuable upon the exercise of warrants and subject to employee stock options, are or will be upon issuance, "restricted securities" as defined in Rule 144. Restricted securities may be sold in the public market only if registered or if they qualify for an exemption from registration under Rules 144 or 701 of the Securities Act, as described below.

**Rule 144** 

In general, a person who has beneficially owned restricted common shares of our Company for at least twelve months, or at least six months in the event we have been a reporting company under the Exchange Act for at least ninety (90) days before the sale, would be entitled to sell such securities, provided that such person is not deemed to be an affiliate of ours at the time of sale or to have been an affiliate of ours at any time during the ninety (90) days preceding the sale. A person who is an affiliate of ours at such time would be subject to additional restrictions, by which such person would be entitled to sell within any three-month period only a number of shares that does not exceed the greater of the following:

· 1% of the number of shares of our common stock then outstanding; which will equal approximately 363,200 shares of common stock immediately after this offering assuming all Shares offered herein are sold; or

· 1% of the average weekly trading volume of our common stock on any national exchange during the four calendar weeks preceding the filing by such person of a notice on Form 144 with respect to the sale;

provided that, in each case, we are subject to the periodic reporting requirements of the Exchange Act for at least 90 days before the sale. Rule 144 trades must also comply with the manner of sale, notice and other provisions of Rule 144, to the extent applicable.

Affiliate resales under Rule 144 are also subject to the availability of current public information about us. In addition, if the number of shares being sold under Rule 144 by an affiliate during any three-month period exceeds 5,000 shares or has an aggregate sale price in excess of $50,000 the seller must file a notice on Form 144 with the SEC with either the placing of a sale order with the broker or the execution directly with a market maker.

Under Rule 144, a person who is not an affiliate of ours at the time of sale, and has not been an affiliate at any time during the 90 days preceding a sale, and who has beneficially owned our common shares for at least six months but less than a year, is entitled to sell such shares subject only to the availability of current public information about us. If such person has held our shares for at least one year, such person can resell without regard to any Rule 144 restrictions, including the 90-day public company requirement and the current public information requirement. Non-affiliate resales are not subject to the manner of sale, volume limitation or notice filing provisions of Rule 144.

**Rule 701**

In general, Rule 701 allows a stockholder who purchased our common stock pursuant to a written compensatory stock or option plan or other written agreement and who is not deemed to be an affiliate of ours during the immediately preceding 90 days, to sell those shares in reliance upon Rule 144, but without being required to comply with the public information, holding period, volume limitation or notice provisions of Rule 144. All holders of Rule 701 shares, however, are required to wait until ninety (90) days after the date of this offering circular before selling shares pursuant to Rule 701.

---

| |
|:---|
| 120 |
| *[**Table of Contents**](#TOC)* |

---

**Lock-Up Agreements**

Upon completion of this offering all of our directors and officers and the holders of our capital stock will have signed lock-up agreements that prevent them from selling any shares of our common stock or any securities convertible into or exercisable or exchangeable for shares of our common stock, subject to certain exceptions, for a period of not less 180 days [from the date of this offering circular] without the prior written consent of Benjamin Securities. Benjamin Securities may, in its sole discretion and at any time without notice, release some or all of the shares subject to lock-up agreements prior to the expiration of the period. When determining whether or not to release shares from the lock-up agreements, Benjamin Securities will consider, among other factors, the stockholder's reasons for requesting the release, the number of shares for which the release is being requested and market conditions at the time.

**PLAN OF DISTRIBUTION**

**In General**

We are offering 1,000,000 Shares on a "best-efforts" basis, at price of $10.00 per share. There is no minimum purchase requirement for investors in this offering. This offering will terminate at the earliest of (a) the date on which the maximum offering has been sold, (b) the date which is one year from this offering being qualified by the SEC or (c) the date on which this offering is earlier terminated by us, in our sole discretion. This offering could terminate without a closing in the event that there is no market or interest for the Shares.

There is no minimum number of Shares that we are required to sell in this offering. All funds derived by us from this offering will be immediately available for use by us, in accordance with the uses set forth in the section entitled "Use of Proceeds" of this offering circular. No funds will be placed in an escrow account during the offering period and no funds will be returned once an investor's subscription agreement has been accepted by us.

The Shares will be offered by Benjamin Securities, Inc. ("Benjamin Securities") and D. Boral (collectively, the "Placement Agents"), on a "best efforts" basis pursuant to the placement agent agreement to be entered into between us and the Placement Agents, which we refer to as the "Placement Agent Agreement." Pursuant to the Placement Agent Agreement, we will pay the Placement Agents, concurrently with each closing of this offering, a cash placement fee equal to 7.0% of the gross proceeds of such closing. In addition, we will also pay Benjamin Securities for its out-of-pocket expenses actually incurred up to a maximum of $160,000, including, but not limited to "road show", due diligence and reasonable legal fees. We have agreed to pay a non-accountable expense allowance to the Placement Agent equal to 2% of the gross proceeds received at the closing of the offering and have paid a total of $50,000 as an advance to be applied towards reasonable out-of-pocket accountable expenses. Any advances will be returned to us to the extent Benjamin Securities' out-of-pocket accountable expenses are not actually incurred or are less than the advances paid. Any advances will be returned to us to the extent the Placement Agent's out-of-pocket accountable expenses are not actually incurred or are less than the advances paid in accordance with FINRA Rule 5110(g)(4).

We or the Placement Agents may also ask other FINRA member broker-dealers that are registered with the SEC to participate as soliciting dealers for this offering.

The following table shows the total discounts and commissions payable (variable depending on the total amount raised) to the Placement Agents in connection with the Shares offered in this offering:

---

| | | | |
|:---|:---|:---|:---|
|  | Price to public | Commissions<sup>(1)</sup> | Proceeds to issuer |
| Per share | $10.00 | $0.70 | $9.30 |
| Total  | $10000000.00 | $700000.00 | $9300000.00 |

---

Any participation of our officers and directors in selling efforts for the Shares in this offering will be conducted in accordance with Rule 3a4-1 under the Exchange Act. None of our officers or directors are subject to any statutory disqualification, as that term is defined in Section 3(a)(39) of the Exchange Act. None of our officers or directors will be compensated in connection with their participation in the offering by the payment of commissions or other remuneration based either directly or indirectly on transactions in our securities. None of our officers or directors are, or have been within the past 12 months, a broker or dealer, and none of them are, or have been within the past 12 months, an associated person of a broker or dealer. At the end of the offering, our officers and directors will continue to primarily perform substantial duties for the Company or on its behalf otherwise than in connection with transactions in securities.

---

| |
|:---|
| 121 |
| *[**Table of Contents**](#TOC)* |

---

**Selling Security holders**

No securities are being sold for the account of security holders. All net proceeds of this offering will go to the Company.

**Procedures for Subscribing**

If you are interested in subscribing for securities in this offering, please submit a request for information by e-mail to [●] at: [●]; all relevant information will be delivered to you by return e-mail. Thereafter, should you decide to subscribe for the Shares, you are required to follow the procedures described in the subscription agreement included in the delivered information, which are:

· Electronically execute and deliver to us a subscription agreement; and

· Deliver funds directly by check or by wire or electronic funds transfer via ACH to our specified bank account.

Acceptance of a subscription may occur up to 10 calendar days after a prospective investor submits a subscription agreement, depending on the volume of subscriptions received. Once a subscription is accepted, Shares will be issued to the subscriber as of the date of settlement, which will not occur until an investor's funds have cleared and we issue the Shares of our common stock. We expect that such clearance will occur within T+1 days of acceptance of a subscription agreement.

We reserve the right to reject any investor's subscription in whole or in part for any reason, including if we determine in our sole and absolute discretion that such investor is not a "qualified purchaser" for purposes of Section 18(b)(4)(D)(ii) of the Securities Act. If the offering terminates or if any prospective investor's subscription is rejected, all funds received from such investors will be returned without interest or deduction and such prospective investor will be promptly notified.

**No Escrow Agent**

None of the proceeds received will be placed in an escrow or trust account. All proceeds from this offering will become immediately available to us and may be used as they are accepted. Purchasers of the Shares will not be entitled to a refund and could lose their entire investment.

**Right to Reject Subscriptions**

The Shares will be issued in a continuous offering which will commence within two calendar days after the qualification of this offering. After we receive your complete, executed subscription agreement and the funds required under the subscription agreement have been transferred to us, we have the right to review and accept or reject your subscription in whole or in part, for any reason or for no reason. We will attempt to accept or reject subscriptions within 10 calendar days of receipt. If we accept your subscription, we or the Placement Agents will email you a confirmation. We anticipate that, once such subscription agreement is accepted, we will settle such transaction on a T+1 basis. If we reject your subscription, we or the Placement Agents will return all monies from rejected subscriptions immediately to you, without interest or deduction. No funds from the offering will be placed in an escrow account and all funds will be available to us upon our acceptance of your subscription.

---

| |
|:---|
| 122 |
| *[**Table of Contents**](#TOC)* |

---

**State Law Exemption and Offerings to "Qualified Purchasers"**

The Shares are being offered and sold to "qualified purchasers" (as defined in Regulation A under the Securities Act). As a Tier 2 offering pursuant to Regulation A under the Securities Act, this offering will be exempt from state "Blue Sky" law review, subject to certain state filing requirements and anti-fraud provisions, to the extent that the Shares offered hereby are offered and sold only to "qualified purchasers."

"Qualified purchasers" include any person to whom securities are offered or sold in a Tier 2 offering pursuant to Regulation A under the Securities Act. We reserve the right to reject any investor's subscription in whole or in part for any reason, including if we determine, in our sole and absolute discretion, that such investor is not a "qualified purchaser" for purposes of Regulation A. We intend to offer and sell the Shares to qualified purchasers in every state of the United States.

**Issuance of Securities**

Upon settlement, that is, at such time as an investor's funds have cleared and we have accepted an investor's subscription agreement, we will either issue such investor's purchased common Shares and warrants in book-entry form or issue a certificate or certificates representing such investor's purchased common shares and warrants.

**Transferability of the Securities**

The Shares will be generally freely transferable, subject to any restrictions imposed by applicable securities laws or regulations.

**Listing of Common Shares** 

There is no public market for the Shares, provided that following the closing of this offering, the Company currently plans to apply for quotation on the OTCQB Market maintained by OTC Markets; however, there can be no assurance that we will obtain such quotation, or as to the level of trading that might occur if we do.

**Ongoing Reporting and Supplements to This Offering Circular**

We will be required to make annual and semi-annual filings with the Commission. We will make annual filings on Form 1-K, which will be due by the end of April each year and will include audited financial statements for the previous fiscal year. We will make semi-annual filings on Form 1-SA, which will be due by September 28 each year, which will include unaudited financial statements for the six months to June 30. We will also file a Form 1-U to announce important events such as the loss of a senior officer, a change in auditors or certain types of capital-raising. We will be required to keep making these reports unless we file a Form 1-Z to exit the reporting system, which we will only be able to do if we have less than 300 shareholders of record and have filed at least one Form 1-K.

At least every 12 months, we will file a post-qualification amendment to the offering statement of which this offering circular forms a part to include the Company's recent financial statements.

We may supplement the information in this offering circular by filing a supplement with the Commission.

All these filings will be available on the Commission's EDGAR filing system. You should read all the available information before investing.

Notwithstanding the above, in the future, we may register a class of our equity securities under the Exchange Act, which will subject us to the periodic and current reporting requirements of Sections 13 and 15(d) of the Exchange Act. If we become subject to the reporting requirements of Sections 13 and 15(d) in the future, we will become subject to the information and periodic reporting requirements of the Exchange Act, and, accordingly, will be required to file annual reports containing financial statements audited by an independent public accounting firm, quarterly reports containing unaudited financial data, current reports, proxy statements (to the extent our securities are registered pursuant to Section 12 of the Exchange Act) and other information with the SEC.

---

| |
|:---|
| 123 |
| *[**Table of Contents**](#TOC)* |

---

Failure to timely file required reports with the SEC could result in the loss of our reporting status, which could adversely affect the liquidity and marketability of our common stock and the ability of holders of restricted shares to rely on resale exemptions under the securities laws.

**Benjamin Securities' Warrants**

We have agreed to issue to Benjamin Securities, Inc., one of the Placement Agents, and/or its affiliates, warrants to purchase 7% of the number of shares of common stock sold in this offering, issuable following each closing of Shares. Benjamin Securities' warrants will be exercisable at any time, and from time to time, in whole or in part, commencing six months from the grant date of such warrants, will have a cashless exercise provision, and will expire five years from the grant date of such warrants, at an exercise price of $12.50 (125% of the public offering price of the common stock). Benjamin Securities' warrants will also provide for customary anti-dilution provisions and registration rights (including a one-time demand registration right and unlimited "piggyback" registration rights) with respect to the registration of the shares of our common stock underlying Benjamin Securities' warrants, which registration rights shall terminate on the fifth anniversary of the commencement date of sales in this offering.

Benjamin Securities's warrant and the underlying shares of common stock may be deemed to be compensation by FINRA and therefore will be subject to FINRA Rule 5110(e)(1). In accordance with FINRA Rule 5110(e)(1), neither Benjamin Securities's warrant nor any of our shares of our common stock issued upon exercise of Benjamin Securities' warrant shall be sold, transferred, assigned, pledged, or hypothecated, or be the subject of any hedging, short sale, derivative, put, or call transaction that would result in the effective economic disposition of the securities by any person for a period of 180 days immediately following the date of the public offering in accordance with FINRA Rule 5110(e)(1).

**Indemnification**

We have agreed to indemnify the Placement Agents against certain liabilities, including liabilities under the Securities Act, or to contribute to payments the Placement Agents may be required to make because of any of those liabilities.

**Lock-up Agreements**

Our officers and directors and holders of our common stock have agreed to enter into lock-up agreements in connection with this offering. Under the lock-up agreements, subject to certain exceptions, each of these persons may not, without the prior written approval of Benjamin Securities, sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock for a period of 180 days [from the date of this offering circular], subject to certain exceptions.

The Company agreed that we will not: (i) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock; (ii) file or cause to be filed any Registration Statement with the SEC relating to the offering of any shares of our capital stock or any securities convertible into or exercisable or exchangeable for shares of our capital stock; (iii) complete any offering of debt securities of the Company, other than entering into a line of credit with a traditional bank; or (iv) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of our capital stock, whether any such transaction described in clause (i), (ii), (iii) or (iv) above is to be settled by delivery of shares of our capital stock or such other securities, in cash or otherwise, in each case without the prior consent of Benjamin Securities for a period of 180 days [from the date of this offering circular], subject to certain exceptions.

---

| |
|:---|
| 124 |
| *[**Table of Contents**](#TOC)* |

---

**Right of First Refusal; Tail Fees**

Pursuant to the engagement letter, dated January 6, 2025, between the Company and Benjamin Securities (as may be amended, the "Engagement Letter"), we have agreed to provide Benjamin Securities the right of first refusal for six (6) months following the consummation of this offering (the "<u>RoFR Period</u>"), to act as sole investment banker, sole book-runner, and/or sole placement agent, at Benjamin Securities' discretion, for each and every future public and private equity and debt offering, including all equity linked financings during such six (6) month period by the Company or any successor to or any current or future subsidiary of the Company, on terms and conditions to be agreed upon by Benjamin Securities and the Company.

If such transaction occurs after the expiration of the RoFR Period, but during the twenty-four (24) month period after the consummation of the offering, Benjamin Securities shall receive a commission equal to twenty percent (20%) of the total commissions paid to all broker-dealers or other intermediaries in connection with such transaction; provided, however, that Benjamin Securities shall not be entitled to such payment if the Company terminates the Engagement Letter for cause, which means (i) general incompetence or non-performance by Benjamin Securities, (ii) failure by Benjamin Securities to perform its obligations under the Engagement Letter, including the performance of the services in a manner that is reasonably acceptable to the Company, (iii) gross negligence or willful misconduct or (iv) Benjamin Securities is legally unable to perform its obligations under the Engagement Letter.

Additionally, Benjamin Securities will be entitled to a cash fee equal to 7.0% of the gross proceeds received by the Company from the sale of any equity, debt and/or equity derivative instruments to any investor introduced to the Company by Benjamin Securities if such financing is consummated at any time during the engagement period set forth in the Engagement Letter or the 18 months thereafter.

**Offering Price Determination**

Prior to this offering, there has been no public market for our common stock. The initial public offering price was negotiated between Benjamin Securities and us. In determining the initial public offering price of our common stock, Benjamin Securities considered:

• the history and prospects for the industry in which we compete;

• our financial information;

• the ability of our management and our business potential and earning prospects;

• the prevailing securities markets at the time of this offering; and

• the recent market prices of, and the demand for, publicly traded shares of generally comparable companies.

**Other Relationships**

Benjamin Securities and certain of its affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. Benjamin Securities and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for the issuer and its affiliates, for which they received or may in the future receive customary fees and expenses.

In the ordinary course of their various business activities, Benjamin Securities and certain of its affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments of the issuer or its affiliates. If Benjamin Securities or its affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. Benjamin Securities and its affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the shares of common stock offered hereby. Any such credit default swaps or short positions could adversely affect future trading prices of the shares of common stock offered hereby. Benjamin Securities and certain of its affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments.

---

| |
|:---|
| 125 |
| *[**Table of Contents**](#TOC)* |

---

**Selling Restrictions**

No action may be taken in any jurisdiction other than the United States that would permit a public offering of the shares or the possession, circulation or distribution of this offering circular in any jurisdiction where action for that purpose is required. Accordingly, this offering circular does not constitute an offer to sell to, or a solicitation of an offer to buy from, anyone in any country or jurisdiction (i) in which such an offer or solicitation is not authorized, (ii) in which any person making such offer or solicitation is not qualified to do so or (iii) in which any such offer or solicitation would otherwise be unlawful. No action has been taken that would, or is intended to, permit a public offer of the shares of common stock or possession or distribution of this offering circular or any other offering or publicity material relating to the shares of common stock in any country or jurisdiction (other than the United States) where any such action for that purpose is required. Accordingly, Benjamin Securities has undertaken that it will not, directly or indirectly, offer or sell any shares of common stock or have in its possession, distribute or publish any offering circular, form of application, advertisement or other document or information in any country or jurisdiction except under circumstances that will, to the best of its knowledge and belief, result in compliance with any applicable laws and regulations and all offers and sales of shares of common stock by it will be made on the same terms.

**EXPENSES OF THIS OFFERING**

Set forth below is an itemization of the total expenses, excluding commissions, which are expected to be incurred in connection with our sale of Shares in this offering. With the exception of the filing fee payable to FINRA, all amounts are estimates.

---

| | |
|:---|:---|
| **Itemized expenses** | **Amount** |
| FINRA filing fee | $650 |
| Printing expenses | $1000 |
| Legal fees and expenses | $150000 |
| Accounting fees and expenses | $80000 |
| Miscellaneous fees and expenses | $3350 |
| **Total** | $235000 |

---

**EXPERTS AND LEGAL MATTERS**

No expert or counsel named in this offering circular as having prepared or certified any part of this offering circular or having given an opinion upon the validity of the securities being registered or upon other legal matters in connection with the registration or offering of the securities was employed on a contingency basis or had, or is to receive, in connection with the offering, a substantial interest, directly or indirectly, in the Company or its subsidiaries. Nor was any such person connected with the Company or any of its subsidiaries as a promoter, managing or principal underwriters, voting trustee, director, officer or employee.

The financial statements of WUND Healing BioPharmaceuticals, Inc. for the years ended December 31, 2025 and 2024, included in this offering circular have been audited by Salberg & Company, P.A., an independent registered public accounting firm, as stated in their report dated appearing herein, and has been so included in reliance upon the report of such firm given upon their authority as experts in accounting and auditing.

The validity of the securities offered by this offering circular will be passed upon for us by The Loev Law Firm, PC, Bellaire, Texas. The Placement Agents are being represented by Bevilacqua PLLC, Washington, D.C.

---

| |
|:---|
| 126 |
| *[**Table of Contents**](#TOC)* |

---

**WHERE YOU CAN FIND MORE INFORMATION**

We have filed with the SEC an offering circular (including amendments and exhibits to the offering circular) on Form 1-A. This offering circular does not contain all of the information set forth in the registration statement. For further information, we refer you to the exhibits and schedules filed as part of this offering circular. If a document has been filed as an exhibit to this offering circular, we refer you to the copy of the document that has been filed. Each statement in this offering circular relating to a document filed as an exhibit is qualified in all respects by the filed exhibit. You should read this offering circular and the documents that we have filed as exhibits to this offering circular completely. The SEC maintains an internet site at www.sec.gov, from which you can electronically access the offering circular and its exhibits.

If you do not have internet access, requests for copies of such documents should be directed to John Laub, the Company's Chief Executive Officer, at WUND Healing BioPharmaceuticals, Inc., 8683 W. Sahara Avenue, Suite 280, Las Vegas, NV 89117.

Information contained in, or that can be accessed through, our website does not constitute a part of this offering circular. We have included our website address in this offering circular solely as an inactive textual reference. We will post on our website any materials required to be so posted on such website under applicable corporate or securities laws and regulations.

---

| |
|:---|
| 127 |
| *[**Table of Contents**](#TOC)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**INDEX TO FINANCIAL STATEMENTS**

<br> FOR THE YEARS ENDED DECEMBER 31, 2025, AND 2024

---

| | |
|:---|:---|
|  | **Page** |
| [Report of Independent Registered Public Accounting Firm](#re) (PCAOB ID 106) | F-1 |
| [Balance Sheets](#bs) | F-2 |
| [Statements of Operations](#so) | F-3 |
| [Statement of Changes in Shareholders' Deficit](#sc) | F-4 |
| [Statements of Cash Flows](#cf) | F-5 |
| [Notes to Financial Statements](#nt) | F-6 |

---

FOR THE THREE MONTHS ENDED MARCH 31, 2026, AND 2025

---

| | |
|:---|:---|
| [Balance Sheets](#bs1) | F-22 |
| [Statements of Operations](#so1) | F-23 |
| [Statement of Changes in Shareholders' Deficit](#sc1) | F-24 |
| [Statements of Cash Flows](#cf1) | F-25 |
| [Notes to Financial Statements](#note1) | F-26 |

---

---

| |
|:---|
| 128 |
| *[**Table of Contents**](#fs)* |

---

![](wund_1aimg11.jpg)

**Report of Independent Registered Public Accounting Firm**

To the Stockholders and the Board of Directors of:

WUND Healing Biopharmaceuticals, Inc.

<u>Opinion on the Financial Statements</u>

We have audited the accompanying balance sheets of WUND Healing Biopharmaceuticals, Inc. (the "Company") as of December 31, 2025, and 2024, the related statements of operations, changes in shareholders' deficit and cash flows for each of the two years in the period ended December 31, 2025, and the related notes (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2025, and 2024, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2025, in conformity with accounting principles generally accepted in the United States of America.

<u>Going Concern</u>

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company had a working capital deficit, accumulated deficit, and shareholder's deficit of approximately $1.27 million, $125 million and $1.13 million, respectively, at December 31, 2025. The Company had no revenues, but had other income during 2025 and 2024. These matters raise substantial doubt about the Company's ability to continue as a going concern. Management's Plan in regard to these matters is also described in Note 2. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

<u>Basis for Opinion</u>

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Salberg & Company, P.A.

SALBERG & COMPANY, P.A.

We have served as the Company's auditor since 2025.

Boca Raton, Florida

June 4, 2026

2295 NW Corporate Blvd., Suite 240 • Boca Raton, FL 33431-7326

Phone: (561) 995-8270 • Toll Free: (866) CPA-8500 • Fax: (561) 995-1920

www.salbergco.com • info@salbergco.com

*Member National Association of Certified Valuation Analysts • Registered with the PCAOB*

---

| |
|:---|
| F-1 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Balance Sheets**

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2025** | **December 31,**<br>**2024** |
| **ASSETS** |  |  |
| **Current assets:** |  |  |
| Cash | $176337 | $67434 |
| Other Receivables-related party |  | 31750 |
| Prepaid Expenses | 5620 | - |
| **Total current assets** | 181957 | 99184 |
| **Non-Current Assets:** |  |  |
| Right-of-use assets | 48280 | 6711 |
| Deferred offering costs | 121126 | 35000 |
| Security deposit | 5336 | 7723 |
| **Total assets** | $356699 | $148617 |
| **LIABILITIES AND SHAREHOLDERS' DEFICIT** |  |  |
| **Current liabilities:** |  |  |
| Accounts payable | $406188 | $363315 |
| Accrued expenses | 262198 | 273793 |
| Accrued expenses, related party | 75000 | 75000 |
| Related party loans and payables | 678710 | 653906 |
| Accrued interest, related party loans | 9695 | 4114 |
| Lease liability, current portion | 22543 | 7659 |
| **Total current liabilities** | 1454334 | 1377787 |
| Lease liability, less current portion | 28045 | - |
| **Total liabilities** | $1482379 | $1377787 |
| Commitments and contingencies (Note 9) |  |  |
| **SHAREHOLDERS' DEFICIT** |  |  |
| Preferred stock, $0.001 par value, 25,000,000 authorized |  |  |
| Series A-1 Convertible preferred stock, $0.001 par value; 3,500,000 shares designated; 3,500,000 shares issued and outstanding at December 31, 2025, and December 31, 2024; Non-voting; No liquidation preference | 3500 | 3500 |
| Series A-2 Convertible preferred stock, $0.001 par value; 3,500,000 shares designated; 3,500,000 shares issued and outstanding at December 31, 2025, and December 31, 2024; Non-voting; No liquidation preference | 3500 | 3500 |
| Common stock, $0.001 par value; 50,000,000 shares authorized at December 31, 2025, and December 31, 2024; 2,632,000 shares and 2,632,000 shares issued and outstanding at December 31, 2025, and December 31, 2024, respectively | 2632 | 2632 |
| Additional paid in capital | 124317347 | 124305368 |
| Accumulated deficit | (125452659) | (125544169) |
| **Total shareholders' deficit** | (1125680) | (1229169) |
| **Total liabilities and shareholders' deficit** | $356699 | $148617 |

---

The accompanying notes are an integral part of these financial statements.

---

| |
|:---|
| F-2 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Statements of Operations**

**For the Years Ended December 31, 2025 and 2024**

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **2024** |
| **Operating expenses:** |  |  |
| Professional fees | $220852 | $114256 |
| Consulting | 352479 | 127000 |
| Lease expense | 36013 | 89888 |
| Marketing expense | 995 |  |
| General and administrative expenses | 10227 | 10475 |
| **Total operating expenses** | 620566 | 341619 |
| Loss from operations | (620566) | (341619) |
| Other income (expense): |  |  |
| Income from participation in future revenues – related party | 718750 | 441000 |
| Interest expense | (6674) | (2342) |
| **Net income** | $91510 | $97039 |
| Basic and diluted net income per common share | $0.04 | $0.04 |
| Weighted average number of common shares outstanding, basic and diluted | 2632000 | 2632000 |

---

The accompanying notes are an integral part of these financial statements.

---

| |
|:---|
| F-3 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Statement of Changes in Shareholders' Deficit** 

**For the Years Ended December 31, 2025 and 2024**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series A-1**<br> **Preferred Stock** | **Series A-1**<br> **Preferred Stock** | **Series A-2**<br> **Preferred Stock** | **Series A-2**<br> **Preferred Stock** | **Common Stock** | **Common Stock** | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Shares** | **Amount** | **Additional**<br> **Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Total Shareholders'**<br>**Deficit** |
| **Balance at December 31, 2023** | 3500000 | $3500 | 3500000 | $3500 | 2632000 | $2632 | $124305368 | $(125641209) | $(1326209) |
| Net income |  |  |  |  |  |  |  | 97039 | 97039 |
| **Balance at December 31, 2024** | 3500000 | $3500 | 3500000 | $3500 | 2632000 | $2632 | $124305368 | $(125544169) | $(1229169) |
| Stock Based Compensation Expense |  |  |  |  |  |  | 11979 |  | 11979 |
| Net Income | - | - | - | - | - | - | - | 91510 | 91510 |
| **Balance at December 31, 2025** | **3500000** | $**3500** | **3500000** | $**3500** | **2632000** | $**2632** | $**124317347** | $**(125452659)** | $**(1125680)** |

---

The accompanying notes are an integral part of these financial statements.

---

| |
|:---|
| F-4 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Statements of Cash Flows**

**For the Years Ended December 31, 2025 and 2024**

---

| | | |
|:---|:---|:---|
|  | **Year Ended December 31,** | **Year Ended December 31,** |
|  | **2025** | **2024** |
| **Cash flows from operating activities** |  |  |
| Net income | $91510 | $97039 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| Lease payments adjusted against security deposit | 7722 | 37909 |
| Stock based compensation expense | 11979 |  |
| Non cash lease expense (income) | 1360 | (9027) |
| Changes in operating assets and liabilities: |  |  |
| Other receivables – related party | 31750 | 24000 |
| Prepaid expenses | (5620) |  |
| Accounts payable | 42874 | (36792) |
| Accrued expenses | (5098) | (46979) |
| Net cash provided by operating activities | 176477 | 66150 |
| **Cash flows from investing activities** |  |  |
| Security deposit paid | (5336) | - |
| Net cash used in investing activities | (5336) | - |
| **Cash flows from financing activities** |  |  |
| Loans received from related parties | 58804 | 25000 |
| Loans received repaid to related parties | (34000) | (11610) |
| Deferred offering costs | (86126) | (35000) |
| Loan repayment- other parties | (916) | (55) |
| Net cash used in financing activities | (62238) | (21665) |
| Net increase in cash | 108903 | 44485 |
| Cash |  |  |
| Beginning of year | 67434 | 22949 |
| End of year | $176337 | $67434 |
| Supplemental disclosure of cashflow information: |  |  |
| Cash paid for: |  |  |
| Interest | $- | 554 |
| Income Taxes | $- | $- |
| Non-Cash Investing and Financing Activities: |  |  |
| Lease Right-of-Use asset and lease liability | $68092 | $- |

---

The accompanying notes are an integral part of these financial statements.

---

| |
|:---|
| F-5 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

**1. Operation and Business Overview**

WUND Healing BioPharmaceuticals, Inc. ("WUND" or the "Company") is a sales and marketing company that has the exclusive rights to market and sell in the United States and Canada, all of the drugs being developed by Zhittya Genesis Medicine, Inc. ("Zhittya") (a related party, see Note 9). Zhittya is the only company with which WUND has signed a sales and marketing agreement. As part of the agreement, Zhittya owns 7 million shares of the Company's preferred stock. Zhittya is developing a portfolio of drugs that can be divided into two groups. The first group is topical and wound healing therapies for treatments such as diabetic foot ulcers and venous ulcers. The second group is the injectable, infusion and intranasal drugs, which are treatments for Parkinson's disease, stroke, type 2 diabetes, cardiovascular disease, and other conditions. The Company was incorporated in the State of Nevada on May 16, 2016.

On May 17, 2016, WUND entered into a product license and commercialization agreement (the "License Agreement") with Zhittya, a company developing a group of drugs designed to trigger the human body's natural regeneration process by stimulating the growth of new blood vessels in tissues and organs. On October 19, 2019, the Company and Zhittya amended the License Agreement and revised the consideration payable to Zhittya to consist of 3,500,000 shares of the Company's Series A-1 preferred stock and 3,500,000 shares of the Company's Series A-2 preferred stock.

On February 24, 2022, the Company entered into a second amendment to the License Agreement, clarifying the fee due to Zhittya on the sale or distribution of injectable and infusion drug treatments licensed pursuant to the License Agreement and clarifying the net revenue sharing arrangement with licensees in different geographic regions. On December 21, 2022, the Company entered into a third amendment to the License Agreement. This amendment allowed the Company access to all of the injectable, infusion and intranasal drugs and also clarified the net revenue sharing arrangement with licensees in different geographic regions for patients traveling to those regions to be treated.

The License Agreement gives WUND the exclusive rights to market, sell and distribute all of the drugs, devices and products, developed by Zhittya, for the United States and Canada. The Company is required to pay up to $375 million in milestone payments upon achieving certain milestones during the process of clinical development and obtaining regulatory body approval for its drugs. WUND will pay Zhittya a 50% royalty on Operating Profits (as defined in the License Agreement) on the topical and wound healing drugs. On the injectable, infusion and intranasal drugs, the Company will have to pay an 80% royalty on Operating Profits. There shall be no fee payable by the Company as licensee from the first $3 million of the Company's operating profits (revenues less marketing and cross border costs), which total $1,563,500 from 2023 to December 31, 2025.

On October 13, 2025, Zhittya agreed to pay WUND $15,000 for each research study done on type 2 diabetes patient conducted in the United States. As of December 31, 2025, the Company has received $300,000 for such studies.

The License Agreement also states if either party believes the other has breached the agreement, they must send a written notice detailing the breach, and the breaching party has 30 days to fix it before the agreement can be terminated with 10 days' notice. Either party can terminate the agreement with 30 days' notice if the other party experiences financial distress, including bankruptcy, insolvency, or appointment of a receiver. Upon termination or expiration, all rights, licenses, and use of technology or trademarks revert to Zhittya, and WUND must return or destroy related materials and pay any outstanding amounts. Termination does not affect any rights accrued prior or obligations intended to survive, which includes certain provisions in the agreement. Failure to act on a termination right does not waive the right to act in future similar situations.

**2. Going Concern**

As of December 31, 2025, the Company had a working capital deficit, an accumulated deficit, and a shareholders' deficit of approximately $1.27 million, $125 million, and $1.13 million, respectively. The Company has experienced significant losses since its inception. The Company has no revenue to date, but has other income. The net losses have principally occurred as a result of office lease expenses and expenses required for developing the administrative and sales and marketing infrastructure of the Company, which includes consulting, marketing, business development, and office expenses. The Company's currently licensed products are undergoing pre-clinical, patient-supported studies which provide other income to the company. The Company believes that these patients supported studies should provide enough funds to meet most of the company's obligations and expects to break even when its products are approved by the regulatory body ("RB") and sold in the United States and Canada. The Company may not generate a recurring source of revenues and does not anticipate doing so for the next several years. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issue date of these financial statements.

---

| |
|:---|
| F-6 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

The Company's plans to address its financing requirements relating to the financial challenges are as follows:

1) plans to raise capital through the public markets in the near future,

2) expects to receive funds from Zhittya's cross border operations,

3) borrowing additional funds, and

4) manage cash outlays.

There is no certainty that the Company will be successful in raising capital and the Company currently has no committed source for borrowings.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

**3. Summary of Significant Accounting Policies**

*Basis of Presentation*

The Company's financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Any references in these notes to applicable guidance is meant to refer to authoritative US GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").

*Use of Estimates*

The preparation of financial statements in conformity with US GAAP requires the Company's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Management's significant estimates in the accompanying financial statements include the lease liability and related right of use asset, stock-based compensation and deferred tax asset valuation allowance. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management's estimates.

*Cash and Cash Equivalents*

Cash and cash equivalents consist of cash on hand and at banks, and short-term deposits with an original maturity of three months or less with financial institutions. At December 31, 2025 and December 31, 2024, there were no cash equivalents.

*Concentration of Credit Risk*

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade accounts receivable and cash deposits. The Company maintains its cash in bank deposits accounts at Chase Bank and Western Alliance Bank. The Company's accounts at these institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000 at each location. At December 31, 2025 and 2024, the Company held cash in various accounts, none of which exceeded Federally insured limits. The Company has not experienced any losses in such accounts through December 31, 2025.

---

| |
|:---|
| F-7 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

*Concentration of Other Receivables*

The Company's other receivable, related party, is with one party, Zhittya.

*Other Receivables, Related Party, Net*

Other receivables are recorded at the invoiced amount and are non-interest bearing. Other receivables are recorded net of allowances for credit losses. The collectability of these receivables are evaluated periodically based on the actual credit terms with the entity. The Company recorded no allowance for credit losses at December 31, 2025 and December 31, 2024 as the collectability of other receivables was deemed probable based on management's assessment.

*Fair Value of Financial Instruments and Fair Value Measurements*

The Company measures its financial assets and liabilities in accordance with US GAAP using ASC 820, "Fair Value Measurements". For certain financial instruments, including cash, other receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities.

The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost).

The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

*Leases*

The Company has entered into operating leases for real estate. The Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease. The Company's leases may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise the option at the commencement date. It is reasonably certain that these options will not be exercised and therefore are not included within the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the lease term. The Company may have lease agreements with lease and non-lease components, in which case the components are accounted for separately.

*Advertising and Marketing Expenses*

Advertising and marketing expenses are recorded as incurred as a reduction to other income. Major components of the costs include advertising costs that are charged by Zhittya (a related party, see Note 9) for the expenditure it incurs to attract and enroll patients in ongoing clinical studies.

---

| |
|:---|
| F-8 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

*Restricted Stock Units*

The Company recognizes compensation expense for all share-based payments based on their grant-date fair value, net of estimated forfeitures. The compensation expense is recognized over the requisite service period, which is typically the vesting period, using the straight-line attribution method.

*Share-Based Compensation*

The Company maintains equity incentive plans for employees and directors. The Company recognizes compensation expense for all equity-classified awards (stock options, Restricted Stock Units (RSUs)) based on their fair value at the grant date, as calculated using the Black-Scholes option-pricing model. This expense is recognized on a straight-line basis over the requisite service period (vesting period), net of forfeitures as they occur. For awards with performance conditions, expense is recognized when it is probable that the performance condition will be achieved.

*Income Taxes*

The Company follows the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes (ASC 740) which states the impact of an uncertain income tax position is recognized at the largest amount that is "more likely than not" to be sustained upon audit by the relevant taxing authority. Management analyzed the tax positions taken by the Company, and has concluded that as of December 31, 2025 and 2024, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Company is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. The Company's policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized any interest or penalties in its statements of operations since inception.

*Income from Participation in Future Revenues*

Through 2017, the Company paid and accrued to Zhittya Genesis Medicine (a related party, see Notes 8 and 9) a total of $1.5 million which provided the company with the right to receive revenue share payments equal to 50% of the net operating profit from the future patient revenue of Zhittya. On October 13, 2025, Zhittya agreed to pay WUND $15,000 for each research study done on type 2 diabetes patient conducted in the United States, which are included in the right to receive revenue share payments arrangements. There are no specific payment terms for the revenue share payments and payments may be perpetual with no maximum. Zhittya is not a customer since there is no performance obligation that the company must meet to receive its revenue share payments, and therefore this arrangement is not considered revenues under ASC 606 "Revenues from Contracts with Customers. This arrangement meets the criteria for treatment as a debt transaction under ASC 470-10-25-2 "Sale of Future Revenues" with the Company as the lender. The Company originally recorded the $1.5 million as a loan receivable on it's balance sheet but impaired that loan receivable prior to year 2023. Accordingly, all cash receipts received by the Company from Zhittya relating to this arrangement since year 2023 are recorded as income from participation in future revenues, a component of other income.

Net operating profit of Zhittya is defined as net revenue (gross revenues less returns) less direct costs associated with commercialization of the product. Direct costs include but are not limited to direct product costs, and product support costs. Direct costs specifically exclude executive salaries and corporate overhead that do not directly relate to commercialization, and sales and marketing costs. Certain advertising and marketing costs incurred by Zhittya, pertaining to the sourcing of patients, are charged against the payments due the Company, and accordingly, the Company recognizes only the net payments received.

---

| |
|:---|
| F-9 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

*Earnings (Loss) per Share*

Basic earnings (loss) per common share ("EPS") is computed by dividing the net income or loss applicable to common shares of the Company by the weighted average number of common shares outstanding for the relevant period. Diluted earnings (loss) per common share ("Diluted EPS") is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted. If the conversion of potentially dilutive instruments into common share is anti-dilutive, then diluted EPS is not presented separately from EPS.

The Company has issued Series A-1 preferred stock and Series A-2 preferred stock. The EPS calculation excludes 7,000,000 common shares that may be issued pursuant to the conversion of the currently outstanding Series A-1 preferred stock and Series A-2 preferred stock. Series A-1 and A-2 preferred stock is convertible into common shares two years after the Company has completed an underwritten initial public offering, and conversion of Series A-2 preferred stock is also conditional on certain trading metrics. Each share of Series A-1 preferred stock and Series A-2 preferred stock is convertible into one share of common stock.

*Segment Information*

The Company operates as a single operating and reportable segment. The Company's chief executive officer (CEO) is the Company's chief operating decision maker (CODM). The CEO reviews the operating results of the Company as a whole to make decisions about allocating resources and assessing financial performance.

The CODM assesses performance for a single segment and decides how to allocate resources based on the net income or loss that is also reported on the statement of operations as Net income or loss. The measure of segment assets is reported on the accompanying balance sheet as total assets.

When evaluating the Company's performance and making key decisions regarding resource allocation the CODM reviews several key metrics which include the following:

---

| | | |
|:---|:---|:---|
|  | **For the Year Ended December 31,** | **For the Year Ended December 31,** |
|  | **2025** | **2024** |
| Income from participation in future revenues- related party | $718750 | $441000 |

---

The CODM reviews the income from participation in future revenues and advertising and marketing expenses to measure and monitor cash. The CODM also reviews general and administrative expenses such as professional fees and consulting expenses to manage, maintain and enforce all contractual agreements to ensure costs are aligned with agreements and budget. General and administrative costs, as reported on the accompanying statements of operations, are the significant segment expenses provided to the CODM on a regular basis.

All other segment items included in net income or loss are reported on the accompanying statements of operations and described within their respective disclosures.

Currently, all of the Company's operations are conducted in the United States and its assets are held in the United States.

*Recently Issued Accounting Pronouncements*

In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on January 1, 2025, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. On January 1, 2025, the Company adopted the new accounting pronouncement ASU No. 2023-09 in the current period and retrospectively. The adoption of ASU No. 2023-09 did not have any impact on the financial statements or results of operations.

---

| |
|:---|
| F-10 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets (ASU 2025-05). The ASU 2025-05 relates to estimating credit losses under the calculation of current expected credit losses (CECL) for current accounts receivable and current contract assets arising from revenue transactions accounted for under ASC 606, Revenue from Contracts with Customers. The provisions of ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company has early adopted ASU 2025-05 on January 1, 2025 on a prospective basis and elected to apply the practical expedient for accounts receivable, however, since the Company does not have any accounts receivable at December 31, 2025, there was no impact of this adoption on the accompanying financial statements or operations.

In November 2024, the FASB issued ASU 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures" to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its financial statements and related disclosures. The adoption of this pronouncement is not expected to have a material impact on the Company's financial statements.

In October 2023, the FASB issued ASU 2023-06 "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative," which incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification ("Codification"). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification topics, allowing investors to more easily compare entities subject to the SEC's existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SEC's regulations. The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this ASU should be applied prospectively. The Company does not expect ASU 2023-06 will have a material impact to its financial statements or related disclosures.

**4. Other Receivables – Related Party**

At December 31, 2025 and December 31, 2024, the Company had $- and $31,750 in other receivables relating to income from participation in future revenues (See Note 8), of which 100% was due from a single related party.

**5. Right of Use Assets and Lease Liabilities**

On January 10<sup>th</sup> 2025, the Company entered into a new 37-month lease with lease agreement for office space which will serve as the Company's headquarters. Under the terms of the lease, the Company leased 1160 square feet for $2,146 of monthly base rent plus operating expenses, subject to scheduled annual rent increases.

On commencement of the lease in 2025 for the Company's office premises the Company recognized a right-of-use asset and lease liability of $68,092. During the year ended December 31, 2025, cash paid relating to operating lease payments was $23,606 and the remaining operating lease term is 25 months.

On October 9, 2019, the Company entered into a 63-month lease agreement for office space, which served as the Company's corporate headquarters. Under the terms of the lease, the Company leases 2,609 square feet at $30.60 per square foot per year or $79,835 annual base rent which was subject to scheduled annual rent increases. On commencement of the lease for the Company's office premises the Company recognized a right-of-use asset and lease liability of $326,223. The lease terminated on January 9, 2025.

The discount rate on both operating leases was 10%.

---

| |
|:---|
| F-11 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

The right of use asset has been stated on the balance sheet net of amortization as stated in the table below.

---

| | | |
|:---|:---|:---|
|  | **December 31,** | **December 31,** |
|  | **2025** | **2024** |
| Right of use asset | $68092 | $326223 |
| Less: accumulated amortization | (19812) | (319512) |
| Balance at end of the year | $48280 | $6711 |

---

Approximate maturities of lease liabilities as of December 31, 2025 are as follows:

---

| | |
|:---|:---|
|  | **Payment amount** |
| 2026 | 26587 |
| 2027 | 27422 |
| 2028 | 2285 |
| Total undiscounted lease payments | 56294 |
| Less: Imputed interest | (5706) |
| Total lease liability  | $50588 |
| Less: current portion | 22543 |
| Lease liability, net of current portion | $28045 |

---

**6. Income Taxes**

During the years ended December 31, 2025 and 2024, the Company recorded net income of $91,510 and $97,039, respectively. Since the Company maintains a full valuation allowance on its deferred tax assets, the Company did not record an income tax benefit for the years ended December 31, 2025 and 2024.

---

| |
|:---|
| F-12 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

The Company's provision for income taxes differs from the expected tax benefit amount computed by applying the statutory federal income tax rate of 21% to income before income taxes as a result of nondeductible differences. A reconciliation of the provision for income taxes computed at the statutory federal income tax rate to the provision for income taxes as reflected in financial statements is as follows:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **December 31,** | **December 31,** | **December 31,** | **December 31,** |
|  | **2025** | **2025** | **2024** | **2024** |
| Income tax expense computed at federal statutory tax rate | 19217 | &nbsp;&nbsp;&nbsp;&nbsp;21.00% | 20378 | &nbsp;&nbsp;&nbsp;&nbsp;21.00% |
| Nondeductible expenses | 60 | 0.06% |  |  |
| Change in valuation allowance | (19277) | -21.06% | (20378) | -21.00% |
| Balance at end of the year  | - | 0.00% | - | 0.00% |

---

Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred taxes as of December 31, 2025 and 2024 are as follows:

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2025** | **December 31,**<br>**2024** |
| Deferred tax assets: |  |  |
| Net operating loss | 430494 | 442722 |
| Accrued expenses | 158147 | 150214 |
| Intangible assets | 76195 | 90261 |
| Lease liability | 10623 | 1608 |
| Gross deferred tax assets | 675459 | 684805 |
| &nbsp;&nbsp;&nbsp;&nbsp; Less: Valuation allowance | (664119) | (683396) |
| Net Deferred tax assets | 11340 | 1409 |
| Deferred tax liabilities: |  |  |
| Right of use asset | (11340) | (1409) |
| Right of use asset | (11340) | (1409) |
| Non-current net deferred tax assets (liabilities) | - | - |

---

In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of deferred tax assets is dependent upon the Company attaining future taxable income during periods in which those temporary differences become deductible. Due to the uncertainty surrounding the realization of the benefits of its deferred assets, including net operating loss carry forwards, the Company has provided a 100% valuation allowance on its deferred tax assets at December 31, 2025 and 2024.

---

| |
|:---|
| F-13 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

As of December 31, 2025, and 2024 the net operating loss carry forwards are approximately $2,100,000. The net operating loss carryforwards of $32, and $35,310 will expire in 2036 and 2037, respectively. The remaining $2.07 million of the Company's net operating losses have an indefinite carryforward period, but utilization for any tax year is limited to 80% of taxable income. After weighing all available and positive and negative evidence for the period, the Company determined a full valuation allowance is necessary against all net operating losses.

**7. Shareholders' Deficit**

*Preferred Stock*

The Series A-1 preferred stock and Series A-2 preferred stock are convertible into common shares two years after the Company completes an underwritten initial public offering. Further Series A-2 preferred stock conversion is conditional upon the 30 days volume weighted average price exceeding $20/share. Zhittya is permitted to convert preferred stock up to an ownership percentage of 4.99% of number of shares of common stock outstanding immediately after the conversion of preferred stock or less.

Each share of Series A-1 preferred stock and Series A-2 preferred stock is convertible into one share of common stock based upon a $1.00 conversion price divided into the $1.00 stated value.

Upon sale of the Company or change of control or other fundamental transaction as defined in the Certificate of designation, if not converted earlier, Series A-1 shares shall automatically convert into common stock and Series A-2 can only be converted if the sale price exceeds $20/share.

The conversion price is subject to standard anti-dilution provisions. There are no voting rights.

In the event of any liquidation, dissolution or winding up of the Company either voluntary or involuntary, the holders of Series A-1 preferred stock and Series A-2 preferred stock will be entitled to receive out of the Company's assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series A-1 preferred stock and Series A-2 preferred stock were fully converted to common stock which amounts will be paid pari passu with all holders of our common stock.

*Common Stock*

The Company is authorized to issue up to 50,000,000 shares of common stock at par value $0.001 per share. The Company had no stock issuances for the years ended December 31, 2025 and 2024.

*Restricted Stock Units*

On January 15, 2025, the Company awarded its Chief Financial Officer (CFO) 50,000 restricted stock units ("RSUs"), which cliff vest as 40% at year two, 30% at year three, and 30% at year four from the grant date. The Company valued the RSUs at $1 per share based on the most recent stock transaction in 2023. The total value of $50,000 will be amortized straight-line over the four year period. The Company recognized $11,979 in stock based consulting expense in 2025, with $38,021 remaining to be amortized from 2026 to 2029.

---

| |
|:---|
| F-14 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

A summary of the status of RSUs outstanding follows:

---

| | | |
|:---|:---|:---|
|  | **RSUs** | **Weighted average grant-date fair value** |
|  | Qty | $ |
| Non-vested balance December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp; Granted | 50000 | 1.00 |
| **Non-vested balance December 31, 2025** | **50000** | **1.00** |

---

The following table summarizes the RSUs that remain outstanding at December 31, 2025:

---

| | | | |
|:---|:---|:---|:---|
| **Issue price** | **RSUs outstanding** | **RSUs outstanding** | **Vesting date<sup>(1)</sup>** |
|  | $Qty | Qty | January 15, 2029 |
|  |  | 50000 |  |
|  |  | **50000** |  |

---

<sup>(1)</sup> RSUs vest over a period of four years. Vesting dates listed above, represent the end of the four-year term.

**8. Income from Participation in Future Revenues**

The Company has a net operating revenue sharing arrangement with Zhittya (a related party, see Note 9), and see Note 3 policy for Income from participation in future revenues, for U.S. and Canadian patients in the Company's licensed territories that enroll in clinical study participation or treatment in various other Zhittya licensed territories (British Virgin Islands and the Bahamas) because of timing of or differences in government approvals (cross-border operation). Zhittya is responsible for the operating expenses relating to the cross-border operation and servicing the patients seeking to participate in the clinical studies. The Company is entitled to 50% of the net operating profit and records the amount it is entitled to as Income from participation in future revenues in its statement of operations under other income (expense). Net operating profit of Zhittya is defined as net revenue (gross revenues less returns) less direct costs associated with commercialization of the product. Direct costs include but are not limited to direct product costs, and product support costs. Direct costs specifically exclude executive salaries and corporate overhead that do not directly related to commercialization, and sales and marketing costs. Certain advertising and marketing costs incurred by Zhittya, pertaining to the sourcing of patients, are charged against the payments due the Company, and accordingly, the Company recognizes only the net payments received. In addition, Zhittya, as of October 2025 began conducting Investor-Funded research studies in the United States in Las Vegas, Nevada. The Company and Zhittya agreed that Zhittya would pay the Company the price of $15,000 per patient treated in these Investor-Funded research studies for the use of FGF-1. During the year ended December 31, 2025, the Company received $300,000 from Zhittya for these Investor-Funded research studies. This income is part of the net revenue sharing arrangement with Zhittya mentioned above.

During the year ended December 31, 2025 the Company recognized $1,192,000 of clinic revenue and $473,250 of advertising and promotion expenses for a net of $718,750 as income from participation in future revenues. During the year ended December 31, 2024 the Company recognized $1,266,000 of clinic revenue and $825,000 of advertising and promotion expenses for a net of $441,000 as income from participation in future revenues.

---

| |
|:---|
| F-15 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

At December 31, 2025, and December 31, 2024, the Company had a related net receivable from Zhittya of $- and $31,750, recorded in other receivables on the accompanying balance sheets, with payment terms of due upon receipt. As of December 31, 2025, and 2024, all of the Company's other income from participation in future revenues was generated from a single related party.

**9. Related Party Transactions**

Zhittya is a strategic partner to the Company and owns 7 million shares of the Company's Preferred Stock, giving Zhittya significant influence over the Company. The Company has a product license and commercialization agreement (the "License Agreement"). Per the License agreement, the Company cannot engage in any business other than the promotion, marketing, and distribution of Zhittya's Products from the date of the first Government Approval of Product for public sale or distribution in the Territory. The Company purchased the License Agreement from Zhittya in 2016 (subsequently amended in December 2022), for consideration of $1,500,000 in cash, which was recorded as payable to Zhittya and 7,000,000 shares of convertible preferred stock. This agreement was subsequently amended in October 2019 to revise the stock consideration to consist of 3,500,000 shares of our Series A-1 preferred stock and 3,500,000 shares of our Series A-2 preferred stock. The Company from 2016 to 2022 has made payments against the payable totaling $890,000. The Company had made no payments to Zhittya for the years ended December 31, 2025 and 2024. At December 31, 2025 and December 31, 2024, the Company had a remaining $610,000 and $610,000 respectively, payable to Zhittya relating to the acquisition of territorial rights under the License Agreement which is included in the related party loans and payables on the accompanying balance sheets. As of December 31, 2025 and December 31, 2024, the Company had 7,000,000 outstanding shares of preferred stock as Series A-1 and Series A-2 in the amount of 3,500,000 shares for each Series. The Company has executed an income sharing agreement (net of certain expenses) with Zhittya relating to clinical studies conducted within or outside the Company's licensed territories. The Company also receives income from Zhittya when it uses FGF-1 in Investor-Funded research studies (See Note 8). The Company has $8,750 payable to Zhittya relating to that agreement, included in related party loans and payables as of December 31, 2025 and $5,500 as of December 31, 2024.

The Company currently has a consulting agreement in place with its Chief Executive Officer (CEO), for services as its CEO and Chairman of the Board. During the year ended December 31, 2025, and 2024, the Company incurred $120,000 and $100,000 towards the agreement. As of December 31, 2025, there is $10,000 owed under this agreement, included in Accounts Payable.

The Company currently has a consulting agreement in place with its Chief Financial Officer (CFO), for services as its CFO effective January 15, 2025. During the year ended December 31, 2025, the Company incurred $172,500 towards the agreement. As of December 31, 2025, there is $7,500 owed under this agreement, included in Accounts Payable.

The Company, until December 2022, had a consulting agreement in place with an individual for his services as its CFO. At December 31, 2025, and December 31, 2024, the Company has a payable of $262,197 towards the agreement. These amounts are recorded in accrued expenses on the accompanying balance sheets.

The Company, until December 2022, had a consulting agreement in place with an individual, its Vice President of Marketing. At December 31, 2025, and December 31, 2024, the Company has a payable of $75,000 payable towards the agreement. These amounts are recorded in accrued expenses on the accompanying balance sheets.

During the year ended December 31, 2025, the Company received a $3,250 advance from Zhittya, included in the $8,750 payable above, and as of December 31, 2025, had a balance due to Zhittya of $618,750 on this loan.

During the year ended December 31, 2025, the Company received $55,554 and repaid $34,000, and during the year ended December 31, 2024, the Company repaid $500, on loans from companies under common ownership and management (related party loans), resulting in a total balance of $59,960 as of December 31, 2025.

---

| |
|:---|
| F-16 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

As of December 31, 2025 and December 31, 2024, the Company has the following related party loan balances on its balance sheet:

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2025** | **December 31,**<br>**2024** |
| Zhittya Genesis Medicine | $618750 | $615500 |
| Companies under common ownership and management | 59960 | 38406 |
| Balance at end of the year | $678710 | $653906 |

---

**10. Commitments and Contingencies**

The License Agreement with Zhittya requires the Company to make milestone and royalty payments to Zhittya contingent upon the occurrence of certain future events linked to the success of the licensed product's development. Milestone payments are contingent upon the successful achievement of an important point in the development lifecycle of the licensed product (e.g. various Phase protocols accepted by the regulatory body (RB); breakthrough drug designation obtained). Based on the License Agreement, the Company will also have to make payments based on a percentage of the operating profits of the sale of licensed products when regulatory approval of the marketing of the licensed product is obtained. The obligations for milestone and royalty payments are differentiated by the type of drugs, either topical drugs or injectable/infusion/intranasal drugs per the license agreement.

*Milestone Payments for Topical Drugs*

The topical drugs listed in the license agreement include 1) diabetic foot ulcers, 2) venous ulcers, 3) burns, 4) male pattern baldness, 5) topical surgical wounds (C-sections, cosmetic surgeries), 6) pressure wounds (bedsores), 7) internal surgical wounds (anastomoses), and 8) second generation FGF-1 drugs. Since the license agreement was signed, Zhittya has expanded this list to all topical drugs it develops. The Company is obligated to make payments to Zhittya if any of its Topical Drugs meet certain clinical progress and regulatory milestones, as stated below, not to exceed $75,000,000 in total.

Under the License Agreement, the Company will pay Zhittya 50% of the Company's Operating Profits from the sale of the topical drugs.

---

| |
|:---|
| F-17 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

---

| | |
|:---|:---|
| **Milestones – Topical Drugs** | **Payment** |
| Complete animal toxicity studies | $200000 |
| Submit Phase I clinical protocol to RB | 100000 |
| Phase I protocol accepted by RB | 100000 |
| First patient treated in Phase I clinical trial | 100000 |
| Final patient treated in Phase I clinical trial | 500000 |
| Phase I study safety endpoints met | 1000000 |
| Submit Phase II clinical protocol to RB | 100000 |
| Phase II protocol accepted by RB | 250000 |
| First patient treated in Phase II clinical trial | 500000 |
| 1/3 patients treated in Phase II clinical trial | 1000000 |
| 2/3 patients treated in Phase II clinical trial | 1000000 |
| Submit "Breakthrough Drug Designation" application to RB | 500000 |
| Final patient treated in Phase II clinical trial | 2000000 |
| Phase II study unblinded and efficacy endpoints met | 5000000 |
| **(If Breakthrough Drug Designation Obtained)** |  |
| "Breakthrough Drug Designation" approved by RB | 5000000 |
| Submit New Drug Application (NDA) to RB for commercial sale of drug | 10000000 |
| RB approval | 10000000 |
| **(If Breakthrough Drug Designation Not Obtained)** |  |
| End of Phase II meeting with RB | 500000 |
| Submit Phase III clinical protocol to RB | 250000 |
| Phase III protocol accepted by RB | 500000 |
| 1/3 patients treated in Phase III clinical trial | 2000000 |
| 2/3 patients treated in Phase III clinical trial | 2000000 |
| Final patient treated in Phase III clinical trial | 2000000 |
| Phase III study unblinded and efficacy endpoints met | 5000000 |
| Submit NDA to RB for commercial sale of drug | 10000000 |
| RB approval | 10000000 |

---

---

| |
|:---|
| F-18 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

The Company's obligation per the license agreement to pay milestone payments to Zhittya can not begin until at least ninety (90) days following the closing of the Company's initial public offering or public sale of shares. Such milestone payments may be made in stock, at the Company's option, following this offering, calculated using the average closing price over the prior 20 trading days prior to issuance, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, the Company is required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock. As of December 31, 2025, the Company has no obligations to make milestone payments relating to its Topical Drugs.

*<u>Milestone Payments for Injectable/Infusion/Intranasal Drugs</u>*

The Injectable/Infusion/Intranasal Drugs listed in the license agreement included 1) Parkinson's disease, 2) stroke, 3) multi-infarct dementia, 4) coronary heart disease, 5) peripheral artery disease 6) lumbar ischemia, 7) chronic traumatic encephalopathy (CTE), 8) traumatic brain injury (TBI), 9) Alzheimer's disease, 10) Huntington's disease, 11) amyotrophic lateral sclerosis (ALS), 12) chronic depression, 13) post-traumatic stress disorder (PTSD), 14) multiple sclerosis (MS), and 15) multiple systems atrophy. Since the agreement was signed, Zhittya has expanded this list to include all injectable/infusion/intranasal drugs. The Company is obligated to make payments to Zhittya if any of its Injectable/Infusion/Intranasal drugs meet certain clinical progress and regulatory milestones as noted below and the payments will not exceed $300,000,000 in total.

When Zhittya's Injectable/Infusion/Intranasal drugs are approved by the RB, the Company will begin selling the drugs. Under the License Agreement, the Company will remit 80% of the Operating Profits to Zhittya on a monthly basis. The License Agreement defines Operating Profits as net revenues less all direct costs. Direct costs include costs associated with direct sales and marketing costs, and exclude costs such as salaries and corporate overhead.

---

| |
|:---|
| F-19 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

The schedule of milestone payments for Zhittya's Injectable/Infusion/Intranasal drugs is as follows:

---

| | |
|:---|:---|
| **Milestones – Injectable/Infusion/Intranasal Drugs** | **Payment** |
| Complete animal toxicity studies | $200000 |
| Submit Phase I clinical protocol to RB | 100000 |
| Phase I protocol accepted by RB | 500000 |
| First patient treated in Phase I clinical trial | 500000 |
| Final patient treated in Phase I clinical trial | 1000000 |
| Phase I study safety endpoints met | 2000000 |
| Submit Phase II clinical protocol to RB | 200000 |
| Phase II protocol accepted by RB | 500000 |
| First patient treated in Phase II clinical trial | 1000000 |
| 1/3 patients treated in Phase II clinical trial | 1000000 |
| 2/3 patients treated in Phase II clinical trial | 1000000 |
| Submit "Breakthrough Drug Designation" application to RB | 500000 |
| Final patient treated in Phase II clinical trial | 4000000 |
| Phase II study unblinded and efficacy endpoints met | 15000000 |
| **(If Breakthrough Drug Designation Obtained)** |  |
| "Breakthrough Drug Designation" approved by RB | 25000000 |
| Submit NDA application to RB | 5000000 |
| "Breakthrough Drug Designation" approved by RB | 25000000 |
| **(If Breakthrough Drug Designation Not Obtained)** |  |
| End of Phase II meeting with RB | 500000 |
| Submit Phase III clinical protocol to RB | 500000 |
| Phase III protocol accepted by RB | 1000000 |
| 1/3 patients treated in Phase III clinical trial | 2000000 |
| 2/3 patients treated in Phase III clinical trial | 2000000 |
| Final patient treated in Phase III clinical trial | 2000000 |
| Phase III study unblinded and efficacy endpoints met | 25000000 |
| Submit NDA application to RB | 5000000 |
| RB approval | 25000000 |

---

---

| |
|:---|
| F-20 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**December 31, 2025, and 2024**

The Company's obligation to pay milestone payments to Zhittya would not begin until at least ninety (90) days following the closing of the Company's initial public offering or public sale of shares. As of December 31, 2025, the Company has no obligations to make milestone payments.

**11. Subsequent Events**

The Company has evaluated all events or transactions that occurred after December 31, 2025, through June 4, 2026, the date these financial statements were available to be issued and determined that there were no events which required disclosure.

---

| |
|:---|
| F-21 |
| *[**Table of Contents**](#fs)* |

---

WUND Healing BioPharmaceuticals, Inc.

**Balance Sheets**

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br> **2026**<br> **(Unaudited)** | **December 31,**<br> **2025** |
| **ASSETS** |  |  |
| **Current assets:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Cash | $159906 | $176337 |
| &nbsp;&nbsp;&nbsp;&nbsp; Prepaid Expenses | 1968 | 5620 |
| **Total current assets** | 161874 | 181957 |
| **Non-Current Assets:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Right-of-use assets - operating lease | 43021 | 48280 |
| &nbsp;&nbsp;&nbsp;&nbsp; Deferred Offering Costs | 168930 | 121126 |
| &nbsp;&nbsp;&nbsp;&nbsp; Security Deposit | 5336 | 5336 |
| **Total assets** | $379161 | $356699 |
| **LIABILITIES AND SHAREHOLDERS' DEFICIT** |  |  |
| **Current liabilities:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Accounts payable | $563096 | $406188 |
| &nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses | 273028 | 262198 |
| &nbsp;&nbsp;&nbsp;&nbsp; Accrued expenses, related party | 75000 | 75000 |
| &nbsp;&nbsp;&nbsp;&nbsp; Related party loans and payables | 226710 | 678710 |
| &nbsp;&nbsp;&nbsp;&nbsp; Accrued interest, related party loans | 10809 | 9695 |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease liability, current portion | 23322 | 22543 |
| **Total current liabilities** | 1171965 | 1454334 |
| Lease liability, less current portion | 21098 | 28045 |
| **Total liabilities** | $1193873 | $1482379 |
| Commitments and contingencies (Note 9) |  |  |
| **SHAREHOLDERS' DEFICIT** |  |  |
| Preferred stock, $0.001 par value, 25,000,000 authorized |  |  |
| Series A-1 Convertible preferred stock, $0.001 par value; 3,500,000 shares designated; 3,500,000 shares issued and outstanding at March 31, 2026, and December 31, 2025; Non-voting; No liquidation preference | 3500 | 3500 |
| Series A-2 Convertible preferred stock, $0.001 par value; 3,500,000 shares designated; 3,500,000 shares issued and outstanding at March 31, 2026, and December 31, 2025; Non-voting; No liquidation preference | 3500 | 3500 |
| Common stock, $0.001 par value; 50,000,000 shares authorized at March 31, 2026, and December 31, 2025; 2,632,000 shares and 2,632,000 shares issued and outstanding at March 31, 2026, and December 31, 2025, respectively | 2632 | 2632 |
| Additional paid in capital | 124320472 | 124317347 |
| Accumulated deficit | (125144816) | (125452659) |
| **Total shareholders' deficit** | (814712) | (1125680) |
| **Total liabilities and shareholders' deficit** | $379161 | $356699 |

---

The accompanying notes are an integral part of these financial statements.

---

| |
|:---|
| F-22 |
| *[**Table of Contents**](#fs)* |

---

WUND Healing BioPharmaceuticals, Inc.

**Statements of Operations**

**For the Three Months Ended March 31, 2026 and 2025**

**(unaudited)**

---

| | | |
|:---|:---|:---|
|  | **Three Months Ended March 31,** | **Three Months Ended March 31,** |
|  | **2026** | **2025** |
| **Operating expenses:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Professional fees | $62772 | $62545 |
| &nbsp;&nbsp;&nbsp;&nbsp; Consulting fees | 99125 | 79104 |
| &nbsp;&nbsp;&nbsp;&nbsp; Lease expense | 8044 | 14991 |
| &nbsp;&nbsp;&nbsp;&nbsp; General and administrative expenses | 4564 | 2630 |
| **Total operating expenses** | 174505 | 159270 |
| Loss from operations | (174505) | (159270) |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Income from participation in future revenues – related party | 484293 | 85750 |
| &nbsp;&nbsp;&nbsp;&nbsp; Interest expense | (1113) | (1595) |
| &nbsp;&nbsp;&nbsp;&nbsp; Other expense | (830) | - |
| **Net income (loss)** | $307844 | $(75115) |
| Basic and diluted net income per common share | $0.12 | $(0.03) |
| Weighted average number of common shares outstanding, basic and diluted | 2632000 | 2632000 |

---

The accompanying notes are an integral part of these financial statements.

---

| |
|:---|
| F-23 |
| *[**Table of Contents**](#fs)* |

---

WUND Healing BioPharmaceuticals, Inc.

**Statement of Changes in Shareholders' Deficit**

**For the Three Months Ended March 31, 2026 and 2025**

**(Unaudited)**

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Series A-1**<br> **Preferred Stock** | **Series A-1**<br> **Preferred Stock** | **Series A-2**<br> **Preferred Stock** | **Series A-2**<br> **Preferred Stock** | | | | | |
|  | **Shares** | **Amount** | **Shares** | **Amount** | **Common Stock**<br>**Shares** |<br>**Amount** | **Additional**<br> **Paid-in**<br>**Capital** | **Accumulated**<br>**Deficit** | **Total Shareholders'**<br>**Deficit** |
| **Balance at December 31, 2024** | 3500000 | $3500 | 3500000 | $3500 | 2632000 | $2632 | $124305368 | $(125544169) | $(1229169) |
| Restricted Stock Unit Expense |  |  |  |  |  |  | 2604 |  | 2604 |
| Net loss |  |  |  |  |  |  |  | (75115) | (75115) |
| **Balance at March 31, 2025** | 3500000 | 3500 | 3500000 | 3500 | 2632000 | 2632 | 124307972 | $(125619284) | $(1301680) |
| **Balance at December 31, 2025** | 3500000 | $3500 | 3500000 | $3500 | 2632000 | $2632 | $124317347 | $(125452660) | $(1125681) |
| Restricted Stock Unit Expense |  |  |  |  |  |  | 3125 |  | 3125 |
| Net loss |  |  |  |  |  |  |  | 307844 | 307844 |
| **Balance at March 31, 2025** | 3500000 | $3500 | 3500000 | $3500 | 2632000 | $2632 | $124320472 | $(125414816) | $(814712) |

---

The accompanying notes are an integral part of these financial statements.

---

| |
|:---|
| F-24 |
| *[**Table of Contents**](#fs)* |

---

WUND Healing BioPharmaceuticals, Inc.

**Statements of Cash Flows**

**For the Three Months Ended March 31, 2026 and 2025**

**(Unaudited)**

---

| | |
|:---|:---|
|  | **For the Three Months**<br> **Ended March 31,** |
|  | **2026** |
| **Cash flows from operating activities** |  |
| Net income (loss) | $307844 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |
| Lease payments adjusted against security deposit |  |
| Stock based consulting expense | 3125 |
| Non cash lease expense (income) | (99) |
| Changes in operating assets and liabilities: |  |
| Other receivables – related party | (440000) |
| Prepaid expenses | 3652 |
| Accounts payable | 156908 |
| Accrued interest, related party loans | 1113 |
| Accrued expenses | 10830 |
| Net cash provided by operating activities | 43373 |
| **Cash flows from investing activities** |  |
| Security deposit paid | - |
| Net cash used in investing activities | - |
| **Cash flows from financing activities** |  |
| Loans received from related parties |  |
| Loans received repaid to related parties | (12000) |
| Deferred Offering Costs | (47804) |
| Loan repayment- other parties | - |
| Net cash provided by (used in) financing activities | (59804) |
| Net increase in cash | (16431) |
| Cash |  |
| Beginning of period | 176337 |
| End of period | $159906 |
| Supplemental disclosure of cashflow information: |  |
| Cash paid for: |  |
| Interest | $- |
| Income Taxes | $- |
| Non-Cash Investing and Financing Activities: |  |
| Loans received offset against accounts receivable | $(440000) |
| Lease Right-of-Use asset and lease liability | $- |

---

The accompanying notes are an integral part of these financial statements.

---

| |
|:---|
| F-25 |
| *[**Table of Contents**](#fs)* |

---

**WUND Healing BioPharmaceuticals, Inc.**

**Notes to Financial Statements**

**March 31, 2026, and 2025**

**1. Operation and Business Overview**

WUND Healing BioPharmaceuticals, Inc. ("WUND" or the "Company") is a sales and marketing company that has the exclusive rights to market and sell in the United States and Canada, all of the drugs being developed by Zhittya Genesis Medicine, Inc. ("Zhittya") (a related party, see Note 9). Zhittya is the only company with which WUND has signed a sales and marketing agreement. As part of the agreement, Zhittya owns 7 million shares of the Company's preferred stock. Zhittya is developing a portfolio of drugs that can be divided into two groups. The first group is topical and wound healing therapies for treatments such as diabetic foot ulcers and venous ulcers. The second group is the injectable, infusion and intranasal drugs, which are treatments for Parkinson's disease, stroke, type 2 diabetes, cardiovascular disease, and other conditions. The Company was incorporated in the State of Nevada on May 16, 2016.

On May 17, 2016, WUND entered into a product license and commercialization agreement (the "License Agreement") with Zhittya, a company developing a group of drugs designed to trigger the human body's natural regeneration process by stimulating the growth of new blood vessels in tissues and organs. On October 19, 2019, the Company and Zhittya amended the License Agreement and revised the consideration payable to Zhittya to consist of 3,500,000 shares of the Company's Series A-1 preferred stock and 3,500,000 shares of the Company's Series A-2 preferred stock.

On February 24, 2022, the Company entered into a second amendment to the License Agreement, clarifying the fee due to Zhittya on the sale or distribution of injectable and infusion drug treatments licensed pursuant to the License Agreement and clarifying the net revenue sharing arrangement with licensees in different geographic regions. On December 21, 2022, the Company entered into a third amendment to the License Agreement. This amendment allowed the Company access to all of the injectable, infusion and intranasal drugs and also clarified the net revenue sharing arrangement with licensees in different geographic regions for patients traveling to those regions to be treated.

The License Agreement gives WUND the exclusive rights to market, sell and distribute all of the drugs, devices and products, developed by Zhittya, for the United States and Canada. The Company is required to pay up to $375 million in milestone payments upon achieving certain milestones during the process of clinical development and obtaining regulatory body approval for its drugs. WUND will pay Zhittya a 50% royalty on Operating Profits (as defined in the License Agreement) on the topical and wound healing drugs. On the injectable, infusion and intranasal drugs, the Company will have to pay an 80% royalty on Operating Profits. There shall be no fee payable by the Company as licensee from the first $3 million of the Company's operating profits (revenues less marketing and cross border costs), which total $2,047,793 from 2023 to 2026 as of March 31, 2026.

On October 13, 2025, Zhittya agreed to pay WUND $15,000 for each research study done on type 2 diabetes patient conducted in the United States. This income is part of the net revenue sharing arrangement with Zhittya mentioned above.

The License Agreement also states if either party believes the other has breached the agreement, they must send a written notice detailing the breach, and the breaching party has 30 days to fix it before the agreement can be terminated with 10 days' notice. Either party can terminate the agreement with 30 days' notice if the other party experiences financial distress, including bankruptcy, insolvency, or appointment of a receiver. Upon termination or expiration, all rights, licenses, and use of technology or trademarks revert to Zhittya, and WUND must return or destroy related materials and pay any outstanding amounts. Termination does not affect any rights accrued prior or obligations intended to survive, which includes certain provisions in the agreement. Failure to act on a termination right does not waive the right to act in future similar situations.

---

| |
|:---|
| F-26 |
| *[**Table of Contents**](#fs)* |

---

**2. Going Concern**

As of March 31, 2026, the Company had a working capital deficit, an accumulated deficit, and a shareholders' deficit of approximately $1.01 million, $125 million, and $0.81 million, respectively. The Company has experienced significant losses since its inception. The Company has no revenue to date, but has other income. The net losses have principally occurred as a result of office lease expenses and expenses required for developing the administrative and sales and marketing infrastructure of the Company, which includes consulting, marketing, business development, and office expenses. The Company's currently licensed products are undergoing pre-clinical, patient-supported studies which provide other income to the company. The Company believes that these patients supported studies should provide enough funds to meet most of the company's obligations and expects to break even when its products are approved by the regulatory body ("RB") and sold in the United States and Canada. The Company may not generate a recurring source of revenues and does not anticipate doing so for the next several years. Accordingly, there is substantial doubt about the Company's ability to continue as a going concern for a period of 12 months from the issue date of these financial statements.

The Company's plans to address its financing requirements relating to the financial challenges are as follows:

1) plans to raise capital through the public markets in the near future,

2) expects to receive funds from Zhittya's US operations,

3) borrowing additional funds, and

4) manage cash outlays.

There is no certainty that the Company will be successful in raising capital and the Company currently has no committed source for borrowings.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

**3. Summary of Significant Accounting Policies**

*Basis of Presentation*

The Company's financial statements included in this report have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP") and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission ("SEC"). Any references in these notes to applicable guidance is meant to refer to authoritative US GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").

*Use of Estimates*

The preparation of financial statements in conformity with US GAAP requires the Company's management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company's management evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. Management's significant estimates in the accompanying financial statements include the lease liability and related right of use asset, stock-based compensation and deferred tax asset valuation allowance. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management's estimates.

*Cash and Cash Equivalents*

Cash and cash equivalents consist of cash on hand and at banks, and short-term deposits with an original maturity of three months or less with financial institutions. At March 31, 2026 and December 31, 2025, there were no cash equivalents.

---

| |
|:---|
| F-27 |
| *[**Table of Contents**](#fs)* |

---

*Concentration of Credit Risk*

Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of trade accounts receivable and cash deposits. The Company maintains its cash in bank deposits accounts at Chase Bank and Western Alliance Bank. The Company's accounts at these institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000 at each location. At March 31, 2026 and December 31, 2025, the Company held cash in various accounts, none of which exceeded Federally insured limits. The Company has not experienced any losses in such accounts through March 31, 2026.

*Other Receivables, Related Party, Net*

Other receivables are recorded at the invoiced amount and are non-interest bearing. Other receivables are recorded net of allowances for credit losses. The collectability of these receivables are evaluated periodically based on the actual credit terms with the entity. The Company recorded no allowance for credit losses at March 31, 2026 and December 31, 2025 as the collectability of other receivables was deemed probable based on management's assessment.

*Fair Value of Financial Instruments and Fair Value Measurements*

The Company measures its financial assets and liabilities in accordance with US GAAP using ASC 820, "Fair Value Measurements". For certain financial instruments, including cash, other receivables, accounts payable and accrued liabilities, the carrying amounts approximate fair value due to their short maturities.

The Company follows accounting guidance for financial assets and liabilities. ASC 820 defines fair value, provides guidance for measuring fair value and requires certain disclosures. This standard does not require any new fair value measurements, but rather applies to all other accounting pronouncements that require or permit fair value measurements. This guidance discusses valuation techniques, such as the market approach (comparable market prices), the income approach (present value of future income or cash flow), and the cost approach (cost to replace the service capacity of an asset or replacement cost).

The guidance utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The following is a brief description of those three levels:

Level 1: Observable inputs such as quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Inputs, other than quoted prices that are observable, either directly or indirectly. These include quoted prices for similar assets or liabilities in active markets and quoted prices for identical or similar assets or liabilities in markets that are not active.

Level 3: Unobservable inputs in which little or no market data exists, therefore developed using estimates and assumptions developed by us, which reflect those that a market participant would use.

*Leases*

The Company has entered into operating leases for real estate. The Company determines if an arrangement is a lease at inception and evaluates each lease agreement to determine whether the lease is an operating or finance lease. For leases where the Company is the lessee, right-of-use ("ROU") assets represent the Company's right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the lease commencement date based on the present value of lease payments over the lease term. As the Company's leases do not provide an implicit interest rate, the Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any prepaid lease payments, lease incentives received, and costs which will be incurred in exiting a lease. The Company's leases may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise the option at the commencement date. It is reasonably certain that these options will not be exercised and therefore are not included within the lease term. Short-term leases with an initial term of 12 months or less are not recorded on the balance sheet. Lease expense is recognized on a straight-line basis over the lease term. The Company may have lease agreements with lease and non-lease components, in which case the components are accounted for separately.

---

| |
|:---|
| F-28 |
| *[**Table of Contents**](#fs)* |

---

*Advertising and Marketing Expenses*

Advertising and marketing expenses are recorded as incurred as a reduction to other income. Major components of the costs include advertising costs that are charged by Zhittya (a related party, see Notes 7 and 8) for the expenditure it incurs to attract and enroll patients in ongoing clinical studies.

*Restricted Stock Units*

The Company recognizes compensation expense for all share payments based on their grant-date fair value, net of estimated forfeitures. The compensation expense is recognized over the requisite service period, which is typically the vesting period, using the straight-line attribution method.

*Share-Based Compensation*

The Company maintains equity incentive plans for employees and directors. The Company recognizes compensation expense for all equity-classified awards (stock options, Restricted Stock Units (RSUs)) based on their fair value at the grant date. Fair value for stock options is calculated using the Black-Scholes option-pricing model. This expense is recognized on a straight-line basis over the requisite service period (vesting period), net of estimated forfeitures. For awards with performance conditions, expense is recognized when it is probable that the performance condition will be achieved.

*Income Taxes*

The Company follows the asset and liability method of accounting for income taxes. Under the asset and liability method, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates applicable to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the period that includes the enactment date. A valuation allowance against deferred tax assets is recorded if, based upon the weight of all available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized.

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes (ASC 740) which states the impact of an uncertain income tax position is recognized at the largest amount that is "more likely than not" to be sustained upon audit by the relevant taxing authority. Management analyzed the tax positions taken by the Company, and has concluded that as of March 31, 2026 and December 31, 2025, there are no uncertain positions taken or expected to be taken that would require recognition of a liability (or asset) or disclosure in the financial statements. The Company is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. The Company's policy is to recognize interest and penalties related to income tax matters in income tax expense. The Company has not recognized any interest or penalties in its statements of operations since inception.

*Income from Participation in Future Revenues*

Through 2017, the Company paid and accrued to Zhittya Genesis Medicine (a related party, see Notes 6 and 7) a total of $1.5 million which provided the company with the right to receive revenue share payments equal to 50% of the net operating profit from the future patient revenue of Zhittya. On October 13, 2025, Zhittya agreed to pay WUND $15,000 for each research study done on type 2 diabetes patient conducted in the United States, which are included in the right to receive revenue share payments arrangements. There are no specific payment terms for the revenue share payments and payments may be perpetual with no maximum. Zhittya is not a customer since there is no performance obligation that the company must meet to receive its revenue share payments, and therefore this arrangement is not considered revenues under ASC 606 "Revenues from Contracts with Customers. This arrangement meets the criteria for treatment as a debt transaction under ASC 470-10-25-2 "Sale of Future Revenues" with the Company as the lender. The Company originally recorded the $1.5 million as a loan receivable on its balance sheet but impaired that loan receivable prior to year 2023. Accordingly, all cash receipts received by the Company from Zhittya relating to this arrangement since year 2023 are recorded as income from participation in future revenues, a component of other income.

---

| |
|:---|
| F-29 |
| *[**Table of Contents**](#fs)* |

---

Net operating profit of Zhittya is defined as net revenue (gross revenues less returns) less direct costs associated with commercialization of the product. Direct costs include but are not limited to direct product costs, and product support costs. Direct costs specifically exclude executive salaries and corporate overhead that do not directly relate to commercialization, and sales and marketing costs. Certain advertising and marketing costs incurred by Zhittya, pertaining to the sourcing of patients, are charged against the payments due the Company, and accordingly, the Company recognizes only the net payments received.

*Earnings (Loss) per Share*

Basic earnings (loss) per common share ("EPS") is computed by dividing the net income or loss applicable to common shares of the Company by the weighted average number of common shares outstanding for the relevant period. Diluted earnings (loss) per common share ("Diluted EPS") is computed by dividing the net income or loss applicable to common shares by the sum of the weighted average number of common shares issued and outstanding and all additional common shares that would have been outstanding, if potentially dilutive instruments were converted. If the conversion of potentially dilutive instruments into common share is anti-dilutive, then diluted EPS is not presented separately from EPS.

The Company has issued Series A-1 preferred stock and Series A-2 preferred stock. The EPS calculation excludes 7,000,000 common shares that may be issued pursuant to the conversion of the currently outstanding Series A-1 preferred stock and Series A-2 preferred stock. Series A-1 and A-2 preferred stock is convertible into common shares two years after the Company has completed an underwritten initial public offering, and conversion of Series A-2 preferred stock is also conditional on certain trading metrics. Each share of Series A-1 preferred stock and Series A-2 preferred stock is convertible into one share of common stock.

*Segment Information*

The Company operates as a single operating and reportable segment. The Company's chief executive officer (CEO) is the Company's chief operating decision maker (CODM). The CEO reviews the operating results of the Company as a whole to make decisions about allocating resources and assessing financial performance.

The CODM assesses performance for a single segment and decides how to allocate resources based on the net income or loss that is also reported on the statement of operations as Net income or loss. The measure of segment assets is reported on the accompanying balance sheet as total assets.

When evaluating the Company's performance and making key decisions regarding resource allocation the CODM reviews several key metrics which include the following:

---

| | | |
|:---|:---|:---|
|  | **For the Three Months Ended March 31,** | **For the Three Months Ended March 31,** |
|  | **2026** | **2025** |
| Income from participation in future revenues- related party | $484293 | $85750 |

---

The CODM reviews the income from participation in future revenues and advertising and marketing expenses to measure and monitor cash. The CODM also reviews general and administrative expenses such as professional fees and consulting expenses to manage, maintain and enforce all contractual agreements to ensure costs are aligned with agreements and budget. General and administrative costs, as reported on the accompanying statements of operations, are the significant segment expenses provided to the CODM on a regular basis.

All other segment items included in net income or loss are reported on the accompanying statements of operations and described within their respective disclosures.

---

| |
|:---|
| F-30 |
| *[**Table of Contents**](#fs)* |

---

Currently, all of the Company's operations are conducted in the United States and its assets are held in the United States.

*Recently Issued Accounting Pronouncements*

In December 2023, the FASB issued ASU No. 2023-09, Improvements to Income Tax Disclosures, which requires disaggregated information about a reporting entity's effective tax rate reconciliation as well as information on income taxes paid. The standard is intended to benefit investors by providing more detailed income tax disclosures that would be useful in making capital allocation decisions. The amendments in this ASU are effective for annual periods beginning on January 1, 2025, and should be applied on a prospective basis with the option to apply the standard retrospectively. Early adoption is permitted. On January 1, 2025, the Company adopted the new accounting pronouncement ASU No. 2023-09 in the current period and retrospectively. The adoption of ASU No. 2023-09 did not have any impact on the financial statements or results of operations.

In July 2025, the FASB issued ASU 2025-05, Measurement of Credit Losses for Accounts Receivable and Contract Assets (ASU 2025-05). The ASU 2025 -05 relates to estimating credit losses under the calculation of current expected credit losses (CECL) for current accounts receivable and current contract assets arising from revenue transactions accounted for under ASC 606, Revenue from Contracts with Customers. The provisions of ASU 2025-05 are effective for annual reporting periods beginning after December 15, 2025, and interim reporting periods within those annual reporting periods. The Company has early adopted ASU 2025-05 on January 1, 2025 on a prospective basis and elected to apply the practical expedient for accounts receivable, however, since the Company does not have any accounts receivable at December 31, 2025 and March 31, 2026, there was no impact of this adoption on the accompanying financial statements or operations.

In November 2024, the FASB issued ASU 2024-03, "Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures" to require more detailed information about specified categories of expenses (purchases of inventory, employee compensation, depreciation, amortization, and depletion) included in certain expense captions presented on the face of the income statement. ASU 2024-03 is effective for fiscal years beginning after December 15, 2026 and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted. The amendments may be applied either (1) prospectively to financial statements issued for reporting periods after the effective date of this ASU or (2) retrospectively to all prior periods presented in the financial statements. The Company is currently evaluating the impact of adopting this guidance on its financial statements and related disclosures. The adoption of this pronouncement is not expected to have a material impact on the Company's financial statements.

In October 2023, the FASB issued ASU 2023-06 "Disclosure Improvements: Codification Amendments in Response to the SEC's Disclosure Update and Simplification Initiative," which incorporates certain SEC disclosure requirements into the FASB Accounting Standards Codification ("Codification"). The amendments in the ASU are expected to clarify or improve disclosure and presentation requirements of a variety of Codification topics, allowing investors to more easily compare entities subject to the SEC's existing disclosures with those entities that were not previously subject to the requirements, and align the requirements in the Codification with the SEC's regulations. The effective date for each amendment will be the date on which the SEC's removal of that related disclosure from Regulation S-X or Regulation S-K becomes effective, with early adoption prohibited. The amendments in this ASU should be applied prospectively. The Company does not expect ASU 2023-06 will have a material impact to its financial statements or related disclosures.

**4. Right of Use Assets and Lease Liabilities**

On January 10<sup>th</sup>, 2025, the Company entered into a new 37-month lease with lease agreement for office space which will serve as the Company's headquarters. Under the terms of the lease, the Company leased 1160 square feet for $2,146 of monthly base rent plus operating expenses, subject to scheduled annual rent increases.

On commencement of the lease in 2025 for the Company's office premises the Company recognized a right-of-use asset and lease liability of $68,092. During the three months ended March 31, 2026, cash paid relating to operating lease payments was $6,647 and the remaining operating lease terms is 25 months.

---

| |
|:---|
| F-31 |
| *[**Table of Contents**](#fs)* |

---

On October 9, 2019, the Company entered into a 63-month lease agreement for office space, which served as the Company's corporate headquarters. Under the terms of the lease, the Company leases 2,609 square feet at $30.60 per square foot per year or $79,835 annual base rent which was subject to scheduled annual rent increases. On commencement of the lease for the Company's office premises the Company recognized a right-of-use asset and lease liability of $326,223. The lease terminated on January 9, 2025.

The discount rate on both operating leases was 10%.

The right of use asset has been stated on the balance sheet net of amortization as stated in the table below.

---

| | | |
|:---|:---|:---|
|  | **March 31,**<br> **2026** | **December 31,**<br> **2025** |
| Right of use asset | $68092 | $68092 |
| Less: accumulated amortization | (25071) | (19812) |
| Balance at end of the period | $43021 | $48280 |

---

Approximate maturities of lease liabilities as of March 31, 2026 are as follows:

---

| | |
|:---|:---|
|  | **Payment amount** |
| 2026 | 19940 |
| 2027 | 27422 |
| 2028 | 2285 |
| Total undiscounted lease payments | 49647 |
| Less: Imputed interest | (5227) |
| Total lease liability  | $44420 |
| Less: current portion | 23322 |
| Lease liability, net of current portion | $21098 |

---

**5. Shareholders' Deficit**

*Preferred Stock*

The Series A-1 preferred stock and Series A-2 preferred stock are convertible into common shares two years after the Company completes an underwritten initial public offering. Further Series A-2 preferred stock conversion is conditional upon the 30 days volume weighted average price exceeding $20/share. Zhittya is permitted to convert preferred stock up to an ownership percentage of 4.99% of number of shares of common stock outstanding immediately after the conversion of preferred stock or less.

Each share of Series A-1 preferred stock and Series A-2 preferred stock is convertible into one share of common stock based upon a $1.00 conversion price divided into the $1.00 stated value.

Upon sale of the Company or change of control or other fundamental transaction as defined in the Certificate of designation, if not converted earlier, Series A-1 shares shall automatically convert into common stock and Series A-2 can only be converted if the sale price exceeds $20/share.

The conversion price is subject to standard anti-dilution provisions. There are no voting rights.

In the event of any liquidation, dissolution or winding up of the Company either voluntary or involuntary, the holders of Series A-1 preferred stock and Series A-2 preferred stock will be entitled to receive out of the Company's assets, whether capital or surplus, the same amount that a holder of common stock would receive if the Series A-1 preferred stock and Series A-2 preferred stock were fully converted to common stock which amounts will be paid pari passu with all holders of our common stock.

*Common Stock*

The Company is authorized to issue up to 50,000,000 shares of common stock at par value $0.001 per share. The Company had no stock issuances for the three month periods ended March 31, 2026 and 2025.

---

| |
|:---|
| F-32 |
| *[**Table of Contents**](#fs)* |

---

*Restricted Stock Units*

On January 15, 2025, the Company awarded its Chief Financial Officer (CFO) 50,000 restricted stock units ("RSUs"), which cliff vest as 40% at year two, 30% at year three, and 30% at year four from the grant date. The Company valued the RSUs at $1 per share based on the most recent stock transaction in 2023. The total value of $50,000 will be amortized straight-line over the four year period. The Company recognized $3,125 and $2,604 in the three months ended March 31, 2026 and 2025 in stock based consulting expense, with $34,896 remaining to be amortized from April 1, 2026 to 2029.

A summary of the status of RSUs outstanding follows:

---

| | | |
|:---|:---|:---|
|  | **RSUs** | **Weighted average grant-date fair value** |
|  | Qty | $ |
| Non-vested balance December 31, 2024 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp; Granted, three months ended March 31, 2025 | 50000 | 1.00 |
| **Non-vested balance March 31, 2025 and 2026** | **50000** | **1.00** |

---

The following table summarizes the RSUs that remain outstanding at March 31, 2026:

---

| | | | |
|:---|:---|:---|:---|
| **Issue price** | **RSUs outstanding** | **RSUs outstanding** | **Vesting date<sup>(1)</sup>** |
|  | $Qty | Qty |  |
|  |  | 50000 | January 15, 2029 |
|  |  | **50000** |  |

---

<sup>(1)</sup> RSUs vest over a period of four years. Vesting dates listed above, represent the end of the four-year term.

**6. Income from Participation in Future Revenues**

The Company has a net operating revenue sharing arrangement with Zhittya (a related party, see Note 7 and 8), and see Note 3 policy for Income from participation in future revenues, for U.S. and Canadian patients in the Company's licensed territories that enroll in clinical study participation or treatment in various other Zhittya licensed territories (British Virgin Islands and the Bahamas) because of timing of or differences in government approvals (cross-border operation). Zhittya is responsible for the operating expenses relating to the cross-border operation and servicing the patients seeking to participate in the clinical studies. The Company is entitled to 50% of the net operating profit and records the amount it is entitled to as Income from participation in future revenues in its statement of operations under other income (expense). Net operating profit of Zhittya is defined as net revenue (gross revenues less returns) less direct costs associated with commercialization of the product. Direct costs include but are not limited to direct product costs, and product support costs. Direct costs specifically exclude executive salaries and corporate overhead that do not directly related to commercialization, and sales and marketing costs. Certain advertising and marketing costs incurred by Zhittya, pertaining to the sourcing of patients, are charged against the payments due the Company, and accordingly, the Company recognizes only the net payments received. In addition, Zhittya, as of October 2025 began conducting Type 2 diabetes research studies in the United States in Las Vegas, Nevada. The Company and Zhittya agreed that Zhittya would pay the Company the price of $15,000 per patient treated in these research studies for the use of FGF-1.

During the three months ended March 31, 2026, the Company recognized $820,000 of clinic revenue and $335,707 of advertising and promotion expenses and referral fees for a net of $484,293 as income from participation in future revenues. During the three months ended March 31, 2025, the Company recognized $216,750 of clinic revenue and $131,000 of advertising and promotion expenses for a net of $85,750 as income from participation in future revenues.

As of March 31, 2026, and 2025, all of its other income from participation in future revenues was generated from a single related party, Zhittya.

---

| |
|:---|
| F-33 |
| *[**Table of Contents**](#fs)* |

---

**7. Related Party Transactions**

Zhittya is a strategic partner to the Company and owns 7 million shares of the Company's Preferred Stock, giving Zhittya significant influence over the Company. The Company has a product license and commercialization agreement (the "License Agreement"). Per the License agreement, the Company cannot engage in any business other than the promotion, marketing, and distribution of Zhittya's Products from the date of the first Government Approval of Product for public sale or distribution in the Territory. The Company entered into the License Agreement with Zhittya in 2016 (subsequently amended in December 2022), for consideration of $1,500,000 in cash, which was recorded as payable to Zhittya and 7,000,000 shares of convertible preferred stock. This agreement was subsequently amended in October 2019 to revise the stock consideration to consist of 3,500,000 shares of our Series A-1 preferred stock and 3,500,000 shares of our Series A-2 preferred stock. The Company from 2016 to 2022 has made payments against the payable totaling $890,000. The Company made payments to Zhittya of $440,000 through an offset of accounts receivable for the three months ended March 31, 2026. At March 31, 2026 and December 31, 2025, the Company had a remaining $170,000 and $610,000 respectively, payable to Zhittya relating to the acquisition of territorial rights under the License Agreement which is included in the related party loans and payables on the accompanying balance sheets. As of March 31, 2026 and December 31, 2025, the Company had 7,000,000 outstanding shares of preferred stock as Series A-1 and Series A-2 in the amount of 3,500,000 shares for each Series. The Company has executed an income sharing agreement (net of certain expenses) with Zhittya relating to clinical studies conducted within or outside the Company's licensed territories. The Company also receives income from Zhittya when it uses FGF-1 in Investor-Funded research studies (See Note 8). The company has $8,750 payable to Zhittya relating to that agreement, included in related party loans and payables as of March 31, 2026 and December 31, 2025.

The Company currently has a consulting agreement in place with its Chief Executive Officer (CEO), for services as its CEO and Chairman of the Board. During the three months ended March 31, 2026, and 2025, the Company incurred $30,000 and $30,000 towards the agreement. As of March 31, 2026, there is $30,000 owed under this agreement, included in Accounts Payable.

The Company currently has a consulting agreement in place with its Chief Financial Officer (CFO), for services as its CFO effective January 15, 2025. During the three months ended March 31, 2026, and 2025, the Company incurred $45,000 and $37,500 towards the agreement. As of March 31, 2026, there is $22,500 owed under this agreement, included in Accounts Payable.

The Company, until December 2022, had a consulting agreement in place with an individual for his services as its CFO. At March 31, 2026, and December 31, 2025, the Company has a payable of $262,197 towards the agreement. These amounts are recorded in accrued expenses on the accompanying balance sheets.

The Company, until December 2022, had a consulting agreement in place with an individual, its Vice President of Marketing. At March 31, 2026, and December 31, 2025, the Company has a payable of $75,000 payable towards the agreement. These amounts are recorded in accrued expenses on the accompanying balance sheets.

During the three months ended March 31, 2025, the Company received a $3,250 advance from Zhittya, included in the $8,750 payable above, and as of March 31, 2025, had a balance due to Zhittya of $618,750 on this loan. During the three months ended March 31, 2026, the Company offset $440,000 in accounts receivable from Zhittya against this loan, resulting in a balance of $178,750 on this loan.

During the three months ended March 31, 2026, the Company repaid $12,000, and during the three months ended March 31, 2025, the Company received $55,000 and repaid $25,000, on loans from companies under common ownership and management (related party loans), resulting in a total balance of $47,960 as of March 31, 2026 and $59,960 as of December 31, 2025.

As of March 31, 2026 and December 31, 2025 the Company has the following related party loan balances on its balance sheet:

---

| | | |
|:---|:---|:---|
|  | **March 31,** <br>**2026** | **December 31,** <br>**2025** |
| Zhittya Genesis Medicine | $178750 | $618750 |
| Companies under common ownership and management | 47960 | 59960 |
| Balance at end of the year | $226710 | $678710 |

---

---

| |
|:---|
| F-34 |
| *[**Table of Contents**](#fs)* |

---

**8. Commitments and Contingencies**

The License Agreement with Zhittya requires the Company to make milestone and royalty payments to Zhittya contingent upon the occurrence of certain future events linked to the success of the licensed product's development. Milestone payments are contingent upon the successful achievement of an important point in the development lifecycle of the licensed product (e.g. various Phase protocols accepted by the regulatory body (RB); breakthrough drug designation obtained). Based on the License Agreement, the Company will also have to make payments based on a percentage of the operating profits of the sale of licensed products when regulatory approval of the marketing of the licensed product is obtained. The obligations for milestone and royalty payments are differentiated by the type of drugs, either topical drugs or injectable/infusion/intranasal drugs per the license agreement.

*Milestone Payments for Topical Drugs*

The topical drugs listed in the license agreement include 1) diabetic foot ulcers, 2) venous ulcers, 3) burns, 4) male pattern baldness, 5) topical surgical wounds (C-sections, cosmetic surgeries), 6) pressure wounds (bedsores), 7) internal surgical wounds (anastomoses), and 8) second generation FGF-1 drugs. Since the license agreement was signed, Zhittya has expanded this list to all topical drugs it develops. The Company is obligated to make payments to Zhittya if any of its Topical Drugs meet certain clinical progress and regulatory milestones, as stated below, not to exceed $75,000,000 in total.

Under the License Agreement, the Company will pay Zhittya 50% of the Company's Operating Profits from the sale of the topical drugs.

---

| | |
|:---|:---|
| **Milestones – Topical Drugs** | **Payment** |
| Complete animal toxicity studies | $200000 |
| Submit Phase I clinical protocol to RB | 100000 |
| Phase I protocol accepted by RB | 100000 |
| First patient treated in Phase I clinical trial | 100000 |
| Final patient treated in Phase I clinical trial | 500000 |
| Phase I study safety endpoints met | 1000000 |
| Submit Phase II clinical protocol to RB | 100000 |
| Phase II protocol accepted by RB | 250000 |
| First patient treated in Phase II clinical trial | 500000 |
| 1/3 patients treated in Phase II clinical trial | 1000000 |
| 2/3 patients treated in Phase II clinical trial | 1000000 |
| Submit "Breakthrough Drug Designation" application to RB | 500000 |
| Final patient treated in Phase II clinical trial | 2000000 |
| Phase II study unblinded and efficacy endpoints met | 5000000 |
| **(If Breakthrough Drug Designation Obtained)** |  |
| "Breakthrough Drug Designation" approved by RB | 5000000 |
| Submit New Drug Application (NDA) to RB for commercial sale of drug | 10000000 |
| RB approval | 10000000 |
| **(If Breakthrough Drug Designation Not Obtained)** |  |
| End of Phase II meeting with RB | 500000 |
| Submit Phase III clinical protocol to RB | 250000 |
| Phase III protocol accepted by RB | 500000 |
| 1/3 patients treated in Phase III clinical trial | 2000000 |
| 2/3 patients treated in Phase III clinical trial | 2000000 |
| Final patient treated in Phase III clinical trial | 2000000 |
| Phase III study unblinded and efficacy endpoints met | 5000000 |
| Submit NDA to RB for commercial sale of drug | 10000000 |
| RB approval | 10000000 |

---

---

| |
|:---|
| F-35 |
| *[**Table of Contents**](#fs)* |

---

The Company's obligation to pay milestone payments to Zhittya would not begin until at least ninety (90) days following the closing of the Company's initial public offering or public sale of shares. Such milestone payments may be made in stock, at the Company's option, following this offering, calculated using the average closing price over the prior 20 trading days prior to issuance, provided that in the event the issuance of any shares of common stock to Zhittya would result in Zhittya owning 5% or more of the Company's outstanding common stock, the Company is required to defer the stock payment until such time as the issuance of such shares will result in Zhittya's ownership of the Company not exceeding 4.99% of the Company's common stock. As of March 31, 2026, the Company has no obligations to make milestone payments relating to its Topical Drugs.

*<u>Milestone Payments for Injectable/Infusion/Intranasal Drugs</u>*

The Injectable/Infusion/Intranasal Drugs listed in the license agreement included 1) Parkinson's disease, 2) stroke, 3) multi-infarct dementia, 4) coronary heart disease, 5) peripheral artery disease 6) lumbar ischemia, 7) chronic traumatic encephalopathy (CTE), 8) traumatic brain injury (TBI), 9) Alzheimer's disease, 10) Huntington's disease, 11) amyotrophic lateral sclerosis (ALS), 12) chronic depression, 13) post-traumatic stress disorder (PTSD), 14) multiple sclerosis (MS), and 15) multiple systems atrophy. Since the agreement was signed, Zhittya has expanded this list to include all injectable/infusion/intranasal drugs. The Company is obligated to make payments to Zhittya if any of its Injectable/Infusion/Intranasal drugs meet certain clinical progress and regulatory milestones as noted below and the payments will not exceed $300,000,000 in total.

When Zhittya's Injectable/Infusion/Intranasal drugs are approved by the RB, the Company will begin selling the drugs. Under the License Agreement, the Company will remit 80% of the Operating Profits to Zhittya on a monthly basis. The License Agreement defines Operating Profits as net revenues less all direct costs. Direct costs include costs associated with direct sales and marketing costs, and exclude costs such as salaries and corporate overhead.

The schedule of milestone payments for Zhittya's Injectable/Infusion/Intranasal drugs is as follows:

---

| | |
|:---|:---|
| **Milestones – Injectable/Infusion/Intranasal Drugs** | **Payment** |
| Complete animal toxicity studies | $200000 |
| Submit Phase I clinical protocol to RB | 100000 |
| Phase I protocol accepted by RB | 500000 |
| First patient treated in Phase I clinical trial | 500000 |
| Final patient treated in Phase I clinical trial | 1000000 |
| Phase I study safety endpoints met | 2000000 |
| Submit Phase II clinical protocol to RB | 200000 |
| Phase II protocol accepted by RB | 500000 |
| First patient treated in Phase II clinical trial | 1000000 |
| 1/3 patients treated in Phase II clinical trial | 1000000 |
| 2/3 patients treated in Phase II clinical trial | 1000000 |
| Submit "Breakthrough Drug Designation" application to RB | 500000 |
| Final patient treated in Phase II clinical trial | 4000000 |
| Phase II study unblinded and efficacy endpoints met | 15000000 |
| **(If Breakthrough Drug Designation Obtained)** |  |
| "Breakthrough Drug Designation" approved by RB | 25000000 |
| Submit NDA application to RB | 5000000 |
| "Breakthrough Drug Designation" approved by RB | 25000000 |
| **(If Breakthrough Drug Designation Not Obtained)** |  |
| End of Phase II meeting with RB | 500000 |
| Submit Phase III clinical protocol to RB | 500000 |
| Phase III protocol accepted by RB | 1000000 |
| 1/3 patients treated in Phase III clinical trial | 2000000 |
| 2/3 patients treated in Phase III clinical trial | 2000000 |
| Final patient treated in Phase III clinical trial | 2000000 |
| Phase III study unblinded and efficacy endpoints met | 25000000 |
| Submit NDA application to RB | 5000000 |
| RB approval | 25000000 |

---

The Company's obligation to pay milestone payments to Zhittya would not begin until at least ninety (90) days following the closing of the Company's initial public offering or public sale of shares. As of March 31, 2026, the Company has no obligations to make milestone payments.

**9. Subsequent Events**

The Company has evaluated all events or transactions that occurred after March 31, 2026, through June 4, 2026 and determined that there were no events which required disclosure.

---

| |
|:---|
| F-36 |
| *[**Table of Contents**](#fs)* |

---

Shares of Common Stock

![](wund_1aimg12.jpg)

**WUND Healing BioPharmaceuticals, Inc.**

<u> </u>

**OFFERING CIRCULAR**

<u> </u>

---

| | |
|:---|:---|
| **Benjamin Securities, Inc.** | **D. Boral** |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**, 2026**

**PART III**

**EXHIBITS**

The documents listed in the Exhibit Index of this report are incorporated by reference or are filed with this Offering Statement, in each case as indicated below.

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 1.1\*\* | Form of Placement Agent Agreement |
| [2.1\*](wund_ex21.htm) | [Articles of Incorporation and Amendments Thereto](wund_ex21.htm) |
| [2.2\*](wund_ex22.htm) | [Certificate of Designations, Preferences and Rights of the Series A-1 Convertible Preferred Stock](wund_ex22.htm) |
| [2.3\*](wund_ex23.htm) | [Certificate of Designations, Preferences and Rights of the Series A-2 Convertible Preferred Stock](wund_ex23.htm) |
| [2.4\*](wund_ex24.htm) | [Amended and Restated Certificate of Designations, Preferences and Rights of the Series A-1 Convertible Preferred Stock](wund_ex24.htm) |
| [2.5\*](wund_ex25.htm) | [Amended and Restated Certificate of Designations, Preferences and Rights of the Series A-2 Convertible Preferred Stock](wund_ex25.htm) |
| [2.6\*](wund_ex26.htm) | [Bylaws as currently in effect](wund_ex26.htm) |
| 3.1\*\* | Form of Placement Agent Warrant |
| 4.1\*\* | Form of Subscription Agreement |
| [6.1\*](wund_ex61.htm) | [Restated and Amended Product License and Commercialization Agreement by and between Zhittya Genesis Medicine Inc. and WUND Healing BioPharmaceuticals Inc. dated December 21, 2022](wund_ex61.htm) |
| [6.2\*](wund_ex62.htm) | [Letter Agreement dated October 13, 2025, between Zhittya Genesis Medicine Inc. and WUND Healing BioPharmaceuticals Inc.](wund_ex62.htm) |
| [6.3\*](wund_ex63.htm) | [Letter Agreement dated January 19, 2026, between Zhittya Genesis Medicine Inc. and WUND Healing BioPharmaceuticals Inc.](wund_ex63.htm) |
| [6.4#\*](wund_ex64.htm) | [Consulting Agreement dated July 22, 2025, and effective January 1, 2025, by and between WUND Healing BioPharmaceuticals Inc. and John Laub](wund_ex64.htm) |
| [6.5#\*](wund_ex65.htm) | [Consulting Agreement dated August 11, 2025, and effective January 15, 2025, by and between WUND Healing BioPharmaceuticals Inc. and Jon Paul](wund_ex65.htm) |
| [6.6#\*](wund_ex66.htm) | [WUND Healing BioPharmaceuticals, Inc. Restricted Stock Unit Plan](wund_ex66.htm) |
| [6.7#\*](wund_ex67.htm) | [WUND Healing BioPharmaceuticals, Inc. Form of Restricted Stock Unit Plan Award Agreement](wund_ex67.htm) |
| [6.8#\*](wund_ex68.htm) | [WUND Healing BioPharmaceuticals, Inc. August 26, 2025 Restricted Stock Unit Plan Award Agreement with Jon Paul](wund_ex68.htm) |
| [10.1\*](#power) | [Powers of Attorney (included in the signature page to this offering circular)](#power) |
| [11.1\*](wund_ex111.htm) | [Consent of Salberg & Company, P.A.](wund_ex111.htm) |
| 12.1\*\* | Opinion of The Loev Law Firm, PC re: the legality of the securities being registered |
| 13.1\*\* | Testing the Waters Materials |

---

# Portions of this exhibit have been omitted in accordance with Item 601(b)(10) of Regulation S-K.

\* Filed herewith.

\*\* To be filed by amendment.

≠ management contract or any compensatory plan.

**SIGNATURES**

Pursuant to the requirements of the Regulation A, the issuer certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form 1-A and has duly caused this offering statement be signed on its behalf by the undersigned, thereunto duly authorized in the City of Las Vegas, State of Nevada, on the day of June 26, 2026.

---

| | |
|:---|:---|
| **WUND Healing BioPharmaceuticals, Inc.** | **WUND Healing BioPharmaceuticals, Inc.** |
| By: | */s/ John Laub* |
|  | Name: John Laub  |
|  | Title: President, Chief Executive Officer and Treasurer |

---

**POWERS OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints John Laub and Jon Paul, or any of them, with full power to act alone, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any or all amendments to this Form 1-A offering statement, and to file the same with all exhibits thereto, and all other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act in person, hereby ratifying and confirming all that said attorneys-in-fact and agents or his or her substitute or substitutes may lawfully do or cause to be done by virtue hereof.

This Power of Attorney may be executed in multiple counterparts, each of which shall be deemed an original, but which taken together shall constitute one instrument.

This offering statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ John Laub* |  |  |
| John Laub | President, Chief Executive Officer, Treasurer, and Chairman of the Board of Directors (Principal Executive Officer) | June 26, 2026 |
| */s/ Jon Paul* |  |  |
| Jon Paul | Chief Financial Officer (Principal Financial and Accounting Officer) | June 26, 2026 |
| */s/ James Lamb* |  |  |
| James Lamb | Director | June 26, 2026 |
| */s/ Gregory Fey*  |  |  |
| Gregory Fey | Director | June 26, 2026 |

---

## Ex1A-2A

**EXHIBIT 2.1**

![](wund_ex31img9.jpg)

![](wund_ex31img10.jpg)

![](wund_ex31img11.jpg)

![](wund_ex31img12.jpg)

![](wund_ex31img13.jpg)

![](wund_ex31img14.jpg)

![](wund_ex31img15.jpg)

![](wund_ex31img16.jpg)

![](wund_ex31img17.jpg)

![](wund_ex31img18.jpg)

## Ex1A-2A

**EXHIBIT 2.2**

![](wund_ex32img1.jpg)

![](wund_ex32img2.jpg)

![](wund_ex32img3.jpg)

![](wund_ex32img4.jpg)

![](wund_ex32img5.jpg)

![](wund_ex32img6.jpg)

![](wund_ex32img7.jpg)

![](wund_ex32img8.jpg)

![](wund_ex32img9.jpg)

![](wund_ex32img10.jpg)

![](wund_ex32img11.jpg)

## Ex1A-2A

**EXHIBIT 2.3**

![](wund_ex33img1.jpg)

![](wund_ex33img2.jpg)

![](wund_ex33img3.jpg)

![](wund_ex33img4.jpg)

![](wund_ex33img5.jpg)

![](wund_ex33img6.jpg)

![](wund_ex33img7.jpg)

![](wund_ex33img8.jpg)

![](wund_ex33img9.jpg)

![](wund_ex33img10.jpg)

![](wund_ex33img11.jpg)

## Ex1A-2A

**EXHIBIT 2.4**

![](wund_ex34img12.jpg)

![](wund_ex34img13.jpg)

![](wund_ex34img14.jpg)

![](wund_ex34img15.jpg)

![](wund_ex34img16.jpg)

![](wund_ex34img17.jpg)

![](wund_ex34img18.jpg)

![](wund_ex34img19.jpg)

![](wund_ex34img20.jpg)

![](wund_ex34img21.jpg)

![](wund_ex34img22.jpg)

![](wund_ex34img23.jpg)

## Ex1A-2A

**EXHIBIT 2.5**

![](wund_ex35img12.jpg)

![](wund_ex35img13.jpg)

![](wund_ex35img14.jpg)

![](wund_ex35img15.jpg)

![](wund_ex35img16.jpg)

![](wund_ex35img17.jpg)

![](wund_ex35img18.jpg)

![](wund_ex35img19.jpg)

![](wund_ex35img20.jpg)

![](wund_ex35img21.jpg)

![](wund_ex35img22.jpg)

![](wund_ex35img23.jpg)

## Ex1A-2A

**EXHIBIT 2.6**

**BYLAWS** 

*of* 

**WUND HEALING BIOPHARMACEUTICALS, INC.**

**ARTICLE I**

**<u>OFFICES</u>**

Section 1.1 <u>Registered Office</u>. The registered office of WUND Healing Biopharmaceuticals, Inc. (the "Corporation") shall be established and maintained at 9501 Royal Windsor Avenue, in the City of Las Vegas, County of Clark, in the State of Nevada; John Laub shall be the registered agent of the Corporation in charge thereof. The registered office and registered agent may be changed from time to time by action of the board of directors of the Corporation (the "Board of Directors") and the appropriate filing by the Corporation in the office of the Secretary of State of the State of Nevada.

Section 1.02. <u>Principal Office</u>. The principal office for the transaction of the business of the Corporation shall be located at 9501 Royal Windsor Avenue, Las Vegas, NV 89149. The Board of Directors is hereby granted full power and authority to change said principal office from one location to another.

Section 1.3 <u>Other Offices</u>. The Corporation may also have offices at such other places, both within and without the State of Nevada, as the Board of Directors may from time to time determine.

**ARTICLE II**

**<u>MEETINGS OF STOCKHOLDERS</u>**

Section 2.1 <u>Annual Meetings</u>. The Annual Meeting of stockholders of the Corporation ("Stockholders") for purposes of the Nevada Revised Statutes ("NRS") 78.330 shall be held on such date and at such time as shall be designated from time to time by the Board of Directors. The election of directors and any other proper business may be transacted at the Annual Meeting of Stockholders.

Section 2.2 <u>Special Meetings</u>. A special meeting of the stockholders (a "Special Meeting") for any purpose or purposes may be called by the president of the Corporation, the Board of Directors or a committee of the Board of Directors that has been duly designated by the Board of Directors and whose powers and authority, as provided in a resolution of the Board of Directors or in these bylaws ("Bylaws"), include the power to call such meetings. Such request shall state the purpose or purposes of the proposed meeting. Unless otherwise prescribed by law, the articles of incorporation of the Corporation, as amended and restated from time to time (the "Articles of Incorporation"), or these Bylaws, a Special Meeting may not be called by any other person or persons. No business may be transacted at any Special Meeting other than such business as may be designated in the notice (or any supplement thereto) calling such meeting.

Section 2.3 <u>Place of Meetings</u>. The president, the Board of Directors, or a committee of the Board of Directors, as the case may be, may designate the time and place, either within or without the State of Nevada, for any Annual Meeting or for any Special Meeting of the Stockholders called by the president, the Board of Directors, or a committee of the Board of Directors. The Board of Directors may, in its sole discretion, determine that any meeting of the stockholders shall be held by means of electronic communications or other available technology in accordance with Section 2.17.

Section 2.4 <u>Notice</u>. Whenever stockholders are required or permitted to take any action at a meeting, a written notice of the meeting shall be given which shall state the place, date and hour of the meeting, the means of electronic communication, if any, and, in the case of a Special Meeting, the purpose or purposes for which the meeting is called. Unless otherwise required by law, written notice of any meeting shall be given not less than ten (10) nor more than sixty (60) days before the date of the meeting to each stockholder entitled to notice of and to vote at such meeting, and shall be delivered in accordance with NRS 78.370.

Section 2.5 <u>Adjournments</u>. Any meeting of the stockholders may be adjourned from time to time to reconvene at the same or some other place, and notice need not be given of any such adjourned meeting if the time and place thereof are announced at the meeting at which the adjournment is taken. At the adjourned meeting, the Corporation may transact any business which might have been transacted at the original meeting. If the adjournment is for more than sixty (60) days, or if after the adjournment a new record date is fixed for the adjourned meeting, notice of the adjourned meeting in accordance with the requirements of Section 2.4 hereof shall be given to each stockholder of record (including the new record date) entitled to notice of and to vote at the meeting.

Section 2.6 <u>Quorum</u>. Unless otherwise required by applicable law or the Articles of Incorporation, the holders of a majority of the Corporation's capital stock issued and outstanding and entitled to vote thereat, present in person or represented by proxy, shall constitute a quorum at all meetings of the stockholders for the transaction of business. A quorum, once established, shall not be broken by the withdrawal of enough votes to leave less than a quorum. If, however, a quorum shall not be present or represented at any meeting of the stockholders, the stockholders entitled to vote thereat, present in person or represented by proxy, shall have power to adjourn the meeting from time to time, in the manner provided in Section 2.5 hereof, until a quorum shall be present or represented.

Section 2.7 <u>Voting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Unless otherwise required by law, the Articles of Incorporation or these Bylaws, any question brought before any meeting of the stockholders, other than the election of directors, shall be decided by the vote of the holders of a majority of the votes cast on a matter at the meeting at which a quorum is present. Directors shall be elected by a plurality of the votes cast at the election. Broker non-votes and abstentions are considered for purposes of establishing a quorum but not considered as votes cast for or against a proposal or director nominee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Unless otherwise provided in the Articles of Incorporation, and subject to Section 2.11(a), each stockholder represented at a meeting of the stockholders shall be entitled to cast one (1) vote for each share of the capital stock entitled to vote thereat held by such stockholder. Such votes may be cast in person or by proxy as provided in Section 2.8. The Board of Directors, in its discretion, or the officer of the Corporation presiding at a meeting of the stockholders, in such officer's discretion, may require that any votes cast at such meeting shall be cast by written ballot.

Section 2.8 <u>Proxies</u>. Each stockholder entitled to vote at a meeting of the stockholders or to express consent or dissent to corporate action in writing without a meeting may authorize another person or persons to act for such stockholder as proxy, but no such proxy shall be voted upon after six months from its date of creation, unless such proxy provides for a longer period, which may not exceed seven years from the date of its creation. Without limiting the manner in which a stockholder may authorize another person or persons to act for such stockholder as proxy, the following shall constitute a valid means by which a stockholder may grant such authority:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) A stockholder may execute a writing authorizing another person or persons to act for such stockholder as proxy. Execution may be accomplished by the stockholder or such stockholder's authorized officer, director, employee or agent signing such writing or causing such person's signature to be affixed to such writing by any reasonable means, including, but not limited to, by facsimile signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) A stockholder may authorize another person or persons to act for such stockholder as proxy by transmitting or authorizing the transmission of an electronic record to the person who will be the holder of the proxy or to a proxy solicitation firm, proxy support service organization or like agent duly authorized by the person who will be the holder of the proxy to receive the transmission, provided that any such electronic record must either set forth or be submitted with information from which it can be determined that the electronic record was authorized by the stockholder. If it is determined that such electronic record is valid, the inspectors or, if there are no inspectors, such other persons making that determination shall specify the information on which they relied.

Any copy, facsimile or other electronic telecommunication or other reliable reproduction of the writing or electronic record authorizing another person or persons to act as proxy for a stockholder may be substituted or used in lieu of the original writing or electronic record for any and all purposes for which the original writing or electronic record could be used; <u>provided</u>, <u>however</u>, that such copy, facsimile telecommunication or other reproduction shall be a complete reproduction of the entire original writing or electronic record.

Section 2.9 <u>Consent of Stockholders in Lieu of Meeting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Unless otherwise provided in the Articles of Incorporation, any action required or permitted to be taken at any Annual or Special Meeting of Stockholders of the Corporation may be taken without a meeting, without prior notice and without a vote, if a consent or consents in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted and shall be delivered to the Corporation's principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of the stockholders are recorded, to the attention of the Secretary of the Corporation. Every written consent shall bear the date of signature of each stockholder who signs the consent and no written consent shall be effective to take the corporate action referred to therein unless, within sixty (60) days of the earliest dated consent delivered in the manner required by this Section 2.9 to the Corporation, written consents signed by a sufficient number of holders to take action are delivered to the Corporation by delivery to the Corporation's principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of the stockholders are recorded, to the attention of the Secretary of the Corporation. Any copy, facsimile or other reliable reproduction of a consent in writing may be substituted or used in lieu of the original writing for any and all purposes for which the original writing could be used, provided that such copy, facsimile or other reproduction shall be a complete reproduction of the entire original writing. Prompt notice of the taking of the corporate action without a meeting by less than unanimous written consent shall be given to those stockholders who have not consented in writing and who, if the action had been taken at a meeting, would have been entitled to notice of the meeting if the record date for such meeting had been the date that written consents signed by a sufficient number of holders to take the action were delivered to the Corporation as provided above in this Section 2.9.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which date shall not be less than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. Any stockholder of record seeking to have the stockholders authorize or take corporate action by written consent shall, by written notice to the Secretary of the Corporation, request the Board of Directors to fix a record date. The Board of Directors shall promptly, but in all events within ten (10) days after the date on which such a request is received, adopt a resolution fixing the record date. If no record date has been fixed by the Board of Directors within ten (10) days of the date on which such a request is received, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation's principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of the stockholders are recorded, to the attention of the Secretary of the Corporation. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the date on which the Board of Directors adopts the resolution taking such prior action.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) In the event of the delivery, in the manner provided by this Section 2.9, to the Corporation of the requisite written consent or consents to take corporate action and/or any related revocation or revocations, the Corporation shall engage independent inspectors of elections for the purpose of performing promptly a ministerial review of the validity of the consents and revocations. For the purpose of permitting the inspectors to perform such review, no action by written consent without a meeting shall be effective until such date as the independent inspectors certify to the Corporation that the consents delivered to the Corporation in accordance with this Section 2.9 represent at least a minimum number of votes that would be necessary to take the corporate action. Nothing contained in this Section 2.9(c) shall in any way be construed to suggest or imply that the board of directors or any stockholder shall not be entitled to contest the validity of any consent or revocation thereof, whether before or after such certification by the independent inspectors, or to take any other action (including, without limitation, the commencement, prosecution, or defense of any litigation with respect thereto, and the seeking of injunctive relief in such litigation).

Section 2.10 <u>List of Stockholders Entitled to Vote</u>. The officer of the Corporation who has charge of the stock ledger of the Corporation shall prepare and make, at least ten (10) days but not more than sixty (60) days, before every meeting of the stockholders, a complete list of the stockholders of record entitled to vote at the meeting, arranged in alphabetical order, and showing the address of each stockholder of record and the number of shares registered in the name of each stockholder of record. Such list shall be open to the examination of any stockholder, for any purpose germane to the meeting, during ordinary business hours, for a period of at least ten (10) days prior to the meeting (i) either at a place within the city where the meeting is to be held, which place shall be specified in the notice of the meeting, or, if not so specified, at the place where the meeting is to be held or (ii) during ordinary business hours, at the principal place of business of the Corporation. The list shall also be produced and kept at the time and place of the meeting during the whole time thereof, and may be inspected by any stockholder who is present. Except as otherwise required by law, such list shall be the only evidence as to who are the stockholders entitled to vote at any meeting of the stockholders. In the event that more than one group of shares is entitled to vote as a separate voting group at the meeting, there shall be a separate listing of the stockholders of each group.

Section 2.11 <u>Record Date</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) In order that the Corporation may determine the stockholders entitled to notice of or to vote at any meeting of the stockholders or any adjournment thereof, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than sixty (60) nor less than ten (10) days before the date of such meeting. If no record date is fixed by the Board of Directors, the record date for determining stockholders entitled to notice of or to vote at a meeting of the stockholders shall be at the close of business on the day before the day on which the first notice is given, or, if notice is waived, at the close of business on the day next preceding the day on which the meeting is held. A determination of stockholders of record entitled to notice of or to vote at a meeting of the stockholders shall apply to any adjournment of the meeting; <u>provided</u>, <u>however</u>, that the Board of Directors may fix a new record date for the adjourned meeting.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b) In order that the Corporation may determine the stockholders entitled to consent to corporate action in writing without a meeting, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted by the Board of Directors, and which record date shall not be more than ten (10) days after the date upon which the resolution fixing the record date is adopted by the Board of Directors. If no record date has been fixed by the Board of Directors, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting, when no prior action by the Board of Directors is required by applicable law, shall be the first date on which a signed written consent setting forth the action taken or proposed to be taken is delivered to the Corporation's principal place of business, or an officer or agent of the Corporation having custody of the book in which proceedings of meetings of the stockholders are recorded, to the attention of the Secretary of the Corporation. If no record date has been fixed by the Board of Directors and prior action by the Board of Directors is required by applicable law, the record date for determining stockholders entitled to consent to corporate action in writing without a meeting shall be at the close of business on the day on which the Board of Directors adopts the resolution taking such prior action.

Section 2.12 <u>Stock Ledger</u>. The stock ledger of the Corporation shall be the only evidence as to who are the stockholders entitled to examine the stock ledger, the list required by Section 2.10 or the books of the Corporation, or to vote in person or by proxy at any meeting of the stockholders.

Section 2.13 <u>Conduct of Meetings</u>. Meetings of stockholders shall be presided over by the chairman of the Board of Directors (the "Chairman"), or, in the absence of the Chairman, by the vice chairman of the Board of Directors, if any, or if there be no vice chairman or in the absence of the vice chairman, by the chief executive officer, if any, or if there be no chief executive officer or in the absence of the chief executive officer, by the president, or, in the absence of the president, or, in the absence of any of the foregoing persons, by a chairman designated by the Board of Directors, or by a chairman chosen at the meeting by the stockholders entitled to cast a majority of the votes which all stockholders present in person or by proxy are entitled to cast. The individual acting as chairman of the meeting may delegate any or all of his or her authority and responsibilities as such to any director or officer of the Corporation present in person at the meeting. The secretary, or in the absence of the secretary an assistant secretary, shall act as secretary of the meeting, but in the absence of the secretary and any assistant secretary the chairman of the meeting may appoint any person to act as secretary of the meeting. The order of business at each such meeting shall be as determined by the chairman of the meeting. The chairman of the meeting shall have the right and authority to prescribe such rules, regulations and procedures and to do all such acts and things as are necessary or desirable for the proper conduct of the meeting, including, without limitation, (i) the establishment of procedures for the maintenance of order and safety, (ii) the establishment of an agenda or order of business for the meeting, (iii) limitation on participation in the meeting to stockholders of record of the Corporation, their duly authorized and constituted proxies and such other persons as the chairman of the meeting shall permit, (iv) limitation on the time allotted for consideration of each agenda item and for questions or comments by meeting participants, (v) restrictions on entry to such meeting after the time prescribed for the commencement thereof, and (vi) the opening and closing of the voting polls. The Board of Directors, in its discretion, or the chairman of the meeting, in his or her discretion, may require that any votes cast at such meeting shall be cast by written ballot.

Section 2.14 <u>Inspectors of Election</u>. In advance of any meeting of the stockholders, the Board of Directors, by resolution, the Chairman or the president shall appoint one or more inspectors to act at the meeting and make a written report thereof. One or more other persons may be designated as alternate inspectors to replace any inspector who fails to act. If no inspector or alternate is able to act at a meeting of the stockholders, the chairman of the meeting shall appoint one or more inspectors to act at the meeting. Unless otherwise required by applicable law, inspectors may be officers, employees or agents of the Corporation. Each inspector, before entering upon the discharge of the duties of inspector, shall take and sign an oath to faithfully execute the duties of inspector with strict impartiality and according to the best of such inspector's ability. The inspector or inspectors may (i) ascertain the number of shares outstanding and the voting power of each; (ii) determine the number of shares represented at a meeting and the validity of proxies or ballots; (iii) count all votes and ballots; (iv) determine any challenges made to any determination made by the inspector(s); and (v) certify the determination of the number of shares represented at the meeting and the count of all votes and ballots.

Section 2.15 <u>Nature of Business at Meetings of Stockholders</u>. Only such business (other than nominations for election to the Board of Directors and the election of directors, which must comply with the provisions of Section 2.16) may be transacted at an Annual Meeting of Stockholders as is either (a) specified in the notice of meeting (or any supplement thereto) given by or at the direction of the Board of Directors (or any duly authorized committee thereof), (b) otherwise properly brought before the Annual Meeting by or at the direction of the Board of Directors (or any duly authorized committee thereof), or (c) otherwise properly brought before the Annual Meeting by any stockholder of the Corporation (i) who is a stockholder of record on the date of the giving of the notice provided for in this Section 2.15 and on the record date for the determination of stockholders entitled to notice of and to vote at such Annual Meeting and (ii) who complies with the notice procedures set forth in this Section 2.15.

In addition to any other applicable requirements, for business to be properly brought before an Annual Meeting by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary of the Corporation.

To be timely, a stockholder's notice to the Secretary must be delivered to or be mailed and received at the principal executive offices of the Corporation not less than ninety (90) days nor more than one-hundred and twenty (120) days prior to the anniversary date of the immediately preceding Annual Meeting of Stockholders; <u>provided</u>, <u>however</u>, that in the event that the Annual Meeting is called for a date that is not within twenty-five (25) days before or after such anniversary date, notice by the stockholder in order to be timely must be so received not later than the close of business on the tenth (10th) day following the day on which such notice of the date of the Annual Meeting was mailed or such public disclosure of the date of the Annual Meeting was made, whichever first occurs. In no event shall the adjournment or postponement of an Annual Meeting, or the public announcement of such an adjournment or postponement, commence a new time period (or extend any time period) for the giving of a stockholder's notice as described above.

To be in proper written form, a stockholder's notice to the Secretary must set forth the following information: (a) as to each matter such stockholder proposes to bring before the Annual Meeting, a brief description of the business desired to be brought before the Annual Meeting and the reasons for conducting such business at the Annual Meeting, and (b) as to the stockholder giving notice and the beneficial owner, if any, on whose behalf the proposal is being made, (i) the name and address of such person, (ii) (A) the class or series and number of all shares of stock of the Corporation which are owned beneficially or of record by such person and any affiliates or associates of such person, (B) the name of each nominee holder of shares of all stock of the Corporation owned beneficially but not of record by such person or any affiliates or associates of such person, and the number of such shares of stock of the Corporation held by each such nominee holder, (C) whether and the extent to which any derivative instrument, swap, option, warrant, short interest, hedge or profit interest or other transaction has been entered into by or on behalf of such person, or any affiliates or associates of such person, with respect to stock of the Corporation and (D) whether and the extent to which any other transaction, agreement, arrangement or understanding (including any short position or any borrowing or lending of shares of stock of the Corporation) has been made by or on behalf of such person, or any affiliates or associates of such person, the effect or intent of any of the foregoing being to mitigate loss to, or to manage risk or benefit of stock price changes for, such person, or any affiliates or associates of such person, or to increase or decrease the voting power or pecuniary or economic interest of such person, or any affiliates or associates of such person, with respect to stock of the Corporation; (iii) a description of all agreements, arrangements, or understandings (whether written or oral) between or among such person, or any affiliates or associates of such person, and any other person or persons (including their names) in connection with the proposal of such business and any material interest of such person or any affiliates or associates of such person, in such business, including any anticipated benefit therefrom to such person, or any affiliates or associates of such person, (iv) a representation that the stockholder giving notice intends to appear in person or by proxy at the Annual Meeting to bring such business before the meeting; and (v) any other information relating to such person that would be required to be disclosed in a proxy statement or other filing required to be made in connection with the solicitation of proxies by such person with respect to the proposed business to be brought by such person before the Annual Meeting pursuant to Section 14 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the rules and regulations promulgated thereunder.

A stockholder providing notice of business proposed to be brought before an Annual Meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.15 shall be true and correct as of the record date for determining the stockholders entitled to receive notice of the Annual Meeting and such update and supplement shall be delivered to or be mailed and received by the Secretary at the principal executive offices of the Corporation not later than five (5) business days after the record date for determining the stockholders entitled to receive notice of the Annual Meeting.

No business shall be conducted at the Annual Meeting of Stockholders except business brought before the Annual Meeting in accordance with the procedures set forth in this Section 2.15; <u>provided</u>, <u>however</u>, that, once business has been properly brought before the Annual Meeting in accordance with such procedures, nothing in this Section 2.15 shall be deemed to preclude discussion by any stockholder of any such business. If the chairman of an Annual Meeting determines that business was not properly brought before the Annual Meeting in accordance with the foregoing procedures, the chairman shall declare to the meeting that the business was not properly brought before the meeting and such business shall not be transacted.

Nothing contained in this Section 2.15 shall be deemed to affect any rights of stockholders to request inclusion of proposals in the Corporation's proxy statement pursuant to Rule 14a-8 under the Exchange Act (or any successor provision of law).

Section 2.16 <u>Nomination of Directors</u>. Only natural persons of at least 18 years of age who are nominated in accordance with the following procedures shall be eligible for election as directors of the Corporation, except as may be otherwise provided in the Articles of Incorporation with respect to the right of holders of preferred stock, if any, of the Corporation to nominate and elect a specified number of directors in certain circumstances. Nominations of persons for election to the Board of Directors may be made at any Annual Meeting of Stockholders, or at any Special Meeting of Stockholders called for the purpose of electing directors, (a) by or at the direction of the Board of Directors (or any duly authorized committee thereof) or (b) by any stockholder of the Corporation (i) who is a stockholder of record on the date of the giving of the notice provided for in this Section 2.16 and on the record date for the determination of stockholders entitled to notice of and to vote at such Annual Meeting or Special Meeting and (ii) who complies with the notice procedures set forth in this Section 2.16.

In addition to any other applicable requirements, for a nomination to be made by a stockholder, such stockholder must have given timely notice thereof in proper written form to the Secretary of the Corporation. To be timely, a stockholder's notice to the Secretary must be delivered to or be mailed and received at the principal executive offices of the Corporation (a) in the case of an Annual Meeting, not less than ninety (90) days nor more than one-hundred and twenty (120) days prior to the anniversary date of the immediately preceding Annual Meeting of Stockholders; <u>provided</u>, <u>however</u>, that in the event that the Annual Meeting is called for a date that is not within twenty-five (25) days before or after such anniversary date, notice by the stockholder in order to be timely must be so received not later than the close of business on the tenth (10th) day following the day on which such notice of the date of the Annual Meeting was mailed or such public disclosure of the date of the Annual Meeting was made, whichever first occurs; and (b) in the case of a Special Meeting of Stockholders called for the purpose of electing directors, not later than the close of business on the tenth (10th) day following the day on which notice of the date of the Special Meeting was mailed or public disclosure of the date of the Special Meeting was made, whichever first occurs. In no event shall the adjournment or postponement of an Annual Meeting or a Special Meeting called for the purpose of electing directors, or the public announcement of such an adjournment or postponement, commence a new time period (or extend any time period) for the giving of a stockholder's notice as described above.

To be in proper written form, a stockholder's notice to the Secretary must set forth the following information: (a) as to each person whom the stockholder proposes to nominate for election as a director (i) the name, age, business address and residence address of such person and that such person is a natural person of at least 18 years of age, (ii) the principal occupation or employment of such person, (iii) (A) the class or series and number of all shares of stock of the Corporation which are owned beneficially or of record by such person and any affiliates or associates of such person, (B) the name of each nominee holder of shares of all stock of the Corporation owned beneficially but not of record by such person or any affiliates or associates of such person, and the number of such shares of stock of the Corporation held by each such nominee holder, (C) whether and the extent to which any derivative instrument, swap, option, warrant, short interest, hedge or profit interest or other transaction has been entered into by or on behalf of such person, or any affiliates or associates of such person, with respect to stock of the Corporation and (D) whether and the extent to which any other transaction, agreement, arrangement or understanding (including any short position or any borrowing or lending of shares of stock of the Corporation) has been made by or on behalf of such person, or any affiliates or associates of such person, the effect or intent of any of the foregoing being to mitigate loss to, or to manage risk or benefit of stock price changes for, such person, or any affiliates or associates of such person, or to increase or decrease the voting power or pecuniary or economic interest of such person, or any affiliates or associates of such person, with respect to stock of the Corporation; and (iv) any other information relating to such person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with solicitations of proxies for election of directors pursuant to Section 14 of the Exchange Act, and the rules and regulations promulgated thereunder; and (b) as to the stockholder giving the notice, and the beneficial owner, if any, on whose behalf the nomination is being made, (i) the name and record address of the stockholder giving the notice and the name and principal place of business of such beneficial owner; (ii) (A) the class or series and number of all shares of stock of the Corporation which are owned beneficially or of record by such person and any affiliates or associates of such person, (B) the name of each nominee holder of shares of the Corporation owned beneficially but not of record by such person or any affiliates or associates of such person, and the number of shares of stock of the Corporation held by each such nominee holder, (C) whether and the extent to which any derivative instrument, swap, option, warrant, short interest, hedge or profit interest or other transaction has been entered into by or on behalf of such person, or any affiliates or associates of such person, with respect to stock of the Corporation and (D) whether and the extent to which any other transaction, agreement, arrangement or understanding (including any short position or any borrowing or lending of shares of stock of the Corporation) has been made by or on behalf of such person, or any affiliates or associates of such person, the effect or intent of any of the foregoing being to mitigate loss to, or to manage risk or benefit of stock price changes for, such person, or any affiliates or associates of such person, or to increase or decrease the voting power or pecuniary or economic interest of such person, or any affiliates or associates of such person, with respect to stock of the Corporation; (iii) a description of all agreements, arrangements, or understandings (whether written or oral) between such person, or any affiliates or associates of such person, and any proposed nominee or any other person or persons (including their names) pursuant to which the nomination(s) are being made by such person, and any material interest of such person, or any affiliates or associates of such person, in such nomination, including any anticipated benefit therefrom to such person, or any affiliates or associates of such person; (iv) a representation that the stockholder giving notice intends to appear in person or by proxy at the Annual Meeting or Special Meeting to nominate the persons named in its notice; and (v) any other information relating to such person that would be required to be disclosed in a proxy statement or other filings required to be made in connection with the solicitation of proxies for election of directors pursuant to Section 14 of the Exchange Act and the rules and regulations promulgated thereunder. Such notice must be accompanied by a written consent of each proposed nominee to being named as a nominee and to serve as a director if elected.

A stockholder providing notice of any nomination proposed to be made at an Annual Meeting or Special Meeting shall further update and supplement such notice, if necessary, so that the information provided or required to be provided in such notice pursuant to this Section 2.16 shall be true and correct as of the record date for determining the stockholders entitled to receive notice of the Annual Meeting or Special Meeting, and such update and supplement shall be delivered to or be mailed and received by the Secretary at the principal executive offices of the Corporation not later than five (5) business days after the record date for determining the stockholders entitled to receive notice of such Annual Meeting or Special Meeting.

No person shall be eligible for election as a director of the Corporation unless nominated in accordance with the procedures set forth in this Section 2.16. If the chairman of the meeting determines that a nomination was not made in accordance with the foregoing procedures, the chairman shall declare to the meeting that the nomination was defective and such defective nomination shall be disregarded.

Section 2.17 <u>Meetings Through Electronic Communications</u>. Stockholders may participate in a meeting of the stockholders by any means of electronic communications, videoconferencing, teleconferencing or other available technology permitted under the NRS (including, without limitation, a telephone conference or similar method of communication by which all individuals participating in the meeting can hear each other) and utilized by the Corporation. If any such means are utilized, the Corporation shall, to the extent required under the NRS, implement reasonable measures to (a) verify the identity of each person participating through such means as a stockholder and (b) provide the stockholders a reasonable opportunity to participate in the meeting and to vote on matters submitted to the stockholders, including an opportunity to communicate, and to read or hear the proceedings of the meeting in a substantially concurrent manner with such proceedings. Participation in a meeting pursuant to this Section 2.17 constitutes presence in person at the meeting.

**ARTICLE III**

**<u>DIRECTORS</u>**

Section 3.1 <u>Number, Election and Term of Directors</u>. The Board of Directors shall consist of not less than one nor more than nine members, the exact number of which shall be fixed from time to time by the Board of Directors. No decrease in the number of authorized directors constituting the Board of Directors of the Corporation shall shorten the term of any incumbent director. Except as provided in Section 3.2, directors shall be elected by a plurality of the votes cast at each Annual Meeting of Stockholders and each director so elected shall hold office until the next Annual Meeting of Stockholders and until such director's successor is duly elected and qualified, or until such director's earlier death, resignation or removal. Directors must be natural persons of at least 18 years of age but need not be stockholders of the Corporation or residents of the State of Nevada.

Section 3.2 <u>Vacancies</u>. Unless otherwise required in the Articles of Incorporation, vacancies on the Board of Directors or any committee thereof arising through death, resignation, removal, an increase in the number of directors constituting the Board of Directors or such committee or otherwise may be filled only by a majority of the remaining directors then in office, though less than a quorum, or by a sole remaining director. The directors so chosen shall, in the case of the Board of Directors, hold office until the next annual election and until their successors are duly elected and qualified, or until their earlier death, resignation or removal and, in the case of any committee of the Board of Directors, shall hold office until their successors are duly appointed by the Board of Directors or until their earlier death, resignation or removal.

Section 3.3 <u>Duties and Powers</u>. The business and affairs of the Corporation shall be managed by or under the direction of the Board of Directors which may exercise all such powers of the Corporation and do all such lawful acts and things as are not by statute or by the Articles of Incorporation or by these Bylaws required to be exercised or done by the stockholders.

Section 3.4 <u>Meetings</u>. The Board of Directors and any committee thereof may hold meetings, both regular and special, either within or without the State of Nevada. Regular meetings of the Board of Directors or any committee thereof may be held without notice at such time and at such place as may from time to time be determined by the Board of Directors or such committee, respectively. Special meetings of the Board of Directors may be called by the Chairman, if any, or the president. Special meetings of any committee of the Board of Directors may be called by the chairman of such committee, if any, the president, or any director serving on such committee. Notice thereof stating the place, date and hour of the meeting shall be given to each director (or, in the case of a committee, to each member of such committee) either by mail not less than seventy-two (72) hours before the date of the meeting, by telephone or electronic mail on twenty-four (24) hours' notice, or on such shorter notice as the person or persons calling such meeting may deem necessary or appropriate in the circumstances.

Section 3.5 <u>Organization</u>. At each meeting of the Board of Directors or any committee thereof, the Chairman of the Board of Directors or the chairman of such committee, as the case may be, or, in his or her absence or if there be none, a director chosen by a majority of the directors present, shall act as chairman. Except as provided below, the Secretary of the Corporation shall act as secretary at each meeting of the Board of Directors and of each committee thereof. In case the Secretary shall be absent from any meeting of the Board of Directors or of any committee thereof, an Assistant Secretary shall perform the duties of secretary at such meeting; and in the absence from any such meeting of the Secretary and all the Assistant Secretaries, the chairman of the meeting may appoint any person to act as secretary of the meeting. Notwithstanding the foregoing, the members of each committee of the Board of Directors may appoint any person to act as secretary of any meeting of such committee and the Secretary or any Assistant Secretary of the Corporation may, but need not if such committee so elects, serve in such capacity.

Section 3.6 <u>Resignations and Removals of Directors</u>. Any director of the Corporation may resign from the Board of Directors or any committee thereof at any time, by giving notice in writing to the Chairman of the Board of Directors, if any, the president or the secretary of the Corporation and, in the case of a committee, to the chairman of such committee, if any. Such resignation shall take effect at the time therein specified or, if no time is specified, immediately; and, unless otherwise specified in such notice, the acceptance of such resignation shall not be necessary to make it effective. Except as otherwise required by applicable law and subject to the rights, if any, of the holders of shares of preferred stock then outstanding, any director or the entire Board of Directors may be removed from office at any time, with or without cause, and only by the affirmative vote of the holders of at least a majority of the combined voting power of the issued and outstanding capital stock of the Corporation entitled to vote in the election of directors, voting together as a single class. Any director serving on a committee of the Board of Directors may be removed from such committee at any time by the Board of Directors.

Section 3.7 <u>Quorum and Voting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Except as otherwise required or permitted by the Articles of Incorporation, the NRS or the rules and regulations of any securities exchange or quotation system on which the Corporation's securities are listed or quoted for trading, at all meetings of the Board of Directors or any committee thereof, a majority of the entire Board of Directors or a majority of the directors constituting such committee, as the case may be, shall constitute a quorum for the transaction of business and the act of a majority of the directors or committee members present at any meeting at which there is a quorum shall be the act of the Board of Directors or such committee, as applicable. If a quorum shall not be present at any meeting of the Board of Directors or any committee thereof, the directors present thereat may adjourn the meeting from time to time, without notice other than announcement at the meeting of the time and place of the adjourned meeting, until a quorum shall be present.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) Each director shall have one vote for any action required or permitted to be taken at any meeting of the Board or any committee thereof or without a meeting as provided herein. In accordance with NRS 78.330, all directors and classes of directors shall have the same voting rights.

Section 3.8 <u>Actions of the Board by Written Consent</u>. Unless otherwise provided in the Articles of Incorporation or these Bylaws, any action required or permitted to be taken at any meeting of the Board of Directors or of any committee thereof may be taken without a meeting, if all the members of the Board of Directors or such committee, as the case may be, consent thereto in writing, and the writing or writings are filed with the minutes of proceedings of the Board of Directors or such committee.

Section 3.9 <u>Meetings by Means of Conference Telephone</u>. Unless otherwise provided in the Articles of Incorporation or these Bylaws, members of the Board of Directors, or any committee thereof, may participate in a meeting of the Board of Directors or such committee by means of a conference telephone or other communications equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this Section 3.9 shall constitute presence in person at such meeting.

Section 3.10 <u>Committees</u>. The Board of Directors may designate one or more committees, each committee to consist of one or more of the directors of the Corporation. Each member of a committee must meet the requirements for membership, if any, imposed by applicable law and the rules and regulations of any securities exchange or quotation system on which the securities of the Corporation are listed or quoted for trading. The Board of Directors may designate one or more directors as alternate members of any committee, who may replace any absent or disqualified member at any meeting of any such committee. Subject to the rules and regulations of any securities exchange or quotation system on which the securities of the Corporation are listed or quoted for trading, in the absence or disqualification of a member of a committee, and in the absence of a designation by the Board of Directors of an alternate member to replace the absent or disqualified member, the member or members thereof present at any meeting and not disqualified from voting, whether or not such member or members constitute a quorum, may unanimously appoint another qualified member of the Board of Directors to act at the meeting in the place of any absent or disqualified member. Any committee, to the extent permitted by law and provided in the resolution establishing such committee, shall have and may exercise all the powers and authority of the Board of Directors in the management of the business and affairs of the Corporation, and may authorize the seal of the Corporation to be affixed to all papers which may require it. Each committee shall keep regular minutes and report to the Board of Directors when required. Notwithstanding anything to the contrary contained in this Article III, the resolution of the Board of Directors establishing any committee of the Board of Directors and/or the charter of any such committee may establish requirements or procedures relating to the governance and/or operation of such committee that are different from, or in addition to, those set forth in these Bylaws and, to the extent that there is any inconsistency between these Bylaws and any such resolution or charter, the terms of such resolution or charter shall be controlling; provided that it complies with the NRS.

Section 3.11 <u>Compensation</u>. The directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors and may be paid a fixed sum for attendance at each meeting of the Board of Directors or a stated salary for service as director, payable in cash or securities. No such payment shall preclude any director from serving the Corporation in any other capacity and receiving compensation therefor. Members of special or standing committees may be allowed like compensation for service as committee members.

Section 3.12 <u>Interested Directors</u>. No contract or transaction between the Corporation and one or more of its directors or officers, or between the Corporation and any other corporation, partnership, association or other organization in which one or more of its directors or officers are directors or officers or have a financial interest, shall be void or voidable solely for this reason, or solely because the director or officer is present at or participates in the meeting of the Board of Directors or committee thereof which authorizes the contract or transaction, or solely because any such director's or officer's vote is counted for such purpose if: (i) the material facts as to the director's or officer's relationship or interest and as to the contract or transaction are disclosed or are known to the Board of Directors or the committee, and the Board of Directors or committee in good faith authorizes the contract or transaction by the affirmative votes of a majority of the disinterested directors, even though the disinterested directors be less than a quorum; or (ii) the material facts as to the director's or officer's relationship or interest and as to the contract or transaction are disclosed or are known to the stockholders entitled to vote thereon, and the contract or transaction is specifically approved in good faith by vote of the stockholders holding a majority of the voting power (the votes of the common or interested directors may be counted); and (iii) the contract or transaction is fair as to the Corporation as of the time it is authorized, approved or ratified by the Board of Directors, a committee thereof or the stockholders. Common or interested directors may be counted in determining the presence of a quorum at a meeting of the Board of Directors or of a committee which authorizes the contract or transaction as set forth herein.

**ARTICLE IV**

**<u>OFFICERS</u>**

Section 4.1 <u>General</u>. The officers of the Corporation shall consist of a chief executive officer, president, chief operating officer, chief financial officer and a secretary, each of whom shall be elected by the Board. Such other officers and assistant officers as may be deemed necessary may be elected or appointed by the Board. All officers must be natural persons and any natural person may hold two or more offices, except that in the event that the Corporation shall have more than one director, the offices of president and secretary shall be held by different persons.

Section 4.2 <u>Election, Qualification and Term of Office</u>. Each of the officers shall be elected by the Board. None of said officers need be a director. Except as hereinafter provided or subject to the express provisions of a contract authorized by the Board of Directors, each of said officers shall hold office from the date of his/her election until the next annual meeting of the Board and until his/her successor shall have been duly elected and qualified or until his or her removal or resignation.

Section 4.3 <u>Voting Securities Owned by the Corporation</u>. Powers of attorney, proxies, waivers of notice of meeting, consents and other instruments relating to securities owned by the Corporation may be executed in the name of and on behalf of the Corporation by the president or any vice president or any other officer authorized to do so by the Board of Directors and any such officer may, in the name of and on behalf of the Corporation, take all such action as any such officer may deem advisable to vote in person or by proxy at any meeting of security holders of any corporation in which the Corporation may own securities and at any such meeting shall possess and may exercise any and all rights and power incident to the ownership of such securities and which, as the owner thereof, the Corporation might have exercised and possessed if present. The Board of Directors may, by resolution, from time to time confer like powers upon any other person or persons.

Section 4.4 <u>Removal</u>. The Board of Directors shall have the right to remove, with or without cause, any officer of the Corporation.

Section 4.5 <u>Resignation</u>. Any officer may resign at any time by giving notice to the Board, the president or the secretary. Any such resignation shall take effect at the date of receipt of such notice or at any later date specified therein; and, unless otherwise specified therein, the acceptance of such resignation shall not be necessary to make it effective.

Section 4.6 <u>Vacancies</u>. The Board of Directors shall fill any office which becomes vacant with a successor who shall hold office for the unexpired term and until his/her successor shall have been duly elected and qualified or until his or her removal or resignation.

Section 4.7 <u>Powers and Duties</u>. The powers and duties of the respective corporate officers shall be determined by the Board.

Section 4.8 <u>Salaries</u>. The salaries of all executive officers of the Corporation shall be fixed by the Board of Directors or by such committee of the Board of Directors as may be designated from time to time by a resolution adopted by a majority of the Board of Directors.

Section 4.9 <u>Other Officers</u>. Such other officers as the Board of Directors may choose shall perform such duties and have such powers as from time to time may be assigned to them by the Board of Directors. The Board of Directors may delegate to any other officer of the Corporation the power to choose such other officers and to prescribe their respective duties and powers.

**ARTICLE V**

**<u>STOCK</u>**

Section 5.1 <u>Shares of Stock</u>. The shares of capital stock of the Corporation shall be represented by a certificate, unless and until the Board of Directors adopts a resolution permitting shares to be uncertificated. Notwithstanding the adoption of any such resolution providing for uncertificated shares, every holder of capital stock of the Corporation theretofore represented by certificates and, upon request, every holder of uncertificated shares, shall be entitled to have a certificate for shares of capital stock of the Corporation signed by, or in the name of the Corporation by, (a) the Chairman, the chief executive officer or the president, and (b) the chief financial officer or the secretary, certifying the number of shares owned by such stockholder in the Corporation.

Section 5.2 <u>Signatures</u>. Any or all of the signatures on a certificate may be a facsimile. In case any officer, transfer agent or registrar who has signed or whose facsimile signature has been placed upon a certificate shall have ceased to be such officer, transfer agent or registrar before such certificate is issued, it may be issued by the Corporation with the same effect as if such person were such officer, transfer agent or registrar at the date of issue.

Section 5.3 <u>Lost Certificates</u>. Unless otherwise provided in the Articles of Incorporation or these Bylaws, the Board of Directors may direct a new certificate or uncertificated shares be issued in place of any certificate theretofore issued by the Corporation alleged to have been lost, stolen or destroyed, upon the making of an affidavit of that fact by the person claiming the certificate of stock to be lost, stolen or destroyed. When authorizing such issuance of a new certificate or uncertificated shares, the Board of Directors may, in its discretion and as a condition precedent to the issuance thereof, require the owner of such lost, stolen or destroyed certificate, or such owner's legal representative, to identify the same in such manner as the Board of Directors shall require and/or to give the Corporation a bond in such sum as it may direct as indemnity against any claim that may be made against the Corporation on account of the alleged loss, theft or destruction of such certificate or the issuance of such new certificate or uncertificated shares.

Section 5.4 <u>Transfers</u>. Stock of the Corporation shall be transferable in the manner prescribed by applicable law and in these Bylaws. Transfers of stock shall be made only on the books of the Corporation, and in the case of certificated shares of stock, only by the person named in the certificate or by such person's attorney lawfully constituted in writing and upon the surrender of the certificate therefor, properly endorsed for transfer and payment of all necessary transfer taxes; or, in the case of uncertificated shares of stock, upon receipt of proper transfer instructions from the registered holder of the shares or by such person's attorney lawfully constituted in writing, and upon payment of all necessary transfer taxes and compliance with appropriate procedures for transferring shares in uncertificated form; <u>provided</u>, <u>however</u>, that such surrender and endorsement, compliance or payment of taxes shall not be required in any case in which the officers of the Corporation shall determine to waive such requirement. With respect to certificated shares of stock, every certificate exchanged, returned or surrendered to the Corporation shall be marked "Cancelled," with the date of cancellation, by the Secretary or Assistant Secretary of the Corporation or the transfer agent thereof. No transfer of stock shall be valid as against the Corporation for any purpose until it shall have been entered in the stock records of the Corporation by an entry showing from and to whom transferred.

Section 5.5 <u>Regulations</u>. The Board of Directors may make such rules and regulations as it may deem expedient, not inconsistent with these Bylaws, concerning the issue, transfer and registration of certificates for shares or uncertificated shares of the stock of the Corporation.

Section 5.6 <u>Dividend Record Date</u>. Subject to compliance with NRS 78.288 and 78.300, and the Articles of Incorporation, in order that the Corporation may determine the stockholders entitled to receive payment of any dividend or other distribution or allotment of any rights or the stockholders entitled to exercise any rights in respect of any change, conversion or exchange of stock, or for the purpose of any other lawful action, the Board of Directors may fix a record date, which record date shall not precede the date upon which the resolution fixing the record date is adopted, and which record date shall be not more than sixty (60) days prior to such action. If no record date is fixed, the record date for determining stockholders for any such purpose shall be at the close of business on the day on which the Board of Directors adopts the resolution relating thereto.

Section 5.7 <u>Record Owners</u>. The Corporation shall be entitled to recognize the exclusive right of a person registered on its books as the owner of shares to receive dividends, and to vote as such owner, and to hold liable for calls and assessments a person registered on its books as the owner of shares, and shall not be bound to recognize any equitable or other claim to or interest in such share or shares on the part of any other person, whether or not it shall have express or other notice thereof, except as otherwise required by law.

Section 5.8 <u>Transfer and Registry Agents</u>. The Corporation may from time to time maintain one or more transfer offices or agencies and registry offices or agencies at such place or places as may be determined from time to time by the Board of Directors.

Section 5.9 <u>Consideration for Shares</u>. The Board of Directors may authorize shares to be issued for consideration consisting of any tangible or intangible property or benefit to the Corporation including, without limitation, cash, services performed or other securities of the Corporation. When the Corporation receives the consideration for which the Board of Directors authorized the issuance of shares, such shares shall be fully paid and non-assessable (if non-assessable stock) and the stockholders shall not be liable to the Corporation or to its creditors in respect thereof.

**ARTICLE VI**

**<u>NOTICES</u>**

Section 6.1 <u>Notices</u>. Whenever written notice is required by the NRS, the Articles of Incorporation or these Bylaws, to be given to any director, member of a committee or stockholder, such notice may be given by mail in accordance with the NRS, and as permitted thereby, addressed to such director, member of a committee or stockholder, at such person's address as it appears on the records of the Corporation, with postage thereon prepaid, and such notice shall be deemed to be given at the time when the same shall be deposited in the United States mail. Written notice may also be given personally or by electronic transmission (by fax, electronic mail, or posting on electronic network).

Section 6.2 <u>Waivers of Notice</u>. Whenever any notice is required by applicable law, the Articles of Incorporation or these Bylaws, to be given to any director, member of a committee or stockholder, a waiver thereof in writing, signed by the person or persons entitled to notice, or by transmission of an electronic record by that person, whether before or after the time stated therein, shall be deemed equivalent thereto.

Attendance of a person at a meeting, present in person or represented by proxy, shall constitute a waiver of notice of such meeting, except where the person attends the meeting for the express purpose of objecting at the beginning of the meeting to the transaction of any business because the meeting is not lawfully called or convened. Neither the business to be transacted at, nor the purpose of, any Annual or Special Meeting of Stockholders or any regular or special meeting of the directors or members of a committee of directors need be specified in any written waiver of notice unless so required by law, the Articles of Incorporation or these Bylaws.

**ARTICLE VII**

**<u>GENERAL PROVISIONS</u>**

Section 7.1 <u>Dividends</u>. Dividends upon the capital stock of the Corporation, subject to the requirements of the NRS and the provisions of the Articles of Incorporation, if any, may be declared by the Board of Directors at any regular or special meeting of the Board of Directors (or any action by written consent in lieu thereof in accordance with Section 3.8 hereof), and may be paid in cash or in property other than shares. Before payment of any dividend, there may be set aside out of any funds of the Corporation available for dividends such sum or sums as the Board of Directors from time to time, in its absolute discretion, deems proper as a reserve or reserves to meet contingencies, or for purchasing any of the shares of capital stock, warrants, rights, options, bonds, debentures, notes, scrip or other securities or evidences of indebtedness of the Corporation, or for equalizing dividends, or for repairing or maintaining any property of the Corporation, or for any proper purpose, and the Board of Directors may modify or abolish any such reserve.

Section 7.2 <u>Disbursements</u>. All checks or demands for money and notes of the Corporation shall be signed by such officer or officers or such other person or persons as the Board of Directors may from time to time designate.

Section 7.3 <u>Fiscal Year</u>. The fiscal year of the Corporation shall be fixed by resolution of the Board of Directors.

Section 7.4 <u>Corporate Seal</u>. The corporate seal shall have inscribed thereon the name of the Corporation, the year of its organization and the words "Corporate Seal, Nevada". The seal may be used by causing it or a facsimile thereof to be impressed or affixed or reproduced or otherwise.

**ARTICLE VIII**

**<u>INDEMNIFICATION</u>**

Section 8.1 <u>Power to Indemnify in Actions, Suits or Proceedings othe</u>r <u>than Those by or in the Right of the Corporation</u>. Subject to Section 8.3 and to the fullest extent permitted by the NRS, the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation), by reason of the fact that such person is or was a director or officer of the Corporation, or is or was a director or officer of the Corporation serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe such person's conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which such person reasonably believed to be in or not opposed to the best interests of the Corporation, and, with respect to any criminal action or proceeding, had reasonable cause to believe that such person's conduct was unlawful.

Section 8.2 <u>Power to Indemnify in Actions, Suits or Proceedings by o</u>r <u>in the Right of the Corporation</u>. Subject to Section 8.3 and to the fullest extent permitted by the NRS, the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that such person is or was a director or officer of the Corporation, or is or was a director or officer of the Corporation serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection with the defense or settlement of such action or suit if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation; except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court in which such action or suit was brought deem proper.

Section 8.3 <u>Authorization of Indemnification</u>. Any indemnification under this Article VIII (unless ordered by a court) shall be made by the Corporation only as permitted by the NRS and authorized in the specific case upon a determination that indemnification of the present or former director or officer is proper in the circumstances because such person has met the applicable standard of conduct set forth in Section 8.1 or Section 8.2, as the case may be. Such determination shall be made, with respect to a person who is a director or officer at the time of such determination, (i) by a majority vote of the directors who are not parties to such action, suit or proceeding, even though less than a quorum, or (ii) by a committee of such directors designated by a majority vote of such directors, even though less than a quorum, or (iii) if there are no such directors, or if such directors so direct, by independent legal counsel in a written opinion or (iv) by the stockholders. Such determination shall be made, with respect to former directors and officers, by any person or persons having the authority to act on the matter on behalf of the Corporation. To the extent, however, that a present or former director or officer of the Corporation has been successful on the merits or otherwise in defense of any action, suit or proceeding described above, or in defense of any claim, issue or matter therein, such person shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by such person in connection therewith, without the necessity of authorization in the specific case.

Section 8.4 <u>Good Faith Defined</u>. For purposes of any determination under Section 8.3, a person shall be deemed to have acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the Corporation, or, with respect to any criminal action or proceeding, to have had no reasonable cause to believe such person's conduct was unlawful, if such person's action is based on the records or books of account of the Corporation or another enterprise, or on information supplied to such person by the officers of the Corporation or another enterprise in the course of their duties, or on the advice of legal counsel for the Corporation or another enterprise or on information or records given or reports made to the Corporation or another enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Corporation or another enterprise. The provisions of this Section 8.4 shall not be deemed to be exclusive or to limit in any way the circumstances in which a person may be deemed to have met the applicable standard of conduct set forth in Section 8.1 or Section 8.2, as the case may be.

Section 8.5 <u>Indemnification by a Court</u>. Notwithstanding any contrary determination in the specific case under Section 8.3, and notwithstanding the absence of any determination thereunder, any director or officer may apply to any court of competent jurisdiction in the State of Nevada for indemnification to the extent otherwise permissible under Section 8.1 or Section 8.2. The basis of such indemnification by a court shall be a determination by such court that indemnification of the director or officer is proper in the circumstances because such person has met the applicable standard of conduct set forth in Section 8.1 or Section 8.2, as the case may be. Neither a contrary determination in the specific case under Section 8.3 nor the absence of any determination thereunder shall be a defense to such application or create a presumption that the director or officer seeking indemnification has not met any applicable standard of conduct. Notice of any application for indemnification pursuant to this Section 8.5 shall be given to the Corporation promptly upon the filing of such application. If successful, in whole or in part, the director or officer seeking indemnification shall also be entitled to be paid the expense of prosecuting such application.

Section 8.6 <u>Expenses Payable in Advance</u>. Expenses (including attorneys' fees) incurred by a director or officer in defending any civil, criminal, administrative or investigative action, suit or proceeding shall be paid by the Corporation in advance of the final disposition of such action, suit or proceeding upon receipt of an undertaking by or on behalf of such director or officer to repay such amount if it shall ultimately be determined that such person is not entitled to be indemnified by the Corporation as authorized in this Article VIII. Such expenses (including attorneys' fees) incurred by former directors and officers or other employees and agents may be so paid upon such terms and conditions, if any, as the Corporation deems appropriate.

Section 8.7 <u>Nonexclusivity of Indemnification and Advancement of Expenses</u>. The indemnification and advancement of expenses provided by, or granted pursuant to, this Article VIII shall not be deemed exclusive of any other rights to which those seeking indemnification or advancement of expenses may be entitled under the Articles of Incorporation, these Bylaws, agreement, vote of stockholders or disinterested directors or otherwise, both as to action in such person's official capacity and as to action in another capacity while holding such office, it being the policy of the Corporation that indemnification of the persons specified in Section 8.1 and Section 8.2 shall be made to the fullest extent permitted by law. The provisions of this Article VIII shall not be deemed to preclude the indemnification of any person who is not specified in Section 8.1 or Section 8.2 but whom the Corporation has the power or obligation to indemnify under the provisions of the NRS, or otherwise.

Section 8.8 <u>Insurance</u>. The Corporation may purchase and maintain insurance on behalf of any person who is or was a director or officer of the Corporation, or is or was a director or officer of the Corporation serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred by such person in any such capacity, or arising out of such person's status as such, whether or not the Corporation would have the power or the obligation to indemnify such person against such liability under the provisions of this Article VIII.

Section 8.9 <u>Certain Definitions</u>. For purposes of this Article VIII, references to "the Corporation" shall include, in addition to the resulting corporation, any constituent corporation (including any constituent of a constituent) absorbed in a consolidation or merger which, if its separate existence had continued, would have had power and authority to indemnify its directors or officers, so that any person who is or was a director or officer of such constituent corporation, or is or was a director or officer of such constituent corporation serving at the request of such constituent corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, shall stand in the same position under the provisions of this Article VIII with respect to the resulting or surviving corporation as such person would have with respect to such constituent corporation if its separate existence had continued.

The term "another enterprise" as used in this Article VIII shall mean any other corporation or any partnership, joint venture, trust, employee benefit plan or other enterprise of which such person is or was serving at the request of the Corporation as a director, officer, employee or agent. For purposes of this Article VIII, references to "fines" shall include any excise taxes assessed on a person with respect to an employee benefit plan; and references to "serving at the request of the Corporation" shall include any service as a director, officer, employee or agent of the Corporation which imposes duties on, or involves services by, such director or officer with respect to an employee benefit plan, its participants or beneficiaries; and a person who acted in good faith and in a manner such person reasonably believed to be in the interest of the participants and beneficiaries of an employee benefit plan shall be deemed to have acted in a manner "not opposed to the best interests of the Corporation" as referred to in this Article VIII.

Section 8.10 <u>Survival of Indemnification and Advancement of Expenses</u>. The indemnification and advancement of expenses provided by, or granted pursuant to, this Article VIII shall, unless otherwise provided when authorized or ratified, continue as to a person who has ceased to be a director or officer and shall inure to the benefit of the heirs, executors and administrators of such a person.

Section 8.11 <u>Limitation on Indemnification</u>. Notwithstanding anything contained in this Article VIII to the contrary, except for proceedings to enforce rights to indemnification (which shall be governed by Section 8.5), the Corporation shall not be obligated to indemnify any director or officer (or his or her heirs, executors or personal or legal representatives) or advance expenses in connection with a proceeding (or part thereof) initiated by such person unless such proceeding (or part thereof) was authorized or consented to by the Board of Directors.

Section 8.12 <u>Indemnification of Employees and Agents</u>. The Corporation may, to the extent authorized from time to time by the Board of Directors, provide rights to indemnification and to the advancement of expenses to employees and agents of the Corporation similar to those conferred in this Article VIII to directors and officers of the Corporation.

**ARTICLE IX**

**<u>MISCELLANEOUS</u>**

Section 9.1 <u>Acquisition of Controlling Interest Statute Opt–Out</u>. The provisions of NRS 78.378 to 78.3793, inclusive, shall not apply to the Corporation or to an acquisition of a "controlling interest" (as defined in NRS 78.3785).

**ARTICLE X**

**<u>AMENDMENTS</u>**

Section 10.1 <u>Amendments</u>. These Bylaws may be altered, amended or repealed at any meeting of the Board of Directors, provided notice of the proposed change was given in the notice of the meeting not less than two days prior to the meeting. Notwithstanding the foregoing sentence, these Bylaws may be amended or repealed in any respect, and new Bylaws may be adopted, in each case by the affirmative vote of the holders of at least fifty (50%) of the outstanding voting power of the Corporation, voting together as a single class.

Section 10.2 <u>Entire Board of Directors</u>. As used in this Article X and in these Bylaws generally, the term "entire Board of Directors" means the total number of directors which the Corporation would have if there were no vacancies.

**CERTIFICATION**

The undersigned, as the duly elected Secretary of WUND Healing Biopharmaceuticals, Inc., a Nevada corporation (the "Corporation"), does hereby certify that the Board of Directors of the Corporation adopted the foregoing Bylaws as of August 20, 2019.

---

| |
|:---|
| */s/ Yvonne Luell* |
| Yvonne Luell, Secretary |

---

## Ex1A-6

**EXHIBIT 6.1**

CONFIDENTIAL

**RESTATED AND AMENDED**

**PRODUCT LICENSE AND COMMERCIALIZATION AGREEMENT**

This Agreement ("Agreement") is made and entered into on December 21, 2022 by and between **Zhittya Genesis Medicine, Inc. ("ZGM"),** a Delaware corporation, with its principal place of business located at 3017 Carbondale Street, Las Vegas, Nevada 89135, and **Wund Healing BioPharmaceuticals Inc. ("WUND"),** a Nevada corporation, with its principal place of business located at 9501 Royal Windsor Avenue, Las Vegas, NV 89149.

WHEREAS, ZGM is the owner of and has the right to grant licenses with respect to certain Technology (as hereinafter defined), the Trademark (as hereinafter defined), and the Product (as hereinafter defined); and

WHEREAS, WUND wished to obtain the exclusive right to Commercialize the Product (as hereinafter defined) as ZGM's exclusive distributor of such Product in the Territory (as hereinafter defined), and to utilize ZGM's Trademark (as hereinafter defined), and to identify the Product in connection with Commercialization in the Territory, and ZGM wishes to grant such rights to WUND on the terms and conditions set forth in this Agreement; and

WHEREAS, ZGM wished to grant to WUND an exclusive license to the Technology and regulatory approvals and the Trademark solely for use in Commercializing the Product in the Territory related to the Licensed Use (as hereinafter defined), and WUND wishes to receive such license, on the terms and subject to the conditions set forth in this Agreement; and ZRM and WUND entered into a Product License and Commercialization Agreement ("Base Agreement") dated May 17, 2016; and Amended on October 30, 2019; and.

WHEREAS, changes in circumstances and planning caused the Parties (hereinafter defined) to make certain revisions and adjustments to the terms of their deal; and the Parties agreed, for their mutual convenience and the avoidance of any misunderstanding, to execute a new document confirming and restating their mutual understanding with the necessary changes and additions included therein.

NOW, THEREFORE, in consideration of the mutual covenants and agreements contained herein, and other good and valuable consideration, the receipt and legal sufficiency of which are hereby mutually acknowledged, ZGM and WUND hereby agree as follows:

This Agreement amends and replaces in its entirety the previous Base Agreement as Amended by the Parties reflecting revised planning, progress to date and changed circumstances.

CONFIDENTIAL

**Article 1. DEFINITIONS**

The following terms, whether used in the singular or plural, shall have the meanings assigned to them below for purposes of this Agreement:

1.1. "**Affiliate**" of a Party means any corporation or other business entity directly or indirectly controlled by, or under common control with, such Party. As used herein, the term "control" means possession of the power to direct, or cause the direction of the management and policies of a corporation or other entity whether through the ownership of voting securities, by contract or otherwise. In the case of a corporation, the direct or indirect ownership of fifty percent (50%) or more, or the ownership percentage as required under local jurisdiction, of its outstanding voting shares or the ability otherwise to elect a majority of the board of directors or other managing authority of the entity shall in any event be deemed to confer control. However, the direct or indirect ownership of a lesser percentage of such shares shall not necessarily preclude the existence of control.

1.2. **"Agreement**" means this agreement, together with all appendices, addenda, exhibits and schedules hereto, as the same may be amended or supplemented in accordance with the terms hereof.

1.3. **"Applicable Law"** means all laws (including common law and court decisions), ordinances, rules and regulations applicable to this Agreement or the activities contemplated hereunder, including without limitation the US Federal Food, Drug, and Cosmetic Act, the Canadian Food and Drugs Act the General Health Law in Mexico, and all other applicable national and sub-national statutes and regulations including without limitation those concerning anti-trust, fair trade, consumer protection, official or other corruption, anti-kickback, tax and relating to requirements concerning Product, Development, and Commercialization activities in the Territory.

1.4. **"Commercialize"** or **"Commercialization"** means any and all activities arising from or related to marketing, promoting, manufacturing, packaging and distributing approved Product, offering for sale and selling of Product in the Territory, and any and all direct and indirect commercial activities necessary, desirable, and/or appropriate to maximize revenues for each Product in the Territory. Such necessary, desirable, and/or appropriate activities include but are not limited to sales, marketing, medical education, developing relationships with relevant stakeholders, advocacy efforts, promotion and support activities for patients, caregivers, providers, and payers.

1.5. **"Commercially Reasonable Efforts"** of a Party means those efforts consistent with the exercise of its prudent business and scientific or technical judgment as applied to other commercialization efforts for products of similar scientific and commercial potential within comparable product lines in the pharmaceutical industry.

1.6. **"Confidential Information"** has the meaning set forth in Section 9.1 hereof.

1.7. **"Coordination Committee"** means the committee consisting of appointed participants from ZGM and WUND as described in Section 5.1 hereof.

1.8. **"Cost of Goods"** means the price at which WUND purchases Product from ZGM**.**

CONFIDENTIAL

1.9. **"CSO"** means a contract sales organization that is engaged by WUND to perform services to assist in promoting or marketing the Product.

1.10. **"Development"** or **"Develop"** means preclinical and clinical drug development activities, including, among other things: test methodology and stability testing, toxicology, formulation, process development, manufacturing scale-up, manufacturing development, quality assurance/quality control, statistical analysis, report writing, clinical studies, regulatory affairs, product approval and registration. For the purposes of this Agreement, Development shall include, without limitation, Pre-Phase I, Phase I, Phase II, Phase IIB, Phase III, Phase IIIB and Phase IV Clinical Trials. When used as a verb, "Develop" means to engage in Development.

1.11. **"Dollars"** or **"$"** means United States Dollars.

1.12. "**Effective Date**" of this Agreement means January 1, 2023.

1.13 **"Good Manufacturing Practices"** ("**GMP")** means all current good manufacturing practices as defined under 21 USC ss. 351(a)(2)(B) and the FDA regulations promulgated thereunder, as are in effect at the time.

1.14. "**GAAP"** shall mean the then current applicable Generally Accepted Accounting Principles in the United States consistently applied as recognized or accepted by the United States Securities and Exchange Commission and the Financial Accounting Standards Board. As used herein, "GAAP" shall also include cost accounting principles and procedures that are generally accepted in the United States.

1.15. **"Government Authority"** ("**GA**") means any national, state, local or foreign governmental agency, office, person or body with jurisdiction and responsibility to act on a matter under then Applicable Law.

1.16. **"Indication"** means the basis for initiation of a treatment for a disease or of a diagnostic test; may be furnished by a knowledge of the cause (causal indication), by the symptoms present (symptomatic indication), or by the nature of the disease (specific indication).

1.17. **"Information"** means all information including, but not limited to, screens, models, inventions, practices, methods, knowledge, know-how, skill, experience, test data including pharmacological, toxicological and clinical test data, analytical and quality control data, marketing, pricing, distribution, costs, sales, manufacturing data, and patent and legal data or descriptions (to the extent disclosure thereof would not result in loss or waiver of privilege or similar protection) and methods as each of the foregoing relate to the Product and is controlled by a Party or its Affiliates.

1.18. **"Injectable, Infusion and Intranasal Drugs"** means ZGM's Product applications that are delivered under the skin, directly into a muscle, directly into the blood stream, directly into heart muscle via catheter delivery, directly into the brain (intracerebroventricular), delivered intranasally or inhaled for respiratory disorders for Licensed Use containing recombinant human fibroblast growth factor-1 (FGF-1) and any current or future modifications to the active FGF-1 component, formulation, content and packaging of that product. ZGM's portfolio of Injectable and Infusion Drugs includes the potential drug treatment for the remediation and/or cure of the following medical indications: (1) Parkinson's Disease; (2) Stroke; (3) Multi-infarct Dementia; (4) Coronary Heart Disease; (5) Peripheral Artery Disease; (6) Lumbar Ischemia; (7) Chronic Traumatic Encephalopathy (CTE); (8) Traumatic Brain Injury (TBI); (9) Alzheimer's Disease; (10) Huntington's Disease; (11) Amyotrophic Lateral Sclerosis (ALS); (12) Chronic Depression, (13) Post Traumatic Stress Disorder (PTSD), (14) Multiple Sclerosis (MS) and (15) Multiple Systems Atrophy (MSA). If ZGM discovers additional potential medical indications that may be amenable to treatment with FGF-1 by injection or infusion, these indications can be added to the Product covered by this Agreement with the written agreement of the Parties.

CONFIDENTIAL

1.19. **"Label"** means the Regulatory Approved content and format for prescribing and use of the Product for a specific disease or condition. Additionally, a Product may have been granted by Government Authority an additional Indication(s) (as hereinafter defined) for its use, with such Indication specifying the specific additional uses of the drug that have been approved by the Government Authority for an additional disease or condition. A Product may receive multiple Indications in addition to its original Labeling.

1.20. **"Licensed Use"** means use of the Product for those medical indications for which Regulatory Approval has been granted as defined in the Product Registration and the Label.

1.21. "**Marketing Plan(s)"** shall mean a marketing plan or plans for specified periods which set forth promotion, Detailing and marketing tactics and strategies related to the Commercialization of Product in the Territory.

1.22. **"Milestone Payments"** means those payment obligations of WUND arising from or related to certain actions or events contained in Article 3 hereof and listed in detail in Exhibits A and B of this Agreement.

1.23. "**Operating Profit**" means net revenues (gross revenues less returns), less all direct costs associated with Commercialization of the Product, including but not limited to direct sales costs, direct marketing costs, direct Product cost, direct Product support costs, etc. Direct costs specifically exclude executive salaries and corporate overhead costs that do not directly relate to Commercialization (such as facility expenses). Net revenues less all direct costs shall equal Operating Profit.

1.24. **"Party"** means ZGM or WUND and, when used in the plural, Parties shall mean both ZGM and WUND.

1.25. **"Person"** means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership, limited liability company, or other business entity, or any government agency, political subdivision, or any official or agent thereof.

1.26. **"Phase I Clinical Trial"** or **"Phase I"** means the introduction of an investigational new drug ("IND") to an initial pool of humans. These studies are closely monitored, and are usually conducted in healthy volunteer subjects. These studies are designed to determine the metabolic and pharmacologic actions of the drug in humans, any side effects associated with dosage levels, and, if possible, to obtain initial data on effectiveness as defined in 21 C.F.R. ss. 312.21(a) for the FDA and equivalent procedures and requirements in other countries. During Phase I, sufficient information about the drug's pharmacokinetics and pharmacological effects should be obtained to permit the design of well-controlled, scientifically valid, Phase II studies.

CONFIDENTIAL

1.27. **"Phase II Clinical Trial"** or **"Phase II"** means a human clinical trial conducted for trials of a Product usually on a larger number of patients with the condition meant to be treated. This is for the purposes of collecting data on dosage, evaluating safety and collecting preliminary information regarding efficacy in the proposed therapeutic indication, as defined in 21 C.F.R. ss. 312.21(b) for the FDA, and equivalent procedures in other countries. Phase II studies are sometimes divided into Phase IIA and Phase IIB. Phase IIA is designed to assess dosing requirements and Phase IIB is designed to study efficacy (how well the drug works at the prescribed dosage).

1.28. **"Phase III Clinical Trial"** or **"Phase III"** means that portion of the clinical development program beyond Phase II, with a larger scale clinical studies of a sufficient number of patients to confirm the clinical efficacy of a Product for one or more indications and its safety, as more fully defined in the United States in 21 C.F.R. ss. 312.21(c) for the FDA, and equivalent procedures in other countries. In some instances, a Phase IIIB trial may be performed near the time of approval to accumulate additional findings which were requested by the Government Authority and may be required as a condition of final Regulatory Approval for public use.

1.29. **"Pre-Phase I"** means that portion of the development program which starts with the selection of a compound for development into a Product or the beginning of toxicological studies relating to such compound. Pre-Phase I includes, but is not limited to, preliminary toxicological, pharmacological and any other studies required by Applicable Law, the results of which may be required for filing, as well as for ZGM product formulation and manufacturing development necessary to obtain the permission of Government Authority to begin and continue subsequent further study or formal clinical trials. Toxicology as used in this definition includes full-scale toxicology using current Good Manufacturing Practices ("cGMPs") material for obtaining Regulatory Approval to commence a formal Phase I Clinical Trial.

1.30. **"Pre-Clearance Period"** has the meaning set forth in Section 5.11.

1.31. "**Product**" means ZGM's various product applications including the Wound Healing drug treatment and Injectable and Infusion Drugs as defined in this Agreement for Licensed Use containing recombinant human fibroblast growth factor-1 (FGF-1) and any current or future modifications to the active FGF-1 structure, formulation, content and packaging of that product. All appropriate dosing concentrations of the Product, as established by clinical testing, are also covered by this Agreement. The lead Product in ZGM's Wound Healing portfolio is the drug to treat diabetic foot ulcers. ZGM will also be pursuing additional FDA-approved indications ("Indications") for the lead Product, which would use the Product in the same formulation for treating other wound types, including but not limited to surgical wounds, gynecological wounds, burns, venous leg ulcers and pressure wounds. Additionally, ZGM will likely have one or more additional Product(s) in its Wound Healing portfolio that treat different wound types and may require a different formulation. Also, covered under this Agreement is a Product containing FGF-1, which may be developed for male pattern baldness. Any such additional Products may each have additional Indications. For the purposes of this Agreement, the term "Product" shall incorporate all Products with Regulatory Approval and all Indications, if any, in ZGM's Wound Healing and Injectable and Infusion Drugs portfolios and all prospective Products and Indications.

CONFIDENTIAL

1.32. **"Product Registration"** means the formal Regulatory Approval by the US FDA or other Government Authority for the sale or distribution of Product to the public.

1.33. **"Regulatory Approval"** means the official clearance, authorization, sanction, consent, or agreement of an action or thing by a Government Authority.

1.34. "**Second-Generation"** drug means a structural change to the composition of human FGF-1 that imparts an improvement to the biological activity, safety, *in vivo* stability or shelf-life of the molecule. If applicable, patent protection would be sought for these novel FGF-1 structures.

1.35. "**Technology**" means ZGM's information including without limitation research and clinical data, know-how, methods, processes, research and clinical results, and Regulatory Approval related to the Product, which is related to the Development, promotion, marketing, distribution and sale of the Product for the Licensed Use in the Territory, and which is provided to WUND as determined by ZGM pursuant this Agreement.

1.36. "**Territorial Rights"** means the exclusive license granted by this Agreement to Commercialize the Product in the Territory for the Term.

1.37. "**Territory**" means within the United States of America and Canada and all territories and possessions thereof where WUND may exercise its Territorial Rights for all prescription uses, including (but not limited to) hospitals, clinics, doctors' offices, pharmacies, etc.

1.38. "**Trademark**" means any word, phrase, symbol, design, mark or combination thereof identifying the goods and services of ZGM, currently or in the future registered, filed or used by ZGM in the future with respect to the Product during the term of this Agreement, as well as any trade name, drug name and logo registered, filed, or used by ZGM with respect to the Product.

1.39. **"Wound Healing"** means the drug treatment for the potential remediation and/or cure of the following medical indications: (1) diabetic foot ulcers; (2) venous ulcers; (3) topical surgical wounds (i.e., C-sections and cosmetic surgeries: (4) pressure wounds (i.e., bedsores); (5) internal surgical wounds (anastomoses); (6) burns; and (7) male pattern baldness. If ZGM discovers additional potential medical indications that may be amenable to treatment with FGF-1 by injection or infusion, these indications can be added to the Product covered by this Agreement with the written agreement of the Parties.

1.40. **"ZGM Affiliates"** means a subsidiary, brother/sister or parent company of ZGM or a contracting company assisting ZGM in the performance of this Agreement.

CONFIDENTIAL

**Article 2. TERM, PRODUCT APPROVAL, EXCLUSIVITY**

2.1. This Agreement shall commence as of the Effective Date, and, unless sooner terminated as provided hereinafter, this Agreement shall continue in force for thirty (30) years from the Effective Date. This Agreement shall then automatically be renewed for an additional single period of thirty (30) years.

2.2. ZGM agrees to use commercially reasonable efforts consistent with its and its suppliers and contractors' normal business practices, which shall in no event be less than efforts standard in the pharmaceutical industry, to Develop the Product for the Licensed Use. ZGM shall continue its development of the Product to obtain Regulatory Approval for the identified Product applications and will conduct necessary required additional studies and trials with the object of obtaining such approval for each prospective Product application.

2.3. ZGM shall be responsible for all actions and decisions regarding regulatory matters relating to or involving obtaining Regulatory Approval of Product applications from a Government Authority. ZGM shall, with respect to matters (a) act as liaison with the appropriate regulatory authorities; (b) prepare and make all necessary submissions, (c) conduct and monitor any required studies or trials; and (d) obtain such Regulatory Approvals as reasonably deemed necessary by ZGM. ZGM shall have sole responsibility for, and shall bear the cost of preparing, all regulatory filings and related submissions with respect to the Product. Unless otherwise specifically agreed in writing by ZGM, all Regulatory Approvals shall be obtained by and in the name of ZGM, solely owned by ZGM, and ZGM shall be the only interface with and otherwise handle all interactions and communications with Government Authority concerning the Product, except to the extent expressly provided otherwise in this Agreement.

2.4. Pursuant to the terms of this Agreement, ZGM hereby grants WUND the exclusive license:

(a) to Commercialize the Product in the Territory, and (b) to use the Trademark and Technology in the Territory solely in connection with the Commercialization of the Product, for the Licensed Use. ZGM's retained rights in the Territory include, the right to make, have made, transport, and use the Product for marketing, sale or distribution outside the Territory, as well as to conduct any research and development activity. WUND shall not subcontract or delegate any of its performance or responsibilities under this Agreement without the express written approval of ZGM. WUND shall not engage in any business other than the promotion, marketing, and distribution of Product from the date of the first Government Approval of Product for public sale or distribution in the Territory. WUND shall never during the term of this Agreement, Commercialize, promote, or support any third-party drug, treatment, or device that competes with any Licensed Use.

2.5. ZGM shall not directly or indirectly market sell or distribute Product to: any other person or entity for Product Commercialization in the Territory or elsewhere; ZGM retains the right to ship Product through distribution channels in the Territory, as long as such shipment is solely in connection with providing Product to ZGM Affiliates for sale outside the Territory or to WUND within the Territory. ZGM's retained rights in the Territory include, the right to make, have made, transport, and use the Product for marketing, sale or distribution outside the Territory, as well as to conduct any research and development activity.

CONFIDENTIAL

2.6. WUND shall not directly or indirectly Commercialize, market, promote, encourage, exploit, offer for sale or sell, or otherwise dispose of the Product: (a) outside the Territory; (b) for use outside the Territory; or (c) inside the Territory for use other than as expressly permitted by this Agreement, without the prior written consent of ZGM. It is acknowledged by the Parties, however, that certain sales of the Product by WUND to a Territory Government, and its subdivisions thereof, may result in the Product being shipped to military bases and other government installations that are outside the area of the Territory and such sales shall not constitute a breach of this Agreement as long as ZGM determines that there is no effect on the market for the Product in these new locations. Such sales shall contain express restrictions on any resale if required by ZGM. ZGM shall use Commercially Reasonable Efforts to ensure that its Affiliates shall not sell the Product, directly or indirectly, to third parties in the Territory for commercial sale.

2.7. Without the prior written consent of ZGM, WUND shall not grant to any third party any rights to act as CSO or to market, promote, advertise, sell or distribute the Product or enter into any agreement or arrangement with respect to Commercializing or promoting the Product. The foregoing notwithstanding, WUND may employ the services of a third party in (a) the detailing of the Product to healthcare professionals in the Territory, so long as any sales representative deployed by such third party for WUND for such purpose shall at such time not detail products that are competitive with the Product, (b) the receiving, warehousing and shipping of the Product for WUND, or (c) the acceptance of orders, generation of invoices and collection and management of receivables with respect to WUND's sales of the Product

2.8. WUND shall not at any time do, and neither shall WUND permit its agents or representatives to do, any act in violation of the Product Registration for any of the Product in the Territory. In the event that any filings are required to be made with or Regulatory Approval required to be obtained in order to sell the Product to WUND or for WUND to initiate Commercialization of Product in the Territory, WUND shall cooperate fully with ZGM to ensure that such filings and approvals are obtained or made as expeditiously as reasonably practicable. WUND shall not alter in any manner any of the Product or its packaging as sold to it by ZGM hereunder and shall resell the Product and packaging without alteration in the form sold to it by ZGM.

2.9. If, during the term of this Agreement, ZGM may develop or otherwise acquire any modifications to the FGF-1 molecule or formulation of the Product including Second Generation FGF-1 drugs, such modifications shall be in the sole and exclusive property and legal interest of ZGM; provided, that WUND shall have the right to become ZGM's exclusive licensee in the Territory with respect to those modifications, under substantially the same terms as those herein except to the extent such terms are inconsistent with any Product modification.

2.10. Except as otherwise expressly provided in this Agreement, under no circumstances shall a Party, as a result of this Agreement, obtain any ownership or other legal interest in or other right to any technology, trade secrets, know-how, patents, pending patent applications, products, or biological materials of the other Party, including items owned, controlled or developed by the

other Party, or transferred by the other Party to said Party, at any time pursuant to this Agreement.

CONFIDENTIAL

2.11. The Parties each hereby agrees to use Commercially Reasonable Efforts to take, or cause to be taken, all actions and to do, or cause to be done, all things necessary or proper to make effective the transactions contemplated by this Agreement, including such actions as may be reasonably necessary to obtain approvals and consents of government bodies.

**Article 3. FINANCIAL TERMS**

3.1. In consideration for WUND's acquisition of the Territorial Rights under this Agreement, WUND shall transfer to ZGM:

**1) $1,500,000** in cash, and

**2) 7,000,000 shares** designated as Series A-1 Convertible Preferred Stock (the "Preferred Stock") of 3,500,000 shares and Series A-2 Convertible Preferred Stock (the "Preferred Stock") of 3,500,000 for a total of 7,000,000 shares of Convertible Preferred Shares for Series A-1 and Series A-2. Each share of Series A-1 is convertible into 1 share of common stock and each share of Series A-2 is convertible into 1 share of common stock. The Preferred Stock shall not be redeemable by WUND at any time. There is no liquidation preference for the Preferred Stock ("Pfd").

**3)** ZRM as holders of the Pfd shall be entitled to receive dividends, out of any assets legally available therefor, prior and in preference to any declaration or payment of any dividend (payable other than in Ordinary Stock or other securities and rights convertible into or entitling the holder thereof to receive, directly or indirectly, additional Ordinary Stock of WUND) on the Ordinary Stock of WUND, payable when, as and if declared by, and in the sole discretion of, the Board of Directors of the Company. Such dividends shall not be cumulative. Any dividends or distributions shall be distributed among all holders of Ordinary Stock and Preferred Stock in proportion to the number of Ordinary Shares that would be held by each such holder if all Preferred Stock were converted to Ordinary Stock at the then effective conversion rate.

**4)** ZGM agrees that the above WUND Convertible Preferred Stock Series A-1 and A-2 shall not be convertible to Common Stock until a period of twenty-four (24) months from the date of the first underwritten or other public offering of shares of Common Stock of WUND has elapsed. Series A-2 preferred stock shall have an additional restriction that those preferred shares cannot be converted until the 30-Day Volume Weighted Average Price ("VWAP") exceeds $20.00.

CONFIDENTIAL

**5)** ZGM also agrees that it cannot convert Preferred Stock that would cause its ownership to exceed 4.99% of the number of shares of the Common Stock outstanding immediately after a conversion of its Preferred Stock. Upon the sale of the ownership or controlling interest in WUND, if not converted earlier, the Series A-1 shall automatically convert and the Series A-2 will only convert if the sale price exceeds $20.00 per share for the issued and outstanding shares of Common Stock. Upon any liquidation, dissolution or winding-up of WUND, whether voluntary or involuntary, the Preferred Stockholders shall be entitled to receive out of the assets, whether capital or surplus, of WUND the same amount that a holder of Common Stock would receive if the Preferred Stock were fully converted to Common Stock which amounts shall be paid pari passu with all holders of Common Stock.

**6)** WUND shall also pay ZGM up to **$75 million** in total **Milestone Payments** for ZGM attaining or fulfilling certain milestones during the process of clinical development and obtaining Regulatory Approval of each **Wound Healing** drug. The milestones and associated payments are identified in **<u>Exhibit A</u>** attached to this Agreement. The milestone payments for the clinical development of the Wound Healing drugs in the portfolio shall be paid in cash or shares of WUND at the then market price of the shares at WUND's sole discretion. The then market price of the shares is defined as the average closing price of WUND shares for the preceding 20 trading days. When ZGM notifies WUND in writing of a Milestone accomplishment, WUND shall have 15 days to agree or disagree and notify ZGM. Once agreed, cash or shares shall be paid to ZGM within 15 days. All Exhibits attached hereto constitute a part of this Agreement.

**7)** If any Milestones Payments are earned by ZGM prior to WUND common stock being publicly traded, then WUND's Milestone Payment obligations shall commence 90 days after the successful closing of the WUND IPO or public sale of shares. ZGM's cumulative earned Milestones may also be satisfied by the payment in WUND shares 60 days after the shares are publicly traded, and shall be valued at the average closing price of the 20 preceding trading days. If payment of WUND shares would take ZGM's ownership to 5% of WUND's outstanding shares, WUND shall segregate such shares and defer the payment until ZGM can in writing verify that payment will not result in its ownership of greater than 4.99% of the WUND outstanding shares. If a Milestone relates to official approval/action by a Government Authority then the documentation of such official action having been taken shall be conclusive and binding on the Parties that the Milestone has been met. If WUND otherwise decides that a Milestone has not been achieved, then the matter shall be referred to a resolution committee of two WUND and two ZGM representatives and a fifth neutral person, who will be agreeable to the Parties. If the Parties cannot agree on the neutral person with in a period of two weeks, then the neutral person shall be a neutral appointed by WUND. Once WUND has paid ZGM $75 million in Milestone Payments, WUND shall have fully satisfied its obligation to ZGM regarding Milestone Payments for Wound Healing Drugs.

3.2. For **Wound Healing Drugs** WUND shall also pay to ZGM **50%** of the Operating Profit ("Fee") from its sales or distribution of each Wound Healing drug under this Agreement. The Parties shall execute an Accounting Standards and Definitions amendment to this Agreement within 90 days of the Effective Date unless extended by consent of the Parties and that may include a more detailed definition of Operating Profit. WUND shall pay the 50% Fee to ZGM within 15 days of each month-end. In the event of an operating loss at WUND, then WUND shall resume monthly Operating Profit payments to ZGM.

CONFIDENTIAL

3.3. For **Injectable and Infusion Drugs** WUND shall pay up to a total of $**300 million** US Dollars in Milestone Payments for ZGM attaining or fulfilling Milestones during the process of clinical development and obtaining Regulatory Approval of any Injectable and Infusion Drugs as set forth in the attached **<u>Exhibit B.</u>** WUND shall also pay to ZGM a Fee of **80%** of the Operating Profit received by WUND arising from or related to the sale or distribution of any Injectable and Infusion Drug.

3.4. There will be different availability of Product for conducting a clinical study or treatment in various ZGM licensed territories because of the timing of or differences in of Government Approvals. There thus may be the opportunity for study participation or treatment elsewhere for patients who otherwise would be accommodated in the territory of WUND or vice-versa **("cross-border operation").** In such event WUND patients may receive approved treatment in another ZGM licensed territory or WUND may treat patients from outside the WUND territory. All ZGM Licensees shall have similar language in their agreements and all shall fully cooperate with this effort in promoting the availability of or providing such treatment or participation.

3.5. The net revenues of any such joint cross-border operations shall be divided equally between the two Licensees involved or then with ZGM if only one licensee is involved for clinical study or testing of the Product in the Territory. The revenue from these cross-border operations shall not apply towards the Milestones as set forth in Exhibits A and B hereinafter. Any cross-border operations shall also be subject to the payment of the following Fees for such use of the Product:

a) There shall be no Fee payable by WUND as Licensee from the first $3 million of its cross-border Operating Profits (revenues less marketing and cross border costs).

b) WUND shall pay ZGM a Fee of 50% of its cross-border Operating Profits from $3 million to $10 million.

c) WUND shall pay ZGM a Fee of 80% of its cross-border Operating Profits after Operating Profits of $10 million have been reached.

3.6. All such cross-border treatments shall be organized and coordinated by ZGM with WUND and the other ZGM Licensee subject to the availability of sufficient Product and patient capacity as determined by ZGM. ZGM shall be responsible for servicing those people seeking to participate and who are not coming from within a licensed territory.

**Article 4. TECHNOLOGY, REGULATION, AND THE MARKET**

4.1. WUND shall aggressively Commercialize and maintain appropriate inventories of the Product in the Territory. ZGM shall from time to time furnish WUND with additional Technology as and to the extent ZGM reasonably determines to assist WUND's efforts to Commercialize the Product in the Territory. WUND, or its ZGM approved contractor or agent shall be responsible for the proper handling, storage and shipping of the Product with input and specifications from ZGM.

CONFIDENTIAL

4.2. ZGM shall also furnish such existing additional Technology as WUND may reasonably request in connection with any regulatory inquiry or compliance matter regarding the Commercialization of the Product in the Territory.

4.3. ZGM shall be responsible for all decisions and actions regarding regulatory matters relating to or involving the Product prior to Product Registration. ZGM shall, with respect to any such regulatory matters, (a) act as liaison with the Government Authority; (b) prepare and make all submissions regarding any regulatory matter; (c) monitor all studies pertinent to a regulatory matter; and (d) obtain Regulatory Approvals, as required or as reasonably deemed necessary by ZGM. WUND shall promptly cooperate with ZGM with respect to such regulatory matters by providing data and information at ZGM's reasonable request. Nevertheless, WUND shall maintain its own counsel as for regulatory matters, for the sole purpose of advising WUND with regard to such regulatory matters and to any data, information, or suggestions that WUND may provide to ZGM, either at ZGM's request or at WUND's discretion. However, WUND shall bare ultimate financial responsibility for any regulatory matters arising from or caused by the actions or inactions of WUND in breach of any obligation under this Agreement or Applicable Law, including reimbursing ZGM for all costs incurred as a result thereof. The Parties shall advise, consult, and fully cooperate with each other on all potentially significant regulatory matters, although ultimate decision-making authority in all regulatory affairs shall rest with ZGM.

4.4. Each Party shall promptly notify the other Party in writing of any technical or clinical advances, useful modifications, side effects, safety issues, problems, any other concerns, or new government regulations relating to the Product that shall come to its knowledge. WUND must promptly inform ZGM of (i) all actions and communications (even if believed by WUND to be without foundation) by or threatened by a Government Authority in the Territory relating to the Product and (ii) of any event from which a claim against either Party is made, threatened, or likely to arise

4.5. WUND shall notify ZGM promptly in writing of any noted changes in market conditions, or new market trends in relation to the Product that shall come to its knowledge and of any new or potential product or market entrant which might be competitive with the Product, together with all known details thereof including prices and copies of any known promotional material.

**Article 5. COMMERCIALIZATION ACTIVITIES**

5.1. The Parties shall establish, as soon as practicable after the Effective Date, a Product Coordination Committee comprised of no more than three (3) senior representatives of each Party. A member designated, by ZGM shall chair this committee. The Coordination Committee shall discuss and exchange information related to relevant Product development, registration and Commercialization issues and shall coordinate these issues in furtherance of this Agreement and to insure effective planning and exchange of information.

CONFIDENTIAL

5.2. The Product Coordination Committee ("PCC") shall first meet within 60 days of the Effective Date with the purpose to review the status of the Development Plan for the Product and to agree on operational principles that shall guide the operations and management of the PCC in furtherance of this Agreement. Thereafter, meetings shall be held once each calendar quarter except if, no later than thirty (30) days in advance of any scheduled meeting, there is a determination by the chairperson of the PCC, and endorsed by the senior WUND representative that no new business or other activity has originated since the previous meeting, in which case that quarterly meeting may be cancelled and the next quarterly meeting shall be scheduled.

5.3. The location of the meetings shall alternate in succession unless agreed upon otherwise by the Parties, with the first meeting to be held at ZGM's offices. By approval of the chairperson, which approval may not unreasonably be withheld, representatives may participate in any meeting of the PCC by conference telephone or similar communications by means of which all persons participating in the meeting can hear each other. Each Party shall use reasonable efforts to cause its representatives to attend the meetings in person. If a Party's representative is unable to attend a meeting, such Party may designate an alternate representative to attend such meeting in place of the absent representative. In addition, each Party may, at its discretion, invite additional employees, and, with the consent of the other Party, consultants or scientific advisors, to attend the meetings of PCC.

5.4. ZGM and WUND acknowledge that the goal both Parties is to maximize the revenues from Commercialization of the Product. The Parties agree that to achieve this goal, they need to ensure that private and public healthcare payers broadly embrace each Product and are sufficiently satisfied with each Product's value proposition so that payers will not introduce obstacles designed to limit physician and patient access to that Product and hence to reduce achievable revenues. The Parties agree that a critical element of achieving Commercialization success is to ensure that payers are satisfied with each Product's healthcare value proposition. The Parties agree to take all reasonable steps to ensure that each Product's healthcare value proposition is not only competitive but also acceptable to payers, and to make all Commercially Reasonable Efforts so that such healthcare value is achieved and maintained.

5.5. Subject to the provisions hereinafter, WUND shall be responsible, at its expense and under its control, for conducting all Commercialization activities for the Product in the Territory. WUND shall organize and maintain a qualified national sales organization, and shall ensure that it gives proper coverage to the Product throughout the Territory on a regular basis. All such Commercialization materials, advertisements, and activities shall be submitted to ZGM for its review and approval prior to any use by WUND. WUND shall ensure that all materials, advertisements and promotional activities comply with, and WUND shall be solely responsible and liable for any failure of such materials and activities to comply with Applicable Law, Labeling and Product Registration for any of the Product, notwithstanding any review or approval of such materials or activities by ZGM.

5.6. WUND shall be solely responsible for compliance with regulatory requirements pertaining to its promotional materials and activities, including, without limitation, for submitting promotional and advertising materials prepared by or for WUND for all necessary governmental approvals. The failure of WUND to comply with Applicable Law. after notice and reasonable opportunity to cure from any Government Authority or ZGM, shall be grounds for termination under Article 12 hereinafter. Notwithstanding the preceding, ZGM may, as part of its global promotional and awareness efforts, publish or present such information in media that is accessible within the Territory.

CONFIDENTIAL

5.7. ZGM shall, at the appropriate time prior to commencing any sales in the Territory, and as soon as is reasonably practicable, give any required notice to the appropriate Government advising them with respect to the Product, that WUND shall be the sole marketer, promoter and distributor of the Product in the Territory, and requesting that any regulatory inquiries and concerns regarding WUND's promotional, marketing and distribution activities be addressed in consultation with ZGM.

5.8. WUND shall promptly, but in no event less than one (1) Business Day after WUND's receipt thereof, provide a copy by electronic mail to ZGM of any correspondence from any Government Authority or person related to the Product in any way to any possible or purported legal or regulatory violations, or legal or regulatory action being considered or taken, including without limitation, copies of any regulatory notices or warning letters.

5.9. Without limiting the indemnification rights ZGM may have under this Agreement, WUND shall promptly reimburse ZGM and its Affiliates for any and all damages, losses, expenses and costs suffered or incurred by ZGM and its Affiliates arising from (i) the failure of any promotional materials or advertising used or activities conducted by WUND to comply with the applicable Labeling, Product Registration, Applicable Law, and/or any comments, guidance or direction given by Government Authority in any pre-clearance process or (ii) the failure of WUND or its representatives or any CSO to promote the Product in compliance with applicable Labeling, Product Registration and/or with Applicable Law. ZGM shall use Commercially Reasonable Efforts to mitigate or limit its losses, expenses and costs incurred in connection with any matter described above and for purposes of the preceding sentence, it is understood and agreed that the losses, expenses and costs incurred by ZGM shall include, without limitation, the losses, expenses and costs incurred by ZGM to so mitigate or limit the effect or impact on ZGM and its Affiliates products or corporate image including, but not limited to, the costs of any remedial action undertaken by ZGM to communicate with physicians or customers.

5.10. If WUND (or ZGM) shall receive any warning letter or notice of violation from any Government Authority, which relates to the marketing, promotion, advertisement, sale or distribution of the Product in the Territory, ZGM shall have the right to call, and WUND shall attend at its expense, a joint meeting (which shall include senior level marketing and sales management of WUND) and ZGM, to be held at a location determined by ZGM. The purpose of such meeting shall be to discuss the material or practices that led to the issuance of the letter or notice, and to discuss any corrective or remedial measures to WUND's procedures. Subsequent to any such meeting or in lieu of such meeting, ZGM may, in its sole and absolute discretion, at any time after the issuance of a warning letter or notice related to the Product, decide to invoke the Procedural Review procedures set forth in Section 5.11 below by sending written notice to WUND (hereinafter, a "Procedural Review Notice").

CONFIDENTIAL

5.11. In the event that ZGM sends a Procedural Review Notice to WUND, WUND shall promptly comply with the procedures set forth in this Section 5.9. WUND shall ensure that all marketing and advertising materials and activities comply with the applicable Labeling and Product Registration for any of the Product and with Applicable Law, including, without limitation, addressing any other issues or concerns that were the subject of such letter or notice. For the period of twelve (12) months after the Procedural Review Notice (the "Pre-Clearance Period"), WUND shall submit to ZGM all of the following for its regulatory review and approval (the "Pre-Clearance Process") prior to use or dissemination; any and all marketing, advertising, promotional and related materials and activities (including, without limitation, detail aids, letters, brochures, reprints and other printed materials shown to or left with healthcare providers, letters, brochures and other printed materials intended for consumers, website content, materials for use in promotional programs, and any print, television, radio, and other media advertising materials intended for healthcare providers or consumers), Labeling, press materials, updates and corrections to the Physicians' Desk Reference with respect to the Product, speaker training materials (including slides and slide kits), sales training materials and other materials and communications originating from home offices, regional offices, local offices or hub offices and sent to the sales force regarding promotional messages or strategies for the Product.

5.12. WUND shall not use any materials or make any claims in advertising, promoting or selling the Product which have not gone through the Pre-Clearance Process and received any required Regulatory Approval; provided, however, that in the case of materials not subject to Regulatory Approval, WUND shall ensure that all such materials and claims are consistent with the materials and claims that have received Regulatory Approval and comply with all comments, direction and guidance given during the Pre-Clearance Period. WUND shall ensure that all promotional programs and activities of all sales representatives promoting the Product comply with any and all comments, direction or guidance given during the Pre-Clearance Period. Upon expiration of the Pre-Clearance Period, WUND shall continue to promote, detail, sell and advertise the Product in a manner consistent with, and in full compliance with, all comments, directions and guidance received therefrom. WUND shall be solely responsible for submitting all promotional and advertising materials prepared by or for it to Government Authority. ZGM shall have the right to terminate this Agreement if WUND shall fail to fully comply with the requirements of this Article 5. In the event that WUND receives a second regulatory warning letter as described in Section 5.8 above following the successful resolution of the problems that prompted the first regulatory warning letter, ZGM shall have the right to immediately terminate this Agreement.

5.13. WUND is granted the nonexclusive right under this Section to use, copy, modify, and distribute ZGM marketing and promotional materials only for the purposes of this Agreement and in furtherance of the rights granted to WUND hereunder, for the Term for any Product to which such works and materials relate. WUND shall ensure that all copyright notices and this permission notice appear on all copies of the written materials provided by ZGM and all adaptations and derivative works thereof. Any and all new promotional material developed by WUND, including that which adapts or utilizes materials supplied to WUND by ZGM, shall be approved by ZGM as per Section 6.3 below and shall have been filed with the Government Authority at the time of the initial dissemination as applicable.

CONFIDENTIAL

5.14. WUND shall have the responsibility, at its expense, for conducting independent and non-independent symposia, speaker training and engagement programs, advisory board meetings and other consulting arrangements, scientific exhibits and other types of scientific exchange, and other such events or programs as WUND, in its sole discretion, deems to be appropriate with respect to the Product within the Territory. However, any and all such events and programs shall be coordinated with ZGM and WUND shall ensure compliance in all respects with Applicable Law and regulatory policies such as for example the FDA's Guidance on Industry-Supported Educational and Scientific Activities.

5.15. WUND shall be solely responsible for the costs of establishing and maintaining its sales force and marketing functions in the Territory for the Product, and for conducting other activities under this Agreement and, subject to the foregoing, shall have the sole authority to control its sales force and direct the activities of its sales force. All the members of WUND's sales force (including management and representatives), and WUND contractor sales force personnel, if any, shall complete a ZGM approved Product-related training program created and conducted by WUND at its cost and expense. The ongoing training of WUND's sales force shall be the responsibility of WUND and at its cost. The contents of any training provided by WUND that relates to the Product shall be developed and coordinated by WUND, and WUND shall be solely responsible for training its sales force (including management and sales representatives) and CSO sales force personnel, if any, with regard to Applicable Law and ensuring that sales force personnel comply with Applicable Law.

**Article 6. TRADEMARK, QUALITY, AND COMPLIANCE**

6.1. WUND shall use the Product Trademarks and Tradenames, on an exclusive basis, for Commercialization of the Product in the Territory. WUND shall not identify the Product by any designation other than by the Trademarks for the Product. WUND agrees to use the Trademark only in the form and manner and with appropriate legends as approved by ZGM, and not to use any other trademark or service mark in combination with the Trademark without prior written approval of ZGM. All Product sold in the Territory shall be sold under a ZGM label, and all Product shall at all times be identified as ZGM Product with WUND identified as the distributor thereof unless otherwise required by Applicable Law. WUND agrees to use the Trademark in accordance with good customary trademark practice, and to avoid taking any action that would in any manner impair or detract from the value of the Trademark or the goodwill and reputation of ZGM. WUND acknowledges ZGM's ownership of the Trademark and related goodwill, both in the Territory and outside the Territory.

6.2. WUND shall not have and shall not represent in any way that it has any title or right to the ownership or registration or their use, except as provided in this Agreement. WUND shall at all times indicate that each Trademark and Tradename is the property of ZGM used under license. With respect to all Product sold by WUND, WUND shall be identified as the distributor of on the Product label if required under Applicable Law. If Applicable Law does not specify how the distributor shall be indicated on a Product label, then as determined jointly by ZGM and WUND.

CONFIDENTIAL

6.3. Except for WUND's right to use the Trademarks pursuant to this Article 6, no right or license under any Trademark, or under any patent rights or know-how, owned or controlled by ZGM or any of its Affiliates to make, or have made the Product is granted to WUND under this Agreement. Without limiting the foregoing, the Parties acknowledge and agree that nothing in this Agreement shall grant to WUND any right or interest in any other medical product or treatment that may be developed by ZGM beyond the scope of the Product.

6.4. ZGM and/or its affiliates shall remain the owner of the Trademarks. WUND shall not at any time do, cause to be done, or permit any of its employees, agents, contractors and subcontractors to commit any act inconsistent with, contesting or in any way impairing, or tending to impair, such ownership. All use of the Trademarks by WUND shall inure to the benefit of and be on behalf of ZGM or its Affiliates and nothing in this Agreement shall give WUND any right, title or interest in the Trademarks other than the right to use the Trademarks within the Territory in accordance with this Agreement. WUND shall not challenge ZGM's or its Affiliates' title to, or ownership of, the Trademarks, or attack or contest the validity of the Trademarks. All goodwill accruing to the Trademarks as a result of the use of the Trademarks in the performance of this Agreement shall belong solely to ZGM or its Affiliates. In the event that WUND acquires any rights in the Trademarks in connection with WUND's activities pursuant to this Agreement, WUND shall assign, and hereby does assign, to ZGM or its Affiliates all such rights, including any related goodwill.

6.5. WUND undertakes to use the Trademarks in respect of the Product only in the Territory and in accordance with the terms of this Agreement and the standards of quality established or approved by ZGM. The nature and quality of all of WUND's advertising, promotional, and other related uses of the Trademark pursuant to this Agreement shall conform to standards set by ZGM. WUND shall submit all proposed marketing materials, advertisements, labels, and packaging to ZGM for its approval prior to its use. WUND shall cooperate fully with ZGM in this regard and shall supply ZGM in advance with specimens of all uses of the Trademark. WUND also agrees to obtain ZGM's written permission regarding the nature and quality of each use of the Trademark, prior to such use, provided, however, that such permission shall be granted unless ZGM reasonably objects on the basis that the proposed use will impair the value of the Trademark or will otherwise fail to conform to the standards set by ZGM. If such permission or objection is not transmitted by ZGM within six (6) business days of ZGM's receipt of the request for permission along with the subject specimens, then ZGM shall be deemed to have granted permission in satisfaction of this section.

6.6. WUND shall use any Trademark or Tradename on television, the internet and other digital media in strict compliance with Applicable Law concerning pharmaceutical advertising. The use of any Trademark or Tradename as a domain name is limited to the relevant country code domain within the Territory. No license is granted to use the ".com generic code domain" or any other such top-level domain. Any domain names containing a Trademark or Tradename shall only be registered and maintained by and in the name of ZGM or its designee. The use of any Trademark or Tradename as a domain name is limited websites with universal resource locaters using the relevant country code domain within the Territory and aimed at audiences in the Territory. Appropriate disclaimers must be included in any website to the effect that it is intended only for residents of the Territory.

CONFIDENTIAL

6.7. If either Party becomes aware that a third party is infringing any Trademark used in connection with the Product, such Party shall give written notice to the other Party describing in detail the nature of such infringement. ZGM and its Affiliates shall have the sole right, but not the obligation, to enforce any such Trademarks against such third Party infringer to the extent deemed necessary or appropriate by ZGM or its Affiliates, in their reasonable discretion, and to settle or compromise any such possible infringement by taking such action as ZGM or its Affiliates may determine in their sole and absolute discretion; provided, however, that ZGM shall not settle any such potential infringement in a manner that materially adversely affects the rights granted to WUND hereunder, except with WUND's prior written consent (which consent shall not be unreasonably withheld). WUND shall provide ZGM all reasonable assistance (including, without limitation, making documents and records available for review and copying, and making persons within its control available for pertinent testimony), at ZGM's expense, in such enforcement.

6.8. ZGM shall have sole responsibility to maintain the Product Registration in the Territory at its expense, including without limitation filing all required reports and paying all fees associated with the Product Registrations in the Territory. ZGM shall keep WUND informed on a timely basis as to any developments that would have a material adverse effect on a Product Registration. WUND shall cooperate with ZGM with respect to obtaining and maintaining the Product Registrations, and shall execute, acknowledge and deliver such further instruments at ZGM's request and expense. WUND shall use Commercially Reasonable Efforts to do all such other acts, as promptly as possible, which may be necessary or appropriate to obtain and maintain Product Registrations in the Territory. WUND shall, on a timely basis, provide to ZGM all information that ZGM determines is necessary and relevant to ZGM's to fulfill its obligations hereunder to fulfill Product Registration maintenance requirements (including, but not limited to Product sales distribution information).

6.9. ZGM shall have the final decision-making authority in every case on whether and how to supplement, amend or otherwise alter a Product Registration and any other issues in connection with such Product Registration (including, but not limited to, decisions, subject to Article 8 below, to recall the Product) and on whether and how to communicate with the Government Authority and other agencies or authorities in connection with Product Registration.

6.10. ZGM and WUND each shall make its facilities available at reasonable times during business hours for inspection by representatives of Government Authority. ZGM and WUND each shall notify the other within twenty-four (24) hours (or, if such twenty-four (24) hour period ends on a day that is not a Business Day, then prior to Noon on the next following Business Day) of receipt, and provide a copy thereof, of any notice of any such governmental inspection, investigation or other inquiry, or other material official notice or communication, relating to the manufacture, sale, marketing, promotion, distribution, or use of the Product within the Territory. WUND and ZGM shall cooperate with each other during any such inspection, investigation or other inquiry.

CONFIDENTIAL

6.11. WUND and ZGM shall discuss any response to observations or notifications received in connection with any such inspection, investigation or other inquiry and each shall give the other an opportunity to comment upon any proposed response before it is made; provided, however, that ZGM shall not be required to discuss with WUND any issues specific to the manufacture of the Product, or to obtain the consent or agreement of WUND with respect to issues related thereto.

6.12. ZGM shall have sole responsibility and authority for, and control of, all package inserts and package labeling (and any changes or supplements thereto) for Product, and shall have the responsibility at its expense for securing any approvals required by FDA to any such changes or supplements thereto. WUND shall not at any time do, and neither shall WUND permit its agents or representatives to do, any act in violation of Product Registration in the Territory. In the event that any filings are required to be made with or approvals required to be obtained from applicable regulatory authorities in order to change or supplement the package inserts and labeling, ZGM shall have the sole responsibility for and authority to affect such filings and the sole right and discretion on how to effect such changes at ZGM's expense. ZGM shall promptly advise WUND in writing of any changes or supplements to the package inserts and package labeling for Product.

**ARTICLE 7 MANUFACTURE OF PRODUCT; REGULATORY MATTERS; COMMUNICATION**

7.1. In order to ensure the quality of the Product to be sold by WUND under the Trademarks, WUND shall purchase exclusively from ZGM or ZGM's contract Manufacturer, and ZGM shall supply exclusively to WUND, or its designated third party ("Drug Distributor") pursuant to the terms and conditions in this Agreement, the entire Product requirements of WUND for marketing, sale and distribution by WUND in the Territory during the Term of this Agreement.

7.2. ZGM shall manufacture or cause the Product to be manufactured in accordance with Product Registration, current Good Manufacturing Practices ("cGMP"), Applicable Law, and, as may otherwise be agreed by the Parties.

7.3 At the time that ZGM and or its contract manufacturer supplies the Product to WUND, the Product shall not be adulterated or misbranded within the meaning of Applicable Law. ZGM shall be responsible for maintaining commercially acceptable quality control standards in all manufacturing relating to the Product it delivers to WUND.

7.4. Unless WUND is at fault, including but not limited to, because of a failure to take reasonably prudent steps, or other steps reasonably suggested by ZGM, to protect the delivered Product, ZGM shall be responsible for and compensate WUND for expenses incurred for any recall, and when necessary for replacement of Product failing to meet commercially acceptable standards or Product release standards that have been hereafter agreed upon by ZGM and the Government Authority.

CONFIDENTIAL

7.5. ZGM shall provide WUND with a complete copy of each Product Registration, including all material amendments and supplements thereto, relating to the Product in the Territory. ZGM shall be the lawful holder of all rights under each Product Registration. ZGM shall comply in all material respects with Applicable Law and regulations in connection with the preparation and submission to the Government Authority of each Product Registration, and each of the Product Registrations shall be officially approved.

7.6. ZGM shall provide, or cause to be provided to WUND, whichever the case may be, a certificate of analysis for each shipment of Product, within 3 business days from the date that such Product are shipped to WUND. Upon receipt by WUND of Product, it shall handle, use and store the Product in compliance with Manufacturer and ZGM requirements, current Good Manufacturing Practice and Applicable Law. Each Party shall cooperate with the other to provide such letters, documentation, and other information on a timely basis, as the other Party may reasonably require to fulfill its reporting and other obligations to Government Authority.

7.7. WUND shall notify ZGM of its rejection of any of Product within 10 business days after delivery of such Product to WUND which shall set forth the basis under this Agreement for such rejection, including any testing or inspection results. However, in the case of Product latent defects, which upon examination in accordance with WUND's reasonable testing or inspection procedures could not have been discovered, WUND must give notice to ZGM within 10 business days after discovery of such defect, setting forth in detail the basis for such rejection. The failure of WUND to so notify ZGM of, or to identify the basis under this Agreement for, rejection of any of the Product within such periods shall constitute acceptance of such Product and, thereafter, WUND shall be obligated to make payment for such Product in accordance with this Agreement.

7.8. If the Parties disagree as to whether any of the Product conforms with applicable Labeling, or the Product Registration for such Product, then samples and/or batch records, as appropriate, from the batch which is in dispute shall promptly be submitted for testing and evaluation to an independent third-party laboratory ("Third-Party") as agreed in writing by the Parties for the determination of whether such Product conforms to applicable Labeling or Product Registration. If the Parties are unable to agree on the process or the results within 30 days, then WUND shall appoint such Third-Party. The determination of such Third- Party as to whether Product conforms to applicable Labeling or the Product Registration for such Product shall be final and binding. Except as provided in Section 7.9 below, the cost of the testing and evaluation by the Third-Party shall be borne by (i) WUND if the Third-Party determines that the Product conform with applicable Labeling and the Product Registration for such Product, and (ii) ZGM if the Third-Party determines that the Product does not conform with applicable labeling or the Product Registration for such Product.

7.9. If ZGM agrees with WUND's notification of non-conforming Product, or ZGM fails to contest such notification in writing within thirty (30) business days after receipt of such notification, or the Third-Party, pursuant to Section 7.8 above, concludes that the subject Product does not conform with the applicable Labeling or the Product Registration for such Product, ZGM shall reimburse WUND for all reasonable costs and expenses incurred by it in connection with the non-conforming Product and ZGM shall, at WUND's option, (i) credit WUND for the invoiced amount paid by WUND for such rejected Product, or (ii) replace such rejected Product as promptly as reasonably practicable, but in no event later than ninety (90) days following receipt of written notice of such rejection, and at no additional cost to WUND. WUND shall, at the expense of ZGM, either deliver such non-conforming Product to ZGM or destroy the same and provide to ZGM written documentation reasonably satisfactory to ZGM to the effect that such non-conforming Product have been destroyed in accordance with Applicable Law. This Section 7.9 shall be WUND's sole remedy for any non-conforming Product.

CONFIDENTIAL

7.10. ZGM shall notify WUND of any issues specific to the manufacture of the Product that could reasonably be expected, in ZGM's discretion, to have a material effect on WUND's ability to distribute Product in the Territory, and have regulatory implications that could reasonably be expected, in ZGM's discretion, have a material effect on WUND's ability to distribute Product in the Territory. WUND and ZGM shall provide each other with copies of all correspondence received by it from, or filed by it with, any Government Authority to the extent pertaining to each of the Product or its, Labeling, packaging, distribution, promotion, advertisement, marketing or sale in the Territory. In addition, ZGM will promptly provide WUND copies of all material correspondence received by ZGM from, or filed by ZGM with, any Government Authority to the extent such correspondence or filing could reasonably, in ZGM's opinion, have an effect on WUND's ability to perform its obligations under this Agreement.

7.11. WUND shall be solely responsible for responding to regulatory inquiries and actions relating to promotional activities and materials as contemplated by this Agreement. WUND shall keep ZGM fully informed of such matters. In the event of disagreement concerning such response, ZGM shall be responsible for deciding the appropriate form and content of any response with respect to any of its activities cited or involved and WUND shall be responsible for deciding the appropriate form and content of any response with respect to any of Government agency cited activities.

7.12. ZGM shall refer all requests and inquiries from healthcare professionals and consumers in the Territory of the Product Territory to WUND, and WUND shall provide to ZGM the telephone number to which such call will be referred. WUND and ZGM shall jointly develop written procedures for the administration of and response to medical inquiries concerning the Product by consumers, physicians, pharmacists and other healthcare professionals. WUND and ZGM shall each comply with the provisions thereof.

7.13. If either WUND or ZGM obtains information that any Product is alleged or proven not to conform with the Labeling or the Product Registration for such Product in the Territory, or of any other seriously adverse information related to the Product, it shall notify the other Party immediately and both Parties shall cooperate fully regarding the investigation and resolution of such matter. ZGM and WUND shall each maintain such traceability records as are sufficient and as may be necessary to permit a Recall as hereinafter defined, or field correction of any Product. In the event (a) any Government Authority should issue a request, directive or order that any of the Product be recalled, or (b) a court of competent jurisdiction orders such a recall, or (c) ZGM or WUND determines that any of the Product already in commerce in the Territory present a risk of injury or is otherwise defective, misbranded and/or adulterated and that recall of such Product is appropriate. Any such event described in (a), (b) or (c), is a "Recall" each Party shall give telephonic notice (confirmed in writing) to the other within twenty-four (24) hours after becoming aware of an event described in (a) or (b), or after making the determination described in (c). ZGM shall have sole responsibility for determining all corrective action to be taken and to implement the Recall, but shall confer with WUND and keep WUND informed on a regular basis of ZGM's progress in planning and implementing the Recall. WUND will use Commercially Reasonable Efforts to cooperate with and assist ZGM in connection therewith as may be requested by ZGM.

CONFIDENTIAL

7.14. ZGM shall be responsible for all expenses of effecting any such Recall (including reasonable and necessary out-of-pocket expenses incurred by WUND), except to the extent such Recall is attributable to any negligence or breach by WUND of its obligations under this Agreement, in which event WUND will reimburse ZGM for its reasonable costs and expenses incurred and attributable to such negligence or breach by WUND. ZGM shall provide to WUND replacement Product for any recalled Product at ZGM's expense, except to the extent that such Recall is attributable to any negligence on the part of WUND or any breach by WUND of its obligations under this Agreement or any other agreement between WUND and ZGM.

7.15. WUND and ZGM each shall maintain complaint files for Product in accordance with current Good Manufacturing Practice. WUND and ZGM each shall record any complaints received with respect to the Product. ZGM shall promptly provide to WUND written notice of any complaints (and provide copies of any written complaints) received by ZGM with respect to any Product. WUND shall promptly provide to ZGM written notice of any complaints (and will provide copies of any written complaints) received by WUND with respect to any Product. WUND shall have responsibility for responding to all complaints, and for promptly providing ZGM with a copy of any responses to complaints, relating to the Product, including but not limited to complaints from competitors regarding promotional activities by WUND. ZGM shall cooperate with WUND to provide any information ZGM, in good faith, deems necessary to respond to such complaints. ZGM shall have sole responsibility at its expense for reporting any complaints relating to the Product to the appropriate governmental authority where required, including, but not limited to, complaints relating to the manufacture and adverse drug experience reports.

7.16. WUND shall (a) not give any Third-Party purchaser of the Product any guarantee or warranty on behalf of ZGM, (b) enter into any sale contracts for the Product as a principal (as opposed to an agent of ZGM), and (c) follow up and investigate all customer, counterfeit Product, and tampering complaints related to the Product. WUND shall keep ZGM informed, as appropriate, as to the nature, status and resolution of such complaints on a timely basis with sufficient information to ZGM to investigate such complaints. WUND shall promptly take all commercially reasonable measures to prevent, investigate and cure any counterfeit Product on the Territory, any other unauthorized sales or distribution of Product, or cross-Territory sales or distribution of Product on or from the Territory.

7.17. Each Party shall use Commercially Reasonable Efforts to maintain in full force and affect all necessary licenses, permits and other authorizations required by Applicable Law to carry out its duties and obligations under this Agreement. WUND shall store and distribute the Product and trade forms in compliance with Applicable Law. Except for such amounts as are expressly required to be paid by a Party to the other under this Agreement, each Party shall be solely responsible for any costs incurred by it to comply with its obligations under Applicable Law.

CONFIDENTIAL

7.18. From time to time as ZGM may elect during the Term, during normal business hours and upon not less than five (5) Business Days' notice, WUND shall permit duly authorized representatives of ZGM to review and inspect WUND's premises, facilities, inventories of the Product, and all records and documentation maintained by WUND for the purpose of determining compliance by WUND with its obligations under this Agreement. WUND may elect during the Term, during normal business hours and upon not less than ten (10) Business Days' notice), and ZGM shall permit and, to the extent possible, cause such of its subcontractors that provide services with respect to the Product, to permit, duly authorized representatives of WUND to review and inspect, on the premises of ZGM or its relevant subcontractors (1) each manufacturing facility for the Product and (2) on the premises of ZGM where such records and inventory are kept, inventory of the Product, Manufacturing Documentation and ZGM's quality control records relating to the storage of the Product to ensure compliance with Good Manufacturing Practices, quality control standards and the packaging and labeling for the Product; and with applicable terms of this Agreement pertaining to the use of the Trademarks.

7.19. However, except as otherwise provided herein, nothing in the foregoing shall allow or be construed to allow WUND to have access to any confidential financial, manufacturing know-how or trade secrets of ZGM or its subcontractors and any records containing or pertaining to the same. If ZGM cannot require a subcontractor to submit to such inspection by WUND, ZGM shall conduct any such inspection on WUND's behalf, and will report any results of such inspection to WUND within thirty-days (30) of completing the inspection.

**Article 8. PURCHASE AND SALE OF PRODUCT**

8.1. ZGM agrees to supply and sell to WUND, and WUND agrees to purchase from ZGM, WUND's entire requirements of the Product in a suitable Government Authority-approved dosage form, and packaged and labeled in accordance with Applicable Law and ZGM standards at the applicable prices specified in this Article 8. The Product sold by ZGM under this Agreement shall be at least 12 months from the stated expiration date on the label as of the shipping date to WUND. ZGM may subcontract all or any part of the manufacture of the Product without the consent of WUND, provided, however, that ZGM shall remain responsible for all of its obligations to WUND under this Agreement, including, without limitation, the performance of its subcontractors in supplying Product to WUND.

8.2. The Parties acknowledge and understand that any project within the field of biotechnology, such as the Commercialization of the Product, is to some extent unpredictable as a consequence of the very nature of recombinant products and also the possible outcomes of clinical development and testing. The Parties assume that there is a degree of complexity in the development of the Product and thus some uncertainty regarding the outcome of Project. WUND acknowledges and accept that the Product may be manufactured by one or more third parties ("Manufacturer") and circumstances may arise with or from a Manufacturer that are beyond the control of ZGM.

CONFIDENTIAL

8.3. The Parties understand that a 4-month period is the minimum generally required by the Manufacturer to adjust its production of Product subject to market conditions and its own available resources and plant capacity relating to its ability to perform. WUND agrees that ZGM is not responsible for market or production issues beyond its control. ZGM will take all commercially reasonable efforts to mitigate the impact of any disruptions in Product production and delivery.

8.4. As soon as practicable the Parties shall confer and develop, for planning purposes, a preliminary "Supply Schedule" for the quantity of Drug required for operations for the first 4 months. This schedule shall take into consideration the current availability of the Drug in proper form, Manufacturer production capacity and timeline, and other supply chain issues. After consultation with the Manufacturer, ZGM shall confirm to WUND the quantities and timing that Manufacturer should be available for the first 4 months to be supplied for continued study or public distribution in the Territory.

8.5. As WUND's operations commence the Parties shall agree on a 12-month Annual Forecast which shall be reviewed with and approved by Manufacturer to facilitate realization of WUND's production requirements. Subsequent Annual Forecasts shall be prepared before October of each year unless otherwise required. By mutual agreement of the Parties and the Manufacturer, the Annual Forecast may be modified at any time as updated Product requirements and capacity become better defined. By mutual agreement of the Parties and the Manufacturer, the Annual Forecast can be modified at any time as Product requirements and availability become better defined.

8.6. Based on developing information the Parties shall prepare a more comprehensive 4-month rolling Supply Schedule for the period starting as soon as practical. The Schedule shall set forth the Product requirements for the forthcoming 4-month period. ZGM shall obtain from the Manufacturer its commitment for the allocation of plant capacity and resources for the production and delivery of sufficient Product to meet WUND requirements for that 4-month period. ZGM shall promptly inform WUND of any issues or adjustments to the Rolling Schedule required by Manufacturer. Throughout the term of this Agreement, WUND shall organize and maintain inventories of the Product in the Territory reasonably sufficient to meet its current 4-month requirements.

8.7. ZGM may establish for any Product a minimum sales price(s) to be charged by WUND unless expressly prohibited by applicable law. In such event the minimum sales price shall be determined by ZGM in accordance with the law. WUND shall not engage in any transaction where the Product price is less than the minimum sales price without the written approval of the ZGM authorized representative.

8.8. WUND shall issue a Purchase Order "PO" to ZGM in the procedure advised by ZGM for the quantity and timing of Product to be purchased. Any deviation in quantity or timing from the agreed upon schedule shall have been previously approved by ZGM in consultation with the Manufacturer, if required. ZGM will be responsible for prompt payment to the Manufacturer consistent with previous payment terms and conditions of the Manufacturer.

CONFIDENTIAL

8.9. ZGM shall issue an invoice to WUND consistent with the payment terms and conditions of the Manufacturer and will represent the actual direct cost of the Product as invoiced by Manufacturer. WUND will have the right to inspect copies of all invoices that ZGM receives from its contract manufacturer that are related to the direct cost of producing the final Product sold to WUND.

8.10. ZGM or Manufacturer shall notify WUND management just prior to the shipment of an order. ZGM or the Manufacturer shall be responsible for selecting the carrier to transport Product under appropriate shipping conditions (i.e., refrigerated) from the ZGM or Manufacturer facilities to the shipping address designated by WUND. The shipper shall have the Product delivered to WUND's loading docks during normal business hours. VAT, freight collect and insurance shall be payable by ZGM and reimbursed by WUND as provided hereinafter. WUND shall be responsible for any additional services or fees related to the Product delivered as invoiced by Manufacturer's normal practice; for example, travel, site visits, and additional Product testing.

8.11. The quantities of Product shipped by Manufacturer shall be within the time period set forth in the agreed upon Schedule. However, ZGM shall have no liability for delivery delays caused by any carrier's failure to meet the delivery times agreed to by such carrier. In the event shipping within the times specified above will not be possible, ZGM shall advise WUND by electronic mail the revised shipping date. If WUND requires additional Product beyond that provided in the current Schedule ZGM will use best efforts to obtain the additional Product.

8.12. Quantities of Product actually shipped by Manufacturer or ZGM may vary from the quantities specified in any Purchase Order by up to 10 percent and still be deemed to comply with such Purchase Order; provided, however, that WUND shall only be invoiced for the quantities that ZGM actually ships to WUND (the "Actual Quantity").

8.13. WUND shall be billed for the Product once an order has been shipped. Payment is due to be received by ZGM within 45 days of Product receipt by WUND. After the first sales of Product commence, WUND shall provide ZGM with accurate monthly financial statements and revenue and/or collection reports. All late payments from WUND shall be subject to interest for the period of late payment at the rate of 12 percent annual interest, compounded monthly.

8.14. All payments to ZGM hereunder shall be made in Dollars and shall be wired to an account designated by ZGM with the costs of any remittance shall be borne by WUND. All payments to be made by WUND under this Agreement shall be made in full, free and clear of and without any deduction of or withholding for or on account of any charge or taxes levied in any country or the Territory or elsewhere; <u>provided</u> that if the WUND shall be required by law to make any deduction or withholding from any payment to ZGM then:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) WUND shall ensure that such deduction or withholding does not exceed the minimum legal liability therefor; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) WUND shall forward to ZGM such documentary evidence as may be required by ZGM in respect of the proposed deduction, withholding or payment; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) Prior to any deduction or withholding the Parties shall attempt in good faith to agree upon revised mutually acceptable pricing and/or payment terms.

CONFIDENTIAL

8.15. In the event that WUND submits a Purchase Order which exceeds the quantity of Product specified for the corresponding period as set forth in the current Supply Schedule or which changes the Delivery Date specified on a previously submitted Purchase Order for the same period, ZGM will make a good faith effort to arrange the supply, but shall have no obligation to supply to WUND the amount of any such excess or to allow any such change in Delivery Date.

8.16. Neither a Supply Schedule nor a Purchase Order may specify a quantity of Product that is less than the minimum quantity for such Product as shall have been agreed to by the Parties in advance; provided, however, that if the amount specified in a Purchase Order is less than the minimum quantity but is an amount that is otherwise agreed to in writing by the Parties the minimum quantity requirement shall not apply to such Purchase Order.

8.17. The quantities of Product ordered shall be delivered within two (2) weeks of the scheduled delivery date set forth in the Purchase Order applicable to such quantities, provided, that ZGM shall have no liability for delivery delays caused by the Manufacturer or any carrier's failure to meet the delivery times agreed to by such carrier. Notwithstanding anything herein to the contrary, in the event delivery within the times specified above will not be possible, ZGM may request (in writing or electronic mail) an alternate delivery date and WUND shall not unreasonably withhold its consent (in writing or electronic mail) to such alternate Delivery Date. Title to and risk of loss with respect to Product shall pass from ZGM and the Manufacturer to WUND upon delivery of the Product to WUND. ZGM shall be responsible for procuring insurance for the transport of the Product from the ZGM or Manufacturer facilities to the shipping address designated by WUND and this insurance fee will also be reimbursed to ZGM by WUND upon receipt of Product by WUND.

8.18. WUND shall not enter into any agreement with any third party that contains provisions conflicting with the terms and conditions of this Agreement. In ordering and delivering Product, WUND and ZGM may use their respective standard forms, provided that nothing in those forms shall be construed to modify or amend the terms and conditions of this Agreement, and, in the case of any conflict herewith, the terms and conditions of this Agreement shall control.

8.19. WUND shall notify ZGM in writing of any claim relating to quantitative deficiencies from the shipping documentation in any shipment of Product for which WUND considers the Manufacturer or ZGM to be responsible within 15 days following receipt of any such shipment. Any claim for a quantitative deficiency from the applicable shipping documentation that is not made within such 15 days shall be deemed to have been waived by WUND and WUND shall be obligated to make payment for such Product.

8.20. In the event WUND determines there is a quantitative deficiency from the shipping documentation, the Parties shall investigate such deficiency and, if the Parties agree that there is a deficiency, the actual quantity shall be adjusted to reflect the Parties' agreement. ZGM shall have the option of rectifying any such deficiency that occurred prior to shipment by promptly arranging shipping of the appropriate quantities of Product to WUND, in which case the actual quantity shall be readjusted to include such shipment. WUND's exclusive remedy for any quantitative deficiencies shall be to pay only for the actual quantities shipped to it or, at ZGM's option, receive the appropriate quantities.

CONFIDENTIAL

8.21. WUND shall be responsible for providing all required information, notices, reports, and filings related to the Product to the appropriate national and state government authorities with respect to Medicaid, Medicare, and other such public financed or supported health programs. ZGM shall cooperate in these efforts by for example supplying any required pricing information not in the possession of WUND. WUND shall process, administer and be financially responsible for all rebates pursuant to any government rebate programs in the Territory and all commercial rebates, with respect to government claims for the Product.

8.22. DISCLAIMER OF WARRANTIES. EXCEPT AS IS EXPRESSLY PROVIDED IN THIS AGREEMENT, THERE ARE NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, MADE OR GIVEN BY EITHER PARTY HEREUNDER, INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE OF ANY PRODUCT.

**Article 9. CONFIDENTIALITY**

9.1. The terms of this agreement shall be strictly confidential between the Parties hereto to the fullest extent permitted by Applicable Law. During the term of this Agreement and for a period of five (5) years after its expiration or termination, WUND shall keep confidential and not disclose to others or use for any purpose other than as expressly authorized herein, any confidential information supplied by ZGM or its employees or representatives and identified as confidential ("Confidential Information"). WUND shall ensure that its employees and agents shall likewise maintain the secrecy of Confidential Information, and shall comply with the confidentiality and non-use provisions of this Section.

9.2 The obligation of confidentiality shall not apply to the extent that WUND can establish that the Confidential Information at issue: (i) entered the public domain without WUND's breach of any obligation owed to the disclosing party; (ii) was permitted to be disclosed by ZGM's prior written consent; (iii) had become known to WUND from a source other than ZGM, other than by breach of a confidentiality obligation owed to ZGM; (iv) was disclosed by ZGM to a Third party without restrictions on its disclosure; or (v) was independently developed by WUND without breach of this Agreement. Further, disclosure may be made pursuant to a requirement of law, or of judicial or administrative process, provided that WUND shall promptly inform ZGM in advance of such disclosure so that ZGM may seek a protective order regarding the disclosed Confidential Information.

9.3. Each Party shall use, and cause each of its Affiliates to use, any Confidential Information obtained by it from the other Party or their respective Affiliates, pursuant to this Agreement or otherwise, solely in connection with the transactions contemplated hereby. The Parties shall have all officers and senior managers as the Parties will agree, execute enforceable confidentiality and non-compete agreements.

CONFIDENTIAL

9.4. Each Party shall be entitled, in addition to any other right or remedy it may have, at Applicable Law or in equity, to an injunction, without the posting of any bond or other security, enjoining or restraining any other Party from any violation or threatened violation of this Article.

**Article 10. REPRESENTATIONS, WARRANTIES, AND COVENANTS**

10.1. ZGM hereby represents, warrants, and covenants the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1.1. ZGM is a corporation duly organized, existing and in good standing under the laws of Delaware, with full right, power and authority to enter into and perform this Agreement and to grant all of the rights, powers, and authorities herein granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1.2. The execution, delivery and performance of this Agreement do not conflict with, violate, or breach any agreement to which ZGM is a party, or ZGM' articles of incorporation or bylaws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;101.3. This Agreement has been duly executed and delivered by ZGM and is a legal, valid and binding obligation enforceable against ZGM in accordance with its terms.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1.4. ZGM shall comply with Applicable Law, consent decrees, and regulations of any federal, state, or other governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1.5. To the best of ZGM's knowledge and belief as of the date of this Agreement, there are no issued or pending patent or trademark applications relating to the Product that would prevent WUND from using or selling the Product in the Territory for its Licensed Use.

10.2. WUND hereby represents, warrants, and covenants the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2.1. WUND is a corporation duly organized, existing and in good standing under the laws of the State of Delaware, with full right, power, and authority to enter into and perform this Agreement and to grant all of the rights, powers, and authorities herein granted.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2.2. The execution, delivery, and performance of this Agreement do not conflict with, violate, or breach any agreement to which WUND is a party, or WUND's articles of incorporation or bylaws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2.3. This Agreement has been duly executed and delivered by WUND and is a legal, valid, and binding obligation enforceable against WUND in accordance with its terms.

CONFIDENTIAL

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2.4. WUND shall comply with Applicable Law, consent decrees, and regulations of any federal, state, or other governmental authority.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2.5. WUND shall in good faith make its best efforts and make reasonable expenditures to market and promote sales of the Product for its Licensed Use in the Territory.

**Article 11. INDEMNIFICATION**

11.1. ZGM shall at all times during and after the term of this Agreement be responsible for, and shall defend, indemnify, and hold WUND harmless from and against any and all losses, claims, suits, proceedings, expenses, recoveries, and damages, including reasonable legal expenses and costs including attorneys' fees, arising out of any claim by a third party relating to the Product, or any aspect of the performance of this Agreement, to the extent such liability results from the negligence or willful misconduct of ZGM, or any breach of a representation or warranty given herein by ZGM; provided, however, that WUND shall give ZGM prompt notice of any such claim or lawsuit and, provided further, that ZGM shall have the right to compromise, settle, or defend such claim or lawsuit.

11.2. WUND shall at all times during and after the term of this Agreement be responsible for, and shall defend, indemnify, and hold ZGM harmless from and against any and all losses, claims, suits, proceedings, expenses, recoveries, and damages, including reasonable legal expenses and costs including attorneys' fees, arising out of any claim by a third party relating to any aspect of the performance of this Agreement, to the extent such liability results from the negligence or willful misconduct of WUND, or any breach of a representation or warranty given herein by WUND; provided, however, that ZGM shall give WUND prompt notice of any such claim or lawsuit and, provided further, that WUND shall have the right to compromise, settle, or defend such claim or lawsuit.

**Article 12. TERMINATION**

12.1. In the event either Party believes the other Party has breached this agreement, the non-breaching Party shall immediately notify the breaching Party, in writing pursuant to the notice provisions of this Agreement, of the breach (a "Breach Notice"). A Breach Notice shall state with specificity, the basis of alleged breach, including, but not limited to, citation to the specific provision of this Agreement the breaching Party is purportedly in violation of. Upon actual receipt of the Breach Notice, the alleged breaching Party shall have thirty (30) days to remedy the breach, unless the Parties agree to a longer period, in writing (the "Cure Period"). If, after expiration of the Cure Period, the breaching Party has not cured the breach, then the non-breaching Party may terminate this Agreement upon ten (10) days' written notice to the defaulting Party.

CONFIDENTIAL

12.2. Either Party shall have the right to terminate this Agreement upon thirty (30) days' notice to the other Party, if that other Party becomes involved in financial difficulties as evidenced: (a) by that other Party's commencement of a voluntary case under any applicable bankruptcy code or statute, or by its authorizing, by appropriate proceedings, the commencement of such a voluntary case; or (b) by its failing to receive dismissal of any involuntary case under any applicable bankruptcy code or statute within sixty (60) days after initiation of such action or petition; or (c) by its seeking relief as a debtor under any applicable law of any jurisdiction relating to the liquidation or reorganization of debtors or to the modification or alteration of the rights of creditors, or by consenting to or acquiescing in such relief; or (d) by the entry of an order by a court of competent jurisdiction finding it to be bankrupt or insolvent, or ordering or approving its liquidation, reorganization, or any modification or alteration of the rights of its creditors or assuming custody of, or appointing a receiver or other custodian for, all or a substantial part of its property or assets; or (e) by its making an assignment for the benefit of, or entering into a composition with, its creditors, or appointing or consenting to the appointment of a receiver or other custodian for all or a substantial part of its property. The failure by a Party to exercise its right to terminate this Agreement pursuant to this Section in the event of any occurrence giving rise thereto shall not constitute waiver of the rights in the event of any subsequent occurrence.

12.3. Except as otherwise provided in this Agreement, upon the expiration or any termination of this Agreement: (a) All rights, privileges and licenses shall immediately terminate and revert to ZGM, and WUND shall not thereafter make any use whatsoever of any Technology or the Trademark, and shall not further market, sell, or distribute the Product; (b) WUND shall promptly return or provide to ZGM all Technology and other similar information regarding the Product; (c) WUND shall promptly destroy or transfer to ZGM at ZGM's election, all marketing, labeling, or advertising materials relating to the Product or Trademark; and (d) WUND shall promptly pay to ZGM all amounts due to ZGM pursuant to the terms of this Agreement.

12.4. The termination or expiration of this Agreement for any reason shall be without prejudice to any rights that shall have accrued to the benefit of either Party prior to such termination or expiration. Such termination or expiration shall not relieve either Party from obligations that are expressly indicated to survive termination or expiration of this Agreement. All of the Parties' rights and obligations under Articles 1, 5, 6, 7, 8, 9, 11, 12 and 13 shall survive any termination or expiration of this Agreement in accordance with their terms.

**Article 13. MISCELLANEOUS**

13.1. Neither Party shall be liable for any default or delay in such Party's performance if such default or delay is caused by any event beyond the reasonable control of such Party, including but not limited to: act of God; war or insurrection; civil commotion; destruction of essential facilities or materials by earthquake, fire, flood or storm; labor disturbance; epidemic; or other similar event; provided, however, that the Party so affected will give prompt notice of such event, and shall use its best efforts to avoid, remove, or alleviate such causes of nonperformance and shall continue performance hereunder with the utmost dispatch whenever such causes are removed.

13.2. This Agreement sets forth and constitutes the entire agreement and understanding between the Parties with respect to the subject matter hereof, and supersedes any and all prior agreements, understandings, promises and representation, whether written or oral, between the Parties with respect to the subject matter hereof. This Agreement may not be released, discharged, amended or modified in any manner except by an instrument in writing, making specific reference to this Agreement, and signed duly by authorized representatives of both Parties. This Agreement shall not be strictly construed against either Party hereto.

CONFIDENTIAL

13.3. The relationship hereby established between ZGM and WUND is solely that of independent contractors. This Agreement shall not create an agency, partnership, joint venture, or employer/employee relationship, and nothing hereunder shall be deemed to authorize either Party to act for, represent or bind the other except as expressly provided in this Agreement.

13.4. If and solely to the extent that any provision of this Agreement shall be invalid or unenforceable, or shall render this entire Agreement to be unenforceable or invalid, such offending provision shall be of no effect and shall not affect the validity of the remainder of this Agreement or any of its provisions; provided, however, the Parties shall use their respective reasonable efforts to renegotiate the offending provisions to best accomplish the original intentions of the Parties.

13.5. Neither Party may assign any right or obligation hereunder without the written consent of the other Party, except that ZGM may assign all of its rights and obligations hereunder to a ZGM Affiliate or to any entity to whom ZGM also assigns the Technology and ZGM may subcontract the manufacturing of Product. This Agreement shall be binding upon and inure to the benefit of the Parties' respective successors and assigns. Any attempted assignment in violation of this provision shall be void and of no effect.

13.6. This Agreement has been entered into in the State of Nevada USA and its interpretation, construction, and the remedies for its enforcement or breach are to be applied pursuant to and in accordance with the laws of the State of Nevada as applied to agreements without application of choice of law rules. The Parties have each consulted with counsel of their choice regarding the Agreement, and each acknowledges and agrees that this Agreement shall not be deemed to have been drafted by one Party or another and will be construed accordingly. Any disputes arising from or related to this Agreement shall be submitted to the applicable State or Federal Court in Nevada for resolution.

13.7. No waiver of any right under this Agreement shall be deemed effective unless contained in writing and signed by the Party charged with such waiver, and no waiver of any right shall be deemed to be a waiver of any future right or any other right arising under this Agreement. All rights, remedies, undertakings, obligations, and agreements contained in this Agreement shall be cumulative and none of them shall be a limitation of any other remedy, right, undertaking, obligation, or agreement.

13.8. Headings in this Agreement are included for ease of reference only and shall have no legal effect. This Agreement is written in the English language and if either Party translates this Agreement into a language other than English, the English version of this Agreement shall control. English shall be the language of all written and oral communication and between the Parties.

CONFIDENTIAL

13.9. Any notice, consent, or approval permitted or required under this Agreement shall be in writing and shall be sent by registered or certified mail, postage pre-paid, or by overnight courier, or by facsimile or telex (confirmed by mail), to the addresses set forth below or to such other address in the United States that the Parties may hereafter specify by notification in accordance herewith, and all notices shall be deemed to be effective on the date of receipt:

---

| | |
|:---|:---|
| If to ZGM: | Dan Montano, CEO<br> Zhittya Genesis Medicine, Inc.<br> 3017 Carbondale Street, Las Vegas, Nevada 89135,<br> with a simultaneous e-mail copy to: <u>dan@zhittyamedicine.com</u>; and <br> <u>jackjacobs@zhittyamedicine.com</u>, |
| If to WUND: | John K. Laub, President<br> Wund Healing BioPharmaceuticals Inc.<br> 1120 N Town Center Drive, Suite 270, Las Vegas, NV 89144 <br> with a simultaneous e-mail copy to: <u>john.k.laub@gmail.com</u> |

---

13.10. Neither Party shall issue any press release or other publicity materials, or make any presentation with respect to the existence of this Agreement or the terms and conditions hereof without the prior written consent of the other Party, which consent shall not be unreasonably withheld. This restriction shall not apply to disclosures required by law or regulation, including as may be required in connection with any filings made with the US Securities and Exchange Commission or by the disclosure policies of a Stock Exchange or other Government Authority.

IN WITNESS WHEREOF, the Parties have executed this Agreement effective as of the date and year first written above.

---

| | |
|:---|:---|
| Zhittya Genesis Medicine, Inc. | Wund Healing BioPharmaceuticals Inc. |
| Sign: _____________________________________ | Sign: _____________________________________ |
| Name: Dan Montano | Name: John K. Laub |
| Title: CEO | Title: President |
| Date: December 21, 2022 | Date: December 21, 2022 |

---

Signed Signature page attached at the end

CONFIDENTIAL

**EXHIBIT A**

**Milestones for the Portfolio of ZGM Wound Healing Drugs**

As of the date of this Agreement ZGM is in the process of developing Wound Healing drugs for the following medical indications:

(1) Diabetic foot ulcers

(2) Venous ulcers

(3) Burns

(4) Male Pattern Baldness

(5) Topical surgical wounds (C-sections, cosmetic surgeries)

(6) Pressure wounds (bedsores)

(7) Internal surgical wounds (anastomoses)

(8) Second Generation FGF-1 drugs as defined in Section 2.9 for the above medical indications

Below are the milestones and milestone payments for each of the above medical indications. The total of milestone payments for all indications shall not exceed $75 million. Once $75 million is reached WUND's obligation to pay milestone payments shall be satisfied except with respect to the Option Rights as provided in **Exhibit B** below. The "RB" referenced below refer to the regulatory bodies of any Government Authority as defined in this Agreement.

**1. Diabetic Foot Ulcers (DFUs)**

---

| | |
|:---|:---|
| Milestone  | Payment ($ million) |
| Complete animal toxicity studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.1 |
| First Patient treated in Phase I clinical trial | 0.1 |
| Final Patient treated in Phase I clinical trial | 0.5 |
| Phase I Study Safety Endpoints Met | 1.0 |
| Submit Phase II Clinical Protocol to RB | 0.1 |
| Phase II Protocol Accepted by RB | 0.25 |
| First Patient treated in Phase II clinical trial | 0.5 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Submit "Breakthrough Drug Designation" application to RB | 0.5 |
| Final Patient treated in Phase II clinical trial | 2.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 5.0 |
| "Breakthrough Drug Designation" approved by RB | 5.0 |
| If Breakthrough Drug Designation Obtained: |  |
| Submit New Drug Application (NDA) to RB for Commercial Sale of Drug | 10.0 |

---

CONFIDENTIAL

---

| | |
|:---|:---|
| RB Approval | 10.0 |
| If Breakthrough Drug Designation Not Obtained: End of Phase II Meeting with RB | 0.5 |
| Submit Phase III Clinical Protocol to RB | 0.25 |
| Phase III Protocol Accepted by RB | 0.5 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 5.0 |
| Submit New Drug Application to RB for Commercial Sale of Drug | 10.0 |
| RB Approval | 10.0 |
| **2. Venous Ulcer Drug** |  |
| Milestone  | Payment ($ million) |
| Complete animal toxicity studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.1 |
| First Patient treated in Phase I clinical trial | 0.1 |
| Final Patient treated in Phase I clinical trial | 0.5 |
| Phase I Study Safety Endpoints Met | 1.0 |
| Submit Phase II Clinical Protocol to RB | 0.1 |
| Phase II Protocol Accepted by RB | 0.25 |
| First Patient treated in Phase II clinical trial | 0.50 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Final Patient treated in Phase II clinical trial | 2.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 5.0 |
| End of Phase II Meeting with RB | 0.50 |
| Submit Phase III Clinical Protocol to RB | 0.25 |
| Phase III Protocol Accepted by RB | 0.50 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 5.0 |
| Submit NDA Application to RB | 10.0 |
| RB Approval | 10.0 |
| 3. **Burns:** |  |
| Milestone | Payment ($ million) |
| Complete animal toxicity studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.1 |
| First Patient treated in Phase I clinical trial | 0.1 |
| Final Patient treated in Phase I clinical trial | 0.5 |
| Phase I Study Safety Endpoints Met | 1.0 |

---

CONFIDENTIAL

---

| | |
|:---|:---|
| Submit Phase II Clinical Protocol to RB | 0.1 |
| Phase II Protocol Accepted by RB | 0.25 |
| First Patient treated in Phase II clinical trial | 0.50 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Final Patient treated in Phase II clinical trial | 2.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 5.0 |
| End of Phase II Meeting with RB | 0.50 |
| Submit Phase III Clinical Protocol to RB | 0.25 |
| Phase III Protocol Accepted by RB | 0.50 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 5.0 |
| Submit New Drug Application to RB | 10.0 |
| RB Approval | 10.0 |
| **4. Male Pattern Baldness** |  |
| Milestone  | Payment ($ million) |
| Complete proof of concept study in rodents | 0.2 |
| Complete animal toxicity studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.1 |
| First Patient treated in Phase I clinical trial | 0.1 |
| Final Patient treated in Phase I clinical trial | 0.5 |
| Phase I Study Safety Endpoints Met | 1.0 |
| Submit Phase II Clinical Protocol to RB | 0.1 |
| Phase II Protocol Accepted by RB | 0.25 |
| First Patient treated in Phase II clinical trial | 0.50 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Final Patient treated in Phase II clinical trial | 2.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 5.0 |
| End of Phase II Meeting with RB | 0.50 |
| Submit Phase III Clinical Protocol to RB | 0.25 |
| Phase III Protocol Accepted by RB | 0.50 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 5.0 |
| Submit New Drug Application to RB | 10.0 |
| RB Approval | 10.0 |

---

CONFIDENTIAL

---

| | |
|:---|:---|
| **5. Topical Surgical Wounds** |  |
| Milestone | Payment ($ million) |
| Complete animal toxicity studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.1 |
| First Patient treated in Phase I clinical trial | 0.1 |
| Final Patient treated in Phase I clinical trial | 0.5 |
| Phase I Study Safety Endpoints Met | 1.0 |
| Submit Phase II Clinical Protocol to RB | 0.1 |
| Phase II Protocol Accepted by RB | 0.25 |
| First Patient treated in Phase II clinical trial | 0.50 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Final Patient treated in Phase II clinical trial | 2.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 5.0 |
| End of Phase II Meeting with RB | 0.50 |
| Submit Phase III Clinical Protocol to RB | 0.25 |
| Phase III Protocol Accepted by RB | 0.50 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 5.0 |
| Submit New Drug Application to RB | 10.0 |
| RB Approval | 10.0 |
| **6. Pressure wounds (bedsores)** |  |
| Milestone | Payment ($ million) |
| Complete animal toxicity studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.1 |
| First Patient treated in Phase I clinical trial | 0.1 |
| Final Patient treated in Phase I clinical trial | 0.5 |
| Phase I Study Safety Endpoints Met | 1.0 |
| Submit Phase II Clinical Protocol to RB | 0.1 |
| Phase II Protocol Accepted by RB | 0.25 |
| First Patient treated in Phase II clinical trial | 0.5 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Final Patient treated in Phase II clinical trial | 2.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 5.0 |
| End of Phase II Meeting with RB | 0.5 |
| Submit Phase III Clinical Protocol to RB | 0.25 |
| Phase III Protocol Accepted by RB | 0.5 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 5.0 |
| Submit New Drug Application to RB | 10.0 |
| RB Approval | 10.0 |

---

CONFIDENTIAL

---

| | |
|:---|:---|
| **7. Internal surgical wounds (anastomoses)** |  |
| Milestone | Payment ($ million) |
| Complete animal toxicity studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.1 |
| First Patient treated in Phase I clinical trial | 0.1 |
| Final Patient treated in Phase I clinical trial | 0.5 |
| Phase I Study Safety Endpoints Met | 1.0 |
| Submit Phase II Clinical Protocol to RB | 0.1 |
| Phase II Protocol Accepted by RB | 0.25 |
| First Patient treated in Phase II clinical trial | 0.5 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Final Patient treated in Phase II clinical trial | 2.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 5.0 |
| End of Phase II Meeting with RB | 0.5 |
| Submit Phase III Clinical Protocol to RB | 0.25 |
| Phase III Protocol Accepted by RB | 0.5 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 5.0 |
| Submit New Drug Application to RB | 10.0 |
| RB Approval | 10.0 |
| **8**. **Second Generation FGFs (payments for each medical indication)** | **8**. **Second Generation FGFs (payments for each medical indication)** |
| Milestone | Payment ($ million) |
| Produce 2nd generation FGF-1 proteins | 0.1 |
| Complete animal toxicity and efficacy studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.1 |
| First Patient treated in Phase I clinical trial | 0.1 |
| Final Patient treated in Phase I clinical trial | 0.5 |
| Phase I Study Safety Endpoints Met | 1.0 |
| Submit Phase II Clinical Protocol to RB | 0.1 |
| Phase II Protocol Accepted by RB | 0.25 |
| First Patient treated in Phase II clinical trial | 0.5 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Final Patient treated in Phase II clinical trial | 2.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 5.0 |
| End of Phase II Meeting with RB | 0.5 |
| Submit Phase III Clinical Protocol to RB | 0.25 |
| Phase III Protocol Accepted by RB | 0.5 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 5.0 |
| Submit NDA Application to RB | 10.0 |
| RB Approval | 10.0 |

---

CONFIDENTIAL

<u>**EXHIBIT B**</u>

**Milestones for the Portfolio of ZRM's Injectable/Infusion/Intranasal Drugs**

Milestone Payments for the Portfolio of ZRM's portfolio of Injectable, Infusion and Intranasal Drugs includes the potential drug treatment for the remediation and/or cure of the following medical indications:

(1) Parkinson's Disease

(2) Stroke

(3) Multi-infarct Dementia

(4) Coronary Heart Disease

(5) Peripheral Artery Disease

(6) Lumbar Ischemia

(7) Chronic Traumatic Encephalopathy (CTE)

(8) Traumatic Brain Injury (TBI)

(9) Alzheimer's Disease

(10) Huntington's Disease

(11) Amyotrophic Lateral Sclerosis (ALS)

(12) Chronic Depression

(13) Post Traumatic Stress Disorder (PTSD)

(14) Multiple Sclerosis (MS)

(15) Multiple Systems Atrophy (MSA)

Below are the Milestones and Milestone Payments for the development of each and any of the above listed medical indications. The total of Milestone Payments for all indications shall not exceed $300 million. Once $300 million is reached WUND's obligation to pay Milestone Payments for any Injectable Infusion, and Intranasal Drug shall be satisfied. As identified by ZGM or a third party, additional medical indications that can be potentially treated with human FGF-1 may be added to the above EXHIBIT B list with the written agreement of both Parties.

The "RB" referenced below refers to the regulatory bodies of any Government Authority as defined in this Agreement.

**Milestone Payments for each Injectable Infusion and Intranasal Drug for the Fifteen (15) Medical Indications noted above and any agreed additions thereto:**

---

| | |
|:---|:---|
| Milestone  | Payment ($ million) |
| Complete animal toxicity studies | 0.2 |
| Submit Phase I Clinical Protocol to RB | 0.1 |
| Phase I Protocol Accepted by RB | 0.5 |
| First Patient treated in Phase I clinical trial | 0.5 |
| Final Patient treated in Phase I clinical trial | 1.0 |
| Phase I Study Safety Endpoints Met | 2.0 |
| Submit Phase II Clinical Protocol to RB | 0.2 |
| Phase II Protocol Accepted by RB | 0.5 |

---

CONFIDENTIAL

---

| | |
|:---|:---|
| First Patient treated in Phase II clinical trial | 1.0 |
| 1/3 Patients treated in Phase II clinical trial | 1.0 |
| 2/3 Patients treated in Phase II clinical trial | 1.0 |
| Submit "Breakthrough Drug Designation" application to RB | 0.5 |
| Final Patient treated in Phase II clinical trial | 4.0 |
| Phase II Study Unblinded and Efficacy Endpoints Met | 15.0 |
| "Breakthrough Drug Designation" approved by RB | 25.0 |
| If Expedited or Breakthrough Drug Designation Obtained: Submit NDA Application to RB | 5.0 |
| RB Approval | 25.0 |
| If Breakthrough Drug Designation Not Obtained: End of Phase II Meeting with RB | 0.5 |
| Submit Phase III Clinical Protocol to RB | 0.5 |
| Phase III Protocol Accepted by RB | 1.0 |
| 1/3 Patients treated in Phase III clinical trial | 2.0 |
| 2/3 Patients treated in Phase III clinical trial | 2.0 |
| Final Patient treated in Phase III clinical trial | 2.0 |
| Phase III Study Unblinded and Efficacy Endpoints Met | 25.0 |
| Submit NDA Application to RB | 5.0 |
| RB Approval | 25.0 |

---

![](wund_ex101img2.jpg)

## Ex1A-6

**EXHIBIT 6.2**

![](wund_ex102img3.jpg)

October 13, 2025

Wund Healing Biopharmaceuticals, Inc.

8683 W. Sahara Avenue, Suite 280

Las Vegas, NV 89117

Daniel Montano, CEO

Zhittya Genesis Medicine

3017 Carbondale Street

Las Vegas, NV 89135

Dear Mr. Montano,

This letter documents that Zhittya Genesis Medicine, Inc. (Zhittya) will pay Wund Healing Biopharmaceuticals, Inc. (Wund) $15,000 per patient for the FGF-1 used in the investor-funded research studies for type 2 diabetes conducted in the United States.

This letter also further clarifies the arrangement as noted in the December 21, 2022 contract between Zhittya and Wund that the net sales from the investor-funded research studies should also be subject to the same terms for cross-border operations in which these sales should qualify for the exemption from royalties payable to Zhittya on the first $3 million of sales, 50% royalites on sales over $3 million to $10 million and up to 80% royalties of sales over $10 million.

Sincerely,

*/s/ John Laub*

John Laub, CEO

Wund Healing Biopharmaceuticals, Inc.

Signed by Zhittya Genesis Medicine, Inc.

---

| | |
|:---|:---|
| */s/ Dan Montano*  | Oct 13, 2025 |
| Dan Montano | Date |

---

## Ex1A-6

**EXHIBIT 6.3**

![](wund_ex103img6.jpg)

January 19, 2026

Wund Healing Biopharmaceuticals, Inc.

8683 W. Sahara Avenue, Suite 280

Las Vegas, NV 89117

Daniel Montano, CEO

Zhittya Genesis Medicine, Inc.

3017 Carbondale Street

Las Vegas, NV 89135

Re: Granting Full Information Rights to Zhittya's FGF-1 Drug Development Data

Dear Mr. Montano,

Wund Healing Biopharmaceuticals, Inc. ("Wund") is requesting that Zhittya Genesis Medicine, Inc. ("Zhittya") grant full information rights to Zhittya's FGF-1 drug development data to Wund.

1. <u>Data Access and Delivery</u>.

The Grantor shall provide the Grantee with full and complete access to all Development Data, which includes but is not limited to:

● **Pre-clinical and Clinical Results**: Raw data, analyzed results, and final reports from all trials.

● **Regulatory Communications**: Copies of all filings, correspondence, and meeting minutes with the FDA, EMA, or other relevant health authorities.

● **CMC Information**: Data regarding Chemistry, Manufacturing, and Controls, including stability studies and manufacturing logs.

2. <u>Frequency and Inspection</u>.

● **Regular Reporting**: The Grantor shall provide written progress reports on an as-needed basis upon request.

● **Audit Rights**: The Grantee shall have the right, upon reasonable notice, to inspect the Grantor's facilities and records to verify the accuracy of the Information.

● **Ad Hoc Updates**: The Grantor must notify the Grantee within 48 hours of any "Material Development Event" (e.g., a clinical hold or unexpected serious adverse event).

3. <u>Format and Interoperability</u>.

All data shall be provided in a searchable, electronic format (e.g., a Secure File Transfer Protocol or a dedicated Virtual Data Room) and shall comply with standard industry formatting (such as CDISC standards for clinical data).

Sincerely,

*/s/ John Laub*

John Laub, CEO

Wund Healing Biopharmaceuticals, Inc.

Grant of Access to development drug data by Daniel C. Montano, CEO of Zhittya Genesis Medicine

---

| | |
|:---|:---|
| */s/ Dan Montano* | 01.19.2026 |
| Daniel Montano | Date |

---

## Ex1A-6

**EXHIBIT 6.4**

**Consulting Agreement - John Laub**

This Consulting Agreement (the **<u>"Agreement")</u>** is entered into as of July 22, 2025, to be effective as of January 1, 2025 (the **<u>"Effective Date")</u>** is by and between Wund Healing Biopharmaceuticals, Inc., a Nevada corporation with its principal place of business at 8683 W. Sahara Avenue, Suite 280, Las Vegas, NV 89117 (the **<u>"Company"),</u>** and John Laub, an individual residing at 9501 Royal Windsor Avenue, Las Vegas, NV 89149 (the **<u>"Consultant")</u>.**

**1. Position and Duties**

· Position: The Consultant shall serve as Chief Executive Officer, shall report to the Board of Directors, and shall complete such services as may be reasonably requested by Consultant from time to time by the Board of Directors.

· Duties: The Consultant shall perform the duties and responsibilities assigned by the Company, consistent with the Consultant's position, and as may be modified by the Company from time to time.

· No Conflicts. During the term of this Agreement, Consultant will not take any action that would directly or indirectly promote any competitor or impair the Company's interests. The Consultant agrees that Consultant does not presently perform and will not perform during the term of Agreement, consulting or other services for companies whose businesses are or would be, in any material way, competitive with the Company, without the Board's prior approval.

**2. Term of Engagement**

· At-Will: The Consultant's contract with the Company is at-will, meaning either party may terminate the relationship at any time, with or without cause or notice, subject to the terms of Section 6 (Termination and Severance).

· Effective Date: This Agreement shall commence on the Effective Date and remain in effect until terminated in accordance with Section 6.

· The Company makes no representations or warranties with respect to the tax consequences of the payments and any other consideration provided to Consultant under the terms of this Agreement. Consultant agrees and understands that he is responsible for payment, if any, of local, state, and/or federal taxes on the payments and any other consideration provided hereunder by the Company and any penalties or assessments thereon. Consultant agrees to indemnify and hold harmless the Company and its affiliates and their directors, officers and employees from and against all taxes, losses, damages, liabilities, costs and expenses, including attorneys' fees and other legal expenses, arising from or in connection with (i) any obligation imposed on the Company to pay withholding taxes or similar items, or (ii) any determination by a court or agency that the Consultant is not an independent contractor pursuant to this Agreement.

Consulting Agreement

John Laub and Wund Healing

Page 1 of 11

**3. Compensation**

3.1 Base

· The Consultant shall receive annual compensation of $120,000 (the  **<u>"Base</u>** "), prorated for partial years, payable bi-weekly. The Base shall accrue beginning on the Effective Date (such accrued amounts from time to time, the  **<u>"Accrued Base")</u>,** and shall be payable, together with Accrued Base, beginning on such date as the Company has the cash flow to make the monthly payments and/or pay the Accrued Base, as determined in the sole discretion of the Board of Directors (the  **<u>"Determination Date")</u>.** 

· The Base shall be subject to applicable tax withholdings and deductions.

· The Compensation Committee of the Board of Directors (the  **<u>"Board")</u>** shall review the Base annually and the Compensation Committee or the Board may adjust the Base at their discretion, provided any decrease requires the Consultant's consent unless part of a company-wide reduction.

3.2 Annual Incentive Bonus

· The Consultant shall be eligible to receive an annual performance-based bonus (the  **<u>"Bonus")</u>** based on the achievement of individual and/or Company performance objectives as determined by the Compensation Committee.

· The Bonus, if earned, shall be paid within 90 days.

· The Compensation Committee reserves the right to modify the Bonus structure or performance criteria annually.

· The Compensation Committee or the Board may award Consultant discretionary bonuses from time to time in its discretion.

· Any bonus earned herein shall be paid by March 15th of the year following the date it is earned.

Consulting Agreement

John Laub and Wund Healing

Page 2 of 11

3.3 Equity Awards

· The Consultant shall be eligible to participate in the Company's equity incentive plan (the  **<u>"Equity Plan")</u>,** subject to the terms of the Equity Plan and any applicable award agreements.

· All equity awards shall be governed by the Equity Plan and separate award agreements, which shall control in the event of any conflict with this Agreement.

3.4 Benefits

· The Consultant shall be eligible to participate in the Company's standard employee benefit plans, including health, dental, vis,ion, life, and disability insurance, retirement plans, and paid time off, subject to the terms and conditions of such plans.

· The Company reserves the right to modify or terminate benefit plans at its discretion, consistent with applicable law.

3.5 Expense Reimbursement

· The Company shall reimburse the Consultant for reasonable and necessary business expenses incurred in the performance of their duties, in accordance with the Company's expense reimbursement policy.

· The Consultant shall submit expense reports with receipts within 30 days of incurring expenses.

**4. Confidentiality and Restrictive Covenants**

· Confidentiality: The Consultant shall not disclose or use any confidential information of the Company, except as required for his duties or as authorized by the Company. The Consultant shall sign and comply with the Company's standard Confidentiality Agreement.  **<u>"Confidential information"</u>** means all confidential information of the Company and its trade secrets relating to the business affairs, customers, suppliers, technology, proprietary rights, patents, research, plans, research data, marketing techniques, manufacturing methods, procedures and techniques, industrial designs, inventions, improvements, discoveries and routines concerning the Company, its business and those of its affiliates and of its customers and their particular business requirements.

**5. Compliance with Company Policies**

· The Consultant shall comply with the Company's Code of Ethics, employee handbook, and other policies, as amended from time to time.

· The Consultant acknowledges receipt of the Company's Code of Ethics and agrees to abide by its terms.

Consulting Agreement

John Laub and Wund Healing

Page 3 of 11

**6. Termination and Severance**

6.1 Termination

· At-Will Termination: Either party may terminate the Consultant's contract at any time, with or without Cause or required pre-termination notice.

· Termination for Cause: The Company may terminate the Consultant for  **<u>"Cause",</u>** defined as: (i) willful misconduct or gross negligence; (ii) fraud, embezzlement, or theft; (iii) material violation of Company policies or this Agreement; (iv) conviction of a felony or crime involving moral turpitude; (v) willful failure to perform duties after written notice and a reasonable opportunity to cure (if curable); or (vi) beach of any provision of this Agreement and failure to cure with 20 days prior notice.

· Termination by Consultant for Good Reason: The Consultant may resign for  **<u>"Good</u> <u>Reason",</u>** defined as: (i) a material reduction in Base or target Bonus opportunity without consent; (ii) a material diminution in duties or authority; or (iii) relocation of the Consultant's primary workplace by more than 50 miles without consent, provided the Consultant gives written notice within 30 days of the event, the Company fails to cure within 30 days, and the Consultant resigns within 60 days of the notice.

· On the effective termination date, the Consultant will deliver to the Company, in a reasonable state of repair, all property including without limitation, all copies, extracts and summaries, whether in written, digital, magnetic or electronic form, of documents and information of the Company in the possession or under the control or direction of the Consultant as at the termination date.

6.2 Severance

· Termination Without Cause or for Good Reason: If the Company terminates the Consultant without Cause or the Consultant resigns for Good Reason, the Consultant shall receive:

· Severance pay equal to 1 year of the Base at the time of termination.

· Payment of any earned but unpaid Bonus for the prior fiscal year.

· Accelerated vesting of 50% of unvested equity awards, subject to the Equity Plan.

· Continuation of health benefits for six months subject to COBRA eligibility and the Consultant's payment of applicable premiums.

Consulting Agreement

John Laub and Wund Healing

Page 4 of 11

· Conditions: Severance payments are conditioned on the Consultant signing a general release of claims in a form provided by the Company and complying with restrictive covenants.

· Termination for Cause or Voluntary Resignation: No severance shall be payable if the Consultant is terminated for Cause or resigns without Good Reason or upon the death or disability of the Consultant.

6.3 Change in Control

· If the Consultant is terminated without Cause or resigns for Good Reason within 12 months following a Change in Control, the Consultant shall receive:

· Severance pay equal to 12 months of Base pay, payable in a lump sum.

· Full accelerated vesting of all unvested equity awards.

· Continuation of health benefits for six months, subject to COBRA eligibility, and the Consultant's payment of applicable premiums.

· For purposes of this Agreement, a  **<u>"Change in Control"</u>** means the happening of any of the following after the date hereof:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) The consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if fifty percent (50%) or more of the combined voting power of the continuing or surviving entity's securities outstanding immediately after such merger, consolidation, or other reorganization is owned by persons who were not shareholders of the Company immediately prior to such merger, consolidation, or other reorganization.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The sale, transfer, or other disposition of all or substantially all of the Company's assets or the complete liquidation or dissolution of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) A change in the composition of the Board of Directors of the Company (the **<u>"Board")</u>** occurring within a two (2) year period, as a result of which fewer than a majority of the directors are Incumbent Directors. **<u>"Incumbent Directors"</u>** shall mean directors who are directors of the Company as of the Effective Date. **<u>"Incumbent Directors"</u>** shall also include directors who are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors (including persons who later become Incumbent Directors hereunder) at the time of such election or nomination, but shall not include an individual not otherwise an Incumbent Director whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company.

Consulting Agreement

John Laub and Wund Healing

Page 5 of 11

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) Any transaction as a result of which any person or group is or becomes the **<u>"beneficial owner"</u>** (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of securities of the Company representing at least thirty percent (30%) of the total voting power of the Company's then outstanding voting securities. For purposes of this paragraph, the term **<u>"person"</u>** shall have the same meaning as when used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but shall exclude: (i) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a subsidiary of the Company; (ii) so long as a person does not thereafter increase such person's beneficial ownership of the total voting power represented by the Company's then outstanding voting securities, a person whose beneficial ownership of the total voting power represented by the Company's then outstanding voting securities increases to thirty percent (30%) or more as a result of the acquisition of voting securities of the Company by the Company which reduces the number of such voting securities then outstanding; or (iii) so long as a person does not thereafter increase such person's beneficial ownership of the total voting power represented by the Company's then outstanding voting securities, a person that acquires directly from the Company securities of the Company representing at least thirty percent (30%) of the total voting power represented by the Company's then outstanding voting securities.

· A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company's incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities immediately before such transaction.

· Severance payments are subject to the same conditions as in Section 6.2.

Consulting Agreement

John Laub and Wund Healing

Page 6 of 11

**7. Tax Matters**

· All payments under this Agreement are subject to applicable federal, state, and local tax withholdings.

· It is intended that all payments and benefits provided under this Agreement or otherwise are exempt from, or comply with, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the  **<u>"Code"),</u>** and the regulations and other guidance thereunder or any state law of similar effect (collectively,  **<u>"Section 409A")</u>** so that none of the payments or benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted in accordance with such intent. For purposes of Section 409A, each payment, installment or benefit payable under this Agreement is hereby designated as a separate payment.

· Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the  **<u>"Severance Benefits")</u>** that constitute  **<u>"deferred</u> <u>compensation"</u>** within the meaning of Section 409A and that are not exempt from Section 409A shall not commence in connection with the Consultant's termination of service unless and until the Consultant has also incurred a  **<u>"separation from service"</u>** (as such term is defined in Treasury Regulation Section 1.409A-l(h)  **<u>("Separation From</u> <u>Service")).</u>** 

· If the Company (or, if applicable, the successor entity thereto) determines that a Severance Benefit constitutes  **<u>"deferred compensation"</u>** under Section 409A and the Consultant is, on the Consultant's Separation From Service, a  **<u>"specified employee"</u>** of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code and the Treasury regulations, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payment shall be delayed until the earlier to occur of: (i) the date that is six (6) months and one (1) day after the Consultant's Separation From Service or (ii) the date of the Consultant's death (such applicable date, the  **<u>"Specified Initial Payment Date")</u>.** On the Specified Initial Payment Date, the Company (or the successor entity thereto, as applicable) shall pay to the Consultant a lump sum amount equal to the Severance Benefit payment that the Consultant would otherwise have received through the Specified Initial Payment Date if the payment of the Severance Benefits had not been so delayed pursuant to this Section.

Consulting Agreement

John Laub and Wund Healing

Page 7 of 11

**8. Indemnification**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1. The Company agrees to indemnify Consultant and hold Consultant harmless from and against any and all losses, claims, damages, liabilities and costs (and all actions in respect thereof and any legal or other expenses in giving testimony or furnishing documents in response to a subpoena or otherwise), including, without limitation, the costs of investigating, preparing or defending any such action or claim, whether or not in connection with litigation in which Consultant is a party, as and when incurred, directly or indirectly caused by, relating to, based upon or arising out of any work performed by Consultant in connection with this Agreement to the full extent permitted by the Nevada Revised Statutes, and by the Articles of Incorporation and Bylaws of the Company, as may be amended and restated from time to time, and pursuant to any indemnification agreement between Consultant and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2. The indemnification provision of this Section 8 shall be in addition to any liability which the Company may otherwise have to Consultant.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.3. If any action, proceeding or investigation is commenced as to which Consultant proposes to demand such indemnification, Consultant shall notify the Company with reasonable promptness. Consultant shall have the right to retain counsel of Consultant's own choice to represent Consultant and the Company shall pay all reasonable fees and expenses of such counsel; and such counsel shall, to the fullest extent consistent with such counsel's professional responsibilities, cooperate with the Company and any counsel designated by the Company. The Company shall be liable for any settlement of any claim against Consultant made with the Company's written consent, which consent shall not be unreasonably withheld or delayed, to the fullest extent permitted by the Nevada Revised Statutes, and by the Articles of Incorporation and Bylaws of the Company, as may be amended and restated from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.4 Notwithstanding the above, in the event of any conflict between this Section 8, and the Nevada Revised Statutes, the Nevada Revised Statutes shall control.

**9. Dispute Resolution**

· Any disputes arising under this Agreement shall be resolved through binding arbitration in Las Vegas, Nevada in accordance with the rules of the American Arbitration Association, except for disputes involving injunctive relief for breaches of confidentiality or restrictive covenants.

· The prevailing party in any dispute shall be entitled to reasonable attorneys' fees and costs, to the extent permitted by law.

Consulting Agreement

John Laub and Wund Healing

Page 8 of 11

**10. Miscellaneous**

· Governing Law: This Agreement shall be governed by the laws of Nevada without regard to conflict of law principles.

· Entire Agreement: This Agreement constitutes the entire agreement between the parties and supersedes all prior agreements or understandings.

· Amendments: This Agreement may only be amended in writing, signed by both parties.

· Severability: If any provision of this Agreement is found to be invalid or unenforceable, the remaining provisions shall remain in full force and effect.

· Assignment: The Consultant may not assign this Agreement. The Company may assign this Agreement to a successor in interest, provided the successor assumes all obligations.

· Notices: Notices shall be sent to the addresses listed above or such other addresses as the parties may designate in writing.

· Clawback: Notwithstanding any provision in this Agreement to the contrary, any portion of the payments and benefits provided under this Agreement, as well as any other payments and benefits which the Consultant receives pursuant to a Company plan or other arrangement, shall be subject to a clawback (a) to the extent necessary to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act or any Securities and Exchange Commission rule or any other applicable law; and/or (b) any policy adopted by the Company and applicable generally to Consultant and other officers of the Company, relating to the recovery of compensation granted, paid, delivered, awarded or otherwise provided to Consultant by the Company or its subsidiaries or any of their respective affiliates, as applicable, as may be amended from time to time.

· Specific Enforcement. If necessary and where appropriate, the Company shall have the right to enforce the provisions of this Agreement by injunction, specific performance or other equitable relief without bond and without prejudice to any other rights and remedies the Company may have.

· Jury Waiver: TO THE EXTENT PERMITTED BY LAW, IT IS MUTUALLY AGREED BY AND BETWEEN THE COMPANY AND CONSULTANT THAT THE RESPECTIVE PARTIES HERETO SHALL, AND THEY DO HEREBY, WAIVE TRIAL BY JURY IN ANY ACTION, PROCEEDING OR COUNTERCLAIM BROUGHT BETWEEN THE PARTIES HERETO OR THEIR SUCCESSORS OR ASSIGNS ON ANY MATTERS ARISING OUT OF, OR IN ANY WAY CONNECTED WITH, THIS AGREEMENT.

Consulting Agreement

John Laub and Wund Healing

Page 9 of 11

· No Presumption from Drafting: This Agreement has been negotiated at arm's-length between persons knowledgeable in the matters set forth within this Agreement. Accordingly, given that all parties have had the opportunity to draft, review and/or edit the language of this Agreement, no presumption for or against any party arising out of drafting all or any part of this Agreement will be applied in any action relating to, connected with or involving this Agreement. In particular, any rule of law, legal decisions, or common law principles of similar effect that would require interpretation of any ambiguities in this Agreement against the party that has drafted it, is of no application and is hereby expressly waived. The provisions of this Agreement shall be interpreted in a reasonable manner to affect the intentions of the parties.

· Review and Construction of Documents: Each party herein expressly represents and warrants to all other parties hereto that (a) before executing this Agreement, said party has fully informed itself of the terms, contents, conditions and effects of this Agreement; (b) said party has relied solely and completely upon its own judgment in executing this Agreement; (c) said party has had the opportunity to seek and has obtained the advice of its own legal, tax and business advisors before executing this Agreement; (d) said party has acted voluntarily and of its own free will in executing this Agreement; and (e) this Agreement is the result of arm's length negotiations conducted by and among the parties and their respective counsel.

**11. Counterparts, Effect of Facsimile, Emailed and Photocopied Signatures.**

This Agreement may be executed in two or more counterparts, each of which shall be deemed to be an original, but all of which shall constitute one and the same agreement. This Agreement and any signed agreement or instrument entered into in connection with this Agreement, and any amendments hereto or thereto, may be executed in one or more counterparts, all of which shall constitute one and the same instrument. Any such counterpart, to the extent delivered by means of a facsimile machine or by .pdf, .tif, .gif, .jpg or similar attachment to electronic mail (including email) or as an electronic download (any such delivery, an **<u>"Electronic Delivery")</u>** shall be treated in all manner and respects as an original executed counterpart and shall be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. At the request of any party, each other party shall re-execute the original form of this Agreement and deliver such form to all other parties. No party shall raise the use of Electronic Delivery to deliver a signature or the fact that any signature or agreement or instrument was transmitted or communicated through the use of Electronic Delivery as a defense to the formation of a contract, and each such party forever waives any such defense, except to the extent such defense relates to lack of authenticity.

**12. Acknowledgment**

The Consultant acknowledges that he has had the opportunity to review this Agreement, consult with legal counsel, and understand its terms.

[Remainder of page left intentionally blank. Signature page follows.]

Consulting Agreement

John Laub and Wund Healing

Page 10 of 11

IN WITNESS WHEREOF, the parties have executed this Agreement as of the Effective Date.

**COMPANY**

![](wund_ex64img3.jpg)<br>

Consulting Agreement

John Laub and Wund Healing

Page 11 of 11

## Ex1A-6

**EXHIBIT 6.5**

**INDEPENDENT CONTRACTOR AGREEMENT**

This Independent Contractor Agreement (this **"Agreement'')** is entered into between Wund Healing Biopharmaceuticals, Inc., a Nevada corporation **("Company"),** and the contractor named on the signature page **("Contractor")** as of January 15, 2025 (the **''Effective Date").** Company wants to retain Contractor as an independent contractor to perform services for Company, and Contractor is willing to perform such services, under the terms described below. The parties agree as follows:

1. **Engagement of Services.** Contractor will provide the services as a contracted Chief Financial Officer (the **"Services").** Contractor shall report to the Chief Executive Officer and perform the duties and responsibilities associated with service as contracted Chief Financial Officer. Contractor will have exclusive control over the manner and means of performing the Services, including the choice of place and time. While on Company's premises, Contractor will comply with Company's then-current access rules and procedures, including those related to safety, security, and confidentiality.

2. **Compensation.** As Contractor's sole compensation for the Services, Company will pay Contractor a base compensation of$180,000 annually and amortized monthly **("Base").** The Base shall accrue beginning on the Effective Date ()"**Accrued Base")** and shall be due and payable upon the date the Parties to this Agreement have determined the Company has sufficient cash flow to pay the base and the Accrued Base. Additionally, the Contractor shall be eligible to receive performance-based bonus as determined and agreed by the Parties to this Agreement. Company shall pay reimbursement for health insurance up to $750 per month for Jon Paul once the company goes public. In addition, Contractor will be reimbursed all reasonable and necessary expenses incurred in the performance of Contractor's duties. Once there is sufficient cash flow as set forth above, Company will pay to Contractor all compensation and reimbursed expenses on or before the first day of each month.

3. **Equity Awards.** The Contractor shall be eligible to participate in the Company's equity incentive plan (the  **<u>"RSU Plan"</u>** (RSU)), subject to the terms of the RSU Plan and any applicable award agreements. *As* additional consideration for the Contractor entering into this Agreement, subject to the Contractor entering into a Subscription Agreement in favor of the Company, and subject to approval by the Board of Directors of the Company, the Contractor shall be awarded 50,000 restricted stock units that will vest at 2 years at 40%, 3 years at 30% and at 4 years at 30%, subject in each case to the terms of the RSU Plan, the award agreement entered into to evidence such award, and the Consultant's continued service to the Company on such vesting dates.

4. **Representations and Warranties.** Contractor represents and warrants to Company that:

---

| | |
|:---|:---|
| a | Contractor has the authority to enter into this agreement and to perform all obligations hereunder. |
| b. | Contractor warrants and represents that Contractor possesses or has applied for an employer identification number or social security number or has filed an income tax return for business or earnings from self-employment with the Internal Revenue Service in the previous year; |
| c. | Contractor warrants and represents that Contractor holds any necessary business registrations or local business licenses and maintains any necessary occupational license, insurance or bonding. |

---

d. Contractor warrants and represents that Contractor has control and discretion over the means and manner of the performance of the work under this Agreement and the result of the work, rather than the means or manner by which the work is performed, is the primary element of this Agreement;

e. Contractor warrants and represents Contractor has control over the time the work that is the subject of this Agreement is performed;

f. Contractor warrants and represents that Contractor is free to perform work for any other business and in any other endeavor; and that Contractor it is not solely economically dependent upon Company.

g. Contractor warrants and represents that Contractor has sole control of his/her/its opportunity for profit or loss and that opportunity is based upon the Contractor's independent skill and initiative.

h. Contractor warrants and represents that Contractor understands that no performance of work for Company creates a joint venture or any other relationship aside from that of an independent contractor.

i. Contractor warrants and represents that Contractor understands, subject to the confidentiality, non-disclosure and non-solicitation provisions of this Agreement, that Contractor is not required to work exclusively for Company;

j. Contractor warrants and represents that Contractor is free to hire employees, subject to the approval of the content of the work by Company, to assist with the work. However, Contractor further warrants and represents that Contractor understands Contractor is solely responsible for the content of the work performed under this Agreement;

k. Contractor warrants and represents that Contractor contributes a substantial investment of capital in Contractor's business;

1. Contractor will perform the Services performed in a professional manner and in accordance with industry standards and all Work Product will comply with the requirements in the applicable Statements of Work;

n. Contractor warrants that neither the Work Product nor any element thereof infringes or misappropriates, or will infringe upon or misappropriate, any copyright, patent, trademark, trade secret, right of publicity or privacy, or any other proprietary right of any person

o. Contractor has the right to grant to Company the license to Preexisting IP set forth in this Agreement; and

p. Contractor will comply with all applicable federal, state, local, and foreign laws governing self-employed individuals, including laws requiring the payment of taxes.

7. **Independent Contractor Relationship.** Contractor is Company's independent contractor, and nothing in this Agreement should be construed to create a partnership, agency, joint venture, or employment relationship between Company and Contractor or any of Contractor's employees or agents. Contractor is not authorized to make any representation, contract, or commitment on Company's behalf. Neither Contractor nor Contractor's employees or agents will be entitled to any of the benefits that Company makes available to its employees, including paid vacation, sick leave, group health or life insurance, profit-sharing, or retirement benefits. Because Contractor is an independent contractor, Company will not withhold or make payments for social security, make unemployment insurance or disability insurance contributions, or obtain workers' compensation insurance on Contractor's behalf. Contractor is solely responsible for, and will file on a timely basis, all tax returns and payments required to be filed with or made to any federal, state, or local tax authority with respect to the performance of the Services and receipt of fees under this Agreement. Contractor is solely responsible for, and must maintain adequate records of, expenses incurred in the course of performing the Services. No part of Contractor's compensation will be subject to withholding by Company for the payment of any social security, federal, state, or any other employee payroll taxes. Company will regularly report amounts paid to Contractor by filing Form 1099-MISC with the Internal Revenue Service as required by law. If Contractor is reclassified as an employee of Company, or any affiliate of Company, by the U.S. Internal Revenue Service, the U.S. Department of Labor, or any other federal, state, or foreign agency as the result of any <u>administrative</u> or judicial proceeding, Contractor will not, as the result of such reclassification, be entitled to or eligible for, on either a prospective or retrospective basis, any employee benefits under any plans or programs established or maintained by Company.

8. **Confidentiality.** Confidentiality: The Contractor shall not disclose or use any confidential information of the Company, except as required for his duties or as authorized by the Company. The Contractor shall sign and comply with the Company's standard Confidentiality Agreement.  **<u>"Confidential</u> <u>information"</u>** means all confidential information of the Company and its trade secrets relating to the business affairs, customers, suppliers, technology, proprietary rights, patents, research, plans, research data, marketing techniques, manufacturing methods, procedures and techniques, industrial designs, inventions, improvements, discoveries and routines concerning the Company, its business and those of its affiliates and of its customers and their particular business requirements.

• **No Conflict of Interest.** During the term of this Agreement, Contractor will not take any action that would directly or indirectly promote any competitor or impair the Company's interests. The Contractor agrees that Contractor does not presently perform and will not perform during the term of Agreement, consulting or other services for companies whose businesses are or would be, in any material way, competitive with the Company, without the Board's prior approval.

9. **Termination.** 

a. **Term.** The term of this Agreement will begin on the Effective Date and will continue until the termination in accordance with this Agreement.

b. **Termination.** Either party may terminate this Agreement: (1) with or without cause upon 30 days' prior written notice (including via email) to the other party; or (2) immediately if the other party has materially breached this Agreement and failed to cure such breach within 30 days after the terminating party gives the non- <u>tenninating</u> party prior written notice of such breach and intent to terminate.

i. **Termination for Cause:** The Company may terminate the Contractor_for "☐", defined as: (i) willful misconduct or gross negligence; (ii) fraud, embezzlement, or theft; (iii) material violation of Company policies or this Agreement; (iv) conviction of a felony or crime involving moral turpitude; (v) willful failure to perform duties after written notice and a reasonable opportunity to cure (if curable); or (vi) beach of any provision of this Agreement and failure to cure with 20 days prior notice.

ii. **Termination by Contractor for Good Reason:** The Contractor may resign for  **<u>"Good Reason",</u>** defined as: (i) a material reduction in Base without consent; (ii) a material diminution in duties or authority; or (iii) relocation of the Consultant's primary workplace by more than 50 miles without consent, provided the Contractor gives written notice within 30 days of the event, the Company fails to cure within 30 days, and the Contractor resigns within 60 days of the notice.

iii. If the Company terminates the Contractor without Cause or the Contractor resigns for Good Reason, the Company shall immediately pay the Contractor 1/&h of the current base compensation along with all unpaid bonus. At that time, there shall be full accelerated vesting of all unvested equity awards.

iv. **Change** in **Control.** If the Contractor is terminated without Cause or resigns for Good Reason within 12 months following a Change in Control, the Company shall immediately pay the Contractor *114<sup>th</sup>* of the current base compensation along with all unpaid bonus. At that time, there shall be full accelerated vesting of all unvested equity awards.

I. For purposes of this Agreement, a  **<u>"Change In Contror</u>** means the happening of any of the following after the date hereof:

a. The consummation of a merger or consolidation of the Company with or into another entity or any other corporate reorganization, if fifty percent (50%) or more of the combined voting power of the continuing or surviving entity's securities outstanding immediately after such merger, consolidation, or other reorganization is owned by persons who were not shareholders of the Company immediately prior to such merger, consolidation, or other reorganization.

b. The sale, transfer, or other disposition of all or substantially all of the Company's assets or the complete liquidation or dissolution of the Company.

c. A change in the composition of the Board of Directors of the Company (the  **<u>"Boarcr)</u>** occurring within a two (2) year period, as a result of which fewer than a majority of the directors are Incumbent Directors.  **<u>"Incumbent Directors"</u>** shall mean directors who are directors of the Company as of the Effective Date.  **<u>"Incumbent Directors"</u>** shall also include directors who are elected, or nominated for election, to the Board with the affirmative votes of at least a majority of the Incumbent Directors (including persons who later become Incumbent Directors hereunder) at the time of such election or nomination, but shall not include an individual not otherwise an Incumbent Director whose election or nomination is in connection with an actual or threatened proxy contest relating to the election of directors to the Company.

d. Any transaction as a result of which any person or group is or becomes the  **<u>"beneficial</u> <u>owner'</u>** (as defined in Rule 13d-3 under the Securities Exchange Act of 1934), directly or indirectly, of securities of the Company representing at least thirty percent (30%) of the total voting power of the Company's then outstanding voting securities. For purposes of this paragraph, the term  **<u>•person"</u>** shall have the same meaning as when used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, but shall exclude: (i) a trustee or other fiduciary holding securities under an employee benefit plan of the Company or of a subsidiary of the Company; {ii) so long as a person does not thereafter increase such person's beneficial ownership of the total voting power represented by the Company's then outstanding voting securities, a person whose beneficial ownership of the total voting power represented by the Company's then outstanding voting securities increases to thirty percent (30%} or more as a result of the acquisition of voting securities of the Company by the Company which reduces the number of such voting securities then outstanding; or (iii) so long as a person does not thereafter increase such person's beneficial ownership of the total voting power represented by the Company's then outstanding voting securities, a person that acquires directly from the Company securities of the Company representing at least thirty percent {30%) of the total voting power represented by the Company's then outstanding voting securities.

e. A transaction shall not constitute a Change in Control if its sole purpose is to change the state of the Company's incorporation or to create a holding company that will be owned in substantially the same proportions by the persons who held the Company's securities immediately before such transaction.

c.  ***Effect of Termination.*** Upon any termination of this Agreement: (I) Contractor will, at Company's option, return or destroy all Confidential Information and any copies in Contractor's possession or control; and (2) Company will pay, within 30 days after the effective date of termination, all amounts owed to Contractor for Services completed prior to the effective date of termination.

d.  ***Survival.*** The following sections will survive termination of this Agreement: Compensation, Representations and Warranties, Independent Contractor Relationship, and Miscellaneous.

---

| | |
|:---|:---|
| 10.  | **Tax Matters.** It is intended that all payments and benefits provided under this Agreement or otherwise are exempt from, or comply with, the requirements of Section 409A of the Internal Revenue Code of 1986, as amended (the **<u>"Code"),</u>** and the regulations and other guidance thereunder or any state law of similar effect (collectively, **<u>"Section 409A")</u>** so that none of the payments or benefits will be subject to the additional tax imposed under Section 409A, and any ambiguities herein will be interpreted in accordance with such intent. For purposes of Section 409A, each payment, installment or benefit payable under this Agreement is hereby designated as a separate payment. |
|  | Notwithstanding anything to the contrary set forth herein, any payments and benefits provided under this Agreement (the **<u>"Severance Benefits")</u>** that constitute **<u>"deferred</u> <u>compensation"</u>** within the meaning of Section 409A and that are not exempt from Section 409A shall not commence in connection with the Consultant's termination of service unless and until the Contractorhas also incurred a **<u>"separation from service"</u>** (as such term is defined in Treasury Regulation Section l.409A-1(h) **<u>("Separation From</u> <u>Service")).</u>** |

---

---

| | |
|:---|:---|
|  | If the Company (or, if applicable, the successor entity thereto) determines that a Severance Benefit constitutes **<u>"deferred compensation"</u>** under Section 409A and the Contractoris, on the Consultant's Separation From Service, a **<u>"specified employee"</u>** of the Company or any successor entity thereto, as such term is defined in Section 409A(a)(2)(B)(i) of the Code and the Treasury regulations, then, solely to the extent necessary to avoid the incurrence of the adverse personal tax consequences under Section 409A, the timing of the Severance Benefit payment shall be delayed until the earlier to occur of: (i) the date that is six (6) months and one (1) day after the Consultant's Separation From Service or (ii) the date of the Consultant's death (such applicable date, the **<u>"Specified Initial Payment Date").</u>** On the Specified Initial Payment Date, the Company (or the successor entity thereto, as applicable) shall pay to the Contractor a lump sum amount equal to the Severance Benefit payment that the Contractor would otherwise have received through the Specified Initial Payment Date if the payment of the Severance Benefits had not been so delayed pursuant to this Section. |
| 11. | **Indemnification.** Company will indemnify and hold Contractor and its affiliates and their respective directors, officers, and employees harmless from any damages, costs, claims, expenses, or other liability (including reasonable attorneys' fees) arising from or relating to: (A) any negligent, reckless, or intentionally wrongful act of Company or Company's employees, contractors, or agents; (B) any breach by Company or Company's employees, contractors, or agents. |
| 12. | **Limitation of Liability.** CONTRACTOR WILL NOT. BE LIABLE FOR ANY INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES, INCLUDING DAMAGES FOR LOST PROFITS OR LOSS OF BUSINESS, HOWEVER CAUSED AND UNDER ANY THEORY OF LIABILITY, REGARDLESS OF WHETHER COMPANY WAS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES AND NOTWITHSTANDING THE FAILURE OF ESSENTIAL PURPOSE OF ANY LIMITED REMEDY. |
| 13. | **Miscellaneous.** |

---

a.  ***Assignment.*** Contractor may not assign, subcontract, or otherwise delegate this Agreement or any of its obligations without Company's prior written consent, and any attempt to do so will be null and void. Company may assign this Agreement without consent to any successor to all or substantially all of Company's relevant assets, whether by merger, consolidation, reorganiz.ation, reincorporation, sale of assets or stock, change of control, or otherwise. This Agreement will be for the benefit of the parties' permitted successors and assigns.

b.  ***Notices.*** Any notice under this Agreement must be in writing using one of the following methods, and will be deemed given as follows: (1) when delivered, if by personal delivery; (2) upon written verification of receipt, if by overnight courier; (3) within one business day of sending, ifby fax or email; or (4) upon verification of receipt, if by certified or registered mail, return receipt requested. Notice must be sent to the addresses set forth on the signature page or such other address as either party may specify in writing.

c.  ***Governing Law.*** This Agreement will be governed by the laws of the State of Nevada, without regard to the conflicts oflaw provisions of any jurisdiction. To the extent that any lawsuit is permitted under this Agreement, the parties consent to the personal and exclusive jurisdiction and venue of the state and federal courts located in Clark County, Nevada.

d.  ***Arbitration.*** Any dispute arising out of or relating to this Independent Contractor Agreement shall be resolved by binding arbitration administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures and conducted in the State of Nevada before one arbitrator. The parties agree that the arbitrator shall have the power to decide any motions brought by any party to the arbitration, including motions for summary judgment and/or adjudication and motions to dismiss prior to any arbitration hearing. The arbitrator shall issue a written, reasoned decision on all motions submitted and all issues raised therein, including ·the arbitrability of any issue. The arbitrator shall be selected :from the JAMS panel of arbitrators by mutual agreement of the parties. If the parties cannot agree upon an arbitrator within thirty(30) days after the commencement of an arbitration proceeding, then a neutral arbitrator shall be appointed by JAMS in accordance with its rules. The arbitrator shall apply Nevada substantive law and the Nevada Rules of Evidence. The parties agree that the arbitrator's award shall be final and binding and that a judgment may be entered upon it in any court having jurisdiction thereof. The parties hereby waive any rights they may have to trial by jucy in regard to claims subject to this Arbitration clause. The parties agree that the arbitrator shall have the power to award any remedies available under applicable law. The provisions of this Arbitration clause shall survive termination, amendment or expiration of this Independent Contractor Agreement.

e.  ***Severability.*** If any provision of this Agreement is held invalid, illegal, or unenforceable, such provisions will be modified, or if not possible, severed, to reflect the fullest valid, legal, and enforceable expression of the intent of the parties, and the remainder of this Agreement will not be affected.

f.  ***Waiver.*** No delay or failure to exercise any right under this Agreement will be deemed to be a waiver of such right or any other right.

g.  ***Electronic Delivery.*** Nothing in this Agreement is intended to imply a right to participate in any of Company's equity incentive plans, but if Contractor does participate in such plans, Company may, in its sole discretion, deliver any documents related to such participation by electronic means or request Contractor's consent to participate in such plans by electronic means. Contractor consents to receive such documents by electronic delivery and agrees, if applicable, to participate in such plans through an online or electronic system established and maintained by Company or a third party designated by Company.

h.  ***Attorneys' Fees.*** In any court action between the parties arising out of or relating to this Agreement, the prevailing party will be entitled to reasonable costs and attorneys' fees, in addition to any other relief to which that party may be entitled.

i.  ***Protected Activity Not Prohibited.*** Nothing in this Agreement limits or prohibits Contractor from engaging in any Protected Activity. **"Protected Activity"** means filing a charge, complaint, or report with, or otherwise communicating, cooperating, or participating in, any investigation or proceeding that may be conducted by any federal, state, or local government agency or commission, including the Securities and Exchange Commission **("Government Agencies").** In connection with any Protected Activity, Contractor may disclose documents or other information as permitted by law, and without giving notice to, or receiving authorization from, Company. Contractor will take all reasonable precautions to prevent any unauthorized use or disclosure of any information that may constitute Company confidential information to any parties other than the Government Agencies. **"Protected Activity"** does not include the disclosure of any Company attorney-client privileged communications or attorney work product.

j. **Clawback:** Notwithstanding any provision in this Agreement to the contrary, any portion of the payments and benefits provided under this Agreement, as well as any other payments and benefits which the Contractor receives pursuant to a Company plan or other arrangement, shall be subject to a clawback (a) to the extent necessary to comply with the requirements of the Dodd-Frank Wall Street Reform and Consumer Protection Act or any Securities and Exchange Commission rule or any other applicable law; and/or (b) any policy adopted by the Company and applicable generally to Contractor and other officers of the Company, relating to the recovery of compensation granted, paid, delivered, awarded or otherwise provided to Contractorby the Company or its subsidiaries or any of their respective affiliates, as applicable, as may be amended from time to time.

k.  ***Entire Agreement.*** This Agreement, together with any exhibits and Statements of Work, is the entire agreement between the parties relating to this subject matter and supersedes all prior or contemponmcol.18 oral or written **agreements** concerning such subject matter. This Agreement will govern all services undertaken by Contractor for Company. If there is any conflict between the terms of this Agreement and any Exhibit, the tenns of the Exhibit will control. This Agreement may only be amended by mutual agreement of the parties in writing. This Agreement may be executed in two or more counterparts, and each of which will be considered an original. Counterparts may be delivered via fax, email (including PDF or any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, or other applicable law).

1.  ***Interpretation.*** Any heading or section title in this Agreement is for convenience only, and does not define or explain any section. Any use of the term "including" should be construed as followed by "without limitation."

*[Signature page follows.]*

The parties have agreed to this Agreement as of <u>August'! 2025.</u>

---

| | |
|:---|:---|
| **PROGRESSIVE SYSTEM SOLUTIONS, INC,** | **WUND HEALING BIOPHARMACEUTICALS, INC.** |
| /s/ *Jon Paul* | /s/ *John Laub* |
| Name: Jon Paul  | Name: John Laub |
| Title: CEO | Title: CEO |
| Mailing Address: | Mailing Address: |
| 1271 Grove Ct. Lake Forest IL 60045 | 8683 W. Sahara Avenue, Suite 280, Las Vegas, NV 89117 |
| Email: jon@growwithsuccess.com | Email:john.k.laub@gmail.com |

---

## Ex1A-6

**EXHIBIT 6.6**

**WUND HEALING BIOPHARMACEUTICALS, INC.<br>RESTRICTED STOCK UNIT PLAN**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Purpose</u>. The name of this plan is the WUND Healing Biopharmaceuticals, Inc. Restricted Stock Unit Plan (the "Plan"). The purpose of the Plan is to enable WUND Healing Biopharmaceuticals, Inc., a Nevada corporation (the "Company"), to attract and retain the Employees, Consultants, and Directors who will contribute to the Company's long-term success.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Eligibility</u>. The individuals eligible to receive Awards are the Employees, Consultants, and Directors of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Definitions</u>.

"**Affiliate**" means a corporation or other entity that, directly or through one or more intermediaries, controls, is controlled by or is under common control with, the Company.

"**Applicable Laws**" means the requirements related to or implicated by the administration of the Plan under applicable state corporate law, United States federal and state securities laws, the Code and the applicable laws of any foreign country or jurisdiction where Awards are granted under the Plan.

"**Award**" means any right to receive Restricted Stock Units under the Plan.

"**Award Agreement**" means a written agreement evidencing the terms and conditions of an individual Award granted under the Plan. Each Award Agreement shall be subject to the terms and conditions of the Plan.

"**Board**" means the Board of Directors of the Company, as constituted at any time.

"**Cause**" means, unless an applicable Award Agreement, employment agreement, or consulting agreement provides otherwise:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) With respect to any Employee or Consultant: (i) failure to perform such duties as are reasonably requested by the Board; (ii) material breach of any agreement with the Company or an Affiliate, or a material violation of the Company's or an Affiliate's code of conduct, including written policies related to discrimination, harassment, performance of illegal or unethical activities, and ethical misconduct; (iii) commission of, or plea of guilty or no contest to, a felony or a crime involving moral turpitude or the commission of any other act involving willful malfeasance or material fiduciary breach with respect to the Company or an Affiliate; (iv) use of illegal drugs or abuse of alcohol that materially impairs the Participant's ability to perform their duties to the Company or an Affiliate; or (v) gross negligence or willful misconduct with respect to the Company or an Affiliate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) With respect to any Director, a determination by a majority of the disinterested Board members that the Director has engaged in any of the following: (i) malfeasance in office; (ii) gross misconduct or neglect; (iii) false or fraudulent misrepresentation inducing the Director's appointment; (iv) willful conversion of corporate funds; or (v) repeated failure to participate in Board meetings on a regular basis despite having received proper notice of the meetings in advance.

"**Change in Control**" means, unless otherwise provided in an applicable employment or consulting agreement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) One Person (or more than one Person acting as a group) acquires ownership of stock of the Company that, together with the stock held by such Person or group, constitutes more than 50% of the total voting power of the stock of the Company; provided, that, a Change in Control shall not occur if any Person (or more than one Person acting as a group) owns more than 50% of the total fair market value or total voting power of the Company's stock and acquires additional stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) One Person (or more than one Person acting as a group) acquires (or has acquired during the twelve-month period ending on the date of the most recent acquisition) ownership of the Company's stock possessing 50% or more of the total voting power of the stock of such corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) A majority of the members of the Board is replaced during any twelve-month period by directors whose appointment or election is not endorsed by a majority of the Board before the date of appointment or election; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) One Person (or more than one Person acting as a group), acquires (or has acquired during the twelve-month period ending on the date of the most recent acquisition) assets from the Company that have a total gross fair market value equal to or more than 50% of the total gross fair market value of all of the assets of the Company immediately before such acquisition(s).

"**Code**" means the Internal Revenue Code of 1986, as amended from time to time.

"**Committee**" means the Compensation Committee of the Board.

"**Common Stock**" means the common stock of the Company.

"**Company**" means WUND Healing Biopharmaceuticals, Inc., a Nevada corporation, and any successor thereto.

"**Consultant**" means any individual who is engaged by the Company to render consulting or advisory services, whether or not compensated for such services.

"**Continuous Service**" means that the Participant's service with the Company or an Affiliate, whether as an Employee, Consultant, or Director, is not interrupted or terminated. The Participant's Continuous Service shall not be deemed to have terminated merely because of a change in the capacity in which the Participant renders service to the Company or an Affiliate as an Employee, Consultant, or Director or a change in the entity for which the Participant renders such service, *provided that* there is no interruption or termination of the Participant's Continuous Service; *provided further that* if any Award is subject to Section 409A of the Code, this sentence shall only be given effect to the extent consistent with Section 409A of the Code.

"**Detrimental Activity**" means any of the following: (i) unauthorized disclosure of any confidential or proprietary information of the Company or any of its Affiliates; (ii) any activity that would be grounds to terminate the Participant's employment or service with the Company or any of its subsidiaries for Cause; (iii) the breach of any non-competition, non-solicitation, non-disparagement or other agreement containing restrictive covenants, with the Company or its Affiliates; (iv) fraud or conduct contributing to any financial restatements or irregularities, as determined by the Committee in its sole discretion; or (v) any other conduct or act determined to be materially injurious, detrimental or prejudicial to any interest of the Company or any of its Affiliates, as determined by the Committee in its sole discretion.

"**Director**" means a member of the Board.

"**Employee**" means any person employed by the Company or an Affiliate.

"**Fair Market Value**" means, on a given date, (i) if there is a public market for the shares of Common Stock on such date, the closing price of the shares as reported on such date on the principal national securities exchange on which the shares are listed or, if no sales of shares have been reported on any national securities exchange, then the immediately preceding date on which sales of the shares have been so reported or quoted, and (ii) if there is no public market for the shares of Common Stock on such date, then the fair market value shall be determined by the Committee in good faith after taking into consideration all factors which it deems appropriate, including, without limitation, Section 409A of the Code.

"**Grant Date**" means the date on which the Committee adopts a resolution, or takes other appropriate action, expressly granting an Award to a Participant that specifies the key terms and conditions of the Award or, if a later date is set forth in such resolution, then such date as is set forth in such resolution.

"**Participant**" means an eligible person to whom an Award is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding Award.

"**Person**" means any individual, entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities Exchange Act of 1934, as amended).

"**Plan**" means this WUND Healing Biopharmaceuticals, Inc., Restricted Stock Unit Plan, as amended or amended and restated from time to time.

"**Restricted Period**" has the meaning set forth in Section 6.

"**Restricted Stock Unit**" or "**RSU**" means an unfunded and unsecured promise to deliver shares of Common Stock, cash, other securities or other property, subject to certain restrictions (including, without limitation, a requirement that the Participant provide Continuous Service for a specified period of time) granted under Section 6 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Administration</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>Authority of Committee</u>. The Plan shall be administered by the Committee or, in the Board's sole discretion, by the Board. Subject to the terms of the Plan, the Committee's charter and Applicable Laws, and in addition to other express powers and authorization conferred by the Plan, the Committee shall have the authority: (a) to construe and interpret the Plan and apply its provisions; (b) to promulgate, amend, and rescind rules and regulations relating to the administration of the Plan; (c) to authorize any person to execute, on behalf of the Company, any instrument required to carry out the purposes of the Plan; (d) to delegate its authority to one or more officers of the Company; (e) to determine when Awards are to be granted under the Plan and the applicable Grant Date; (f) from time to time to select, subject to the limitations set forth in this Plan, those Participants to whom Awards shall be granted; (g) to determine the number of shares of Common Stock to be made subject to each Award; (h) to prescribe the terms and conditions of each Award, including, without limitation, the vesting provisions, and to specify the provisions of the Award Agreement relating to such grant; (i) to amend any outstanding Awards, including for the purpose of modifying the time or manner of vesting, or the term of any outstanding Award; (j) to determine the duration and purpose of leaves of absences which may be granted to a Participant without constituting termination of their employment for purposes of the Plan, which periods shall be no shorter than the periods generally applicable to Employees under the Company's employment policies; (k) to make decisions with respect to outstanding Awards that may become necessary upon a change in corporate control or an event that triggers anti-dilution adjustments; (l) to interpret, administer, reconcile any inconsistency in, correct any defect in and/or supply any omission in the Plan and any instrument or agreement relating to, or Award granted under, the Plan; (m) to determine the effect of all matters and questions relating to whether a Participant has been discharged for Cause; and (n) to exercise discretion to make any and all other determinations which it determines to be necessary or advisable for the administration of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>Acquisitions and Other Transactions</u>. The Committee may, from time to time, assume outstanding awards granted by another entity, whether in connection with an acquisition of such other entity or otherwise, by either (i) granting an Award under the Plan in replacement of or in substitution for the award assumed by the Company, or (ii) treating the assumed award as if it had been granted under the Plan if the terms of such assumed award could be applied to an Award granted under the Plan. Such assumed award shall be permissible if the holder of the assumed award would have been eligible to be granted an Award hereunder if the other entity had applied the rules of this Plan to such grant. The Committee may also grant Awards under the Plan in settlement of or in substitution for outstanding awards or obligations to grant future awards in connection with the Company or an Affiliate acquiring another entity, an interest in another entity, or an additional interest in an Affiliate whether by merger, stock purchase, asset purchase or other form of transaction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 <u>Committee Decisions Final</u>. All decisions made by the Committee pursuant to the provisions of the Plan shall be final and binding on the Company and the Participants, unless such decisions are determined by a court having jurisdiction to be arbitrary and capricious.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Shares Subject to the Plan</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Share Pool</u>. Subject to adjustment in accordance with Section 8, a total of 50,000 shares of Common Stock shall be available for the grant of Awards under the Plan. During the terms of the Awards, the Company shall keep available at all times the number of shares of Common Stock required to satisfy such Awards. Shares of Common Stock available for distribution under the Plan may consist, in whole or in part, of authorized and unissued shares or treasury shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Reissuance</u>. Any shares of Common Stock subject to an Award that is canceled or forfeited, either in full or in part, shall again become available for issuance under the Plan. Notwithstanding anything to the contrary contained herein: shares subject to an Award under the Plan shall not again be made available for issuance or delivery under the Plan if such shares are delivered or withheld by the Company to satisfy any tax withholding obligation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>Restricted Stock Units</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1 <u>Generally</u>. The terms and conditions of a grant of RSUs shall be reflected in an Award Agreement. No shares of Common Stock shall be issued at the time an RSU is granted, and the Company will not be required to set aside funds for the payment of any such Award. A Participant shall have no voting rights with respect to any RSUs granted hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2 <u>Restrictions</u>. RSUs awarded to a Participant shall be subject to (A) forfeiture until the expiration of the Restricted Period and satisfaction of any applicable performance goals during such period, to the extent provided in the applicable Award Agreement, and to the extent such RSUs are forfeited, all rights of the Participant to such RSUs shall terminate without further obligation on the part of the Company and (B) such other terms and conditions as may be set forth in the applicable Award Agreement. The Committee shall have the authority to remove any or all of the restrictions on the RSUs whenever it may determine that, by reason of changes in Applicable Laws or other changes in circumstances arising after the Grant Date, such action is appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3 <u>Restricted Period</u>. Unless otherwise provided in an Award Agreement, the Restricted Period shall commence on the Grant Date and end at the time or times set forth on a schedule established by the Committee in the applicable Award Agreement. The Committee may, but shall not be required to, provide for an acceleration of vesting in the terms of any Award Agreement upon the occurrence of a specified event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4 <u>Settlement of Restricted Stock Units</u>. Upon the expiration of the Restricted Period with respect to any outstanding RSUs, the Company shall deliver to the Participant, or the Participant's beneficiary, one share of Common Stock for each outstanding RSU or, in the case of any RSUs that settle in cash, payment equal to the Fair Market Value of one share of Common Stock as of the date on which the Restricted Period lapsed for each outstanding RSU. <u>Securities Law Compliance</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <u>Securities Registration</u>. No Awards shall be granted under the Plan and no shares of Common Stock shall be issued and delivered under the Plan unless and until the Company and/or the Participant have complied with all applicable federal and state registration, listing and/or qualification requirements and all other requirements of law or of any regulatory agencies having jurisdiction.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <u>Representations; Legends</u>. The Committee may, as a condition to the grant of any Award under the Plan, require a Participant to (i) represent in writing that the shares of Common Stock received in connection with such Award are being acquired for investment and not with a view to distribution and (ii) make such other representations and warranties as are deemed appropriate by counsel to the Company. Each certificate representing shares of Common Stock acquired under the Plan shall bear a legend in such form as the Company deems appropriate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Miscellaneous</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1 <u>Acceleration</u>. The Committee shall have the power to accelerate the time at which an Award or any part thereof vests in accordance with the Plan, notwithstanding the provisions in the Award stating the time during which it will vest, except to the extent inconsistent with Section 409A of the Code if the applicable Award is subject thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.2 <u>Shareholder Rights</u>. Except as provided in the Plan or an Award Agreement, no Participant shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Common Stock subject to an Award unless and until such Participant has satisfied all requirements for settlement of the Award pursuant to its terms and no adjustment shall be made for dividends (ordinary or extraordinary, whether in cash, securities or other property) or distributions of other rights for which the record date is prior to the date such Common Stock certificate is issued.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.3 <u>No Employment or Other Service Rights</u>. Nothing in the Plan or any instrument executed or Award granted pursuant thereto shall confer upon any Participant any right to continue to serve the Company or an Affiliate in the capacity in effect at the time the Award was granted or shall affect the right of the Company or an Affiliate to terminate (a) the employment of an Employee with or without notice and with or without Cause or (b) the service of a Director pursuant to the by-laws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which the Company or the Affiliate is incorporated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.4 <u>Transfer; Approved Leave of Absence</u>. For purposes of the Plan, no termination of employment by an Employee shall be deemed to result from either (a) a transfer of employment to the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another, or (b) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the Employee's right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Committee otherwise so provides in writing, in either case, except to the extent inconsistent with Section 409A of the Code if the applicable Award is subject thereto.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.5 Withholding Obligations. To the extent provided by the terms of an Award Agreement and subject to the discretion of the Committee, the Participant may satisfy any federal, state or local tax withholding obligation relating to the acquisition of Common Stock under an Award by any of the following means (in addition to the Company's right to withhold from any compensation paid to the Participant by the Company) or by a combination of such means: (a) tendering a cash payment; (b) authorizing the Company to withhold shares of Common Stock from the shares of Common Stock otherwise issuable to the Participant as a result of the acquisition of Common Stock under the Award, *provided, however*, that no shares of Common Stock are withheld with a value exceeding the maximum amount of tax required to be withheld by law; or (c) delivering to the Company previously owned and unencumbered shares of Common Stock of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Adjustments Upon Changes in Stock</u>. In the event of changes in the outstanding Common Stock or in the capital structure of the Company by reason of any stock or extraordinary cash dividend, stock split, reverse stock split, an extraordinary corporate transaction such as any recapitalization, reorganization, merger, consolidation, combination, exchange, or other relevant change in capitalization occurring after the Grant Date of any Award, Awards granted under the Plan and any Award Agreements, and the maximum number of shares of Common Stock subject to Awards stated in Section 5 will be equitably adjusted or substituted, as to the number, price, or kind of a share of Common Stock or other consideration subject to such Awards to the extent necessary to preserve the economic intent of such Award.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Effect of Change in Control</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1 In the event of a Change in Control, the Committee may, but shall not be obligated to: (a) accelerate, vest or cause the restrictions to lapse with respect to all or any portion of any Award; (b) cancel Awards and cause to be paid to the holders of vested Awards the value of such Awards, if any, as determined by the Committee, in its sole discretion; or (c) provide for the issuance of substitute Awards or the assumption or replacement of such Awards.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.2 The obligations of the Company under the Plan shall be binding upon any successor corporation or organization resulting from the merger, consolidation or other reorganization of the Company, or upon any successor corporation or organization succeeding to all or substantially all of the assets and business of the Company and its Affiliates, taken as a whole.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Amendment of the Plan and Awards</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1 <u>Amendment of the Plan</u>. The Board at any time, and from time to time, may amend or terminate the Plan. It is expressly contemplated that the Board may amend the Plan in any respect the Board deems necessary or advisable to provide eligible Employees, Consultants, and Directors with the maximum benefits provided or to be provided under the provisions of Section 409A of the Code and/or to bring the Plan and/or Awards granted under it into compliance therewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.2 <u>Amendment of Awards</u>. The Committee at any time, and from time to time, may amend the terms of any one or more Awards; *provided, however*, that the Committee may not affect any amendment which would otherwise constitute an impairment of the rights under any Award unless the Participant consents in writing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>General Provisions</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1 <u>Clawback; Forfeiture</u>. Notwithstanding anything to the contrary contained herein, the Committee may, in its sole discretion, provide in an Award Agreement or otherwise that the Committee may cancel such Award if the Participant has engaged in or engages in any Detrimental Activity. The Committee may, in its sole discretion, also provide in an Award Agreement or otherwise that (i) if the Participant has engaged in or engages in Detrimental Activity, the Participant will forfeit any gain realized on the vesting or settlement of any Award, and must repay the gain to the Company and (ii) if the Participant receives any amount in excess of what the Participant should have received under the terms of the Award for any reason (including, without limitation, by reason of a financial restatement, mistake in calculations or other administrative error), then the Participant shall be required to repay any such excess amount to the Company. Without limiting the foregoing, all Awards shall be subject to reduction, cancellation, forfeiture or recoupment to the extent necessary to comply with Applicable Laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2 <u>Unfunded Plan</u>. The Plan shall be unfunded. Neither the Company, the Board nor the Committee shall be required to establish any special or separate fund or to segregate any assets to assure the performance of its obligations under the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3 <u>No Fractional Shares</u>. No fractional shares of Common Stock shall be issued or delivered pursuant to the Plan. The Committee shall determine whether cash, additional Awards or other securities or property shall be issued or paid in lieu of fractional shares of Common Stock or whether any fractional shares should be rounded, forfeited or otherwise eliminated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.4 <u>Section 409A</u>. The Plan is intended to comply with Section 409A of the Code to the extent subject thereto, and, accordingly, to the maximum extent permitted, the Plan shall be interpreted and administered to be in compliance therewith. Any payments described in the Plan that are due within the "short-term deferral period" as defined in Section 409A of the Code shall not be treated as deferred compensation unless Applicable Laws require otherwise. Notwithstanding anything to the contrary in the Plan, to the extent required to avoid accelerated taxation and tax penalties under Section 409A of the Code, amounts that would otherwise be payable and benefits that would otherwise be provided pursuant to the Plan during the six (6) month period immediately following the Participant's termination of Continuous Service shall instead be paid on the first payroll date after the six-month anniversary of the Participant's separation from service (or the Participant's death, if earlier). Notwithstanding the foregoing, neither the Company nor the Committee shall have any obligation to take any action to prevent the assessment of any additional tax or penalty on any Participant under Section 409A of the Code and neither the Company nor the Committee will have any liability to any Participant for such tax or penalty.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.5 <u>Beneficiary Designation</u>. Each Participant under the Plan may from time to time name any beneficiary or beneficiaries by whom any right under the Plan is to be exercised in case of such Participant's death. Each designation will revoke all prior designations by the same Participant, shall be in a form reasonably prescribed by the Committee and shall be effective only when filed by the Participant in writing with the Company during the Participant's lifetime.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.6 <u>Expenses</u>. The Company shall pay the costs of administering the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.7 <u>Severability</u>. If any of the provisions of the Plan or any Award Agreement is held to be invalid, illegal or unenforceable, whether in whole or in part, such provision shall be deemed modified to the extent, but only to the extent, of such invalidity, illegality or unenforceability and the remaining provisions shall not be affected thereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.8 <u>Plan</u> <u>Headings</u>. The headings in the Plan are for purposes of convenience only and are not intended to define or limit the construction of the provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.9 <u>Non-Uniform Treatment</u>. The Committee's determinations under the Plan need not be uniform and may be made by it selectively among persons who are eligible to receive, or actually receive, Awards. Without limiting the generality of the foregoing, the Committee shall be entitled to make non-uniform and selective determinations, amendments and adjustments, and to enter into non-uniform and selective Award Agreements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Choice of Law</u>. The law of the State of Nevada shall govern all questions concerning the construction, validity and interpretation of this Plan, without regard to such state's conflict of law rules.

As adopted by the Board of Directors of WUND Healing Biopharmaceuticals, Inc. on August 26, 2025.

As approved by the shareholders of WUND Healing Biopharmaceuticals, Inc. on Coming.

## Ex1A-6

**EXHIBIT 6.7**

**WUND HEALING BIOPHARMACEUTICALS, INC.<br>RESTRICTED STOCK UNIT PLAN**

**[FORM OF] AWARD AGREEMENT**

This Award Agreement (this "**Agreement**") is made and entered into as of [DATE] (the "**Grant Date**") by and between WUND Healing Biopharmaceuticals, Inc., a Nevada corporation (the "**Company**") and [GRANTEE] (the "**Grantee**").

**WHEREAS**, the Company has adopted the WUND Healing Biopharmaceuticals, Inc., Restricted Stock Unit Plan (the "**Plan**") pursuant to which awards of Restricted Stock Units may be granted; and

**WHEREAS**, the Committee has determined that it is in the best interests of the Company and its shareholders to grant the award of Restricted Stock Units provided for herein.

NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Grant of Restricted Stock Units</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 Pursuant to Section 6 of the Plan, the Company hereby issues to the Grantee on the Grant Date an Award consisting of [NUMBER] Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of Common Stock, subject to the terms and conditions set forth in this Agreement and the Plan. Capitalized terms that are used but not defined herein have the meaning ascribed to them in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 The Restricted Stock Units shall be credited to a separate account maintained for the Grantee on the books and records of the Company (the "**Account**"). All amounts credited to the Account shall continue for all purposes to be part of the general assets of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Vesting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 Except as otherwise provided herein, provided that the Grantee remains in Continuous Service through the applicable vesting dates, the Restricted Stock Units will vest in accordance with the below schedule. Once vested, the Restricted Stock Units become "**Vested Units**."

---

| | |
|:---|:---|
| **Vesting Date** | **Percentage Vested** |
| [DATE] | [PERCENTAGE] |
| [DATE] | [PERCENTAGE] |
| [DATE] | [PERCENTAGE] |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 If the Grantee's Continuous Service terminates for any reason at any time before all of the Restricted Stock Units have vested, the Grantee's unvested Restricted Stock Units shall be automatically forfeited upon such termination of Continuous Service and neither the Company nor any Affiliate shall have any further obligations to the Grantee under this Agreement. Notwithstanding the preceding sentence, if the Grantee's Continuous Service terminates without Cause, for Good Reason, or as a result of the Grantee's death or Disability, 100% of the unvested Restricted Stock Units shall vest as of the date of such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 If a Change in Control occurs and the Grantee's Continuous Service is terminated by the Company or an Affiliate without Cause or by the Grantee for Good Reason, and the Grantee's date of termination occurs (or in the case of the Grantee's termination of Continuous Service for Good Reason, the event giving rise to Good Reason occurs), during the period beginning on the date of the Change in Control and ending on the date that is twelve months following the Change in Control, 100% of the unvested Restricted Stock Units shall automatically vest on the Grantee's date of termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 For purposes of this Section, "**Disability**" means, unless otherwise provided in an applicable employment or consulting agreement, that the Grantee is considered disabled for purposes of the Company's long-term disability policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 For purposes of this Section, "**Good Reason**" means, unless otherwise provided in an applicable employment or consulting agreement, the occurrence of one or more of the following events or conditions without Grantee's express written consent: (a) a material diminution in Grantee's title or position or in the nature or status of Grantee's authority, duties, or responsibilities; (b) a material reduction in Grantee's base salary in excess of 20%; (c) a change in Grantee's principal place of employment to a location that is more than 50 miles from its current location; or (d) a material reduction in the level of benefits provided to Grantee, unless such reduction is also made to the benefits provided to other similarly situated employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Restrictions</u>. Subject to any exceptions set forth in this Agreement or the Plan, during the Restricted Period and until such time as the Restricted Stock Units are settled in accordance with Section 5, the Restricted Stock Units or the rights relating thereto may not be assigned, alienated, pledged, attached, sold, or otherwise transferred or encumbered by the Grantee. Any attempt to assign, alienate, pledge, attach, sell, or otherwise transfer or encumber the Restricted Stock Units or the rights relating thereto shall be wholly ineffective, and if any such attempt is made, the Restricted Stock Units will be forfeited by the Grantee and all of the Grantee's rights to such units shall immediately terminate without any payment or consideration by the Company. Prior to an initial public offering, no shares of Common Stock acquired on settlement of the RSUs may be transferred or disposed of in any way by the Grantee, except by will or the laws of descent and distribution, or pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Rights as Shareholder; No Dividend Equivalents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 The Grantee shall not have any rights of a shareholder with respect to the shares of Common Stock underlying the Restricted Stock Units unless and until the Restricted Stock Units vest and are settled by the issuance of such shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 Upon and following the settlement of the Restricted Stock Units, the Grantee shall be the record owner of the shares of Common Stock underlying the Restricted Stock Units unless and until such shares are sold or otherwise disposed of, and as record owner shall be entitled to all rights of a shareholder of the Company (including voting rights).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 The Grantee shall not be entitled to any dividend equivalents with respect to the Restricted Stock Units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Settlement of Restricted Stock Units</u>. Within 60 days of the vesting date, and in any event no later than March 15 of the calendar year following the calendar year in which such vesting occurs, the Company shall (a) issue and deliver to the Grantee the number of shares of Common Stock equal to the number of Vested Units and (b) enter the Grantee's name on the books of the Company as the shareholder of record with respect to the shares of Common Stock delivered to the Grantee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>No Right to Continued Service</u>. Neither the Plan nor this Agreement shall confer upon the Grantee any right to be retained in any position, as an Employee, Consultant, or Director of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company to terminate the Grantee's Continuous Service at any time, with or without Cause.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Adjustments</u>. If any change is made to the outstanding Common Stock or the capital structure of the Company, if required, the Restricted Stock Units shall be adjusted or terminated in any manner as contemplated by Section 8 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Tax Liability and Withholding</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 The Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the Grantee pursuant to the Plan, the amount of any required withholding taxes in respect of the Restricted Stock Units and to take all such other action as the Committee deems necessary to satisfy all obligations for the payment of such withholding taxes. The Committee may permit the Grantee to satisfy any federal, state, or local tax withholding obligation as described in Section 7.5 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding ("**Tax-Related Items**"), the ultimate liability for all Tax-Related Items is and remains the Grantee's responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or settlement of the Restricted Stock Units or the subsequent sale of any shares; and (b) does not commit to structure the Restricted Stock Units to reduce or eliminate the Grantee's liability for Tax-Related Items.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Public Offering and Lock-Up Agreement</u>. The Grantee agrees that in the event the Company files a registration statement under the Securities Act with respect to an underwritten public offering of any shares of Common Stock, the Company (or a representative of the underwriters) may require that the Grantee not sell or otherwise dispose of any shares of Common Stock during such period (not to exceed 180 days) following the effective date of the registration statement. The Grantee further understands that the Company may impose stop-transfer restrictions with respect to securities subject to these restrictions until the end of such period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Compliance with Law</u>. The issuance and transfer of shares of Common Stock shall be subject to compliance by the Company and the Grantee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which the Company's shares of Common Stock may be listed. No shares of Common Stock shall be issued or transferred unless and until any then applicable requirements of state and federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel. The Grantee understands that the Company is under no obligation to register the shares of Common Stock with the Securities and Exchange Commission, and any state securities commission or any stock exchange to effect such compliance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Notices</u>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Chief Financial Officer of the Company (or the Chief Executive Officer of the Company with respect to awards to the Chief Financial Officer) at the Company's principal corporate offices. Any notice required to be delivered to the Grantee under this Agreement shall be in writing and addressed to the Grantee at the Grantee's address as shown in the records of the Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Governing Law</u>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict of law principles.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Clawback/Forfeiture</u>. By accepting the Restricted Stock Units, the Grantee acknowledges that the Restricted Stock Units are subject to clawback or forfeiture in accordance with the terms of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Interpretation</u>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or the Company to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Grantee and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>Restricted Stock Units Subject to Plan</u>. This Agreement is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. <u>Shareholders' Agreement</u>. Notwithstanding anything in this Agreement to the contrary, and in accordance with the terms of the Plan, as condition to the settlement of the Restricted Stock Units in shares of Common Stock, the Grantee may be required to execute and become a party to the shareholders' agreement among the Company and its shareholders, which shall set forth certain restrictions on the transferability of the shares of Common Stock and such other terms as the Board or Committee shall from time to time establish.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. <u>Successors and Assigns</u>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Grantee and the Grantee's beneficiaries, executors, and administrators and the person(s) to whom the Restricted Stock Units may be transferred by will or the laws of descent or distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. <u>Severability</u>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable to the extent permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. <u>Discretionary Nature of Plan</u>. The Plan is discretionary and may be amended, cancelled, or terminated by the Company at any time, in its discretion. The grant of the Restricted Stock Units in this Agreement does not create any contractual right or other right to receive any Restricted Stock Units or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Grantee's employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20. <u>Amendment</u>. The Committee has the right to amend, alter, suspend, discontinue, or cancel the Restricted Stock Units, prospectively or retroactively; provided, that no such amendment shall adversely affect the Grantee's material rights under this Agreement without the Grantee's consent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21. <u>Section 409A</u>. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Grantee on account of non-compliance with Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22. <u>No Impact on Other Benefits</u>. The value of the Grantee's Restricted Stock Units is not part of the Grantee's normal or expected compensation for purposes of calculating any severance, retirement, welfare, insurance, or similar employee benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23. <u>Counterparts</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24. <u>Acceptance</u>. The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement. The Grantee has read and understands the terms and provisions thereof and accepts the Restricted Stock Units subject to all of the terms and conditions of the Plan and this Agreement. The Grantee acknowledges that there may be adverse tax consequences upon the vesting or settlement of the Restricted Stock Units or disposition of the underlying shares and that the Grantee has been advised to consult a tax advisor prior to such vesting, settlement, or disposition.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

---

| |
|:---|
| WUND HEALTH BIOPHARMACEUTICALS, INC. |
| By: |
| Name: |
| Title: |
| [GRANTEE] |
| By: |
| Name: |

---

## Ex1A-6

**EXHIBIT 6.8**

**WUND HEALING BIOPHARMACEUTICALS, INC.** 

**RESTRICTED STOCK UNIT PLAN<br>AWARD AGREEMENT**

This Award Agreement (this "**Agreement**") is made and entered into as of January 15, 2025 (the "**Grant Date**") by and between WUND Healing Biopharmaceuticals, Inc., a Nevada corporation (the "**Company**") and Jon Paul (the "**Grantee**").

**WHEREAS**, the Company has adopted the WUND Healing Biopharmaceuticals, Inc., Restricted Stock Unit Plan (the "**Plan**") pursuant to which awards of Restricted Stock Units may be granted; and

**WHEREAS**, the Committee has determined that it is in the best interests of the Company and its shareholders to grant the award of Restricted Stock Units provided for herein.

NOW, THEREFORE, the parties hereto, intending to be legally bound, agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. <u>Grant of Restricted Stock Units</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 Pursuant to Section 6 of the Plan, the Company hereby issues to the Grantee on the Grant Date an Award consisting of 50,000 Restricted Stock Units. Each Restricted Stock Unit represents the right to receive one share of Common Stock, subject to the terms and conditions set forth in this Agreement and the Plan. Capitalized terms that are used but not defined herein have the meaning ascribed to them in the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.2 The Restricted Stock Units shall be credited to a separate account maintained for the Grantee on the books and records of the Company (the "**Account**"). All amounts credited to the Account shall continue for all purposes to be part of the general assets of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. <u>Vesting</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 Except as otherwise provided herein, provided that the Grantee remains in Continuous Service through the applicable vesting dates, the Restricted Stock Units will vest in accordance with the below schedule. Once vested, the Restricted Stock Units become "**Vested Units**."

---

| | |
|:---|:---|
| **Vesting Date** | **Percentage Vested** |
| January 15, 2027 | 40% |
| January 15, 2028 | 30% |
| January 15, 2029 | 30% |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.2 If the Grantee's Continuous Service terminates for any reason at any time before all of the Restricted Stock Units have vested, the Grantee's unvested Restricted Stock Units shall be automatically forfeited upon such termination of Continuous Service and neither the Company nor any Affiliate shall have any further obligations to the Grantee under this Agreement. Notwithstanding the preceding sentence, if the Grantee's Continuous Service terminates without Cause, for Good Reason, or as a result of the Grantee's death or Disability, 100% of the unvested Restricted Stock Units shall vest as of the date of such termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.3 If a Change in Control occurs and the Grantee's Continuous Service is terminated by the Company or an Affiliate without Cause or by the Grantee for Good Reason, and the Grantee's date of termination occurs (or in the case of the Grantee's termination of Continuous Service for Good Reason, the event giving rise to Good Reason occurs), during the period beginning on the date of the Change in Control and ending on the date that is twelve months following the Change in Control, 100% of the unvested Restricted Stock Units shall automatically vest on the Grantee's date of termination.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.4 For purposes of this Section, "**Disability**" means, unless otherwise provided in an applicable employment or consulting agreement, that the Grantee is considered disabled for purposes of the Company's long-term disability policy.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.5 For purposes of this Section, "**Good Reason**" means, unless otherwise provided in an applicable employment or consulting agreement, the occurrence of one or more of the following events or conditions without Grantee's express written consent: (a) a material diminution in Grantee's title or position or in the nature or status of Grantee's authority, duties, or responsibilities; (b) a material reduction in Grantee's base salary in excess of 20%; (c) a change in Grantee's principal place of employment to a location that is more than 50 miles from its current location; or (d) a material reduction in the level of benefits provided to Grantee, unless such reduction is also made to the benefits provided to other similarly situated employees.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. <u>Restrictions</u>. Subject to any exceptions set forth in this Agreement or the Plan, during the Restricted Period and until such time as the Restricted Stock Units are settled in accordance with Section 5, the Restricted Stock Units or the rights relating thereto may not be assigned, alienated, pledged, attached, sold, or otherwise transferred or encumbered by the Grantee. Any attempt to assign, alienate, pledge, attach, sell, or otherwise transfer or encumber the Restricted Stock Units or the rights relating thereto shall be wholly ineffective, and if any such attempt is made, the Restricted Stock Units will be forfeited by the Grantee and all of the Grantee's rights to such units shall immediately terminate without any payment or consideration by the Company. Prior to an initial public offering, no shares of Common Stock acquired on settlement of the RSUs may be transferred or disposed of in any way by the Grantee, except by will or the laws of descent and distribution, or pursuant to this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. <u>Rights as Shareholder; No Dividend Equivalents</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.1 The Grantee shall not have any rights of a shareholder with respect to the shares of Common Stock underlying the Restricted Stock Units unless and until the Restricted Stock Units vest and are settled by the issuance of such shares of Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2 Upon and following the settlement of the Restricted Stock Units, the Grantee shall be the record owner of the shares of Common Stock underlying the Restricted Stock Units unless and until such shares are sold or otherwise disposed of, and as record owner shall be entitled to all rights of a shareholder of the Company (including voting rights).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.3 The Grantee shall not be entitled to any dividend equivalents with respect to the Restricted Stock Units.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. <u>Settlement of Restricted Stock Units</u>. Within 60 days of the vesting date, and in any event no later than March 15 of the calendar year following the calendar year in which such vesting occurs, the Company shall (a) issue and deliver to the Grantee the number of shares of Common Stock equal to the number of Vested Units and (b) enter the Grantee's name on the books of the Company as the shareholder of record with respect to the shares of Common Stock delivered to the Grantee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. <u>No Right to Continued Service</u>. Neither the Plan nor this Agreement shall confer upon the Grantee any right to be retained in any position, as an Employee, Consultant, or Director of the Company. Further, nothing in the Plan or this Agreement shall be construed to limit the discretion of the Company to terminate the Grantee's Continuous Service at any time, with or without Cause.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. <u>Adjustments</u>. If any change is made to the outstanding Common Stock or the capital structure of the Company, if required, the Restricted Stock Units shall be adjusted or terminated in any manner as contemplated by Section 8 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. <u>Tax Liability and Withholding</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1 The Grantee shall be required to pay to the Company, and the Company shall have the right to deduct from any compensation paid to the Grantee pursuant to the Plan, the amount of any required withholding taxes in respect of the Restricted Stock Units and to take all such other action as the Committee deems necessary to satisfy all obligations for the payment of such withholding taxes. The Committee may permit the Grantee to satisfy any federal, state, or local tax withholding obligation as described in Section 7.5 of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.2 Notwithstanding any action the Company takes with respect to any or all income tax, social insurance, payroll tax, or other tax-related withholding ("**Tax-Related Items**"), the ultimate liability for all Tax-Related Items is and remains the Grantee's responsibility and the Company (a) makes no representation or undertakings regarding the treatment of any Tax-Related Items in connection with the grant, vesting, or settlement of the Restricted Stock Units or the subsequent sale of any shares; and (b) does not commit to structure the Restricted Stock Units to reduce or eliminate the Grantee's liability for Tax-Related Items.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. <u>Public Offering and Lock-Up Agreement</u>. The Grantee agrees that in the event the Company files a registration statement under the Securities Act with respect to an underwritten public offering of any shares of Common Stock, the Company (or a representative of the underwriters) may require that the Grantee not sell or otherwise dispose of any shares of Common Stock during such period (not to exceed 180 days) following the effective date of the registration statement. The Grantee further understands that the Company may impose stop-transfer restrictions with respect to securities subject to these restrictions until the end of such period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. <u>Compliance with Law</u>. The issuance and transfer of shares of Common Stock shall be subject to compliance by the Company and the Grantee with all applicable requirements of federal and state securities laws and with all applicable requirements of any stock exchange on which the Company's shares of Common Stock may be listed. No shares of Common Stock shall be issued or transferred unless and until any then applicable requirements of state and federal laws and regulatory agencies have been fully complied with to the satisfaction of the Company and its counsel. The Grantee understands that the Company is under no obligation to register the shares of Common Stock with the Securities and Exchange Commission, and any state securities commission or any stock exchange to effect such compliance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11. <u>Notices</u>. Any notice required to be delivered to the Company under this Agreement shall be in writing and addressed to the Chief Financial Officer of the Company (or the Chief Executive Officer of the Company with respect to awards to the Chief Financial Officer) at the Company's principal corporate offices. Any notice required to be delivered to the Grantee under this Agreement shall be in writing and addressed to the Grantee at the Grantee's address as shown in the records of the Company. Either party may designate another address in writing (or by such other method approved by the Company) from time to time.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12. <u>Governing Law</u>. This Agreement will be construed and interpreted in accordance with the laws of the State of Nevada without regard to conflict of law principles.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13. <u>Clawback/Forfeiture</u>. By accepting the Restricted Stock Units, the Grantee acknowledges that the Restricted Stock Units are subject to clawback or forfeiture in accordance with the terms of the Plan.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;14. <u>Interpretation</u>. Any dispute regarding the interpretation of this Agreement shall be submitted by the Grantee or the Company to the Committee for review. The resolution of such dispute by the Committee shall be final and binding on the Grantee and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;15. <u>Restricted Stock Units Subject to Plan</u>. This Agreement is subject to the Plan. The terms and provisions of the Plan as it may be amended from time to time are hereby incorporated herein by reference. In the event of a conflict between any term or provision contained herein and a term or provision of the Plan, the applicable terms and provisions of the Plan will govern and prevail.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;16. <u>Shareholders' Agreement</u>. Notwithstanding anything in this Agreement to the contrary, and in accordance with the terms of the Plan, as condition to the settlement of the Restricted Stock Units in shares of Common Stock, the Grantee may be required to execute and become a party to the shareholders' agreement among the Company and its shareholders, which shall set forth certain restrictions on the transferability of the shares of Common Stock and such other terms as the Board or Committee shall from time to time establish.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17. <u>Successors and Assigns</u>. The Company may assign any of its rights under this Agreement. This Agreement will be binding upon and inure to the benefit of the successors and assigns of the Company. Subject to the restrictions on transfer set forth herein, this Agreement will be binding upon the Grantee and the Grantee's beneficiaries, executors, and administrators and the person(s) to whom the Restricted Stock Units may be transferred by will or the laws of descent or distribution.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18. <u>Severability</u>. The invalidity or unenforceability of any provision of the Plan or this Agreement shall not affect the validity or enforceability of any other provision of the Plan or this Agreement, and each provision of the Plan and this Agreement shall be severable and enforceable to the extent permitted by law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19. <u>Discretionary Nature of Plan</u>. The Plan is discretionary and may be amended, cancelled, or terminated by the Company at any time, in its discretion. The grant of the Restricted Stock Units in this Agreement does not create any contractual right or other right to receive any Restricted Stock Units or other Awards in the future. Future Awards, if any, will be at the sole discretion of the Company. Any amendment, modification, or termination of the Plan shall not constitute a change or impairment of the terms and conditions of the Grantee's employment with the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20. <u>Amendment</u>. The Committee has the right to amend, alter, suspend, discontinue, or cancel the Restricted Stock Units, prospectively or retroactively; provided, that no such amendment shall adversely affect the Grantee's material rights under this Agreement without the Grantee's consent.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21. <u>Section 409A</u>. This Agreement is intended to comply with Section 409A of the Code or an exemption thereunder and shall be construed and interpreted in a manner that is consistent with the requirements for avoiding additional taxes or penalties under Section 409A of the Code. Notwithstanding the foregoing, the Company makes no representations that the payments and benefits provided under this Agreement comply with Section 409A of the Code and in no event shall the Company be liable for all or any portion of any taxes, penalties, interest or other expenses that may be incurred by the Grantee on account of non-compliance with Section 409A of the Code.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22. <u>No Impact on Other Benefits</u>. The value of the Grantee's Restricted Stock Units is not part of the Grantee's normal or expected compensation for purposes of calculating any severance, retirement, welfare, insurance, or similar employee benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23. <u>Counterparts</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original but all of which together will constitute one and the same instrument. Counterpart signature pages to this Agreement transmitted by electronic mail in portable document format (.pdf), or by any other electronic means intended to preserve the original graphic and pictorial appearance of a document, will have the same effect as physical delivery of the paper document bearing an original signature.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;24. <u>Acceptance</u>. The Grantee hereby acknowledges receipt of a copy of the Plan and this Agreement. The Grantee has read and understands the terms and provisions thereof and accepts the Restricted Stock Units subject to all of the terms and conditions of the Plan and this Agreement. The Grantee acknowledges that there may be adverse tax consequences upon the vesting or settlement of the Restricted Stock Units or disposition of the underlying shares and that the Grantee has been advised to consult a tax advisor prior to such vesting, settlement, or disposition.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first above written.

---

| | |
|:---|:---|
| WUND HEALING BIOPHARMACEUTICALS, INC. | WUND HEALING BIOPHARMACEUTICALS, INC. |
| By: | ![](wund_ex68img1.jpg) |
| Name: | John Laub |
| Title: | President |
| JON PAUL | JON PAUL |
| By: | ![](wund_ex68img2.jpg) |
| Name: | Jon Paul |

---

## Ex1A-11

**EXHIBIT 11.1**

**Consent of Independent Registered Public Accounting Firm**

We hereby consent to the use of our report dated June 4, 2026, on the financial statements of WUND Healing Biopharmaceuticals, Inc as of December 31, 2025 and 2024 and for each of the two years in the period ended December 31, 2025 included in this Regulation A Offering Statement of WUND Healing Biopharmaceuticals, Inc on Form 1-A.

/s/ *Salberg & Company, P.A.*

SALBERG & COMPANY, P.A.

Boca Raton, Florida

June 26, 2026

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 1-A

### REGULATION A OFFERING STATEMENT
### UNDER THE SECURITIES ACT OF 1933

### Item 1. Issuer Information

**Exact name of issuer:** WUND Healing BioPharmaceuticals, Inc.

**Jurisdiction of Incorporation/Organization:** NV

**Year of Incorporation:** 2016

**CIK:** 0002078607

**I.R.S. Employer Identification Number:** 81-3752318

**Primary Standard Industrial Classification Code:** 2836

**Total number of full-time employees:** 0

**Total number of part-time employees:** 0

**Address of Principal Executive Offices:** 8683 W. Sahara Avenue, Suite 280, Las Vegas, NV 89117

**Company Phone:** 702-800-0030

**Person to contact:** The Loev Law Firm, PC

### Financial Statements

**Balance Sheet Information**

| Metric                                   | Amount      |
|:---|:---|
| Cash and Cash Equivalents                | $159906.00  |
| Investment Securities                    | $0.00       |
| Accounts and Notes Receivable            | $0.00       |
| Property, Plant and Equipment (PP&E)     | $0.00       |
| Total Assets                             | $379161.00  |
| Accounts Payable and Accrued Liabilities | $1171965.00 |
| Long-Term Debt                           | $21908.00   |
| Total Liabilities                        | $1193873.00 |
| Total Stockholders' Equity               | $-814712.00 |
| Total Liabilities and Equity             | $379161.00  |

**Statement of Comprehensive Income Information**

| Metric                                    | Amount     |
|:---|:---|
| Total Revenues                            | $0.00      |
| Costs and Expenses Applicable to Revenues | $174505.00 |
| Depreciation and Amortization             | $0.00      |
| Net Income                                | $307844.00 |
| Earnings Per Share - Basic                | 0.12       |
| Earnings Per Share - Diluted              | 0.12       |

**Auditor Information**

| Metric          | Amount                  |
|:---|:---|
| Name of Auditor | Salberg & Company, P.A. |

### Outstanding Securities

| Class        |   Outstanding | CUSIP   | Publicly Traded   |
|:---|---:|:---|:---|
| Common stock |       2632000 | 00000   | N/A               |
| N/A          |             0 |  |  |
| N/A          |             0 |  |  |

### Item 2. Issuer Eligibility
- [x] The issuer certifies that all of the statements in this part are true.

### Item 3. Application of Rule 262
- [x] The issuer certifies that it is not disqualified and has not been involved in any disqualifying event.

### Item 4. Summary Information Regarding the Offering

**Tier:** Tier2

**Financial Statement Status:** Audited

**Type of Securities Offered:** Equity (common or preferred stock)

**Is this a delayed or continuous offering?** Yes

**Was or is the offering to take place within one year after qualification?** No

**Was or is the offering to commence within two days after qualification?** No

**Is this a best efforts offering?** Yes

**Was there any solicitation of interest?** No

**Are there any resale securities by affiliates of the issuer?** No

**Offering Amounts**

| Description                                                     | Amount   |
|:---|:---|
| Number of securities offered                                    | 1000000  |
| Number of securities outstanding                                | 2632000  |
| Price per security                                              | $10.00   |
| Issuer's aggregate offering price                               | $10.00   |
| Aggregate offering price of securities held by security holders | $0.00    |
| Aggregate price of securities offered concurrently              | $0.00    |
| Total aggregate offering price                                  | $10.00   |

**Anticipated Fees**

| Service Provider   | Name                  | Fees       |
|:---|:---|:---|
| Auditor            | Salberg & Co.         | $40000.00  |
| Legal              | The Loev Law Firm, PC | $185000.00 |
| Promoters          |  | $0.00      |

**Estimated Net Proceeds to the Issuer:** $9020000.00

### Item 5. Jurisdictions in Which Securities are to be Offered

- All States and Territories